AD-A154 658 CLINICAL INVÉSTIGATION PROGRAM ANNUAL PROGRESS REPORT (U) FITZSIMONS ARMY MEDICAL CENTER AURORA CO 30 SEP 84 1/3 **UNCLASSIFIED** F/G 6/5 NL



MICROCOPY RESOLUTION TEST CHART
NATIONAL BUREAU OF STANDARDS-1963-A



Laboratory Report No. 20



# CLINICAL INVESTIGATION PROGRAM ANNUAL PROGRESS REPORT

4 658

AD-A154

30 September 1984



TIC FILE COPY
DEPARTMENT OF CLINICAL INVESTIGATION

DTIC ELECTE JUN 5 1985

This document has been approved for public and sale; the distribution is unlimited.

Fitzsimons Army Medical Center Aurora, Colorado 80045-5001

E

85

5 03

03

APPROVED FOR PUBLIC RELEASE: DISTRIBUTION UNLIMITED.

DESTROY THIS REPORT WHEN NO LONGER NEEDED. DO NOT RETURN IT TO THE ORIGINATOR.

THE FINDINGS IN THIS REPORT ARE NOT TO BE CONSTRUED AS AN OFFICIAL DEPARTMENT OF THE ARMY POSITION UNLESS SO DESIGNATED BY OTHER AUTHORIZED DOCUMENTS.

Acces	sion For	
NTIS	GRA&I	
DTIC	TAB	
Unann	ounced [	
Justi	fication	
By Distr	ibution/	
	lability Codes	
	Avail and/or	
Dist	Special	
A/I		•:



# DEPARTMENT OF CLINICAL INVESTIGATION REPORT CONTROL SYMBOL MED-300

# CLINICAL INVESTIGATION PROGRAM ANNUAL PROGRESS REPORT

30 September 1984

CLINICAL INVESTIGATIONS (U)

FITZSIMONS ARMY MEDICAL CENTER
AURORA, COLORADO 80045-5000

Approved for public release; distribution unlimited

#### FOREWORD

This report identifies the research activities conducted by Fitzsimons Army Medical Center investigators through protocols approved by the Institutional Review Committee and registered with the Department of Clinical Investigation during Fiscal Year 1983 along with other known presentations and publications by FAMC professional staff.

The research protocols described in this report were conducted under the provisions of AR 40-38, Clinical Investigation Program, AR 40-7, Use of Investigational Drugs in Humans, AR 70-25, Use of Volunteers as Subjects of Research, and HSC Reg 40-23, as amended, Management of Clinical Investigation Protocols and Reports, to insure the medical safety, well being, preservation of rights and dignity of human subjects who participated in these investigations.

In conducting the research described in this report, the investigator(s) adhered to AR 70-18, Laboratory Animals, Procurement, Transportation, Use, Care, and Public Affairs and the "Guide for Laboratory Animal Facilities and Care", as promulaged by the Committee or the Guide for Laboratory Animal Resources, National Academy of Sciences, National Research Council.

The Department of Clinical Investigation is especially grateful to BRIGADIER GENERAL Philip K. Russell, MC, Commanding General of Fitzsimons Army Medical Center, his professional and administrative staff, and to the Commanding Officers and staffs of other supporting activities for the cooperation and assistance provided this Department of Clinical Investigation in our efforts to accomplish our mission. Finally, I would like to recognize the outstanding work, dedication, and wholehearted corroboration of my entire staff. I would especially like to thank my Protocol/Editorial Assistant, Ms. Val McCrill and Mrs. Lilly C. Montoya, Secretary, without whose assistance and support this report would not have been possible.

DONALD G. CORBY, M.D.

Colonel, MC

Chief, Department of Clinical Investigation

TABLE OF CONTENTS

## TABLE OF CONTENTS

REPORT NO. 20

(CE)	10. 20	Page
Table of Unit Su Publica Present	d  f Contents	i ii xii 001 013
	DETAIL SUMMARY SHEETS	
MEDICIN	E	
74/110	Reactive Hypoglycemia: An Analysis of Glucose- Insulin-Glucagon Interrelationships and Counter Hormonal Regulatory Factors. (0)(P)(PR)	030
78/102	The Development of Specific and Cross Sensitivity in the Tracheal Tissue of Guinea Pigs Treated	-
78/114	with Isoproterenol and Aminophylline.(T)(P)(PR) In Vitro Effect of Minoxidil on Collagen Production by Normal and Scleroderma Fibroblasts.(O)	034
78/123	(PR)	036
78/124	Plethysmography. (O) (P) (PR)	037
79/105	Measurement.(O)(P)(PR)  Breathing Pattern Effects on Steady-State DLCO	039
79/109	Measurement.(O)(P)(PR) Control of Nausea and Vomiting with Delta-9-Te- trahydrocannabinol (THC) Combined with Standard	041
79/112	Antiemetics (A Phase II Study).(T)	043
80/104	Alternative. A Pilot Study.(0)	044
80/115	ment of Small Cell Lung Cancer.(T)	045
	Cardiac Arrhythmias.(0)	046
Ongoing	(O). Completed (C). Terminated (T). Published (P)	

		raye
80/117	Correlation of Clinical Signs and Symptoms with Assays of Circulating Immune Complexes.(0)(PR)	047
80/118	5-Azacytidine in the Treatment of Acute Non-	
	lymphocytic Leukemia.(0)	049
80/120	Evaluation of Carbohydrate Metabolism in Thyro- toxicosis: Investigations into the Frequency, Type and Mechanisms of Carbohydrate Tolerance.	
/	(0)	050
80/121	An Evaluation of Pituitary and Thyroid Hormonal Responses to a 4-Hour Continuous and a Bolus In- travenous Infusion of TRH as a Useful Test of	
01 /101	Thyroidal Functional Reserve.(O)(PR)(P)	051
81/101	Development and Evaluation of Rapid Immunologic Procedures for the Diagnosis of Giardiasis.	
	(O) (PR)	053
81/104	The Incidence of Host Defense Deficiency in	
	Patients Presenting with Frequent or Prolonged	
01 /206	Infections.(0)	055
81/106	Clinical Effectiveness and Development of Sub-	
	sensitivity with Chronic Administration of Atro- pine Methonitrate.(0)(PR)	056
81/109	Southwestern Oncology Group: Collaborative	056
01/103	Studies. (0)	057
81/111	Comparative Effect of Major Corticosteroids on	
,	Lymphocyte Blastogenesis and Assessment of the	
	Corticosteroid Sparing Effect of Troleandomycin	
	(T) (PR)	058
81/113	Aminocaproic Acid for the Control of Hemorrhage	
/	in Thrombocytopenic Patients.(T)	059
81/115	Comparison of Modalities for Treatment of SLE	000
01 /116	Nephritis.(0)	
81/116 81/117	Hypertransfusion in Acute Leukemia.(T)	
81/118	Hypothalamic Pituitary Gonadal Function in Hypo-	002
01/110	thyroidism. (0)	064
81/119	The Effect of Thyrotropin Releasing Hormone on	004
02, 22,	Gonadotropin Releasing Hormone Stimulated Gonado-	
	tropin Secretion.(C)	065
81/121	IgA Nephropathy: A Prospective Evaluation. (O) (PR, P	
81/122	Utility of Furosemide in Early Oliguric or Non-	
	Oliguric Renal Failure.(T)	068
81/123	Primary Renal Hematuria: A Prospective Evalua-	
	tion.(0)(P)(PR)	069

		tage
81/124	Intra-Coronary Streptokinase in Evolving Myocar-	
81/125	dial Infarction.(T)(PR)	071
	A Multi-Center Study.(0)	073
82/100	Combined Prednisone and Cyclophosphamide Therapy	
	Coupled with Basmapheresis in the Treatment of Anti-glomerular Basement Membrane (Anti-GBM)	
	Antibody Induced Disease (0)	075
82/101	Steroid and Immunosuppressive Drug Therapy in	0,5
·	Idiopathic Crescentic Glomerulonephritis.(0)	076
82/103	A Survey of Lymphocyte Subpopulations in Patients	
02/104	with Malignancies.(T)	077 078
82/104 82/106	Clinical Usage of High Frequency Jet Ventilation.	0/6
02/ 100	(0)	079
82/107	Interstitial Lang Disease Protocol.(T)	080
82/109	Correlation of Birth Weight with maternal Hemo-	001
82/110	globin S Concentration: A Retrospective Study.(0) An Investigation of Immunologic Reaction to Human	081
02/110	Serum Albumin. (C) (P, PR)	082
82/111	Investigation of the Efficacy and Side Effects of	
	Oral and Inhaled Beta Adrenergic Bronchodilators	
00 /310	in Patients on Optimal Theophylline Therapy.(O)(PR)	084
82/112	The Use of the Modified RAST in Determining Initial Immunotherapy Doses.(C)(PR)(P)	085
82/113	The Effect of Inhaled Corticosteroids on the	005
<b>52,</b> 5	Development of Beta Adrenergic Subsensitivity.(0).	087
82/114	Growth of Basal Cell Carcinoma Cells in Defined	
	Medium and Study of their Growth and Immunological	000
82/115	Characteristics.(0)(P)(PR)	088
02/113	tion of Acute Anterior Myocardial Infarctions for	
	Detection of Left Ventricular Thrombi.(0)	089
82/116	Assessment of Regional Wall Motion Abnormalities	
	by Radionuclide Angiography: Effect of Sublingual	090
83/100	Introglycerin.(0)	090
03/ 100	coli.(C)	91
83/101	Investigation into the Genetics of Exfoliatin B	
	Production From Clinical Isolates of Staphylococ-	
	cus aureus Which Produced Staphylococcal Scaled Skin Syndrome (0)	092
	SUBJECT SMILL SYLKELURE (U/	リフム

		rage
83/102	A Survey of Extrachromosomal Elements of <u>Legion-</u> <u>ella pneumophilia</u> Serotype 1, from Environ-	
	mental and Clinical Isolates.(0)	093
83/103	Role of Vitamin K in Bone Metabolism.(0)	094
83/106	Efficacy of Weekly Pulse Methotrexate in the Treatment of Rheumatoid Arthritis: A Double-blind	
	Crossover Study.(0)	095
83/107	Use of Isotretinoin in Prevention of Basal Cell Carcinoma.(0)	096
83/108	Multicenter, Double-blind, Randomized, Parallel	0,0
03, 100	Comparison of Two Different Dosage Regimens of	
	Naproxen Sodium in Patients with Bone Pain Due to	
	Metastatic Cancer.(T)	097
83/109	Early Regional Wall Motion Abnormalities in Non-	097
	Transmural Myocardial Infarction.(0)	098
83/112	Steroid Therapy in Chronic Obstructive Lung	
	Disease - Prediction of Response by Lung	
	Mechanics.(T)	099
83/113	Growth of Human Keratinocyte(0)	100
83/114	A Multi-centered, Double-blind, Randomized Study	
	of the Steroid Sparing Effect of Budesonide vs.	
	Placebo in Adult Patients with Chronic Asthma. (T).	101
83/115	The Effect of Oral Ketotifen on the Development of	
00, 0=0	Subsensitivity to Inhaled Beta Agonists	102
83/116	Intraarterial Cisplatin Therapy for Unresectable or	
•	Recurrent Adenocarcinoma of the Pancreas. A Phase I	I
	Study. (T)	103
83/117	The Role of Altered Arachidonic Acid Metabolism in	
•	the Atherogenesis and Bleeding Tendency of Hypo-	
	thyroidism, and the Response of this System to	
	Thyroid Hormone Replacement. (O) (PR)	105
83/119	Sardoidosis: Varying Lymphocyte Concentration in	
00,	Sequential Bronchoalveolar Lavage. (0) (PR)	107
83/120	Correlation of Renal Concentrating Ability with	_0.
03/ 120	Hemoglobin S Concentration in Healthy Military	
	Personnel with Sickle Cell Trait: A Clinical	
	Study. (0)	108
83/121	Expiratory Spirometry/Lung Compartment Ratios for	100
03/ 121	Assessment of Pulmonary Impairment.(0)	109
83/122	The Role of Food Allergy in the Pathogenesis of	107
UJ/ 144	Migraine Headaches.(0)	110
83/123	In Vitro Testing of Cryopreserved Parathyroid	
JJ, 16J	Tissue: Functional Viability and Replicative	
	Capacity after using a "Simplified" Freezing	
	Technique (0)	112

		Page
83/124	A Prospective Evaluation of Esophageal Changes in Patients Undergoing Esophageal Radiation.(0)	114
83/125	Carbon Dioxide Retention with PEEP during High	
(	Frequency Jet Ventilation.(0)(PR)	115
83/126	The Role of Altered Prostaglandin Synthesis in the Impaired Water Excretion and Abnormal Renin-	
	Aldosterone Axis of Hypothyroidism. (0)	116
83/127	Double-blind Controlled Trial of Individually	
	Polymerized Grass Pollens in the Treatment of	
84/100	Seasonal Allergic Rhinitis.(0)	118
04/ 100	Metabolism of Theophylline and Methylprednisolone.	
	(0)	
84/101	Antibiotic Therapy of Acute Exacerbations of Chronic	
84/102	Bronchitis: A Controlled Study using TMP/SMX.(0)  Development of Radioimmunoassay for Gastric	120
0., 202	Inhibitory Polypeptides (GIP).(0)	121
84/103	Gastric Inhibitory Polypeptide (GIP) in Various	100
84/106	Disorders of Carbohydrate Metabolism.(0)	122 123
84/107	Survey of Aspergillus Contamination of the Enviro-	14,5
·	nment During Hospital Renovation, and, the Efficacy	
	of Infection Control Measures in Preventing	104
84/108	Nosocomial Aspergillosis.(0)  The Effect of Ultraviolet Light (UVB) on the Pro-	124
0., 200	duction of Prostacyclin (PGI2) by Cultured Human	
(2.0.	Microvasculature EndothelialCells.(O)(P)(PR)	126
84/109	Two Dimensional Echocardiographic Evaluation of Exercise-Induced Wall Motion Abnormalities:	
	Detection of Coronary Artery Disease.(0)	127
84/110	Survey of the Extrachromosomal Elements of	
	Campylobacter Species Obtained from Environmental	100
84/111	and Clinical Isolates (0)	129
<b>4.</b> ,	Needle Aspiration and Fiberoptic Bronchoscopy. (0).	131
84/112	Proteinuria and Congestive Heart Failure.(0)	132
84/113	Functional Assay to Determine Shelflife of Metha- choline and Atropine Methylnitrate Solutions.(0)	134
84/114	The Relative Development of Subsensitivity to the	137
	Bronchodilator and Musculoskeletal Side Effects	
84/115	of Specific beta-2 Adrenergic Agonists.(0) Heterotransplantation of Basal Cell Carcinomas	135
04/113	to Nude Mice. (0) (P) (PR)	136
84/116	EU: Carnitine (T)	138

#### SURGERY

73/219	Treatment of Urinary Tract Trauma in the Laboratory Animal.(0)(P)(PR)	140
78/200	Anastomosis of the Dog Vas Deferens Using Micro-	
	surgical Technique.(O)(P)(PR)	142
78/201	Clinical Study for Intraocular Lenses.(0)(PR)	143
80/200	Hearing Loss in Hypothyroidism.(0)	145
80/201	Comparison of Cardiac Output and Left Ventricular	
	Stroke Work Before and After Standard Anesthesia	
	Induction of Patients Undergoing Surgical Correc-	
	tion of Combined Mitral Valve Disease and Coronary	
	Artery Disease.(T)	146
81/202	Treatment of Recurrent Otitis Media: Chemopro-	_
	phylaxis vs Tympanostomy Tubes.(C)	147
82/201	Prospective Double-blind Randomized Study of the	
	Effects of Supplemental Dietary Calcium and Vita-	
	min D on the Healing of Distal Radius Fractures in	
	Adults.(0)	148
82/202	Lateral Electrical Stimulation for the Treatment	
	of Scoliosis.(T)	149
82/203	Effectiveness of EMG Biofeedback in Maintaining	
	Fluency Obtained in an Intensive Stuttering Treat-	350
00 /00 4	ment Program. (0)	150
82/204	Evaluation of Treatment Methods for Extravasation of	
00/005	Chemotherapeutic Agents.(C)(PR)	TOT
82/205	The Effects of Immediate and Staged Repair of the Torn Anterior Cruciate (cranial cruciate) Liga-	
	ment in Dogs as Evaluated by Serial Arthroscopic Examinations.(C)(PR)	152
83/200	Evaluation of a Nonabsorbable Anterior Cruciate	172
03/ 200	Liagment Prosthesis. (0)	154
83/201	CT Diagnoses of Medial Meniscal Tears.(0)	155
83/202	Microbiology of Eyebank Eyes Taken From Septic	
03, 202	Donors.(0)	156
83/203	Laser Trabeculoplasty: Correlation of the Number	
33, 233	of Laser Applications to Short- and Long-term	
	Effects.(0)	157
83/204	The Role of Minimal Surgical Debridement in the	
·	Treatment of Vesicant Extravasations.(0)(PR)	159
84/200	Prevention of Macular Injury from High Illumination	
	Levels of the Operating Room Microscope by the Use	
	of a Corneal Light Blocking Device.(T)	
84/201	Q-Switched Nd: YAG Laser in Discission of Secondary	
	Membranes.(0)	162

#### CLINICAL INVESTIGATION

72/302	Comparison of Metabolic and Functional Changes in Defects of Platelet Function.(0)(P)(PR)	164
77/300	Immunologic Disorders in Children and Adults:  I. Correlation of Immune Functions in the Immuno-	
	deficiency State. II. Correlation of Immune Func-	
	tions of Leukemia and other Childhood Malignan-	
	cies.(0)(PR)	168
79/300	A Study of the Hormone-dependent Growth of Human	
	Mammary Tumors In Vitro.(T)(P)(PR)170	
79/301	Basic Studies to Hasten Recovery from or Help	
	Prevent Bone Injury.(C)(P)(PR)	171
80/302	Rapid Detection of Bacterial Antigens in Patient	
	Specimens Using Counterimmunoelectrophoresis	174
80/303	(CIE).(C)(P)Study of Sensitivity of Tumors to Chemotherapy.(O)	1/4
<b>60/303</b>	(P) (PR)	176
81/302	Induction of Cerebellar Hypoplasia in Pups by	
<b>,</b>	Intrauterine Inoculation of Canine Parvovirus. (C).	179
81/304	Electron Microscopic Observations of the In	
	Vitro Interactions Between Giardia lamblia	
	Trophozoites and Peripheral Blood Cells and	
	Peritoneal Cells of Small Laboratory Animals.(0)	
	(SP) (PR)	180
81/305	Development of a Standardized Method for Minimum	
	Inhibitory Concentration (MIC) Antibiotic Testing	
	of Alpha-hemolytic Streptococci.(T)	182
81/306	Histopathologic and Electron Microscopic Observa-	
	tions of the <u>In Vitro</u> Interactions Between	
	Giardia lamblia trophozoites and the Small	
	Intestinal Mucosa of a Variety of Small Labora-	
	tory Animals.(T)	183
82/300	Studies of Immunologically Mediated Thrombocyto-	
/	penia.(C)(P)	184
82/301	The Antigenic Evaluation of Axenically-Cultivated	
00/: 0	Giardia lamblia.(C)	185
82/3 2	The Evaluation of Recently Introduced, Commercial-	
	Available Clinical Microbiology Products for	
	ble Use in the FAMC Diagnostic Microbiology	100
00/202	Lau ory. (0)	186
82/303	A Study of Canine and Feline Mammary Tumors: Correlation of Steroid Hormone Receptors of Primary	
	Tumor Sites with those of the Metastases. (T)	107
83/300		187
03/300	Is Mg(OH) <sub>2</sub> (Milk of Magnesia) a Potentially Effective Antidote for Acute Iron Salt Overdose?	
	(C)(P)(PR)	188
83/301	Evaluation of Psyllium Mucilloid: A Potential	100
UJ/ JUL	Trapping Agent for Ingested Solvents.(0)(P)(PR)	190
84/300	Protein A as an Extracorporeal Immunotherapeutic	170
J-1/ J00	Treatment for Canine Mammary Adenocarcinoma. (0)	192

Georgitis, W.J., Treece, G.L. and Hofeldt, F.D.: Gonadotropin Releasing Hormone Provokes Prolactin Release in Postmenopausal Women: A Response Not Altered by Dexamethasone. Clin Endocrinol 19:319, 1983. (C).

Georgitis, W.J., Treece, G.L. and Hofeldt, F.D.: Resolution of Recurrent Thyroid Cysts with Tetracycline Instillation. (Abst.) Clinical Research 29:1, 27A, 1984.

Greathouse, D.T., McDermott, M.T., Kidd, G.S. and Hofeldt, F.D.: Pure Primary Hyperaldosteronism Due to an Adrenal Cortical Carcinoma. Am J Med 76:1132, 1984.

Hofeldt, F.D., Kidd, G.S., Bornemann, M. and McDermott, M.T., et al.: Practical Application of Fine Needle Thyroid Aspiration Biopsy in Clinical Medicine. Mil Med 149(9):522, 1984.

Kidd, G.S., Graff, G.E., Davies, B.F., McDermott, M.T., Aeling, J.I and Hofeldt, F.D.: Glucose Tolerance in Granuloma Annulare: Early Abnormalities Due to Insulin Resistance. (In Press, Diabetes Care, 1984)

Kidd, G.S., Smith, C.E. and Wray, H.L.: Effect of Thyroid Status on the Renal Responses to Vasopressin (Submitted for Publication, J Clin Endocrinol Metab, 1984)

McDermott, M., Kidd, G.S., Dodson, L.E. and Hofeldt, F.D.: Radioiodine Induced Thyroid Storm: Case Report and Literature Review. 1984 Year Book of Endocrinology 4-15, p. 104-105, eds. T.B. Schwartz and W.G. Ryan.

McDermott, M.T., Kidd, G.S., Dodson, Jr., L.E. and Hofeldt, F.D.: Radioiodine-Induced Thyroid Storm. Am J Med 75:353, 1983.

McDermott, M.T., Kidd, G.S. and Hofeldt, F.D.:
Radioiodine-Induced Thyroid Storm: A Point of Controversy. Am J
Med 76:A98, 1984.

McDermott, M.T. and Kidd, G.S.: Subacute Thyroiditis after Influenza Vaccination. Brit Med J 288:1880, 1984.

McDermott, M.T.: Health Care Among the Sinai Bedouin. Mil Med 149(8):142, 1984.

McDermott, M.T., Kidd, G.S., Dodson, L.E. and Hofeldt, F.D.: Hyperthyroidism Following Hypothyroidism: Report of Two Cases and Review of the Literature. (In Press, American Journal of Medical Science, 1984)

<sup>(</sup>C) Direct result of approved registered protocol.

West, S.G., McMahon, M.J. and Portanova, J.P.: Quinidine-Induced Lupus Erythematosus. Ann Int Med 100:6:840-842, 1984.

#### Dermatology Service

Bennion, S.D., Fitzpatrick, J.E., Harbell, J., Swanson, E. and O'Barr, T.: The Effect of UVB on 6-Keto-PGF production by Cultured Human Endothelial Cells. J Invest Dermatol 82:428a, 1984. (C)

Bennion, S.D. and Patterson, J.W.: Keratosis Punctata Palmaris et Plantaris and Adenocarcinoma of the Colon. Jou Amer Acad of Derm Vol 10:4:587-591, 1984.

Bennion, S.D.: The Occurrence of Malignant Melanoma in a Patient with Kaposi's Sarcoma and Acquired Immune Deficiency Syndrome. J of Oncol and Surg, Pending Publication.

Fitzpatrick, J.E., McDermott, M., May, D and Hofeldt, F.D.: Eruptive Neurofibromatosis Associated with Anorexa Nervosa. Arch Dermatol 119:1019-1021, 1983.

Grimwood, R.E., Huff, J.C., Harbell, J.W. and Clark, R.A.F.: Fibronectin in Basal Cell Epithelioma: Sources and Significance. J Invest Dermatol 82:145-149, 1984. (C)

Grimwood, R.E., Johnson, C.A., Ferris, C.F., Mercill, D.B., Mellette, J.R. and Huff, J.C.: Transplantation of Human Basal Cell Carcinomas in Athymic Mice. Accepted for publication in Cancer, 1984. (C)

Grimwood, R.E., Johnson, C.A., Ferris, C.F., Mercill, D.B., Mellette, J.R. and Huff, J.C.: The Scurce of Fibronectin in Basal Cell Epithelioma. (Abstract) Clin Res 31:569A, 1983.

#### Endocrinology Service

Bornemann, M. and Hofeldt, F.D.: Insulin Induced Hypoglycemia in Type I Diabetics. (In Press, Diabetes Educator, 1984).

Bornemann, M., Kidd, G.S. and Hofeldt, F.D.: Comparison of Thyrotropin Releasing Hormone Bolus and Infusion Testing in Patients with Suspected Subclinical Hypothyroidism. Clinical Research 32:No. 1:19A, 1984. (C)

Fitzpatrick, J., McDermott, M., May, D. and Hofeldt, F.D.: Eruptive Neurofibromatosis Associated with Anorexia Nervosa. Arch Dermatol 119:1019, 1983.

<sup>(</sup>C) Direct result of approved registered protocol.

Venter, J.C., Fraser, C.M., Nelson, H.S. and Middleton, E. Jr.: Adrenergic Agents. In: eds E Middleton Jr., CE Reed, EF Ellis. Allergy: Principles and Practice, vol 1, 2d, St. Louis, The C.V. Mosby Company, 1983, pages 511-527.

Weber, R.W. and Nelson, H.S.: Chenopod-amaranth Cross-allergenicity Evaluated by RAST Inhibition. Ann Allergy 52:226, 1984. (C)

Weber, R.W. and Nelson, H.S.: Pirbuterol Hydrochloride: Evaluation of beta adrenergic Agonist Activity in Reversible Obstructive Pulmonary Disease and Congestive Heart Failure. Pharmacotherapy 4:1-10, 1984. (C)

#### Cardiology Service:

Cohen, I.S., Raible, S.J. and Ansinelli, R.A.: Two-Dimensional Echocardiography in the Detection of Noneffusive Cardiac Involvement by Intrathoracic Neoplasms. Amer Heart J 107:3:532-536, 1984.

Newell, J.D., Thomas, H.M. and Maurer, J.W.: Computed Tomographic Demonstration of Displaced Right Upper Lobe Bronchus in an Adult Woman with Congenital Heart Disease. CT: The J of Computed Tomography 8:75-79, 1984.

Sung, R.J., Shen, E.N., Keung, E.C., Bhandari, A. and Svinarich, J.T.: Beta-Adrenergic Blockade and Chronic Ventricular Tachycardias Possibly Caused by Re-entry, Automaticity and Triggered Activity. Circ. Part II. 68:4:III-421, 1983.

Sung, R.J., Tai, D.Y., Keung, E.C. and Svinarich, J.T.: Clinical and Electrophysiologic Characteristics of Ventricular Tachycardia Suppressible with Verapamil: Re-entry Versus Triggered Activity. JACC 3:2:585, 1984.

Svinarich, J.T., Tai, D.Y. and Sung, R.J. Clinical Indications and Results of Electrophysiologic Studies in Patients with Supraventricular Tachycardias. Clin Prog in Pacing and Electrophysiol 2:2:95-111, 1984.

Svinarich, J.T., Tai, D.Y. and Sung, R.J.: Is Beta-Adrenergic Blockade Contraindicated in Wolff-Parkinson-White Patients Prone to Atrial Fibrillation? Circ (in press).

Svinarich, J.T., Keung, E.C. and Sung, R.J.: Electrophysiologic Demonstration of Concealed Conduction in Anomalous Atrioventricular Bypass Tracts. JACC 3:2:611, 1984.

<sup>(</sup>C) Direct result of approved registered protocol.

#### **PUBLICATIONS**

#### DEPARTMENT OF MEDICINE

#### Allergy Service

Brown, J.S., Ledoux, R., Tipton, W.R. and Nelson, H.S.: An Investigation of the Immunologic Reaction to Human Serum Albumin. Ann Allergy 52:221, 1984. (C)

Kray, K.T., Squire, E.N., Tipton, W.R., Selner, J.C., O'Day, J. and Nelson, H.S.: Cromolyn Sodium in Seasonal Allergic Conjunctivitis. Ann Allergy 52:223, 1984. (C)

Long, W.F., Taylor, R.J. and Nelson, H.S.: Histamine and Morphine or Antigen Skin Test on the Effect of Antihistamines. Ann Allergy 52:241, 1984. (C)

Mansfield, L.E., Nelson, H.S. and Schur, P.H.: IgG Subclasses in Asthmatic Patients. J. Asthma 20:189, 1983.

Moyer, D.B., Bowen, R.E. and Nelson, H.S.: The Use of the Modified RAST in Determining Initial Immunotherapy Doses. (Abst) Ann Allergy 52:220, 1984.

Nelson, H.S.: Combination of Oral Theophylline and Aerosolized Beta\_-agonists, in Jonkman, J.H.G, Jenne, J.W., Simons, F.E.R., eds: Sustained Release Theophylline in the Treatment of CRAO, International Workshop Mont Ste Marie, Canada, Exerpta Medica, 1984, p 181-7. (C)

Nelson, H.S.: Routine Sinus Roentgenograms and Chronic Urticaria. JAMA 251:1680-1, 1984.

Nelson, H.S.: What is Atopy? Sidestepping Semantics. Postgrad Med 76:118-129, 1984.

Nelson, H.S.: Gastroesophageal Reflux and Pulmonary Disease. J A'lergy Clin Immunol 73:547-556, 1984.

Taylor, R.J., Long, W.F. and Nelson, H.S.: Development of Subsensitivity to Antihistamines. Ann Allergy 52:240, 1984.

Tipton, W.R.: Evaluation of Skin Testing in the Diagnosis of IgE Mediated Disease. Symposium on Pediatric Allergy. Pediatric Clinics of North America. Vol. 30, no. 5, 785-793, 1983.

<sup>(</sup>C) Direct result of approved registered protocol.

**PUBLICATIONS** 

Other protocols yieldiing interesting results during FY 84 were those involving plasmids of <u>Legionella pneumophila</u> and <u>Campylobacter spp.</u>, and one testing a new method of rapidly demonstrating vaginal colonization by Group B streptococci in women experiencing premature labor.

LTC Engelkirk and Mr. Steven Koester (of the Immunology Service, DCI) have submitted, to the <u>Journal of Medical Technology</u>, a review article describing putative functions of eosinophils. The article features eight previously unpublished transmission electron micrographs.

#### Funding

The OMA costs have not been itemized by protocol number because it is not feasible or practical to do so.

MEDCASE item(s) puchased for protocols and general laboratory use are listed as follows:

<u>ITEM</u>	COST
Cryolathe for Ophthamology	\$66,500
Waters HPLC	\$63,000
J6M Beckman Centrifuge	\$17,500
J6M Beckman Centrifuge	\$18,000
Beckman Airfuge	\$9,995
Radiomatic Detector	\$21,000

Studies on the vitamin D-calcium metabolism interrelationship in the chick model has progressed to the studying of vitamin D metabolites and their effects on calcium transport and uptake by the intestinal epithelial cell membranes.

#### Cell Physiology Service

This newly established service was created to support research on normal and disease state human tissues using in vitro and heterotransplantation model systems. To these ends, a second laminar hood has been added to the tissue culture clean room. Two CO humidified incubators were also added to grow normal dermal cell types. A second sterile room was added to the athymic nude mouse breeding and holding facility to meet protocol support requirements. The electron microscopy capabilities have also been greatly increased by the installation of a Siemens TRM.

#### Immunology Service

A flow cytometer (cell sorter) has been procured and procedures for performing lymphocyte phenotyping have been implemented. Development of procedures for utilizing flow cytometry for detecting antiplatelet antibodies, quantitating immune complexes, and quantitating antitetanus antibodies are also being performed to determine the capability of flow cytometric procedures for measuring neutrophil function.

### Microbiology Service

The diagnostic mycobacteriology laboratory continued to achieve perfect scores on the quarterly CAP proficiency surveys during FY 84, bringing its record to ten consecutive perfect scores. During FY 84, a total of 2983 specimens were received for mycobacteriology processing (AV = 249/mo.).

Considerble progress was made on a research protocol designed to determine the in vitro effects of various humoral and cellular immune components of rats and humans on Giardia lamblia trophozoites. Two posters were presented during FY 84, an additional poster has been accepted for presentation in FY 85, an electron micrograph has been accepted for publication on the cover of ASM News (a monthly publication of the American Society for Microbiology, circulation 30,000), and three manuscripts are in preparation. A cytotoxicity assay was developed which utilizes the radionuclide, lll-Indium. It was also demonstrated that human peripheral blood eosinophils are capable of ingesting G. lamblia trophozoites, and that they deposit the nzyme, peroxidase, onto the surfaces of partially and fully ingested trophozoites.

steam sterilizer has been installed and has proven to be a valuable resource. Air locks have been installed on the cage washer to prevent the simultaneous opening of both doors thus preventing the contamination of the clean side storage area. The cage washer has been equipped with a constant voltage transformer to prevent voltage surges to the control panel which resulted in the burnout of several circuit boards. The service has requested the procurement of modular housing units for the purpose of housing domestic (farm) animals. The increased use of domestic animals will be brought about due to the decreased use of dogs and cats for teaching and training.

The Service also obtained a renovated blood gas analyzer from Respiratory Therapy and an ACA Automated Chemanalyzer from USAMEOS.

The Service was site visited by the American Association for the Accreditation of Laboratory Animal Care (AAALAC) and received provisional accreditation pending the correction of cited deficiencies. The Service has corrected the deficiencies, notified AAALAC of the corrections that have been made and expects to receive full accreditation within several months.

Five Animal Resources Service personnel are participating in American Association for Laboratory Animal Science Training which will lead to their certification as Laboratory Animal Technologists. Larry Jones, Animal Resource Facility manager received the Commander's Award for his excellent work in facility startup operations and his work in preparation for the AAALAC inspection.

#### Biochemistry Service

The implication of prostaglandins as mediators of the early stage of UVB-induced erythema has been examined. Specifically, the ability of cultured human microvasculature endothelial cells to produce prostacylin (PGI<sub>2</sub>) in response to UVB was studied. UVB irradiated cells were found to produce progressively greater amounts of PGI<sub>2</sub> as the intensity of radiation was increased.

The generation of thromboxane A<sub>2</sub> (TxA<sub>2</sub>) by platelets and PGI<sub>2</sub> by aorta rings from rats made hypothyroid with I was documented over a 16 week period. By comparison with euthyroid animals, the hypothyroid state resulted in a decrease in platelet TxA<sub>2</sub> and a concomitant increase in spontaneous PGI<sub>2</sub> formation by aorta rings. These prostaglandin alterations are in keeping with the platelet dysfunction seen in human hypothyroidism and may contribute to the acute protective effect of hypothyroidism on unstable angina.

Description	Grade MOS	Br Auth	Req Act	Name
Microbiologist	11 0403	GS 2	2 2	Lima Paine
Microbiologist	09 0403	GS 3	6 4	Koester Morse Nelson Wuerz
Med Technologist	11 0644	GS 0	1 1	Rush
Med Technician	07 0645	GS 2	2 2	Hakes Ramirez
Research Chem	09 1320	GS 3	4 4	Noble Swanson Waldrup Feuerstein
Bio Lab Tech (animal)	08 0404 09 0404	GS 1 GS 1	1 1 1 1	Jones Mercill
Ed Asst	06 0318	GS 1	1 1	McCrill
Animal Caretaker	05 7706	WG 1	3 2	Slatton Hitchcock
Clerk-Steno	05 0318	GS 1	1 1	Montoya
	FY 81	FY 82	F	Y 83 FY 84
Civilian Pay	474,832	526,991	565	,020 553,099
Travel	7,629	5,350	3	,901 6,292
Supplies	222,999	239,833	249	,086 210,167
Equipment	153,912	201,002	200	,395 148,571
Contracts	23,540	25,592	11	,392 18,864
Other(Military)	417,320	470,174	439	,878 405,432

## Animal Resources Service

The management and staff of the Animal Resources Service continue to make improvements in the operating efficiency of the new 7,000 square foot animal housing facility. A new

Use of Investigational Drugs in Humans; AR 70-25, Use of Volunteers as Subjects in Research; AR 70-18, Laboratory Animals, Procurement, Transportation, Use, Care, and Public Affairs; HSC Reg 40-23, Management of Clinical Investigation Protocols and Reports, as amended; FAMC Reg 15-2, Institutional Review Committee. This Department provides guidance, assistance, and coordinates the FAMC program with higher headquarters and other facilities.

<u>Manpower:</u> Current authorized strength is outlined.

Authorized

<u>Description</u> Chief	Grade	MOS	Br	Aut	h Re	q Act	Name	Rank
Dept Clin Inv	06	60P9B	MC	1	1	1	Corby	COL
C, Micro Svc	04	68A00	MSC	1	1	1	Engelkir	k LTC
Lab Res Mgr	03	68F00	MSC	0	1	1	Quigg I	MAJ(P)
C, Biochem Svc	03	68C00	MSC	1	1	0		
C, Immunol Svc	03	68E00	MSC	1	1	1	Rickman	CPT
C, Cell Phys. Svc.	03	<b>68J00</b>	MSC	1	1	1	Ferris	CPT
C, Animal Res Svc	04	68F00	VC	1	1	1 N	k:Cullen (	CPT(P)
NCOIC-Med Lab	E7	92B4R		1	1	1	Engle	SFC
Sr Med Lab SP	E6	92B3R		1	1	1	Fernande:	z SGT
Operating Rm Sp	<b>E</b> 5	91D2R		1	1	1	Dugan	SP5
Bio Sci Asst	E5	01H2R		1	1	1	Kramer	SP5
Bio Sci Asst	E5	01H3R		1	1	1	Chadwick	SP6
Bio Sci Asst	<b>E</b> 5	01H2R		1	1	1	Jones	SP5
Bio Sci Asst	E4	01H3R		1	1	1	Sanders	SP4
Vet Sp	<b>E</b> 5	91T2R		1	2	1	Barrett	SP5
Vet Sp	<b>E</b> 3	91 <b>T</b> 1R		0	0	1	Lamb	PEC
Vet Sp	<b>E</b> 3	91T2R		0	0	1	Phillips	PFC
Supv Res Chem	13	1320		1	1	1	O'Barr	

#### UNIT SUMMARY

#### Clinical Investigation Program, FAMC

Clinical Investsigation efforts by FAMC personnel in FY 84 culminated in the publication of 121 articles and 124 presentations and lectures at national, international, and regional scientific meetings. As of 30 September 1984, there were 128 research protocols on the DCI register. Of these, 88 projects were ongoing and 40 were new registrations.

#### Objectives:

To encourage the performance of clinically-oriented investigation by personnel assigned to the Fitzsimons Army Medical Center (FAMC). To aid in the planning, development, support, and execution of experimental clinical studies, both in patients and by directly related laboratory work, into the clinical problems of significant concern in the health care of members of the military community. To provide physician experience in research and investigative procedures by furnishing a highly educated and trained staff of specialists, laboratory facilities, administrative services and funding for: supplies, equipment, consultants, publications and reprints. To achieve continuous improvement in the quality of patient care by providing an atmosphere of inquiry, maintaining high professional standing and accreditation of advanced health programs.

The Clinical Investigation Program differs from Medical Research and Development in that the emphasis is on the health care problems existing in our patient populations, i.e.; active duty, retired, and dependents and not solely on medical problems affecting combat readiness and the fighting strength. It is, by its nature, an integral part of the triad of patient care and medicine. It promotes and supports the finest ideals and traditions of Military Medicine and enhances the vitality of the teaching programs which in turn elevates the standard of medical care. The research program operates on the premise that all approved protocols will be supported to the fullest extent allowed by current funding. This concept allows for a larger number of physicians and ancillary personnel to participate in research rather than as in the grant system used elsewhere. This means that virtually every investigator is given a chance to pursue his research without having to compete for funds with "established" names in the field.

#### Technical Approach:

This support, direction and management is carried out under the aegis of AR 40-38, Clinical Investigation Program; AR 40-7,

UNIT SUMMARY

PRIMARY	CARE and COMMUNITY MEDICINE	
74/651	Establishment of and Training in Methods for Special Studies of Abnormal Hemoglobins.(0)	226
78/650	Evaluation of Thalassemia as Cause of Hypochromic Microcytic Anemia and In Interaction with Hemo-	
80/650	globin Variants.(O)(P)	227
	Opossum (Didelphis Virginia).(O)(P)(SP)	229
NURSING		
83/700	A Comparison of Fluid Assessment Methods Utilizing Central Venous Pressure Versus Serum Osmolarity in Conjunction with Conventional Methods in Adults Undergoing Abdominal Surgery. (0)	233
FAMC TEX	NANT	
02 /000		
83/800	The Health Evaluation Project (of the OCHAMPUS Employee Health Promotion Program).(0)	235
MEDDAC		
83/902	Training Study: Emergency Medical Procedures.(0).	239
83/903	Stabilization of Hemoglobins and Hematocrits in Females Traveling from Lower to Higher Elevations.	
83/904	(C) (P) (PR)	240
03/ 704	ment of Neonatal Jaundice.(0)	242
83/905	Coronary Artery Disease. (T)	243
84/900	Clinical Evaluation of AME Physio-Stim Therapy System. (T)	244
CIVILIA	N HOSPITALS	
82/950	Case-Control Study of Invasive Cervical Cancer.(C)	246
Investi	gators Index	247
Key Word	l Index	253
Distrib	ition	260

		PAG
OB-GYN		
80/350 83/351	GOG Protocols	194
84/350	A Prospective Study of the Effects of CO2 Laser Vaporization of the Cervix for Cervical Intra- epithelial Neoplasia on Cervical Factors and Subsequent Fertility (0)	197 199
PEDIATR		199
81/402	Diagnosis of Respiratory Syncytial Virus (RSV) Infection in Infants by Enzyme-Linked Immunosorbent Assay (ELISA).(T)	201
82/400	The Effect of Glycerin Suppository Administration on Bilirubin Levels in Infants Receiving Photo-	
82/401 82/403 83/400	therapy.(0)	202 203 204
	Different Sites in Very Low Birth Weight Infants.	209
83/401	Prevalence of Endometriosis Externa in Adolescent Women Complaining of Severe Dysmenorrhea.(0)	210
83/402 83/403	B2-Microglobulin as a Measure of Renal Tubular Function in the Neonate (O)(P)(PR) Myelography in Medulloblastoma (T)	212 215
84/401	Neonatal Xanthine and Aminoglycoside Kinetics (O) (PR)	216
84/402 84/403		
04/ 103	Hematuria (0)	218
RADIOLO	GY	
80/602	I.V. Administration of 131-I-6-B Iodomethylnor- cholesterol (NP-59) for Adrenal Evaluation and	
82/601	Imaging (0) Effects on the Human Auditory Mechanism Following	220
82/602	in Utero Exposure to Diagnostic Ultrasound.(C) Gallium Index: Qualitative vs. Quantitative	221
83/601	Analysis.(0)	222
84/600	Blood Components.(0)	223
	Ultrasound on the Human Auditory Mechanism Following in Utero Exposure.(0)	

Sjoberg, R.J., McMillan, V.M., Bartram, L.S. and Copley, J.B.: Renal Failure with Minimal Change Nephrotic Syndrome: Reversal with Hemodialysis. Clin Nephrology 20(2):98:100, 1983.

Sjoberg, R.J., Kidd, G.S. and Hofeldt, F.D.: Granuloma Annulare and Carbohydrate Tolerance. (Abst) Diabetes 33(Suppl 1):106A, 1984.

Treece, G.L., Georgitis, W.J. and Hofeldt, F.D.: Resolution of Recurrent Thyroid Cysts with Tetracycline Instillation. Arch of Int Med 143:2285, 1983.

#### Gastroenterology Service

Brewer, T.G., Berry, W.R., Harmon, J.W., Walker, S.H. and Dunn, M.A.: Urea Synthesis After Protein Feeding Reflexts Hepatic Mass in Rats. Hepatology (in press--5(4), 1984. (C)

Dunn, M.A. and Brewer, T.G.: Non-viral Liver Infections. The Liver Annual (4/1084). (IM Arias, M. Frenkel and JMP Wilson, Editors) Elsevier-North Holland, New York, 1984.

Moses, F.M., Wong, R.K.H. and Peura, D.A.: Squamous Cell Carcinoma of the Esophagus Associated with Peptic Duodenal Ulcer. Amer J Gastro 78:712-4, 1983.

Moses, F.M., Peura, D.A. and Johnson, L.F.. Triple Lumen Pylorus, A Complication of Peptic Ulcer Disease: Case Report. Gastrointestinal Endoscopy (in press).

Mases, F.M., Peura, D.A., Wong, R.K.H. and Johnson, L.F.: Palliative Dilation of Esophageal Carcinoma. Gastrointestinal Endoscopy (in press).

McNally, P.R., Herrera, J.L., Engelkirk, P.G., Visvesvara, G.S. and Brewer, T.G.: Prospective Evaluation of Immunofluorescent Antibody (IFA) Testing in the Diagnosis of Giardiasis.

Manuscript submitted for publication. (C)

Shaw, C.T.: Marked Elevation of Serum Transaminases Associated with Extrahepatic Biliary Tract Disease. Manuscript submitted for publications.

#### Nephrology Service

Copley, J.B. and Hasbargen, J.A.: "Primary" Hematuria: A Prospective Evaluation (Abstract) Kidney International (In Press)

#### Neurology Service

Hurst, D.L.: Metatarsus Adductus in Two Brothers with Aarskog Syndrome. J Med Genetics 20:477, 1983.

(C) Direct result of approved registered protocol.

Hurst, D.L.: Valproic Acid Embryopathy. (Abstract)

Hurst, D.L.: Intraventyricular Rupture of a Middle Cerebral Artery Aneurysm. (Abstract)

Hurst, D.L.: Distal Fibroma - Facial Focal Atrophy Syndrome - A New Neurocutaneous Disorder. (Abstract)

Hurst, D.L. and Hurst, M.J.G.: Bromide Poisoning in the Ordeal of Gilbert Pinfold. (Abstract)

Hurst, D.L.: The Use of Imipramine as an Anticonvulsant for Minor Motor Seizures. (Abstract)

Murphy, M.G., Hurst, D.L., Merenstein, G.B. and Pierce, J.R.: Mortality and Morbidity in Surviving Twin after Single Intrauterine Fatal Demise. (Abstract).

Wolf, B., Grier, R.E., Allern, R.J., Goodman, S.I., Kien, C.L., Parker, W.D., Howell, D.M. and Hurst, D.L.: Phenotypic Variation in Biotinidase Deficiency. J Pediatr 103:233-237, 1983.

#### Pulmonary Disease

Perry, M.E., Blue, P.W. and Kindig, N.B.: Pressure Waveform Correlation with Xenon Washout in a Physical Model of High Frequency Oscillation. Syllabus of the Postgraduate Course on High Frequency Ventilatin. P 127-128, 1983, Memorial Sloan Kettering Cancer Center. (C).

Perry, M.E., Blue, P.W., Kindig, N.B. and Ghaed, N.: Gas Washout Pressure Waveform Characteristics of High Frequency Oscillation. Crit Care Med 12: Sept 1984. (C).

Schlachter, M.D.: Plethysmographic Determination of Lung Mechanics During Frequency Jet Ventilation with CPAP. (Abst) Syllabus of the Postgraduate Course on High Frequency Ventilation. p 81-82 1983, Memorial Sloan Kettering Cancer Conter. (C).

Schlachter, M.D. and Perry, M.E.: Effect of Continuous Positive Airway Pressure on Lung Mechanics during High Frequency Jet Ventilation. Crit Care Med 12: Sept 1984. (C).

#### Rheumatology

Andersen, P., West, S., Claypool, R., O'Dell, J., Kotzin, B. and Via, C.: Pulse Methotrexate Therapy for Rheumatoid Arthritis: A Double-blind Crossover Study. (Abst) Arth Rheum 27:S25, 1984. (C).

<sup>(</sup>C) Direct result of approved registered protocol.

O'Dell, J., Andersen, P., Hollister, R. and West, S.: Anterior Tibial Mass: An Unusual Complication of Popliteal Cysts. Arth Rheum 27:113-115, 1984.

West, S., McMahon, M. and Portanova, J.: Quinidine-induced Lupus Erythematosus. Ann Int Med 100:840-842, 1984.

West, S. and Andersen, P.: Urefulness of Immunologic Tests of the CSF in the Diagnosis of CNS Lupus. (Abst) Arth Rheum 27:540, 1984. (C).

#### DEPARTMENT OF CLINICAL INVESTIGATION

Brady, W.K., Paine, D.D., Frye, L.P., Sarno, A.P., Borchardt, K.A. and Engelkirk, P.G.: Evaluation of New Plastic Envelope M'crobiology (PEM) Methods as Adjuncts in the Diagnosis of Candida albicans and Trichomonas vaginalis Vaginitis.

Obstet. Gynecol. (submitted). (C).

Corby, D.G., Chadwick, E., McCullen, A. and Decker, W.: Effect of Oral Magnesium Hydroxide in Experimental Iron Intoxication. (Abstsract) (C).

Engelkirk, P.G. and Williams, J.F.: <u>Taenia taeniaeformis</u> (Cestoda) in the Rat: Ultrastructure of the Host-Parasite Interface on Days 8 to 22 Postinfection. J Parasitol 69:828-837, 1983. (C).

Koester, S.K. and Engelkirk, P.G.: A Glass Cover Slip Technique for Studying in Vitro Interactions Between Giardia Trophozoites and Host Leukocytes by TEM, SEM, and Light Microscopy. J Parasitol 70: (in press) (C).

Koester, S.K., Engelkirk, P.G., Paine, D.D., Wuerz, D.J., Rothlauf, M.V. and Erlandsen, S.L.: Immunological and Ultrastructural Aspects of Short Term in Vitro Interactions Between Giardia lamblia Trophozoites and Rat Peritoneal Leukocytes. J Parasitol (submitted) (C).

Morse, P.L. and Opal, S.M.: (Letter) Adsorption of Clostridium difficile Antiserum for Rapid Detection of Toxin. Diag Microbiol Infect Dis 2:169, 1984, (C).

Purdon, A., Hanna, J.H., Morse, P.L., Paine, D.D. and Engelkirk, P.G.: An Evaluation of Single-Dose Metronidazole Treatment for Gardnerella vaginalis Vaginitis. Obstet Gynecol 64:271-274, 1984 (C).

<sup>(</sup>C) Direct result of approved registered protocol.

Renaud, M.T.: Effects of Discontinuing Cover Gowns on a Postpartal Ward upon Cord Colonization of the Newborn. JOGN Nursing 399-401, 1983.

#### DEPARTMENT OF PATHOLOGY

Stoker, J.T. and Ishak, K.G.: Mesenchymal Hamartoma of the Liver: Report of 30 Cases and Review of Literature. Ped Pathol 1:245-267, 1983.

Stoker, J.T.: Pediatric Lung Disease, Editorial Enterprises Corporation, Gainesville, Florida, 40 page syllabus, 200 color slides, 1983.

Stoker, J.T.: Pathology of Long Standing "Heated" Bronchopulmonary Dysplasia: An Autopsy Study of 26 Cases in Children 3 to 40 Months of Age. Abstract, Laboratory Investigation, 50:138, 1984.

#### DEPARTMENT OF PEDIATRICS

Arthur, J.D. and Pierce, J.R.: Citrobacter Diversus Meningitis and Brain Abscess in a Neonate Associated with Bacteroides Melaninogenicus. Ped Inf Dis (in press).

Cole, J.W., Portman, R.J., Lim, Y., Perlman, J.M. and Robson, A.M.: Urinary Beta-2-Microglobulin in Full Term Newborns: Evidence for Proximal Tubular Dysfunction in Infants with Meconium Stained Amniotic Fluid. (Submitted for Publication to Pediatrics).

Kilbride, H.W. and Merenstein, G.B.: Continuous Transcutaneous Oxygen Monitoring in Acutely Ill Preterm Infants. Crit Care Med 12:121, 1984.

Pierce, J.R., Blake, W.W. and Kilbride, H.W.: Developmental F-llow-Up of Military Dependents Requiring Neonatal Intensive Care. Mil Med 149, 339, 1984.

Pierce, J.R. and Merenstein, G.B.: Intravenous Immunoglobulin in Neonatal Group B Streptococcal Disease. Am J Med 76:117, 1984.

Pierce, J.R., Merenstein, G.B. and Stoker, J.T.: Immediate Post-Mortem Cultures in an Intensive Care Nursery. Ped Inf Dis (in press).

Portman, R.J., Cole, J.W., Perlman, J.M., Yin, L. and Robson, A.M.: Tubular Dysfunction in Infants with Meconium Stained Amniotic Fluid-Diagnosis Using B2-Microglobulin, Ped Res 18:341A, 1984. (C).

<sup>(</sup>C) Direct result of approved registered protocol.

Sanders, J.M.: Prevention and/or Delay of Subsequent Pregnancy. The Adolescent Family, Report of the Fifteenth Ross Roundtable on Critical Approaches to Common Pediatric Problems, June 1984.

Todd, W.A. JR., Todd, J.K., Todd, N. and Damato, J.:
Bacteriology and Treatment of Purulent Nasopharyngitis: A Double
Blind, Placebo Controlled E-aluation. Ped Infect Dis 3(3):
227-231, 1984. (C).

Weisman, LE., Merernstein, G.B. and Steenbarger, J.R.: Oxygen Tension Changes During Lumbar Puncture of the Neonate. Am J Dis Child:137, 1077, 1983. (C).

Weisman, L.E., Merenstein, G.B. and Steenbarger, J.R.: Oxygen Tension Changes During Lumbar Puncture on the Neonate and Mechanisms of Action in Continuous Transcutaneous Blood Gas Monitoring, Edited by Huch, R. and Huch, A. New York, Marcel Dekker, Inc., 1983. (C).

#### DEPARTMENT OF PRIMARY CARE AND COMMUNITY MEDICINE

Bethlenfalvay, N.D., Lima, J.E. and Waldrup, T.: Studies on the Energy Metabolism on Opposum (Didelphis Virginiana) Erythrocytes. I. Utilization of Carbohydrates and Purine Nucleosides. J Cell Physiol 120:69-74, 1984. (C).

#### DEPARTMENT OF RADIOLOGY

Blue, P.W.: Regional Ventilation Analysis Using 133-Xenon. Medical B lletin of the U.S. Army, Europe 41, 2:15, 1984.

Hopper, K.D., Komppa, G.H., Bice, P., Williams, M.D., Cotterill, R.W. and Ghaed, N.: A Reevaluation of Placental Gradingand Its Clinical Significance. Journal of Ultrasound in Medicine 3:287, 1984.

#### DEPARTMENT OF SURGERY

#### Orthopedic Service

Loth, T.S.: Familial Multiple Myeloma. Blood 62(5) Suppl p 193a, November, 1983. Clin Ortho and Related Res, No.

Loth, T.S. and Eversmann, W.W. Jr.: Treatment of Chemotherapeutic Agent Extravasations: A Comparative Study. Orthopedic Transactions, Vol 8(1), p 178, 1984. (C).

<sup>(</sup>C) Direct result of approved registered protocol.

#### Otolaryngology Service

Blakeslee, D.B., Vaughn, C.W., Simpson, G.T., Shapshay, S.M. and Strong, M.S.: Excisional Biopsy in the Selective Management of Tl Glottic Cancer: Laryngoscope 94:488-494, April, 1984.

Hasbrouck, J.M.: An Intensive Stuttering Treatment Program. Communication Disorders: A Journal for Continuing Education 8:153-167, 1983. (C).

#### Urology Service

Chilton, C.P., Vordermark, J.S. and Ransley, P.G.: Transurecteroureterostomy: A Review of its Use in Modern Pediatric Urology. (In Press).

Fauver, H.E., et al: State D Adenocarcinoma of Prostate. Urology, Vol XXIII, #2, p 118-121, 1984.

Fauver, H.E., et al: Acid Phosphatase: It's Influence on Pelvic Lymph Node Dissection. JU, Vol 131, 1984.

Fauver, H.E., et al: Adverse Drug Reactions and the Urologist. A.U.A. Update Series, Vol II, June 1984.

Man, D.W.K., Vordermark, J.S. and Duckett, J.W.: A Technique for Open Renal Biopsy in Children. Brit J Urol 56:443-444, 1984.

Man, D.W.K., Vordermark, J.S. and Ransley, P.G.: Hypospadias: A Review of a One Year Experience. (In Preparation).

Thomas, D.W., Turner-Warwick, R.T., Vordermark, J.S., et al: Pelvic Fracture Strictures: A Review of 100 Consecutive Cases.

Turner-Warwick, R.T. and Vordermark, J.S.: Complex Hypospadias-An Approach to Management (In Press).

Vordermark, J.S. and Ransley, P.G.: Fowler-Stephens Orchidopexy (In Preparation).

Vordermark, J.S., Mazoni, A., Man, D.W.K. and Ransley, P.G.: Mid-Ureteric Stenosis (In Preparation).

Vordermark, J.S. and Pfister, R.T.: The Acute Scrotum in Childhood: A Review. (In Press).

Vordermark, J.S. and Hudson, L.D.: Behcet's Disease: Report of a Case with Genito-Urinary Manifestations. Urology 24:41-42, 1984.

<sup>(</sup>C) Direct result of approved registered protocol.

Vordermark, J.S.: The Persisting Mesonephric Duct Syndrome: The Description of a New Syndrome. J Urol 130:958-961, 1983.

Vordermark, J.S.: Testicular Torsion: Management with the Ultrasonic Doppler Flow Detector. (In Press).

Vordermark, J.S.: The Acute Scrotum: Adjunctive Diagnostic Techniques. Emergency Medicine Annual, 1984, Wolcott and Rund, Ed.

Vordermark, J.S.: Approaches to Block Dissection of the Inguinal L mph Nodes. (In Press).

Vordermark, J.S.: The Acute Scrotum: Management with the Use of Ancillary Diagnostic Techniques. A.U.A. Update Series, Vol III, 1984.

Vordermark, J.S.: Acute Epididymitis: Experience with 123 Cases. (In Press).

#### General Surgery Service

Clark, J.R.: The Pancreas (Chapter in Book) Liechty, R.D., Soper: Synopses of Surgery, Lipencot Publishers; submitted for publication Spring 1984.

# DEPARTMENT OF PRIMARY CARE AND COMMUNITY MEDICINE

Bethlenfalvay, N.C., Lima, J.E. and Waldrup, T.: Studies on the energy Metabolism of Opossum (Didelphis Virginiana) Erythrocytes. I. Utilization of Carbohydrates and Purine Nucleosides. J Cellular Physiology 120:69-74, 1984. (C).

#### MEDDAC

Wallace, L.S.: Stabilization of Hemoglobins and Hematocrits in Females Travelling from a Lower to Higher Altitude. Submitted for Publication. (C).

<sup>(</sup>C) Direct result of approved registered protocol.

PRESENTATIONS

#### **PRESENTATIONS**

#### DEPARTMENT OF MEDICINE

# Allergy Service

Bowen, R.E.: Double-blind, Crossover Study of Long-term Inhaled Atropine Methonitrate. Presented: 2nd Annual Aspen Allergy Conference, Aspen, CO, 26-29 July 1984. (C).

Brown, J.S.: Evaluation of Possible Immunologic Response to Human Serum Albumin in Allergy Extracts. Presented: Carl W. Tempel Symposium on Pulmonary Disease and Allergy-Immunology, FAMC, 23-27 January 1984. (C).

Brown, J.S.: An Investigation of the Immunologic Reaction to Human Serum Albumin. Presented: 40th Annual Congress of the American College of A'lergists, San Francisco, CA, 7-11 April 1984. (C).

Brown, J.S.: An Investigation of the Immunologic Reaction to Human Serum Albumin. Presented: 2nd Annual Aspen Allergy Conference, Aspen, CO, 26-29 July 1984. (C).

Iyengar, V.: Correlation of Clinical Signs and Symptoms with Assay of Circulating Immune Complexes. Presented: H-matology-Oncology Meeting, San Francisco, September 1984.

Kray, K.T.: Cromolyn Sodium in Seasonal Allergic Conjunctivitis. Presented: 40th Annual Congress of the American College of Allergists, San Francisco, CA, 7-11 April 1984. (C).

Kray, K.T.: Double-blind Study of Long-term Oral Terbutaline: Efficacy and Side Effects. Presented: 2nd Annual Aspen Allergy Conference, Aspen, CO, 26-29 July 1984. (C).

Long, W.: Studies on Antihistamine Tolerance and the Use of Histamine as a Control Skin Test. Presented: Carl W. Tempel Symposium on Pulmonary Disease and Allergy-Immunology, FAMC, 23-27 January 1984. (C).

Long, W.F.: Histamine and Morphine on Antigen Skin Tests and the Effect of Antihistamines. Presented: 40th Annual Congress of the American College of Allergists, San Francisco, CA, 7-11 April 1984. (C).

<sup>(</sup>C) Direct result of approved registered protocol.

- Moyer, D.: Prediction of Allergy Immunotherapy Starting Dose---Use of the Modified RAST. Presented: Carl W. Tempel Symposium on Pulmonary Disease and Allergy-Immunology, FAMC, 23-27 January 1984. (C).
- Moyer, D.: The Use of the Modified RAST in Determining Initial Immunotherapy Doses. Presented: 40th Annual Congress, American College of Allergists, San Francisco, CA, 7-11 April 1984. (C).
- Moyer, D.B.: The Use of the Modified RAST in Determining Initial I-munotherapy Doses. Presented: 2nd Annual Aspen Allergy Conference, Aspen, CO, 26-29 July 1984. (C).
- Nelson, H.S.: Immunotherapy of Rhinitis/Asthma: Old and New Preparations. Presented: Keystone Summit, 1984, on Allergy, Immunology Pulmonary and ENT, Keystone, CO, 1 February 1984.
- Nelson, H.S.: The Effect of Long-term Administration of beta Adrenergic Stimulants on the Clinical Efficacy of These Drugs. Presented: Corsendonct, Turnhout, Belgium, 23 March 1984. (C).
- Nelson, H.S.: Bronchial Asthma, Pathogenesis and Management. Presented: First Annual Clinical Immunology and Pulmonary Disease Up-Date, Aspen, CO, 27 March 1984.
- Nelson, H.S.: Stepwise Therapy of Bronchial Asthma: beta Agonists. Presented: Annual Meeting, American College of Allergists, San Francisco, CA, 9 April 1984.
- Nelson, H.S.: Readministration of Local Anesthetics to Patients with a History of a Previous Reaction. Presented: Annual Meeting of the American College of Allergists, San Francisco, CA, 11 April 1984.
- Nelson, H.S.: Histamine, Morphine or Antigen Skin Tests and the Effect of Antihistamines. Presented: 2nd Annual Aspen Allergy Conference, Aspen, CO, 26-29 July 1984.
- Squire, E.N.: The Effect of Corticosteroids on Theophylline Metabolism. Presented: 2nd Annual Aspen Allergy Conference, Aspen, CO, 26-29 July 1984. (C).
- Taylor, R.J.: The Development of Subsensitivity to Antihistamines. Presented: 40th Annual Congress of the American College of Allergists, San Francisco, CA, 7-11 April 1984.
- Taylor, R.J.: The Development of Subsensitivity to Antihistamines. Presented: 2nd Annual Aspen Allergy Conference, Aspen, CO, 26-29 July 1984.

(C) Direct result of approved registered protocol.

Weber, R.W.: Chenopod-Amaranth Cross Allergenicity: Evaluation by RAST Inhibition. Presented: 40th Annual Congress of the American College of Allergists, San Francisco, CA, 7-11 April 1984.

### Cardiology Service

Davis, R.C. Jr.: The Intra-Aortic Balloon Pump: Clinical Efficacy. Presented: Course for Intensive Care Nurses, Denver, CO, September 1984.

Florek, R.C.: Potassium Loading to Unmask Wolff-Parkinson-White Syndrome. Presented: Army Cardiology Meeting, Walter Reed Army Medical Center, Washington, D.C., May 1984.

Jordan, L.W. and Wortham, D.C.: Thallium Exercise Scintigraphy in the Evaluation of Army Active Duty Personnel Over the Age of Forty. Presented: Annual Meeting of the Association of Military Cardiologists, Washington, D.C., 1984.

Piegari, G.N. and Thomas, H.M.: Atrial Septal Defect. Presented: Army Cardiology Meeting, Walter Reed Army Medical Center, Washington, D.C., May 1984.

Raible, S.J., Schaaf, M., Oetgen, W.J. and Smallridge, R.C.: Acromegaly and the Heart: Evaluation of Cardiac Function by Radionuclide Angiocardiography. Presented: Army Cardiology Meeting, Walter Reed Army Medical Center, Washington, D.C., May 1984.

Svinarich, J.T.: Exercise Training. Current Concepts in Internal Medicine. Presented: San Francisco, CA, October 1983.

Svinarich, J.T.: Electrophysiologic Demonstration of Concealed Conduction in Anomalous Atrioventricular Bypass Tracts. American College of Cardiology Scientific Sessions, Dallas, TX, March 1984.

Svinarich, J.T., White, C.J. and Watson, T.D.: Coronary Artery Aneurysm as a Complication of Balloon Angioplasty: Report of Four Cases., Army Cardiology Meeting, Walter Reed Army Medical Center, Washington, D.C., May 1984.

Svinarich, J.T.: Electrophysiologic Demonstration of Concealed Conduction in Anomalous Atrioventricular Bypass Tracts. Army Cardiology Meeting, Washington, D.C., May 1984.

<sup>(</sup>C) Direct result of approved registered protocol.

Svinarich, J.T.: Is Beta Adrenergic Blockade Contraindicated in Wolff-Parkinson-White Patients Prone to Atrial Fibrillation? American Heart Association Scientific Session, Miami, FL, November 1984.

# Dermatology Service

Bennion, S.D., Fitzpatrick, J.E., Harbell, J., Swanson, E. and O'Barr, T.: The Effect of UFB on 6-keto-PGF<sub>1</sub> Production by Cultured Human Endothelial Cells. Presented: SID Meeting, Washington, D.C., May 1984. (C).

Fitzpatrick, J.E.: Current Management of Sexually Transmitted Disease. Presented: 31st Annual Family Pract Seminar, Estes Park, CO, 15 June 1984.

Fitzpatrick, J.E.: Fungal Infections - Update 1984. Presented: Aspen Skin Seminar, Aspen, CO, July 1984.

Fitzpatrick, J.E.: Superficial Cutaneous Fungal Infections. Presented: 31st Annual Family Practice Seminar, Estes Park, CO, 15 June 1984.

Fitzpatrick, J.E.: Toilet Seats and Spirochetes. Presented: Aspen Skin Seminar, Aspen, CO, July 1984.

Grimwood, R.E., Johnson, C.A., Kramer, L.C., Mercill, D.B. and Huff, J.C.: Heterotransplantation of Human Basal Cell Epitheliomas in Nude Mice. Presented: SID Meeting, Washington, D.C., May 1984. (C).

Melette, J.R.: Practical Office Surgery I. Presented: Aspen Winter Skin Seminar, Aspen, CO, February 1984.

Melette, J.R.: Practical Office Surgery II. Presented: Aspen Winter Skin Seminar, Aspen, CO, February 1984.

Melette, J.R.: Treatment of BCC, SCC Cancers. Presented: Aspen Winter Skin Seminar, Aspen, CO, February 1984.

## Hematology-Oncology Service

Howard, J.E.: A Microtiter-Enzyme-Linked Immunosorbent Assay (ELISA) for Quantitation of Platelet Bindable IgG (PBIgG). Presented: Fourth Annual Concepts in Hematology and Medical Oncology, Madigan Army Medical Center, Tacoma, Washington, 7 February 1984. (C).

<sup>(</sup>C) Direct result of approved registered protocol.

Tyengar, V.G.: Inhibitory Effects of Serum from Burn Patients on Colony Stimulating Factor (CSF) Production by Normal Monocytes. Presented: Fourth Annual Current Concepts in Hematology and Medical Oncology, Madigan Army Medical Center, Tacoma, W-shington, 8 February 1984. (C).

Iyengar, V.G.: Inhibitory Effects of Serum from Brn Patients on Colony Stimulating Factor (CSF) Production by Normal Monocytes. Presented: American Burn Association Annual Meeting, San Francisco, California, 11 April 1984. (C).

Zaloznik, A.J.: Mediastinal CT Scanning in Staging of Bronchogenic Carcinoma. Presented: 36th Annual Carl W. Tempel Symposium on Pulmonary Disease and Allergy-Immunology, Fitzsimons Army Meidcal Center, 24 January 1984.

Zaloznik, A.J.: Progress in Chemotherapy. Presented: Cancer Update 1984 sponsosred by American Cancer Society, 7 April 1984.

Zaloznik, A.J.: New Theories of Tumor Invasion and Metastasis. Presented: 38th Annual Rocky Mountain Cancer Conference, 9 August 1984.

# Pulmonary Disease Service

Hendrix, C.: Bronchoalveolar Lavage Analysis in Sarcoidosis. Presented: 36th Annual Carl Tempel Symposium, Denver, CO, January 1984. (C).

Hendrix, C.: Bronchoalveolar Lavage in Analysis in Sarcoidosis. Presented: American College of Physicians Associates Meeting, Denver, CO, March 1984. (C).

Schlachter, M.D.: Lung Mechanics During HIgh Frequency Jet Ventilation Determined with Body Plethysmography in Mongrel Dogs. Presented: 36th Annual Carl Tempel Pulmonary Symposium, Denver, CO, January 1984. (C).

Schlachter, M.D.: Plethysmographic Determination of Lung Mechanics During High Frequency Jet Ventilation with CPAP. Presented: International Symposium on HIch Frequency Ventilation, New York City, N.Y., November 1983. (C).

Wolfe, G.K.: Transbronchial Needle Aspiration - FAMC Experience. Presented: 36th Annual Carl Tempel Symposium, Denver, Co., January 1984. (C).

Wolfe, G.K.: Transbronchial Needle Aspiration in the Staging of Lung Cancer. Presented: American College of Physicians Meeting, Denver, CO., March 1984. (C).

<sup>(</sup>C) Direct result of approved registered protocol.

### Rheumatology Service

Andersen P., West, S., Claypool, R., Odell, J., Kotzin, B. and Via, C.: Pulse Methotrexate Therapy for Rheumatoid Arthritis: A Double-Blind Crossover Study. Presented: National ARA Meeting, Minneapolis, Minnesota, June 1984. (C).

West, S. and Andersen, P.: Usefulness of Immunologic Tests of the CSF in the Diagnosis of CNS Lupus. Presented: National ARA Meeting, Minneapolis, Minnesota, June 1984. (C).

### DEPARTMENT OF CLINICAL INVESTIGATION

Engelkirk, P.G., Paine, D.D., Purdon, A., Frye, L.P., Brady, W.K., Mahood, J.D. and Borchardt, K.A.: Evaluation of Plastic-Envelope-Microbiology (PEM) Technology for Rapid Diagnosis of Candida albicans and Trichomonas vaginalis Vaginitis. Presented: Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Las Vegas, Nevada, October 1983. (C).

Engelkirk, P.G.: Of Eosinophils, Mast Cells, and Parasites. Presented: Rocky Mountain Branch of the American Society for Microbiology. Presented: Summer Symposium on Host-Microbe Interactions, Pingree Park, Colorado, August 1984. (C).

Koester, S.K., Engelkirk, P.G., Paine, D.D., Wuerz, D.J. and Rothlauf, M.V.: Influence of Anti-Giardia Antibody, Heat-Labile Serum Components, and Sensitized Host Cells on Short-Term in Vitro Interactions Between G. lamblia Trophozoties and Rat Paritonnal Leukocytes. Presented: Annual Meeting of the American Society for Microbiology, St. Louis, Missouri, March 1984. (C).

Foester, S.K. and Engelkink, P.G.: Glass Cover Slip Technique for Stodwing in Vitro Interactions Between Giardia
Trophozoites and Host neukocytes by TEM, SEM, and Light
Microscopy. Presented: Rocky Mountain Branch of the American
Society for Microbiology, Summer Symposium on Host-Microbe
Interactions, Pingree Park, Colorado, August 1984. (C).

McNally, P., Herrera, J., Engelkirk, P. and Brewer, T.: Clinical Findings and the Immanofluorescent Antibody (IFA) Test in Entionts with Cindiasis. Presented: William Beaumont Castrolutestical Symposium, El Paso, Texas, March 1984. (C).

#### DEPARTMENT OF NURSING

Forcestin, D.K.: Nursing Role in Supporting Patients Who Have Experienced a NeuroDeath Experience. Presented: Fitzsimons Army Medical Center, Aucora, CO. May 19, 1984.

SERVICE Endocrine

**DEPARTMENT** Medicine

- (1) Hofeldt, F.D.: Reactive Hypoglycemia: Update 1980. Presented: Endocrine Grand Rounds, University of Colorado Health Sciences Center, Denver, CO, 16 January 1980.
- (2) Sanders, L.R.: Reactive Hypoglycemia. Presented: Grand Rounds, University of Colorado Health Sciences Center, Denver, CO, 13 March 1979.
- (3) Sanders, L.R.: Reactive Hypoglycemia. Presented: Medical Grand Rounds, Denver General Hospital, Denver, CO, 15 March 1979.
- (4) Sanders, L.R.: Reactive Hypoglycemia. Presented: Endocrine Grand Rounds, University of Colorado Health Sciences Center, Denver, CO, 11 April 1979.
- (5) Hofeldt, F.D.: Hypoglycemia. Grand Rounds, Delgado Amphitheater, Tulane Medical School Charity Hospital, New Orleans, LA, 28 April 1982.
- (6) Hofeldt, F.D. and Scarlett, J.A.: Reactive Hypoglycemia.
  Presented: Endocrine Grand Rounds, University of Colorado Health
  Sciences Center, Denver, CO, March 1982.

P	r	0	t	0	N	o	74	/	l	1	0	

SERVICE Endocrine DEPARTMENT Medicine

(1) Abrams, R., Hofeldt, F.D., Adler, R., O'Barr, T.P., and Morse, P.: Late Reactive Hypoglycemia in Hypothyroidism. (Accepted for publication in American Journal of the Medical Sciences.)

- (2) Hofeldt, F.D.: Transitional Low Blood Glucose States. Rocky Mountain Medical Journal 76:30, 1979.
- (3) McCowen, K.D., Adler, R.A., O'Barr, T.P., and Hofeldt, F.D.: Clinical Implications of Flat Oral Glucose Tolerance Test. Military Medicine 144:177, 1979.
- (4) Charles, M.A., Hofeldt, F.D., Dodson, L.E., Shackelford, A., Waldeck, N., Bunker, D., Coggins, J.T., and Eichner, H.: Comparison of Glucose Tolerance Tests and Mixed Meals in Patients with Idiopathic Reactive Hypoglycemia: Absence of Hypoglycemia After Mixed Meals. Diabetes 30:465, 1981.
- (5) Sanders, L.R., Hofeldt, F.D., Kirk, M., and Levin, J.: Refined Carhohydrate as a Contributing Factor in Reactive Hypoglycemia. Southern Medical Journal 75:1072, 1982.
- (6) Crapo, P.A., Scarlett, J.A., Kolterman, O., Sanders, L., Hofeldt, F.D., and Olefsky, J.: The Effects of Oral Fructose, Sucrose and Glucose in Subjects With Reactive Hypoglycemia. Diabetes Care 5:512, 1982.
- (7) Sanders, L.R., Hofeldt, F.D., Kirk, M.C., and Levin, J.: Refined Carbohydrate as a Contributing Factor in Reactive Hypoglycemia. Southern Medical Journal 75:1072-1075, 1982.

CONTINUATION SHEET, FY 84 ANNUAL PROGRESS REPORT Proto No.: 74/110

#### (16) Continued

prolactins and cortisols are sampled and values are determined by a sensitive radioimmunoassay. Blood glucoses are assessed by the Ames Reflectance Meter immediately after sampling. The procedure is designed to provide a minimum of patient inconvenience in the performance of these well standardized procedures. Many normal individuals experience a low blood sugar state sometime after glucose administration, the significance of a low blood glucose state is observed by recording appropriate adrenergic symptoms at the nadir of the glucose and determining if there is a counter hormonal responsiveness to defend the stress of a low blood glucose state. This approach allows strict definition of bona fide reactive hypoglycemia, and clearly distinguishes it from the benign low blood glucose states.

#### (17) Progress:

This study continues to be an active endocrine protocol with recruitment of new patients for evaluation and study. Several publications elucidating the unusual features of this disorder have resulted from this study. During the last year, patients have been entered onto a computer for ease in data management and retrieval of information. Efforts are now being made to organize the data in the preparation for commencing several written reports on hypoglycemia in general, and some specific aspects that have studied in the present ongoing protocol.

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (Ref. HSCR 40-23, as amended)

(1)	Date: 30 Sep 84 (2) Protocol	WU#:	<b>74/110</b> (3) Status: Ongoing
(4)			alysis of Glucose-Insulin-Glucagon er Hormonal Regulatory Factors
(5)	Start Date: FY71	(6)	Est Compl Date: Indefinite
(7)	Principal Investigator: Michael Bornemann, MD, COL, MC	(8)	Facility: FAMC
(9)	Dept/Svc: Medicine/Endocrine	(10)	Assoc Investigators:
	Key Words: reactive hypoglycemia glucose tolerance counter-regulatory hormones		Fred D. Hofeldt, M.D. T. P. O'Barr, Ph.D., DAC Annelie Shackelford, MT, DAC Gerald S. Kidd, MD, LTC, MC
(12)	Accumulative MEDCASE:* *Refer to Unit Summary Sheet of	_	Est Accum OMA Cost:* s report.
$(14)^{}$	a. Date, Latest HUC Review: 10/83	3	b. Review Results: Ongoing
c. N	lumber of Subjects Enrolled Durin	g Re	eporting Period: 18

d. Total Number of Subjects Enrolled to Date:

On Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. (May be continued on a separate sheet, and designated as "(14)e".

#### None.

### (15) Study Objective:

The objectives of the hypoglycemic study is to continue to investigate in our clinic population the glucose-insulin-glucagon and prolactin interrelationships and the response of counter-regulatory hormones to hypoglycemic stress. This project is a continuation of the previous project initiated in 1969 at the University of California Medical Center, Moffatt Hospital, San Francisco, CA.

#### (16) Technical Approach:

The clinical research protocol involves evaluation of control subjects and hypoglycemic patients to assess the interrelationships of beta cell and alpha cell responsiveness to oral and intravenous glucose administration. Based upon findings in controls and patients with disease states, a classification system has been proposed. The data have allowed for an understanding of the basic pathophysiology of reactive hypoglycemia disorders. The clinical studies are being conducted in the Department of Medicine, Endocrine Clinic, with the assistance of an assigned GS-5 Medical Technician to perform blood sampling and to assist during the testing. During the glucose tolerance test, the patient has an indwelling catheter for frequent sampling of blood glucose, and is continually monitored by a cardiac monitor system and blood sampling. After glucose administration, blood insulins, glucagons, growth hormones,

MEDICINE

DETAIL SUMMARY SHEETS

# EXPLANATION of ANNUAL PROGRESS REPORT DETAIL SHEETS

- (1) DATE: Fiscal Year ending date.
- (2) PROTOCOL NO: FAMC Work Unit Number of the study.
- (3) STATUS: Indicates if the study is Ongoing, Completed, or Terminated.
- (4) TITLE: Project title of the study.
- (5) START DATE: The date the study started.
- (6) ESTIMATED COMPLETION DATE: The projected completion date of the study.
- (7) PRINCIPAL INVESTIGATOR(s): List of all Principal Investigator(s) involved in the study.
- (8) FACILITY: Fitzsimons Army Medical Center.
- (9) DEPARTMENT/SECTION: Department or Service the protocol originated from.
- (10) ASSOCIATE INVESTIGATOR(s): List of all Associate Investigator(s) involved in the study.
- (11) KEY WORDS: Key words pertaining to the particular area of research involved in the study.
- (12) ACCUMULATIVE MEDCASE COST: See Unit Summary Sheet Funding.
- (13) ESTIMATED ACCUMULATIVE OMA COST: See Unit Summary Sheet Funding
- (14) PERIODIC REVIEW RESULTS: Date of the continuing review by the Institutional Review Committee.
- (15) STUDY OBJECTIVE: A summary of objectives to be accomplished during the study.
- (16) TECHNICAL APPROACH: A brief summary of the technical approach to be taken during the study.
- (17) PROGRESS: A summary of prior and current progress since inception of the study.

The Continuation Sheets are used as extensions for (1) - (17) and as an accumulative listing for Publications and Presentations that are a direct result from the study.

The Detail Sheets were submitted in final form by the Principal Investigators and have not been edited.

Hendrix, W.H., Rodriquez, A.R. and Presley, A.: Stress Effect on Organizational Outcomes and Prediction of CAD Risk. Presented: 92nd Annual American Psychological Association Convention, Toronto, Canada, August 1984.

Rodriquez, A.R., Iverson, D.C., Hendrix, W.H. and Presley, A.: An Employee Directed Wellness Project: Early Findings from the OCHAMPUS Health Promotion Program. Presented: American Public H-alth Association Meeting, Dallas, Texas, November 1983.

## MEDDAC

Wallace, L.S.: Stabilization of Hemoglobins and Hematocrits in Frmales Travelling from a Lower to Higher Altitude. Presented: Nursing Research Symposium, Washington, D.C., 10-14 September 1984.

<sup>(</sup>C) Direct result of approved registered protocol.

Vordermark, J.S.: Transureteroureterostomy: A Review of its Use in Modern Pediatric Urology. Presented: British Association Urologic Surgeons Meeting, Dublin, Ireland, June 1984.

Vordermark, J.S.: Pelvic Fracture Strictures: A Review of 100 Consecutive Cases. Presented: British Association Urologic Surgeons Meeting, Dublin, Ireland, June 1984.

### DEPARTMENT OF RADIOLOGY

Perry, M., Blue, P., Kindig, N. and Ghaed, N.: Pressure Wave Form Correlation with Xenon Wash-Out Time in a Physical Model of High Frequency Ventilation. Presented: Sloan-Kettering Cancer Center, November 1983. (C).

Tucker, A.S. and Crimmins, L.: Exhibit: A Case Report of Multiple Esophageal Duplications. Presented: European Pediatric Society, Florence, I+aly, April 1984.

Tucker, A.S. and Crimmins, L.: Exhibit: A Case Report of Multiple Esophageal D plications. Presented: Rocky Mountain Radiology Scoiety, Denver, Colorado, August 1984.

## DEPARTMENT OF PRIMARY CARE AND COMMUNITY MEDICINE

Bethlenfalvay, N.C., Hadnagy, m.C.S. and Heimpel, H.: A New Type of Congenital Dyserythropoietic Anemia: Evidence for Delayed Denucleation. Presented: 27th Annual Meeting of the Hungary Society of Homatology, Szeged, Hungary, August 1984.

#### FAMC TENANT

Hendrix, W.H. and Rodriquez, A.R.: Effects of Stress on Individual Productivity, Absenteeism, and Wellness. Presented: Ninth Biennial Psychology in the DOD Symposium, USAFA, Colorado, April 1984. (C).

Hendrix, W.H., Rodriquez, A.R. and Presley, A.: Effects of Stress and Exercise on Employee Health. Presented: Fifth Annual Meeting of the Society of Behavioral Medicine, Philadelphia, PA, May 1984. (C).

Hendrix, W.H., Rodriquez, A.R. and Presley, A.: Job and Personal Factors Related to Job Stress and Risk of Developing Coronary Artery Disease. Presented: American Industrial Hygiene Conference, Detroit, Michigan, May 1984. (C).

<sup>(</sup>C) Direct result of approved registered protocol.

Scharfenaker, S.K.: A Reactive Language Approach to Apraxia Therapy with Children. Presented: Colorado Speech-Language-Hearing Association Annual Convention, Copper Mountain, April 1984.

## Urology Service

Fauver, H.E.: Paratesticular Tumors: Presented: Kimbrough Urological Seminar, San Francisco, CA, November 1983.

Fruver, H.E.: Benign Testis Masses. Presented: Kimbrough Urological Seminar, San Francisco, CA, November 1983.

Fauver, H.E.: Endometrial Cancer of Prostate. Presented: AUA Meeting, New Orleans, LA, May 1984.

Vordermark, J.S.: Complex Hypospadias. Presented: Seminar on Plastic Surgery, sponsored by the British Association of Plastic Surgeons, Birmingham, England, April 1984.

Vordermark, J.S.: The Acute Scrotum: Diagnosis and Mangement. Presented: Seminar on Urological Emergencies, Institute of Urology, London, England, May 1984.

Vordermark, J.S.: Principles of Plastic and Reconstructive Urological Surgery. Presented: Seminar on Reconstructive Urological Surgery, Institute of Urology, London, England, April 1984.

Vordermark, J.S.: The Hypospadias Cripple. Presented: Seminar on Reconstructive Urological Surgery, Institute of Urology, London, England, April 1984.

Vordermark, J.S.: Hypospadias and Epispadias and Extrophy - The State of the Art. Presented: West Middlesex Hospital, London, England. Presented: Regional Center for Plastic and Reconstructive Surgery, Mount Vernon Hospital, Northwood, Middlesex, England.

Vordermark, J.S.: Epididymitis: Ancillary Diagnostic Techniques. Presented: Queen Elizabeth Royal Army Medical Hospital, Woolich Arsenal, England, June 1984.

Vordermark, J.S. and Jones, B.M.: Approaches to Block Dissection of the Inquinal Lymph Nodes. Presented: British Association of Plastic Surgeons, London, England, November 1983.

<sup>(</sup>C) Direct result of approved registered protocol.

Loth, T.S. and Eversmann, W.W. Jr.: Treatment of Chemotherapeutic Agent Extravasations: A Comparative Study. Presented: Barnard Lectureship presented to the Rocky Mountain Chapter of the Western Orthopaedic Society, Denver, CO., December 1983. (C).

# Otolaryngology Service

Blakeslee, D.B., Becker, G.D., Simpson, G.T., Patten, D.H. and Sprengelmeyer, J.: Lymphoscintography of the Neck after Tumor Injection. Presented: Research Forum, Anaheim, CA., 22 October 1983.

Hasbrouck, J.M., Doherty, J., Mehlmann, M.A., Nelson, R., Randle, B. and Whitaker, R.: Intensive Stuttering Therapy in a Public School Setting. Presented: Colorado Speech-Language-Hearing Association Annual Convention, Copper Mountain, CO., April 1984. (C).

Hasbrouck, J.M. and Lowry-Romero, M.F.: An Intensive Therapy Approach to Eliminating Stuttering and Maintaining Fluency. Presented: American Speech-Language-Hearing Association Annual Convention, Cincinnati, OH., November 1983. (C).

Hasbrouck, J.M. and Lowry-Romero, M.F.: An Intensive Therapy Approach to Eliminating Stuttering and Maintaining Fluency. Presented: Colorado Speech-Language-Hearing Association Annual Convention, Copper Mountain, CO., April 1984. (C).

Lowry-Romero, M.F.: Care and Treatment of the Professional Voice. Presented: Colorado Speech-Language-Hearing Association Annual Convention, Copper Mountain, CO., April 1984.

McMahan, D.A.: A Hearing Impaired Child's Learning Style vs. Educator's Teaching Preferences - A Case Study. Presented: Colorado Speech-Language-Hearing Association Annual Convention, Copper Mountain, CO., April 1984.

McMahan, D.A., Hasbrouck, J.M., Scharfenaker, S.K. and Porter, M.: Let's Look at Children's Learning Styles, Not Educators' Teaching Preferences. Presented: A.G. Bell Association for the Deaf International Convention, Portland, OR., June 1984.

Prescott, T. and Lowry-Romero, M.F.: Alaryngeal Voice: State of the Art. Presented: Colorado Speech-Language-Hearing Association Annual Convention, Copper Mountain, CO., April 1984.

<sup>(</sup>C) Direct result of approved registered protocol.

Merenstein, G.B. and Kirk, E.P.: A View to the Future: What Next in Transport? Regionalization? Presented: Maternal Transport, Bend, OR., May 1984.

Merenstein, G.B.: Neonatal Manpower. Presented: Military Perinatal Research, Aspen, CO., July 1984.

Murphy, M.G.: Application of a Bayesian Drug Dosing Program in Newborns. Presented: Uniformed Services Pediatric Seminar, Reno, NV, March 1984.

Murphy, M.G.: Revisions of Gentamycin Therapy with a Bayesian Computer Program. Presented: Mead Johnson Perinatal Research Meeting, Aspen, CO., July 1984. (C).

### DEPARTMENT OF SURGERY

### General Surgery Service

Allen, J.J. and Clark, J.R.: Cecal Volvulus: Report of 10 Cases and a Review of the Literature. Presented: Gary Wratten Surgical Symposium/Workshop, Walter Reed Army Medical Center, Washington, D.C., April 1984.

# Orthopedic Service

Houseworth, S.W., Curl, W.W., Smith, C.K. and Eilert, R.E.: Use of the Arthroscope to Evaluate Immediate and Delayed Anterior Cruciate Ligament Reconstruction: An Experimental Study in the Dog. Presented: Yearly Barnard Seminar with the University of Colorado Orthopedic Surgery Program, 5 December 1984. (C).

Houseworth, S.W., Mauro, V.J. and Mellon, B.S.: The Intercondylar Notch in Acute Tears of the Anterior Cruciate Ligament: A Computer Graphics Study. Presented: Anterior Cruciate Ligament Study Group. Steamboat Springs, CO., March 16-18, 1984. (C).

Loth, T.S.: Minimal Surgical Debridement of Cehmotherapeutic Agent Extravasations. Presented: Mid-Central States Orthopedic Society, Lake of Ozarks, MO., June 1, 1984. (C).

Loth, T.S.: Minimal Surgical Debridement of Chemotherapeutic Agent Extravasations. Presented: Denver Children's Hospsital Orthopedic Day, Denver, CO., 27 April 1984. (C).

Loth, T. and Eversmann, W.W. Jr.: Treatment of Chemotherapeutic Agent Extravasations: A Comparative Study. Presented: American Society for Surgery of the Hand Meeting, Atlanta, GA., 6 February 1984. (C).

<sup>(</sup>C) Direct result of approved registered protocol.

Merenstein, G.B. and Kirk, E.P.: A View to the Future: What Next in Transport? Regionalization? Presented: Maternal Transport, Bend, OR., May 1984.

Merenstein, G.B.: Neonatal Manpower. Presented: Military Perinatal Research, Aspen, CO., July 1984.

Murphy, M.C.: Application of a Bayesian Drug Dosing Program in Newborns. Presented: Uniformed Services Pediatric Seminar, Reno, NV, March 1984.

Murphy, M.G.: Revisions of Gentamycin Therapy with a Bayesian Computer Program. Presented: Mead Johnson Perinatal Research Meeting, Aspen, CO., July 1984. (C).

### DEPARTMENT OF SURGERY

#### General Surgery Service

Allen, J.J. and Clark, J.R.: Cecal Volvulus: Report of 10 Cases and a Review of the Literature. Presented: Gary Wratten Surgical Symposium/Workshop, Walter Reed Army Medical Center, Washington, D.C., April 1984.

### Orthopedic Service

Houseworth, S.W., Curl, W.W., Smith, C.K. and Eilert, R.E.: Use of the Arthroscope to Evaluate Immediate and Delayed Anterior Cruciate Ligament Reconstruction: An Experimental Study in the Dog. Presented: Yearly Barnard Seminar with the University of Colorado Orthopedic Surgery Program, 5 December 1984. (C).

Houseworth, S.W., Mauro, V.J. and Mellon, B.S.: The Intercondylar Notch in Acute Tears of the Anterior Cruciate Ligament: A Computer Graphics Study. Presented: Anterior Cruciate Ligament Study Group. Steamboat Springs, CO., March 16-18, 1984. (C).

Loth, T.S.: Minimal Surgical Debridement of Chemotherapeutic Agent Extravasations. Presented: Mid-Central States Orthopedic Society, Lake of Ozarks, MO., June 1, 1984. (C).

Loth, T.S.: Minimal Surgical Debridement of Chemotherapeutic Agent Extravasations. Presented: Denver Children's Hospsital Orthopedic Day, Denver, CO., 27 April 1984. (C).

Loth, T. and Eversmann, W.W. Jr.: Treatment of Chemotherapeutic Agent Extravasations: A Comparative Study. Presented: American Society for Surgery of the Hand Meeting, Atlanta, GA., 6 February 1984. (C).

<sup>(</sup>C) Direct result of approved registered protocol.

### DEPARTMENT OF PATHOLOGY

Stocker, J.T.: Congenital Lung Disease. Presented: Armed Forces Institute of Pathology Course on Pediatric Pathology, Washington, D.C., 27 October 1983.

Stocker, J.T.: Pulmonary Sequestration. Presented: Webb Waring Pediatric Pulmonary Lecture Series, Denver, CO., 20 January 1984.

Stocker, J.T.: Interlobar Sequestration; an Acquired Disorder. Presented: Symposium on Pulmonary Medicine, FAMC, 24 January 1984.

Stocker, J.T.: Bronchopulmonary Dysplasia. Presented: Society for Pediatric Pathology, San Francisco, CA., 10 March 1984.

Stocker, J.T.: Pediatric Liver Tumors, Polyposis Syndrome, Congenital Lung Disease. Presented: Aspen Conference on Pediatric Disease, Aspen, CO., 6-10 August 1984.

#### DEPARTMENT OF PEDIATRICS

Berkenbaugh, J.T.: Polycythemia/Hyperviscosity: Some Unanswered Questions. Presented: Military Perinatal Research Meeting, Aspen, CO., July 1984.

Portman, R.J., Cole, J.W., Perlman, J.M., Lim, Y. and Robson, A.M.: Tubular Dysfunction in Infants with Meconium Stained Amniotic Fluid Diagnosis Using B2 Microglobulins. Presented: Society for Pediatric Research, San F-ancisco, CA., May 1984. (C).

Portman, R.J.: Tubular Dysfunction in Neonates Diagnosed by the Urinary Concentration of B2 Microglobulins. Presented: Aspen Conference on Military Perinatal Research, Aspen, CO., August 1984. (C).

Sanders, J.M.: Adolescent Medicine in the Military, Present and Future Issues. Presented: 19th Annual Uniformed Services Pediatric Seminar, Reno, NV, March 1984.

Sanders, J.M.: General Approach to the Adolescent Patient: Substance Abuse. Presented: 62nd Annual Meeting of the Texas Pediatric Society, Dallas, TX, September 1984.

Merenstein, G.B.: Maternal Transport: A Military Perspective. Presented: Maternal Transport, Bend, OR., May 1984.

<sup>(</sup>C) Direct result of approved registered protocol.

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (Ref. HSCR 40-23, as amended)

(1) Date: 30 Sep 84 (2) Protocol	WU#: 78/102 (3) Status: terminated
(4) Title: The development of s	pecific and cross sensitivity in the
tracheal tissue of guinea pigs	treated with isoproterenol and
aminophylline	
(5) Start Date: 1978	(6) Est Compl Date: 1984
(7) Principal Investigator:	(8) Facility: FAMC
W.R. Tipton, MD, COL, MC	
Wed In Llangu	(10) 4 T
(9) Dept/Svc: Med/Allergy	(10) Assoc Investigators:
(11) Key Words: subsensitivity	none
beta agonists	
guinea pig trachea	}
(12) Accumulative MEDCASE:#	(13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of	,
(14) a. Date, Latest HUC Review:	D. Heview Results:
c. Number of Subjects Enrolled Durin	
d. Total Number of Subjects Enrolled	d to Date: NA
e. Note any adverse drug reactions	reported to the FDA or sponsor for stud-
	ed IND. (May be continued on a separate
sheet, and designated as "(14)e"	%1.7
	NA

- (15) Study Objective: This study is designed to measure the development of the subsensitivity to two drugs, isoproterenol and theophylline, by examining both their dilating response on histamine contracted tracheal tissue and ability to increase levels of cyclic-AMP in tracheal tissue and parenchymal lung tissue.
- (16) Technical Approach: Guinea pig tracheal and peripheral lung strips will be analyzed for cyclic nucleotide levels, metabolites of arachodonic acid and physiologic response to various medicators employing a continuous flow tissue bath system. The equipment for this study is presently available at Fitzsimons Army Medical Center.
- (17) Progress: Terminated.

Publications: Tipton WR, Nelson HS, Souhrada JF, Morris, HG, Jacobson KW: Dynamics of isoproterenol subsensitivity in guinea pig airway smooth muscle. Lung 159:199; 1981.

PRESENTATIONS FOR FY 84 Annual Progress Report

Proto No. 78/102

SERVICE Allergy

**DEPARTMENT** Medicine

- 1. Tipton WR: Dynamics and mechanism of guinea pig trachea subsensitivity to isoproterenol. Presented: 31st Annual Pulmonary Disease Symposium, FAMC, Sep 78.
- 2. Tipton WR: Dynamics and mechanism of guinea pig trachea subsensitivity to isoproterenol. Presented: American Thoracic Society, Las Vegas, NV, May 79.

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (Ref. HSCR 40-23, as amended)

(3) Status: Ongoing

- Date: 30 Sep 84 (2) Protocol WU#: 78/114 (4) Title: In vitro effect of minoxidil on collagen production by normal and scleroderma fibroblasts. (Previously titled: "The use of minoxidil in treating progressive systemic scleroderma." Est Compl Date: Oct 84 (6) Start Date: Jan 1979 (7) Principal Investigator: James E. Fitzpatrick MD (8) Facility: FAMC Maj, MC DOM/Dermatology (10) Assoc Investigators: (9) Dept/Svc: (!1) Key Words: scleroderma/minoxidil/ Thomas P. O'Barr PhD, DAC Ellen Swanson MS, DAC fibroblasts/collagen
- (12) Accomulative MEDCASE:# N/A (13) Est Accum OMA Cost: \* N/A \*Refer to Unit Summary Sheet of this report.
- (14) a. Date, Latest HUC Review: b. Review Results: N/A o. Number of Subjects Enrolled During Reporting Period: d. Total Number of Subjects Enrolled to Date:

Don Mercill, DAC

- Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. (May be continued on a separate N/A sheet, and designated as "(14)e".
- (15) Study Objective: To determine if minoxidil inhibits the in-vitro production of collagen by normal and scleroderma fibroblasts.
- (16) Technical approach: Fibroblast cell lines have been established from human dermis obtained from normal and scleroderma patients. The fibroblasts are then incubated in the presence of various concentrations of minoxidil. The production of collagen will be measured by uptake of radioactive proline.
- (17) Progress: The in vivo portion of the protocol was completed as of 30 September 1982.

The in-vitro portion of the portocol is almost complete. The incubation and sampling portion of the protocol is finished. We are currently in the process of analyzing the samples and if all goes well the protocol will be finished in 2 to 4 weeks.

Publications and Presentations:

(1)	Date: 30 Sep 84 (2) Protocol	WU#: 78/123 (3) Status: ongoing
(4)	Title:	erer and Dubois Techniques of Airway
(5)	Start Date: 1979	(6) Est Compl Date: indefinite
(7)	Principal Investigator: Michael Perry, COL MC	(8) Facility: FAMC
	Dept/Svc:Medicine/Pulmonary Key Words: Alveolar Pressure Airway resistance body plethysmography	(10) Assoc Investigators: Robert W. Zimmere, Ph.D. Robert J. Browning, B.S. DAC
(12)	Accumulative MEDCASE:* *Refer to Unit Summary Sheet of	(13) Est Accum OMA Cost:* this report.
(14)	a. Date, Latest HUC Review:	b. Review Results:
e. t	lumber of Subjects Enrolled Durin	ng Reporting Period: 0
d. 1	Total Number of Subjects Enrolled	i to Date:7
	• • • • • • • • • • • • • • • • • • •	reported to the FDA or sponsor for studed IND. (May be continued on a separate

- (15) Study Objective: To compare a clinically untried measurement of airway resistance with a standard technique.
- (16) Technical Approach: Forced expiratory maneuvers are performed with the subject seated in a constant volume body plethysmograph, while plethysmograph pressure and airflow are monitored with a DEC computer. With this information and the previously determined FRC of the patient, alveolar pressure is calculated throughout the expiratory maneuver. Pressure/flow relationships are then related to the patient's maximal expiratory flow volume loop.
- (17) Progress: This protocol had been inactive during the past FY due to extensive changes and modifications of our equipment, including a new computer, new plethysmograph and recording system and the ongoing rewrite of our entire computer program.

Proto No. 78/12	23	
-----------------	----	--

### SERVICE Pulmonary

## DEPARTMENT Medicine

- 1). Perry, M.E., Zimmerer, R.W., Browning, R.J.: Non-Invasive Alveolar Pressure/Flow Pattern Determination by Computerized Plethysmography (Abstract) Symposium on Computers in Critical Care in Pulmonary Medicine, Page 47, June 1980.
- 2). Perry, M.E., Zimmerer, R.W., Nelson, R.A., Browing, R.J., Non-Invasive Determination of Alveolar Pressure-Flow Relationship (Abstract) American Review of Respiratory Disease, Volume 121, Page 389, April 1980.
- 3). Zimmerer, R.W., Perry, M.E., Browning, R.J: Expiratory Pressure/Flow Assessment by Plethysmography (Abstract) AAMI 15th Annual Meeting, Page 246, April 1980.
- 4). Perry, M.E., Zimmerer, R.W., Browning, R.J: "Non-Invasive Alveolar Pressure/Flow Pattern Determinations by computerized Plethysmography", Computers in Critical Care and Pulmonary Medicine, Volume 2, PP 75-77 Plenum Press, 1982.

#### PRESENTATIONS:

- 1) Perry, M.E., Zimmerer, R.W., Browning, R.J.: Non-Invasive Alveolar Pressure/Flow Pattern Determination by Computerized Plethysmography, presented at the Annual Computers in Critical Care and Pulmonary Medicine, Lund, Sweden, June 3-6, 1980.
- Assessment by Plethysmography, presented at the AAMI 15th Annual Meeting San Francisco, April 13-17, 1980.

U#78/124 (3) Status: ongoing
of Single-Breath DLCO measurement
6) Est Compl Date: indefinite 8) Facility: FAMC
10) Assoc Investigators:  Neal B. Kindig, Ph.D Robert J. Browning, P.S.
13) Est Accum OMA Cost:* his report.
b. Review Results:  Reporting Period:  to Date:  Sported to the FDA or sponsor for stud- IND. (May be continued on a separate

- (15) Study Objective: To Experimentally comfirm a proposed new method of DLCO Measurement.
  - (16) Technical Approach: Data will be sampled during the single breath DLCO determination at various breath-holding times at various exhaled lung volumes. Data will be analyzed online by computer which will correct for volume averaging and effective breathi-holding time. If the theoretical approach as outlined in the original protocol is self-consistent, the calculated diffusion capacity should remain constant regardless of breathing pattern of gas collection timing.
- (17) Progress: This protocol remains inactive this FY due to other commitments within the service.

SERVICE Pulmonary

DEPARTMENT Medicine

- 1). Zimmerer, R.W.: Simulated Diffusion Testing. Presented: 32nd Annual Pulmonary Symposium, FAMC, Aurora, CO, September 1979.
- 2). Browning, R.J., Kindig, N.B., Perry, M.E., "Computer Control Aspects of a Single Breath DLCO Station." Presented at the Nineteenth International Instrument Society of America Biomedical Sciences Instrumentation Symposium, Denver, CO, April, 1982.
- 3). Kindig, N.B., Perry, M.E., Browning, R.J., "Single Breath DLCO: Inspiratory Timing and Volume Averaging". Presented at the Annual FASEB Meeting, New Orleans, April, 1982.
- 4). Kindig, N.B., "Single Breath DLCO: Improved Time and Volume Measurement". Persented at the Annual Carl W. Tempel Pulmonary Symposium, Denver, CO, Jan, 1982.
- 5). Perry, M.E., "Mechanism of Carbon Monoxide Effect on Oxyhemoglobin Dissociation".
  Persented at the Annual Carl W. Tempel Pulmonary Symposium, Denver, CO, Jan, 1982.

#### PUBLICATIONS:

- 1). Kindig, N.B., Hazlett, D.R., Filley, G.F.: "Timing and Volume Averaging in Single Breath DLCO Measurement". The Physiologist, 21:64, 1978
- 2). Browning, R.J., Kindig, N.B., Perry, M.E., "Computer Control Aspects of a Single Breath DLCO Station." Biomedical Sciences Instrumentation, Volume 18, April, 1982.
- 3). Kindig, N.B., Perry, M.E., Browning, R.J., "Single Breath DLCO: Inspiratory Timing and Volume Averaging (ABS) Federation Proceedings, Volume 41, Mar, 1982.

PRESENTATIONS	FOR F	Y 84	Annua1	Progress	Report	Proto	No. 79/105
SERVICE Pulmor	nary				DEPARTMENT	Medicine	

- Kindig, N.B.: DLCO correction using PaCO back pressure predicted from venous blood. Presented: Carl E. Tempel Pulmonary Symposium, Denver, CO, January, 1981.
- Perry, M.E.: Simplified room air (A-a)0 calculation. Presented: Carl E. Tempel Pulmonary Symposium, Denver, Colorado, January, 1981.

## PUBLICATIONS:

1). Perry, M.E., Browning, R.J., Kindig, N.B., "The Abbreviated Alveolar Air Equation Revisited, Chest, Volume 80, pp 763-764, December, 1981.

FAMC	A.P.R. (RCS MED 300) Detail Summary Sheet (Ref. HSCR 40-23, as amended)
(1)	Date: 30 Sep 84 (2) Protocol WU#: 79/109 (3) Status: Terminated
(4)	Title: Control of Nausea and Vomiting with Delta-9-tetrahydrocannabinol (THC) Combined with Standard Antiemetics (A Phase II Study)
(5)	Start Date: June 1980 (6) Est Compl Date: July 1984
(7)	
	Nicholas J. DiBella, M.D., COL, MC
	Dept/Svc Medicine/Hema/Oncology (10) Assoc Investigators: Key Words:
	Chemotherapy, nausea and vomiting control  Arlene J. Zaloznik, M.D., MAJ, MC
(12)	Accumulative MEDCASE: * (13) Est Accum OMA Cost: * *Refer to Unit Summary Sheet of this report.
e. 1 d. 1 e. 1	a. Date, Latest HUC Review: Sep 83 b. Review Results: Continued Number of Subjects Enrolled During Reporting Period: 0  Total Number of Subjects Enrolled to Date: 54  Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. (May be continued on a separate sheet, and designated as "(14)e".
(15)	<ol> <li>3tudy Objective:</li> <li>To determine if THC has a useful antiemetic effect when added to standard antiemetic regimen.</li> <li>To determine if the antiemetic effect is additive or potentiating.</li> <li>To determine if THC reduces nausea and vomiting in those patients who do not respond to standard antiemetics.</li> </ol>
(16)	Technical Approach: Clinical study
(17)	This protocol was terminated by the principal investigator. All remaining

THC was returned to the NCI.

Publications and Presentations: None

FAMC	MC A.P.R. (RCS MED 300) Detail Summary Sheet ()	Ref. HSCR 40-23, as amended)
(1)	) Date: 30 Sep 84 (2) Protocol WU#: 79/112	(3) Status: Ongoing
(4)	) Title: Use of Sodium Salt of Allopurinol to Patients with No Therapeutic Alterna	
		npl Date: 1985 ty: FAMC
(9) (11)	1) Key Words:	Investigators: h Beougher, MAJ, MSC
(12)	2) Accumulative MEDCASE: (13) Est Acc *Refer to Unit Summary Sheet of this report.	eum OMA Cost:*
o. 1 d. 7 o. 1	Total Number of Subjects Enrolled to Date:	Period: <u>None</u> Three The FDA or sponsor for stud-
(15)	To determine the effect of a parenteral for hyperuricemia when the patient is unable to (commercially available).	
(16)	) Technical Approach: Clinical Study	
(17)	No new patients have been entered on this sopen since the medication is not commercial needed in the patient who requires antitumo take oral allopurinol.	ly available and it may be
	Publications and Presentations: None	

FAMC	A.P.R. (RCS MED 300) Detail Sum	mary Sheet (Ref. HSCR 40-23, as amended)
( <b>i</b> )	Date: 30 Sep 84 (2) Protocol	WU#: 80/104 (3) Status: Terminated
(4)	Title: Etoposide Combined with	n Cyclophosphamide Plus Vincristine Compared
	to Both Doxorubicin Plus Cycloph of Small Cell Lung Cancer	nosphamide Plus Vincristine in the Treatment
	Start Date: 1980	(6) Est Compl Date: July 1984
(7)	Principal Investigator:	(8) Facility: FAMC
	Arlene J. Zaloznik,M.D.,MAJ,MC	
(9)	Dept/Svc Medicine/Hema-Oncology	(10) Assoc Investigators:
	Key Words:	Nicholas J. DiBella, M.D., COL, MC
	Small cell	Micholas o. Dibella, M.D., Con, R.
	Oat cell	
	Chemotherapy	
(12)	Accumulative MEDCASE:#	(13) Est Accum OMA Cost:*
	*Refer to Unit Summary Sheet of	this report.
(14)	a. Date, Latest HUC Review: Ser	83 b. Review Results: Ongoing
c,	Number of Subjects Enrolled Duri	ng Reporting Period: 0
d.	Total Number of Subjects Enrolle	d to Date: NA
		reported to the FDA or sponsor for stud- ed IND. (May be continued on a separate . None
(15)	Study Objective:	
	To assess the efficacy of Etopo the treatment of small cell lun	oside combined with other chemotherapy for ng cancer.
(16)	Technical Approach: Clinical s	study.
(17)		ecome commercially available and is FDA shave closed the protocol. No data is as

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (Ref. HSCR 40-23, as amended) ( L ) 30 Sep 84 (2) Protocol WU#: Date: 80/115 (3) Status: Ongoing (4) Title: EVALUATION OF AMIODARONE FOR THE THERAPY OF CARDIAC ARRHYTHMIAS (5) Start Date: 1980 (6) Est Compl Date: Indefinite (7) Principal Investigator: (8) Facility: FAMC RICHARD C. DAVIS, JR., MD, Ph.D. LTC, MC ASST CHIEF, CARDIOLOGY SERVICE (10) Assoc Investigators: (9) Dept/Svc: (11) Key Words: Amiodarone Cardiac Arrhythmias (17) Accumulative MEDCASE:\* (13) Est Accum OMA Cost: \* \*Refer to Unit Summary Sheet of this report. (14) a. Date, Latest HUC Review: b. Review Results: c. Number of Subjects Enrolled During Reporting Period: 4 (thru Aug 84) d. Total Number of Subjects Enrolled to Date: 10

e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. (May be continued on a separate

- (15) Study Objective: To control symptomatic cardiac arrhythmias which have not been responsive to the conventional and accepted forms of treatment or whose control is dependent upon the use of a drug which has been shown to be harmful to or in other ways not tolerated by the individual.
- (16) Technical Approach: After patient selection, baseline laboratory results as outlined in the protocol will be obtained. After initiation of therapy, the patient will be followed regularly by the principal investigator with frequent Holter monitors to assess the efficacy of the drug and other laboratory tests and examinations to warn of potential toxicity.
- (17) Progress: Four additional patients have been recruited. Four have shown a satisfactory response while one did not respond.

Publications and presentations: None.

sheet, and designated as "(14)e".

FAMC A.P.R. (RCS MED 300) Detail Summ	mary Sheet (Ref. HSCR 40-23, as amended)
	WU#: 80/117 (3) Status: on-qoing cal signs and symptoms with assay s.
(5) Start Date: Oct 80 (7) Principal Investigator: W.Ronald Tipton, MD, COL, MC	(6) Est Compl Date: 1984 (8) Facility: FAMC
(1) Dept/Sve: Medicine/Allergy (11) Key Words: immune complexes ClQ laboratory assays	(10) Assoc Investigators: V. Iyengar, MD, LTC, MC Jeneen Nelson
(12) Accumulative MEDCASE:*  *Refer to Unit Summary Sheet of	(13) Est Accum OMA Cost:* this report.
(14) a. Date, Latest HUC Review: c. Number of Subjects Enrolled Durir d. Total Number of Subjects Enrolled	ng Reporting Period: NA
d, local Number of Subjects Enrolled	i co pace.

(15) Study Objective: The purpose of this study is to determine the relative sensitivity of several laboratory assays for immune complexes in patients with suspected immune complex disorders.

Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. (May be continued on a separate

NA

sheet, and designated as "(14)e".

- (16) Technical Approach: Patients in whom serum submitted for antinuclear antibodies will have a standard clinical evaluation and their serum will be examined by a standardized battery of four assays for the circulating immune complexes. Correlations will then be made to determine which of the assays best reflects clinical disease.
- (17) Progress: Approximately 250 samples have been correlated with the chart review by Dr. Iyengar. Correlation coefficient statistics have indicated no significant correlation between the two parameters; however, further analysis is being done utilizing different clinical criteria.

PRES <b>ENTA</b> T I	ONS	FOR	FY 84	Annual	Progress	Report	Proto No. <u>80/117</u>
SERVICE	Al	ler	дУ	· · · · · · · · · · · · · · · · · · ·		DEPARTMENT	Medicine
T	17.	mb		h			for managed this of the

Iyengar V: This paper has been accepted for presentation at a Hematology-Oncology Meeting in San Francisco, Sep 84.

Publications: None

FAMC	A.P.R. (RCS MED 300) Detail Summ	mary Sheet (Ref. HSCR 40-23, as amended)	
(1)	Date: 30 Sep 84 (2) Protocol	WU#: 81/117 (3) Status: Ongoing	
(4)	Title: The Role of Calcitonin in	n Osteoporosis	
(5)	Start Date: November 1982	(6) Est Compl Date: December 1984	
(7)	Principal Investigator:	(8) Facility: FAMC	
	Michael T. McDermott, MD, MAJ,M		
(9)	Dept/Svc: Medicine/Endocrine	(10) Assoc Investigators:	
	Key Words:	Gerald S. Kidd, MD, LTC, MC	
	osteoporosis	Peter Blue, MD, LTC, MC	
	calcitonin deficiency	Nasser Ghaed, MD, COL, MC	
	bone density	Fred D. Hofeldt, M.D.	
$\overline{(12)}$	Accumulative MEDCASE:*	(13) Est Accum OMA Cost:*	
	*Refer to Unit Summary Sheet of	this report.	
		82 b. Review Results: Ongoing	
	Total Number of Subjects Enrolled to Date: 60		
	ote any adverse drug reactions reported to the FDA or sponsor for stud-		
	es conducted under an FDA-awarded IND. (May be continued on a separate sheet, and designated as "(14)e".		
	None		

#### (15) Study Objective:

The objectives of this study are to further investigate the role of calcitonin, or its deficiency, in the development of osteoporosis and to determine if thyroidectomized patients, who are calcitonin deficient, are at increased risk of developing osteoporosis.

#### (16) Technical Approach:

Four groups of individuals are studied with bone densitometry using the Norland apparatus. A control group of normals and a thyroid suppressed group of patients compared with a group of thyroidectomized patients who are therefore calcitonin deficient.

## (17) Progress:

Sixty patient have had serial bone density measurements on two occasions; 40 patients have also had a third bone density measurement. The remainder of the patients are currently being scheduled for their third measurement. Pentagastrin infusions have not yet been done because of difficulty with the calctionin radioimmunoassay. Data from the first bone density measurements has already been published.

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (Ref. HSCR 40-23, as amended) 30 Sep 84 (2) Protocol WU#: 81/116 Status: Terminated (1) Date: (3) (4) Title: Hypertransfusion in Acute Leukemia (5) Start Date: October 1981 Est Compl Date: Unknown (7) Principal Investigator: (8) Facility: FAMC Arlene J. Zaloznik, M.D., MAJ, MC (9) Dept/Svc Medicine/Hema-Oncology (10) Assoc Investigators: (11) Key Words: Nicholas J. DiBella, M.D., COL, MC Hypertransfusion Acute Leukemia (13) Est Accum OMA Cost:\* (12) Accumulative MEDCASE:\* \*Refer to Unit Summary Sheet of this report. (14) a. Date, Latest HUC Review: Sep 83 b. Review Results: c. Number of Subjects Enrolled During Reporting Period: 0 Total Number of Subjects Enrolled to Date: e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. (May be continued on a separate sheet, and designated as "(14)e". No adverse drug reactions. (15) Study Objective: To determine the advantage of maintaining an elevated hematocrit during induction chemotherapy for acute leukemia vs the maintenance of an adequate hematocrit. (16)Technical Approach: Patients undergoing induction chemotherapy for acute leukemia are randomized into receiving packed red blood cells to maintain a hematocrit greater than 45% during induction vs those who receive packed red blood cells only if clinically indicated.

(17) Progress:

Although initially there appeared to be a trend in the hypertransfused group of the platelet count not dropping as low as the nontransfused group this apparent trend did not continue to be upheld. The study was terminated because it was felt by the principal investigator that it offered no significant benefit to those patients who were being hypertransfused.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (Ref. HSCR 40-23, as amended) (1) Date: 30 Sep 84 (2) Protocol WU#: 81-115 (3) Status: Ongoing (4) Title: Comparison of Modalities for Treatment of SLE Nephritis Est Compl Date: 1986 (5) Start Date: 1982 (7) Principal Investigator: (8) Facility: FAMC Sterling G West, MD, C, Rheumatology Svc, MAJ, MC; Peter A. Andersen, MD, AsstC, Rheumatology Svc, MAJ, MC (10) Assoc Investigators: (9) Dept/Svc: Mark Nelson, MD, MAJ, MC (11) Key Words: SLE, nephritis, steroids, Chlorambucil (12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\* \*Refer to Unit Summary Sheet of this report. (14) a. Date, Latest HUC Review: June 1984 b. Review Results: Ongoing

c. Number of Subjects Enrolled During Reporting Period: three

d. Total Number of Subjects Enrolled to Date: \_\_seven

e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. (May be continued on a separate sheet, and designated as "(14)e".

One patient developed neutropenia

(15) Study Objective: a. To evaluate the efficacy and side effects of single daily dose corticosteroids versus split dose steroid therapy. b. Provide an alternative form of therapy in patients with SLE nephritis that have not responded to conventional steroids and to evaluate the patient's clinical and serologic response to therapy.

(16) Technical Approach: Patients with lupus nephritis are randomly assigned after informed consent to one of two modes of therapy--either split dose or single dose steroids. A variety of serologic parameters are monitored indicating a response to these medications. Patients who do not respond to this therapy are randomized to either receiving high-dose pulse steroids or Chlorambucil again on a random method. Again, serologic parameters are followed to indicate response to this therapy.

(17) Progress: During the past fiscal year there have been three patients at this institution who have fulfilled entry criteria for incorporation into the protocol. Review of the protocol with the other medical centers in the Army revealed, furthermore, that there has been a significant difficulty in enrolling additional patients. The rigid entry requirements which increase the power of this analysis limits the applicability of the protocol to some patients. It is expected that further evaluation of the status will be made during the next fiscal year.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (Ref. HSCR 40-23, as ame						
(1)	Date: 30 Sep 84 (2) Protocol	WU#: 81/113 (3) Status: Terminated				
~	Title: Aminocaproic Acid for the Control of Hemorrhage in Thrombocytopenic Patients					
(5)	Start Date: May 1981	(6) Est Compl Date:				
	Principal Investigator:	(8) Facility: FAMC				
	Arlene J. Zaloznik, M.D., MAJ, MC					
(9)	Dept/Svc:Medicine/Hema-Oncology	(10) Assoc Investigators:				
	Key Words:	Nicholas J. DiBella, M.D., COL, MC				
	Aminocaproic Acid Thrombocytopenia					
(12)	Accumulative MEDCASE:#	(13) Est Accum OMA Cost:*				
	*Refer to Unit Summary Sheet of this report.					
e. I	<u> </u>	reported to the FDA or sponsor for stud- ed IND. (May be continued on a separate				
(15)	phylactic platelet transfusions	Prophylactic AMICAR compared with pro- to prevent hemorrhage in thrombocytopenia th platelet transfusions to control patients.				
(16)	Technical Approach: Patients who had a platelet count less than 20,000 who were considered refractory to platelet transfusion and who had evidence of severe bleeding that appeared refractory to platelets were eligible for the study.					
(17)	Progress: The protocol was ter patients AMICAR that were throm	minated due to lack of interest in giving bocytopenic.				
	Publications and Presentations:	None				

(1) Date: 30 Sep 84 (2) Protocol	WU#:81/111 (3) Status: terminated
(4) Title: Comparative effect o	f major corticosteroids on lymphoent of the corticosteroid sparing
(5) Start Date: 1981	(6) Est Compl Date: 1984
(?) Principal Investigator:	(8) Facility: FAMC
James S. Brown, LTC, MC	Dept. of Clinical Investigation
(9) Dept/Svc: Medicine/Allergy	(10) Assoc Investigators:
(11) Key Words:	W. Ronald Tipton, COL, MC
•	R. Stephen Whitaeker, CPT, MSC
corticosteroids	1
lymphocyte blastogenesis	
dosage of steroids	
(12) Accumulative MEDCASE:*	(13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of	this report.
(14) a. Date, Latest HUC Review:	b. Review Results:
c. Number of Subjects Enrolled Durin	ng Reporting Period: NA
d. Total Number of Subjects Enrolled	to Date: NA
e. Note any adverse drug reactions r	reported to the FDA or sponsor for stud-
ies conducted under an FDA-awarde	ed IND. (May be continued on a separate
sheet, and designated as "(14)e".	•

(15) Study Objective: To determine if various classes of corticosteroids differ in magnitude of suppression of lymphocyte blastogenesis and to ascertain the effect of troleandomycin in combination with these corticosteroids on lymphocyte blastogenesis.

NA

- 16) Technical Approach: This is an in vitro study using normal lymphocyte populations for blastogenesis as triggered by mitogens and measured by incorporation of titrated thmidine.
- (17) Progress: Relevant potency of various corticosteroids have been determined. In addition, the effect of troleandomycin has been tested and found not to have any effect in this system.

Publications: None

Presentations: Brown JS: The potency of various corticosteroids - inhibition of lymphocyte mitogenesis in humans. Presented: 35th Annual Carl W. Tempel Symposium, FAMC, Jan 83.

FAMC	A.P.R. (RCS MED 300) Detail Summ	mary Sheet (Ref. HSCR 40-23, as amended)
(1)	Date: 30 Sep 84 (2) Protocol	WU#: 81/109D (3) Status: Ongoing
(4)	Title:	
	Southwestern Oncology Group Col	laborative Studies
(5)	Start Date:	(6) Est Compl Date: Indefinite
	Principal Investigator:	(8) Facility: FAMC
	Arlene J. Zaloznik, M.D., MAJ, MC	
(9)	Dept/Svc:	(10) Assoc Investigators:
	Key Words:	
	Chemotherapy	
	C.C. C.	{
$(1\overline{2})$	Accumulative MEDCASE:*	(13) Est Accum OMA Cost:*
	*Refer to Unit Summary Sheet of	this report.
d. ' e. f	· · · · · · · · · · · · · · · · · · ·	d to Date:  reported to the FDA or sponsor for studed IND. (May be continued on a separate
(15)	Study Objective: Variable according to protocols	involved.
(16)	Technical approach:	
	Clinical approach	
(17)	Progress:	
	Patients are continuing to be roof data per the SWOG studies.	registered on SWOG protocols with accumulati
	Publications and Presentations:	None

(1) Date: 30 Sep 84 (2) Protocol	WU#: 81/ 106 (3) Status: ongoing			
(4) Title: Clinical Effectiveness at Chronic Administration o	nd Development of Subsensitivity with f Atropine Sulfate			
(5) Start Date: 1984	(6) Est Compl Date: 1984			
(7) Principal Investigator: Harold S. Nelson, COL, MC	(8) Facility: FAMC			
(9) Dept/Svc: Medicine/Allergy	(10) Assoc Investigators:			
(11) Key Words:	Robert Bowen, MAJ, MC			
Atropine	Raymond Vaughan, CPT, MC			
bronchodilator				
subsensitivity				
(12) Accumulative MEDCASE:*  *Refer to Unit Summary Sheet of	(13) Est Accum OMA Cost:* this report.			
(14) a. Date, Latest HUC Review:	b. Review Results:			
c. Number of Subjects Enrolled Durin				
d. Total Number of Subjects Enrolled				
. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. (May be continued on a separate sheet, and designated as "(14)e".				
(15) Study Objective:				
	esponse to atropine sulfate initially regular use.			

(16) Technical Approach:

The bronchocilator response to nebulized saline and atropine sulfate will be measured for two hours on two separate days. Then, the subject will be given either saline or atropine sulfate to employ at home by nebulization four times daily. At the end of two eeeks the patient would return and receive the same medication that he would have employed for the previous two weeks and again pulmonary function response would be followed for two hours.

(17) Progress: None

Publications & Presentations: None

(1) Date: 30 Sep 84 (2) Protocol	WU#: 81/104 (3) Status: ongoing			
(4) Title: The incidence of host de	fense deficiencies in patients presenting			
with frequent or prolonged infect	ions.			
(b) Start Date: 1981	(6) Est Compl Date: 1987-88			
(7) Principal Investigator:	(8) Facility: FAMC			
W. Ronald Tipton, MD, COL, MC,	Allergy-Immunology Service			
Assistant Chief, Allergy Service	112228, 212228			
(9) Dept/Svc: Med/Allergy	(10) Assoc Investigators:			
(11) Key Words:	Harold S. Nelson, MD, COL, MC			
immunodefiency	William Rickman, CPT, MSC			
infection	Joseph Lima, BAC			
laboratory tests	Fellows, Allergy-Immunology Service			
(12) Accumulative MEDCASE:#	(13) Est Accum OMA Cost:*			
*Refer to Unit Summary Sheet of	this report.			
(14) a. Date, Latest HUC Review:	b. Review Results:			
. Number of Subjects Enrolled Durin	ng Reporting Period:			
1. Total Number of Subjects Enrolled to Date: 12				
Note any adverse drug reactions reported to the FDA or sponsor for stud-				
ies conducted under an FDA-awarde	ed IND. (May be continued on a separate			

(15) Study Objective:

sheet, and designated as "(14)e".

To determine the cost effectiveness of performing various laboratory evaluations of immune responsiveness in patients presenting with frequent or prolonged infections.

none

- (16) Technical Approach: Patients who are referred for this protocol will have a standardized clinical evaluation by the Fellows in the Allergy-Immunology Service and will have a standard battery of tests performed to evaluate their immune status and phagocytic function. On the basis of the clinical history certain laboratory tests will be determined to have been clinically indicated. Subsequently, the yield from the battery of routine tests will be compared to the yield from those tests which were thought to have been clinically indicated.
- (17) This protocol is continuing. We have now enrolled 12 patients. It is anticipated that it will take approximately 5-6 years to accumulate enough patients to complete the protocol.

No publications or presentations.

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (Ref. HSCR 40-23, as ammended) CONTINUATION SHEET

(1) DATE: 30 Sept 84 (2) Protocol WUæ 81-101 (3) Status: Ongoing

(17) Results of this phase of the study were presented by CPT Peter McNally (medicine resident) at the 13th Annual William Beaumont Gastrointestinal Symposium in April 1984. The enclosed copy of the manuscript has been submitted for publication.

Pending review of study results to this date and discussion with the Immunology Service, Department of Clinical Investigation, FAMC, the undersigned officer will request an addemdum and extension to provide ongoing study of this area.

(1) Date: 30 Sep 84 (2) Protocol	WU#: 81-101 (3) Status: Ongoing(see below)
(4) Title:	
Development and evaluation of rapid i	mmunodiagnostic procedures for the diagnosis
of Giardiasis.	
(5) Start Date: 5 May 1981	(6) Est Compl Date: May 1984(request extension
(7) Principal Investigator: Thomas G. Brewer, M.D., LTC,MC	(8) Facility: FAMC FAMC
(9) Dept/Svc: Gastroenterology/DCI (11) Key Words: Diarrhea, Giardiasis Giardia Lamblia immunodiagnosis	(10) Assoc Investigators:
(12) Accumulative MEDCASE:*	(13) Est Accum OMA Cost:*

\*Refer to Unit Summary Sheet of this report.

(14) a. Date, Latest HUC Review: May 1984 b. Review Results: Ongoing

e. Number of Subjects Enrolled During Reporting Period: None

d. Total Number of Subjects Enrolled to Date: Forty-four

e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. (May be continued on a separate sheet, and designated as "(14)e".

N/A - no drug administration

### (15) Study Objective:

To develop immunodiagnostic procedures for rapid detection of Giardia lamblia antigen in fecal and duodenal aspirate specimens and detection of anti-Giardia antibodies in the serum of patients infected with Giardiasis. To evaluate the efficacy of these tests for rapid diagnosis of Giardiasis in a select patient population.

(16) Technical Approach: We have not deviated from the technical approach described in detail in the protocol except for an alteration of the protocol in which patients undergoing diagnosis of Giardiasis by the use of enterotest string procedure are asked to undergo a followup enterotest examination after treatment with medication of the primary physician's choice. Ammendment to the patient consent form which includes this alteration had been previously forwarded and cleared through the Chief, Judge Advocate's Office, FAMC (25 Oct 83).

<sup>(17)</sup> Progress: Immunofluorescent antibody test on the sera of 38 patients with confirmed Giardiasis was performed by Dr. G.S. Visvesvara at the Parasitic Disease Branch, Center for Disease Control, Atlanta, GA. Results of the IFA test are noted in the enclosed copy of a manuscript which is currently submitted for publication. Results of the antibody test revealed that IFA is only of moderate sensitivity in the detection of Giardiasis (45%) but was significantly higher in patients with severe illness (greater than 10-1b; weight loss) regardless of duration of illness.

CONTINUATION SHEET, FY 84 ANNUAL PROGRESS REPORT Proto No.: 80/121

## (17) Progress:

Complete data compiled on 25 patients with the data on one other patient pending. Data on 8 patients is incomplete and/or mission, and hence these patients will not be included in this statistical analysis. Aside from a paper submitted for the Hugh Mahon Lectureship Award in June 1983, the only other paper to date from this research was an abstract entitled "Comparison of Thyrotopin Releasing Hormone Bolus in Infusion Testing in Patients With Subclinical Hypothyroidism" which appeared in Clinical Research, Vol. 32, No. 1, February 1984, page 19a. At present, laboratory data is pending on one patient and it is felt that one or two further control patients can be recruited during the next 6 to 7 months before completing the study and preparing a final paper. It is anticipated that the study will be concluded by July 1985.

### PUBLICATIONS:

- Bornemann, M.: Pitfalls in Mild Subclinical Hypothyroidism: Comparison of the TRH Bolus and Infusion. Submitted for Hugh Mahon Lectureship Award, FAMC, May 1983.
- 2. Bornemann, M., Kidd, G.S., and Hofeldt, F.D.: Comparison of Thyrotropin Releasing Hormone Bolus and Infusion Testing in Patients with Suspected Subclinical Hypothyroidism. (Abst.) Clin. Res. 32:1, 1984.

### PRESENTATIONS:

1. Bornemann, M., Kidd, G.S., and Hofeldt, F.D.: Comparison of Thyrotropin Releasing Hormone Bolus and Infusion Testing in Patients with Suspected Subclinical Hypothyroidism. Presented: Western Section, Western Meeting, Carmel, CA, February 1984.

(1)	Date: 30 Sep 84 (2) Protocol	WU#:	80/121 (3) Status: Ongoing
(4)	Title: An Evaluation of Pituita	ry and	d Thyroid Hormonal Responses to a
	4-Hour Continuous and a	Bolus	Intravenous Infusion of TRH as a
	Useful Test of Thyroidal	Func	tional Reserve
(5)	Start Date: March 1981	(6)	Est Compl Date: July 1985
(7)	Principal Investigator:	(8)	Facility: FAMC
	Michael Bornemann, MD, COL, MC	Ì	
		1	
		Į.	
		ł	
		<u> </u>	
(9)	Dept/Svc: Medicine/Endocrine	(10)	Assoc Investigators:
(11)	Key Words:	1	Gerald S. Kidd, MD, LTC, MC
	thyroid functional reserve	İ	William J. Georgitis, MD, MAJ, MC
	pituitary	l	
	thyroid axis	ł	
	TRH infusion	<u> </u>	
(12)	Accumulative MEDCASE:*		Est Accum OMA Cost:*
	*Refer to Unit Summary Sheet of	this	rep rt.
(14)	a. Date, Latest HUC Review: 9/8	3	b. Review Results: Ongoing
	Number of Subjects Enrolled Duris		
đ.	Total Number of Subjects Enrolled	to I	Date: 34
e.	Note any adverse drug reactions :	report	ted to the FDA or sponsor for stud-
	ies conducted under an FDA-awarde	ed INI	). (May be continued on a separate
	sheet, and designated as "(14)e".	•	
	None		

### (15) Study Objective:

The objective of this study is to determine if the diagnosis of mild or subclinical hypothyroidism can be more clearly established by some integrated parameter reflecting both the pituitary and thyroidal reserve responses to intravenous thyrotopin releasing hormone.

## (16) Technical Approach:

Three groups of subjects will be evaluated in this protocol. Group 1 will consist of normal control patients; Group 2 will consist of patients with mild hypothyroidism diagnosed by an elevated TSH level but normal thyroid hormone levels; Group 3 will consist of patients with the Thyroid Clinic with high-normal TSH values and normal thyroid function tests, but who are clinical suspects of having mild hypothyroidism. The patients will undergo two TRH infusion tests in a random manner consisting of conventional bolus administration of 500 ug of TRH solution and the constant infusion of TRH over a 4-hour period with 500 ug of TRH diluted in normal saline and diffused at a rate of 2 ug per minute over the 4 hours using a Harvard infusion pump. The TSH values in the various groups of patients will be determined and statistically analyzed for differences between the groups.

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (Ref. HSCR 40-23, as amended) Date: 30 Sep 84 (2) Protocol WU#: 80/120 (3) Status: Title: Evaluation of Carbohydrate Metabolism in Thyrotoxicosis: Investigations Into the Frequency, Type and Mechanisms of Carbohydrate Tolerance (6)Est Compl Date: (5) Start Date: April 1981 October 1985 (8) (7) Principal Investigator: Facility: FAMC Gerald S. Kidd, MD, LTC, MC (9) Dept/Svc: Medicine/Endocrine (10) Assoc Investigators: (11) Key Words: T. P. O'Barr, Ph.D., DAC carbohydrate intolerance Fred D. Hofeldt, MD, COL, MC (ret) thyrotoxicosis Robert J. Sjoberg, MD, CPT, MC (12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\* \*Refer to Unit Summary Sheet of this report. (14) a. Date, Latest HUC Review: b. Review Results: c. Number of Subjects Enrolled During Reporting Period: 3 d. Total Number of Subjects Enrolled to Date: 10 (only 4 of these have e. Note any adverse drug reactions reported to the FDA or sponsor for stud- completed) ies conducted under an FDA-awarded IND. (May be continued on a separate sheet, and designated as "(14)e". N/A (15) Study Objective: The first objective of the study is to determine the frequency and reversibility of carbohydrate intolerance in thyrotoxicosis and to determine the importance of gut factors by doing oral and intravenous glucose tolerance tests. The second objective is to study the mechanisms of carbohydrate intolerance. This objective will be approached by measuring glucose, insulin, glucagon and free fatty acids, basally and after oral or intravenous glucose and by measuring the responses to exogenous insulin. (16) Technical Approach: Ten non-diabetic patients who are taking no medications, are less than age 45, are less than 120% of ideal body weight, will be studied while thyrotoxic and after recovery. Each patient will have an oral and an intravenous glucose tolerance test. Each patient will have an insulin tolerance test basally and following glucose infusion. (17) Progress: In FY84, 3 new patients have been studied during thyrotoxic phase but only 4 of the total (10) have been retested during the euthyroid phase. Many delays have been encountered but progress continues.

Publications and Presentations: None

i new	W. F. R. (Nes Pied 300) Decall Sum	mary sheet (her. hisch 40-23, as amended)
(1)	Date: 30 Sep 84 (2) Protocol	WU#: 80/118D (3) Status: Ongoing
(4)	Title:	<u> </u>
	5-Azacytidine in the Treatment o	f Acute Nonlymphocytic Leukemia
(5)	Start Date: Nov 80	(6) Est Compl Date: Unknown
(7)	Principal Investigator:	(8) Facility: FAMC
	Arlene J. Zaloznik, M.D., MAJ, MC	
(9)	Dept/Sve Medicine/Hema-Oncology	(10) Assoc Investigators:
(11)	Key Words:	1
	5-Azacytidine,	
	Acute leukemia	
(12)	Accumulative MEDCASE:*	(13) Est Accum OMA Cost:*
(,	*Refer to Unit Summary Sheet of	
(20)		
(14)	a. Date, Latest HUC Review: Sep	83 b. Review Results: Ongoing
	lumber of Subjects Enrolled Durin	
	Total Number of Subjects Enrolled	
e. 1	lote any adverse drug reactions r	reported to the FDA or sponsor for stud-
	ies conducted under an FDA-awarde	ed IND. (May be continued on a separate
:	sheet, and designated as "(14)e".	No adverse drug reactions.
(15)	Study Objective:	
	To determine the efficacy of 5-	Azacytidine in patients with acute non-
		elapsed after conventional chemotherapy.
	-7.1.F.10.1.7.5.20 LOWIGHER WIS 12.10 L	orașio de
(16)	Technical Approach:	
	Dationts also have married to be	on from the control of the control o
	The second secon	refractory to standard forms of acute
	leukemia are given 5-Azacytidin	e in an attempt to induce remission
(17)	Progress:	
,	- 3 - 2 - 2 - 2	
		registered during the last year it is
		continue to be open for patients with
	refractory leukemia until such	time as 5-Azacytidine becomes commercially
	available.	-
	Dublications and Decembrations	None
	Publications and Presentations:	None

Proto No. 81/117

# SERVICE Endocrine

DEPARTMENT Medicine

- (1) McDermott M., Kidd, G., Blue, P., et al.: Bone mineral content in totally thyroidectomized patients; possible effect of calcitonin deficiency. (Abst.) 64th Meeting of the Endocrine Society, San Francisco, California, June 1982.
- (2) McDermott, M.T., Kidd, G.S., Blue, P., Ghaed, V., and Hofeldt, F.D.:
  Reduced Bone Mineral Content in Totally Thyroidectomized Patients:
  Possible Effect of Calcitonin Deficiency. J. Clin. Endocrinol. Metab.
  56:936-939, 1983.

## PRESENTATIONS:

(1) McDermott, M.T.: Bone Mineral Content in Totally Thyroidectomized Patient. Presented: Uniformed Services Society of Endocrinology, San Francisco, CA, June 1982.

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (Ref. HSCR 40-23, as amended) Date: 30 Sep 84 (2) Protocol WU#:81/118 (3) Status: Ongoing (4) Title: Hypothalamic Pituitary Gonadal Function in Hypothyroidism Start Date: 3 September 1981 (6) Est Compl Date: Indefinite (7) Principal Investigator: (8) Facility: Michael T. McDermott, MD, MAJ, MC (10) Assoc Investigators: (9) Dept/Svc: Medicine/Endocrine (11) Key Words: hypothyroidism Gerald S. Kidd, MD, LTC, MC Fred D. Hofeldt, M.D. **HPG** axis GONADAL FUNCTION (12) Accumulative MEDCASE:# (13) Est Accum OMA Cost:\* \*Refer to Unit Summary Sheet of this report. b. Review Results: Ongoing (14) a. Date, Latest HUC Review: Nov 82 e. Number of Subjects Enrolled During Reporting Period: Total Number of Subjects Enrolled to Date: Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. (May be continued on a separate

(15) Study Objective:
The objectives of this protocol are to define more clearly the mechanisms of gonadal dysfunction occurring in hypothyroidism and to see if these abnormalities resolve after treatment of the hypothyroid state.

### (16) Technical Approach:

A prospective study to assess in a pair manner results of alterations in HPG axis as a consequence of hypothyroidism when evaluated with GnRH infusion and TRH testing, clinical stimulation and HCG testing in males and females.

### (17) Progress:

None.

One patient has been studied and her frozen serum has not yet been assayed.

Publications and Presentations: None

sheet, and designated as "(14)e".

(1) Date: 30 Sep 84 (2) Protocol	WU#: 81/119 (3) Status: Completed			
(4) Title:				
The Effect of Thyrotropin Relea	sing Hormone on Gonadotropin			
Releasing Hormone Stimulated Go	nadotropin Secretion			
(5) Start Date: March 1983	(6) Est Compl Date: March 1984			
(7) Principal Investigator:	(8) Facility: FAMC			
Michael T. McDermott, MD, MAJ, M				
	i			
(0) D. 10	(10) Assoc Transfer			
(9) Dept/Svc: Medicine/Endocrine	(10) Assoc Investigators:			
(11) Key Words:	Complete wide ND two NO			
gonadotropin releasing hormone	Gerald S. Kidd, MD, LTC, MC			
Thyrotropin releasing hormone	Fred D. Hofeldt, MD			
	Í			
(12) Accumulative MEDCASE:*	(13) Est Accum OMA Cost:*			
*Refer to Unit Summary Sheet of	, ,			
	·			
(14) a. Date, Latest HUC Review: Nov				
Number of Subjects Enrolled During Reporting Period: 8				
Total Number of Subjects Enrolled to Date:				
e. Note any adverse drug reactions reported to the FDA or sponsor for s ies conducted under an FDA-awarded IND. (May be continued on a sepa				
None.				
15) Study Objective:				
INT STUDY UNIECTIVE!				

In order to gain a better insight into the mechanism of gonadal dysfunction in hypothyroidism, the objective of this protocol is to study the effect of a thyrotropin releasing hormone (TRH) infusion on basal and gonadotropin releasing hormone (GnRH) stimulated gonadotropins in normal subjects.

### (16) Technical Approach:

Ten normal males will be studied with either a normal saline infusion or a TRH infusion. During these infusions, GnRH will be given as a bolus with measurement of appropriate hormones to determine interaction between releasing hormones.

## (17) Progress:

Eight subjects have completed the study. Raw data is awaiting statistical analysis.

Publications and Presentations: None

(5) Start Date: Dec. 81 (7) Principa: Investigator:	(6) Est Compl Date: Dec 85 (8) Facility: FAMC
AMES A. HASBARGEN, MD AJ, M.C.	(o) Facility. Fam.
hief, Nephrology Service	
(9) Dept/Svc: Medicine/Nephrology (11) Key Words: IgA nephropathy, erger's Disease, prospective valuation	(10) Assoc Investigators:
(12) Accumulative MEDCASE:# #Refer to Unit Summary Sheet of	(13) Est Accum OMA Cost:* this report.
	ng Reporting Period: 6

(15) Study Objective: To determine pathologic and clinical pathologic criteria for the diagnosis of IgA nephropathy, prognosis of patients with such a diagnosis, suitability for continued military service. The extent of the evaluation and degree of follow up required for such patients, and the sensitivity and specificity of various non-invasive diagnostic techniques which potentially could obviate the necessary for renal biopsy.

None

sheet, and designated as "(14)e".

(16) Technical Approach: Patients who meet patient selection criteria established in protocol enrolled and subjected to the following: skin biopsy, serum IgA level, IgA coated peripheral lymphocyte analysis, and HLA typing. In addition, a kidney biopsy is closely scrutinized and the patient examined reference symptoms accompanying their disease and other associated symptomatology. Follow up is conducted indefinitely at six month intervals and if patient develops a marked decrease in renal function, kidney biopsy is repeated. Repeat skin biopsy is accomplished only for episodes of gross hematuria.

(17) Progress: Total of 20 patients have been enrolled including 6 during the past year. The study represents a collaborative effort utilizing WRAMC, DDEAMC, and recently Brooke AMC. Thus far approximately 50 patients have been enrolled totaling the study amongst the centers, and abstraction and presentation based on data gained from this protocol as well as the hematuria protocol are noted in the accompanying paper. Due to failure of laboratory freezer, the IgA coated lymphocyte portion of this study has suffered a major setback. It is anticipated that several more papers will ensue over the accompanying several years. Follow up of the patients in the protocol will be indefinite.

PRESENTATI	ONS FOR FY 84	Annual	Progress	Report	Proto N	No. 81-121-N
SERVICE	Nephrology			DEPARTMENT_	Medicine	

- 1. Presentation at 9th International Congress of Nephrology, Los Angeles, California, June 1984.
- 2. Tapp, D., Copley, J. Hasbargen, J. Moore, J. Gouge, S., Antonovycht, V. and Guggenheim, S.: IgA Nephropathy and Pathologic Correlation. Presented Current Concepts in Internal Medicine. San Francisco, CA, Oct. 84

# Publications:

1. Copley, J.B., Hasbargen, J.A.: "Primary" Hematuria: A Prospective Evauation.

Kidney International, 25: 161, 1984 (Abstract)

(1) Date: 30 Sep 84 (2) Protocol WU#:81-122/N (3) Status: DISCONTINUED
(4) Title:

Utility of Furosemide in Early Oliguric or Non-Oliguric Renal Failure

(5) Start Date: Feb. 82	(6) Est Compl Date: Oct 84
(7) Principal Investigator:	(8) Facility: FAMC
JAMES A. HASBARGEN, MD	
MAJ, M.C.	
(9) Dept/Svc: Medicine/Nephrology	(10) Assoc Investigators:
(11) Key Words: Furosemide,	JACK MOORE, JR., MAJ, M.C.
oliguric, renal failure	Chief, Nephrology Service, WRAMC
<b>3,</b>	ROBERT W. SCHRIER, MD
	Chief, Department of Medicine
	Univ. of Colo. Health Sciences Center
(12) Accumulative MEDCASE:*	(13) Est Accum OMA Cost:#
*Refer to Unit Summary Sheet of	this report.

(14)	а.	Date.	Latest	HUC	Review:	b. Review Resu	ilts:	
		-				During Peronting Period	, ,	 

c. Number of Subjects Enrolled During Reporting Period: 1
d. Total Number of Subjects Enrolled to Date: 8

e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. (May be continued on a separate sheet, and designated as "(14)e". None

Publications and Presentations: None

<sup>(15)</sup> Study Objective: To prospectively determine if Furosemide is capable of producing diuresis and thereby attentuating the severity of acute renal failure when administered early in the course of oliguria. An additional purpose is to determine if non-oliguric acute renal failure patients would benefit from Furosemide therapy; to determine if their need for dialysis could be decreased.

<sup>(16)</sup> Technical Approach: Patients accepted for the protocol per parameters listed therein are randomized into two therapeutic trial groups, Furosemide or Saline. Patients are then given specific doses by weight of Furosemide or specific amounts of Saline and their responses to same is monitored immediately and over ensuring days.

<sup>(17)</sup> Progress: This study represents a collaborative study between the Renal Division, University of Colorado Health Sciences Center and Departments of Nephrology, WRAMC, William Beaumont AMC, and FAMC. Fitzsimons has provided a total of 7 patients for this study group since approval of the protocol. It is too early to determine utility of Furosemide and it is anticipated a relatively large number of patients will need to be enrolled in this study to stratify the multiple variables encountered.

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (Ref. HSCR 40-23, as amended) 30 Sep 84 (2) Protocol WU#: 81/123 (3) Status: Ongoing (l) Date: Title: Primary Renal Hematuria: A Prospective Evaluation (5) Start Date: Feb. 82 (6) Est Compl Date: Feb 85 (7) Principal Investigator: (8) Facility: FAMC JAMES A. HASBARGEN, MD MAJ, M.C. Chief, Nephrology Service (9) Dept/Svc: Medicine/Nephrology (10) Assoc Investigators: (11) Key Words: primary renal hematuria, prospective evaluation (12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\* \*Refer to Unit Summary Sheet of this report. (14) a. Date, Latest HUC Review: b. Review Results: c. Number of Subjects Enrolled During Reporting Period: 3 d. Total imber of Subjects Enrolled to Date: e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. (May be continued on a separate

sheet, and designated as "(14)e".

<sup>(15)</sup> Study Objective: To determine the etiology and significance of hematuria microscopic and macroscopic, as well as prognosis in patients who have neither personal or family history of renal disease, nor evidence of systemic disease or extra renal causes of hematuria.

<sup>(16)</sup> Technical Approach: Patients who meet established criteria contained within the protocol are evaluated with skin biopsy, serum IgA levels and IgA coated peripheral lymphocytes. Most patients then undergo renal biopsy and/or renal arteriography (dependent upon age). HLA typing is accomplished on all patients and patients are followed every six months for an indefinite period of time regardless of renal biopsy findings to determine the course of their disease (17) Progress: This study represents a collaborative study with Walter Reed AMC, Eisenhower AMC, possibility of Beaumont AMC, and Brooke AMC participating in addition to FAMC. It is hoped that over a three year period at least 50 individuals will be enrolled in the protocol. Fitzsimons has thus far contributed a total of 7 patients with a goal of 50 patients which can be reached over a three year period.

PUBLICAT	IONS for	FY 8	34 Annual	Progress	Report	Proto No.	81/123
SERVICE	Nephrol	ogy			DEPARTMENT	Medicine	

1. Copley, J.B., and Hasbargen, J.A. "Primary" Hematuria: A Prospective Evaluation (Abstract). Kidney International. (In Press)

### Presentations:

1. Copley, J.B., and Hasbargen, J.A. "Primary" Hematuria: A Prospective Evaulation. Kidney International, 25: 161, 1984. Presented to American Society of Nephrology Conference, December 1984

# DETAIL SUMMARY SHEET

(Ref: HSCR 40-23 & HSPA-I Ltr, 8 July 1982

(4)	Date:	FY 1984	(2) Pr	otocol WU	Nr.: 81/124 <sup>(3)</sup>	Status: Terminated
17/	Title	•				
	IN	TRA-CORO	NARY STREPTOK	INASE		
			G MYOCARDIAL		N	
$\overline{(5)}$	Start	Date:	December 19	B1 (6)	Est Compl Date:	1983
(7)	<del></del>	ipal Inve			Facility: FAMC	
• •			· ·		•	
KENNE:	MHE. MA	inka md m	A.T MC			
				į		
(9)	Dept/S	Svc: Dent	of Med Card	SVC (10)	Assoc Investig	ators:
	) Key Wo		WA THE TOTAL		-	
	-		eptokinase			JR MD PhD LTC MC
			nfarction	CAI	RLOS A. MENDOZA	MD MAJ MC
AC	uce riyoc	aruiai I	inarction	İ		
712	) Accumi	late MED	CASE:*	(13)	Est Accum OMA Co	nst:*
(12			Summary Shee			
717					b. Review Resul	+s•
C.					porting period:	
đ.			subjects enr			23
е.					ted to the FDA	
₹:•			ed under an F			None
	Studies	s conduct	eu under an r	DA-awarde	d IND	THORIC
					<del></del>	
						·· (1/\\-\\
700	ntinua	n 2 con	rata chaat d	ocionatin	a thic continual	
				esignatin	g this continua	cion as (14/c.)
(15	) Study	Objectiv	e:			
(15	) Study <b>To ass</b> es	Objectiv s the ef	e: ficiency and :	safety of	intra-coronary	streptokinase
(15	) Study <b>To ass</b> es	Objectiv s the ef	e: ficiency and :	safety of		streptokinase
(15	) Study <b>To ass</b> es	Objectiv s the ef	e: ficiency and :	safety of	intra-coronary	streptokinase
(15	) Study <b>To asses</b> <b>infusio</b> n	Objectives the efactions in pata	e: ficiency and : ients with ac	safety of	intra-coronary	streptokinase
(16	) Study To asses infusion ) Tech	Objectives the efformation of the control of the co	e: ficiency and : ients with ac roach:	safety of ute myoca	intra-coronary rdial infarction	streptokinase 1.
(16	O Study To asses infusion O Techi After in	Objectives the efforts in patameters of the control	e: ficiency and : ients with ac roach: aluation of e	safety of ute myocar ach patier	intra-coronary rdial infarction	streptokinase n. Formed consent
(16	O Study To asses infusion  O Techi  After in to the s	Objectives the effective of the control of the cont	e: ficiency and sients with acroach: aluation of extends, the fo	safety of ute myocar ach patier llowing pr	intra-coronary rdial infarction that who gives information to the contract of the coronary rocedures are performance of the coronary rocedures are performance of the coronary rocedures are performance of the coronary rocedures are performance of the coronary rocedures are performance of the coronary rocedures are performance of the coronary rocedures are performance of the coronary red and the coronary red and the coronary red are coronary red and the coronary red an	streptokinase  formed consenterformed:
(16	To asses infusion  Tech  After into the scomplete	Objectives the effect of the part of the p	e: ficiency and a ients with act  roach: aluation of ea tocol, the for history, com	safety of ute myocar ach patier llowing proplete phys	intra-coronary rdial infarction  nt who gives infrocedures are posical exam, ches	streptokinase  formed consenterformed: st x-ray,
(16	To assessinfusion  Technology  After into the secomplete	Objectives the effect of the pate of the p	e: ficiency and a ients with act  roach: aluation of ea tocol, the for history, com	safety of ute myocar ach patier llowing proplete phys	intra-coronary rdial infarction  nt who gives infrocedures are posical exam, ches	streptokinase  formed consent erformed: st x-ray, PTT (see continuat
(16	To assessinfusion  Technology  After into the secomplete  EKG, CBC  Program	Objectives the effect of the control	e: ficiency and : ients with ac roach: aluation of ex tocol, the for history, com ry profile, m	safety of ute myocar ach paties llowing proplete phys	intra-coronary rdial infarction  nt who gives infrocedures are persical exam, chess isoenzymes, PT	streptokinase  formed consent erformed: st x-ray, PTT (see continuat sheet)
(16	To assessinfusion  Technology  After in  to the secomplete  EKG, CBC  Programme in	Objectives the effect of the second of the s	e: ficiency and : ients with ac roach: aluation of ex tocol, the for history, com ry profile, m of protocol	safety of ute myocar ach patier llowing prolete phys yocardial	intra-coronary rdial infarction of the who gives infrocedures are posical exam, ches isoenzymes, PT, er 1981, a total	streptokinase  formed consent erformed: st x-ray, PTT (see continuat sheet) L of 23 patients
(16	To assessinfusion  Technology  After into the secomplete  EKG, CBC  Program  Since into the bee	Objectives the effect of the partial every protest of the partial enterest of the	e: ficiency and : ients with ac  roach: aluation of ex tocol, the for history, com ry profile, m of protocol i under the p	safety of ute myocar ach patien llowing prolete phyo yocardial in Decemberotocol.	intra-coronary rdial infarction of the who gives inforcedures are posical exam, chestisoenzymes, PT, er 1981, a total Analysis has sh	streptokinase  formed consent erformed: st x-ray, PTT (see continuat sheet) l of 23 patients nown a trend toward
(16	To assessinfusion  Technology  Technology  After into the secomplete  EKG, CBC  Program  Since into the second	Objectives the effect of the partial eventual entered in Living and the control of the control o	e: ficiency and dients with action of extremely compary profile, my of protocol di under the profile.	safety of ute myocar ach patier llowing proplete phyocardial in December rotocol. Using a to	intra-coronary rdial infarction of the who gives infrocedures are posical exam, ches isoenzymes, PT, er 1981, a total Analysis has shotal dose of 160	streptokinase  formed consent erformed: st x-ray, PTT (see continuat sheet) l of 23 patients nown a trend toward ),000 units of
(16	To assessinfusion  Technology  Technology  Technology  After in  to the secondlete  EKG, CBC  Program  Since in  have been  improvem  Streptok	Objectives the effect of the partial eventual properties:  attitudy properties:  attitution on enterect in Lititation in enterect in Lititation in enterect in Lititation enterect in L	e: ficiency and relation of extending the formula of protocol of under the protocol of function.	safety of ute myocar ach patier llowing proplete phys yocardial in December rotocol. Using a to	intra-coronary rdial infarction of the who gives infrocedures are posical exam, chestisoenzymes, PT, er 1981, a total Analysis has shotal dose of 160 ary showed a significant coronary coron	streptokinase  formed consent erformed: st x-ray, PTT (see continuat sheet) l of 23 patients sown a trend toward 0,000 units of mificant drop in
(16	To asses infusion  Technology	objectives the effect of the structure o	e: ficiency and dients with action of extending the formation of extending profile, my profile, my profile, my function. Ininistered in and prolonger and prolonger.	safety of ute myocar ach patier llowing proplete phys yocardial in December rotocol. Using a to	intra-coronary rdial infarction of the who gives infrocedures are posical exam, chestisoenzymes, PT, er 1981, a total Analysis has shotal dose of 160 ary showed a significant coronary coron	streptokinase  formed consent erformed: st x-ray, PTT (see continuat sheet) l of 23 patients nown a trend toward ),000 units of
(16	To asses infusion  Technology	objectives the effect of the part of the p	e: ficiency and dients with action of extending the formation of extending profile, my profile, my profile, my function. Ininistered in and prolonger and prolonger.	safety of ute myocar ach patier llowing proplete phys yocardial in December rotocol. Using a to	intra-coronary rdial infarction of the who gives infrocedures are posical exam, chestisoenzymes, PT, er 1981, a total Analysis has shotal dose of 160 ary showed a significant coronary coron	streptokinase  formed consent erformed: st x-ray, PTT (see continuat sheet) l of 23 patients nown a trend toward ),000 units of mificant drop in

### Continuation sheet:

- (16) thrombin time, fibrinogen level, UA. Right and left heart catheterization is then performed to include hemodynamic parameters, left heart ventriculogram and selective coronary angiography. After locating a totally obstructed coronary artery, 1c NTG is given followed by 1c streptokinase consisting of a 10,000 unit bolus and 2500 units/minute for a total of 60 minutes. Repeat LV ventriculogram is performed with repeat hemodynamic measurements. The patient is then taken to the CCU for routine post MI treatment.
- (17) Presented at the Army Cardiology Meeting in May 1982 and May 1983. No technical problems have arisen with the procedure. Two patients died who were entered in the protocol, one 12 hours after the procedure with an extensive anterior MI and the second patient at 72 hours with an extensive anterolateral MI. Both patients are felt to have died from the extensive myocardial infarction and not from the procedure.

(1) Date: 30 Sep 84 (2) Protocol	WU#: 81-125 (3) Status: Ongoing
(4) Title: Flexible Fiberoptic Esophageal Vein	
(5) Start Date: September 1981	(6) Est Compl Date: June 1984
(7) Principal Investigator:	(8) Facility: FAMC
Thomas G. Brewer, MD, LTC, MC	FAMC(participating facilities include the University of Colorado Medical Center, Denver Veteran's Hospital, and Denver General Hospital)
(9) Dept/Svc: Medicine/GI Service (11) Key Words:	(10) Assoc Investigators:
Esophageal varices, upper gastroin- testinal hemorrhage fiberoptic vein sclerosis	None
(12) Accumulative MEDCASE:*  *Refer to Unit Summary Sheet of	(13) Est Accum OMA Cost:* this report.
(14) a. Date, Latest HUC Review: March c. Number of Subjects Enrolled Durin d. Total Number of Subjects Enrolled e. Note any adverse drug reactions r	n 1984b. Review Results: Ongoing g Reporting Period: Five (5) to Date: Forty (40) eported to the FDA or sponsor for stud-

None

sheet, and designated as "(14)e".

(15) Study Objective: To determine the therapeutic efficacy and safety of flexible fiberoptic vein sclrosis in preventing recurrent bleeding in patients with recent hemorrhage from esophageal varices.

ies conducted under an FDA-awarded IND. (May be continued on a separate

- (16) Technical Approach: We have not deviated from the technical approach to sclerosing esophageal varices as outlined in the protocol. Endoscopic sclerotherapy has been accomplished in all five patients entered in the study with a maximum number of sclerotherapies accomplished being nine in one study patient. Olympus single and double channeled panendoscopes have been used with Olympus and Medi Teck injectors which contain a retractable 23-gauge needle with 3% Sotradecol (Sodium Tetradecyl sulfate -TSS).
- (17) Progress: Of the current total number of patients (noted above) entered from all centers into the study, we have entered 5 patients all of whom have been randomized to the sclerosis group. Endoscopic esophageal vein sclerosis has been completed in each patient's case with complete ablation of varices and without occurrence of any major complication. There have been no mortalities in any of the patients entered in this study at FAMC since 1981 with a mean followup at this time of approximately 18 months. Transient substernal chest pain with occasional dysphagia lasting 24 to 48 hours has been noted in 4 of the cases at some point during the sclerotherapy regimen but has resolved in every case. As noted, all patients are currently alive and all but one patient continue clinical follow up with regular

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (Ref. HSCR 40-23, as ammended Continuation Sheet

(1) DATE: 30 Sept 84 (2) Protocol WUæ: 81-125 (3) Status: Ongoing

Publications and Presentations: None.

<sup>(17)</sup> followup in the FAMC GI Clinic. One patient has discontinued followup as of June 1984 because of a move to a different state.

(1) Date: 30 Sep 84 (2) Protocol	WU#: 82/100-N (3) Status: Ongoing
(4) Title: Combined Prednisone and C	yclophosphamide Therapy Coupled with Plasmapheresis
In The Treatment of Anti-glomerular Ba	sement Membrane (Anti-GBM) Antibody Induced
Disease	,
(5) Start Date: Mar 82	(6) Est Compl Date: 86
(7) Principal Investigator:	(8) Facility: FAMC
JAMES A. HASBARGEN, MD	•
MAJ, M.C.	
Chief, Nephrology Service	
(9) Dept/Svc: Medicine/Nephrology	(10) Assoc Investigators:
(11) Key Words:	<b>3</b>
Prednisone, Cyclophosphamide,	
Plasmapheresis, anti-GBM	
antibody induced disease	
(12) Accumulative MEDCASE:#	(13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of	
(14) a. Date, Latest HUC Review:	h Pouisu Poult
c. Number of Subjects Enrolled Durin	
d. Total Number of Subjects Enrolled	
ies conducted under an FDA consider	eported to the FDA or sponsor for stud-
	d IND. (May be continued on a separate
sheet, and designated as "(14)e".	None

(15) Study Objective: To determine if Prednisone and Cyclophosphamide alone or in combination with plasmapheresis is efficacious in lowering circulating anti-GBM bi-levels and thereby affecting the clinical course of anti-GBM induced nephritis. In addition, it is desirable to learn if treatment with Prednisone and Cytotoxin with or without plasmapheresis has a role in the prevention of, or is therapeutic for pulmonary manifestations of anti-GBM induced disease.

(16) Technical Approach: Patients with anti-GBM antibody disease are randomized into one to two treatment groups consisting of Prednisone and Cyclophosphamide alone or in combination with plasmapheresis. Patients are monitored with history, physical, hematologic and chemistry monitoring to include renal function parameters as well as anti-GBM antibody titers. Criteria for withdrawl from the study as well as analysis of the study are indicated within the protocol.

(17) Progress: AntiGBM ab mediated pulmonary-renal disease is a rare entity which accounts for the collaborative nature of the study between FAMC, WRAMC, National Naval Medical Center and NIH. Thus far since inception of protocol, FAMC has not had any patients who met entry into the protocol standards. It is anticipated over the next several years that we will be able to contribute one to two patients to the protocol.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summ	mary Sheet (Ref. HSCR 40-23, as amended)
(1) Date: 30 Sep 84 (2) Protocol (4) Title: teroid And Immunosuppressive Drug The	WU#: 82/101-N (3) Status: Ongoing erapy In Idiopathic Crescentic Glomerulonephritis
(5) Start Date: Apr 82 (7) Principal Investigator: AMES A. HASBARGEN, MD AJ, M.C.	(6) Est Compl Date: Apr 85 (8) Facility: FAMC
(9) Dept/Svc: Medicine/Nephrology (11) Key Words: steroid mmunosuppressive drug, idiopathic rescentic, glomerulonephritis, apidly progressive glomerulonephritis	(10) Assoc Investigators:  JAMES E. BALOW, M.D. and HOWARD A. AUSTIN, MI National Institutes of Health Bethesda, Maryland
*Refer to Unit Summary Sheet of  (14) a. Date, Latest HUC Review: c. Number of Subjects Enrolled Durin d Total Number of Subjects Enrolled e. Note any adverse drug reactions r	b. Review Results:  g Reporting Period:

Publications and Presentations: None


sheet, and designated as "(14)e".

<sup>(15)</sup> Study Objective: To compare the efficacy of intravenous methylprednisolong is. intravenous cyclophosphamide in the treatment of idiopathic crescentic glomerulo-ephritis. Comparison will be made of the number of favorable outcomes of renal function and renal pathology as well as as drug related toxicities manifested by each reatment group at the time of the 6 study month.

<sup>(16)</sup> Technical Approach: Patients with idiopathic crescentic glomerulonephritis are randomized into one of two study groups to receive either monthly intravenous also methylprednisolong for six months or monthly intravenous pulse cyclophosphamide for 6 months. All patients are treated with oral prednisolone in addition. Effects of therapy are monitored with frequent histories and physical examinations as well as hematologic, urinalysis and renal function monitoring. At the end of 6 months second renal biopsy is accomplished to determine the effect of the above mentioned therapy. Criteria for withdrawal from the study, retreatment of patients who exacerbate their course of glomerulonephritis, and analysis of the study are as indicated in the study protocol.

<sup>(17)</sup> Progress: Idiopathic crescentic glomerulonephritis is a rare disease, and it is for this reason this protocol represents a collaborative effort between FAMC, WRAMC, and NIH. Since the inception of the protocol one patient at FAMC has been enrolled and was randomized to the pulse methyprednisolone group.

CLINICAL INVESTIGATION PROGRAM ANNUAL PROGRESS REPORT (U) FITZSIMONS ARMY MEDICAL CENTER AURORA CO 30 SEP 84 AD-A154 658 2/3 . UNCLASSIFIED F/G 6/5 NL



MICROCOPY RESOLUTION TEST CHART
NATIONAL BUREAU OF STANDARDS-1963 A

## DETAIL SUMMARY SHEET

(Ref: HSCR 40-23 & HSPA-I Ltr, 8 July 1982

(1	)	Date:	FY	1984	(2)	Protocol	WU	Nr.:	82/103	(3)	) Status: T	erminated
7.	7	Title										

A Survey of Lymphocyte Subpopulations in Patients with Malignancies

J.

(5) Start Date: April 1982	(6) Est Compl Date: March 1984
(7) Principal Investigator Nicholas J. DiBella, M.D. and R. S. Whiteaker, Ph.D.	(8) Facility: FAMC Hematology/Oncology Service and inpatient wards
(9) Dept/Svc: Hem/Onc & DCI (11) Key Words: Lymphocytes Neoplasia	(10) Assoc Investigators: Stephen G. Oswald, D.O.
(12) Accumulate MEDCASE:*	(13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of	
(14) a. Date, Latest HUC Review:	
c. Number of subjects enrolled duri	
d. Total number of subjects enrolle	
e. Note any adverse drug reactions studies conducted under an FDA-a	reported to the FDA or sponsor for warded IND.: N/A

(Continue on a separate sheet, designating this continuation as (14)c.)

(15) Study Objective:
To determine if there are any abnormalities of peripheral blood lymphocyte populations in patients with malignancies.

(16) Technical Approach:

Monoclonal antibody markers were applied to peripheral blood lymphocytes of patients prior to treatment and normal controls.

# (17) Progress:

Study has been terminated. To date, 22 patients and 11 controls have been studied. In general, the more advanced the stage of the cancer the greater the depression of total lymphocyte count. There was no consistent pattern of change noted in any of the monoclonal lymphocyte subtypes. It was concluded that further study of this problem would not provide any new useful information.

(1)	Date: 30 Sep 84 (2) Protocol	WU#: 82/104 (3) Status: Ongoing						
(4)	Title:	Was RZ/104 (3) Seconds Oligoting						
` ',	The Effect of Tamoxifen on Gynecomastia							
	The Effect of Tamoxiten on Gyner	Comascia						
(5)	Start Date: 30 Sep 82	(6) Est Compl Date: March 1985						
(7)	Principal Investigator:	(8) Facility: FAMC						
Mi	ichael T. McDermott, MD, MAJ, MC							
		(20)						
(9)	Dept/Svc:	(10) Assoc Investigators:						
(11)	Key Words:							
	Tamoxifen	Fred D. Hofeldt, MD						
	gynecomastia	Gerald S. Kidd, Md, ltc, mc						
	therapy							
/121	Accumulative MEDCASE:	(13) Est Accum OMA Cost:*						
(12)	*Refer to Unit Summary Sheet of	· •						
(14)		83 b. Review Results: Ongoing						
c.	Number of Subjects Enrolled Duris							
d.	Total Number of Subjects Enrolle							
e.		reported to the FDA or sponsor for stud-						
		ed IND. (May be continued on a separate						
	sheet, and designated as "(14)e"	•						
	None.							

(15) Study Objective:

The objective of this protocol is to evaluate, in a double-blind placebo controlled prospective trial, the effect of Tamoxifen on males with gynecomastia and to characterize any co-existent hormonal changes.

(16) Technical Approach:

A randomized, double-blind placebo controlled study of the effects of Tamoxifen therapy on idiopathic gynecomastia will be performed. Breast size will be assessed by photographs, palpation and measurement of tissue.

(17) Progress:

Five patients have entered the study. Two, with stage 5 gynecomastia, did not show objective reduction in breast size but one reported decreased tenderness. Two currently under study have not had the double-bline codrevealed. One other failed to return for followup appointment.

Publications and Presentations: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (Ref. HSCR 40-23, as amended) 30 Sep 84 (2) Protocol WU#:82/106 (1) Status: ongoing Date: (3) Title: Clinical Usage of High Frequency Jet Ventilation Est Compl Date: Indefinite Start Date: June 1981 (6) (8) Facility: FAMC (7) Principal Investigator: Michael Perry COL MC (10) Assoc Investigators: (9) Dept/Svc: Pulmonary/Medicne (11) Key Words: High Frequency Jet Ventilation (13) Est Accum OMA Cost:\* (12) Accumulative MEDCASE:\* \*Refer to Unit Summary Sheet of this report. (14) a. Date, Latest HUC Review: b. Review Results: c. Number of Subjects Enrolled During Reporting Period: Total Number of Subjects Enrolled to Date: e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. (May be continued on a separate sheet, and designated as "(14)e". (15) Study Objective: All patients with bronchopleural fistulae or who are difficult to ventilate with standard technique are candidates for thismode of ventilation. Assessment will be made concerning the efficacy of high frequency jet ventilation for the various clinical problems encountered. (16) Technical Approach: A standard VS 600 Jet Ventilator will be used, with an injection catheter placed into the endotracheal tube. Adjustment of driving pressures (up to #50/sq in) will be made along with I:E ratio and frequency (up to 200/min) to determine the optimum settings for maximum ventilation and oxygenation. (17) Progress: Since approval human use has been unavailable because of the too stringent protocol criteria. The portocol has been modified to allow entry of patients not truly moribound to allow for a more meaningful experience. Extensive work has been performed in the facilities of the clinical investigation service using animals with this ventilator which we hope to apply to the patients entering this protocol after modifications have been approved. Publications and Presentations: None

(1)	Date: 30 Sep 84 (2) Protocol	WU#:	82/107 (3) Status: Terminated
(4)	Title: Interstitial Lung Dise	ase P	rotocol
(5)	Start Date: June 1981	(6)	Est Compl Date: Terminated
(7)	Principal Investigator: Gary R. Ripple, MD CPT, MC	(8)	Facility: FAMC
<del> </del>	Dept/Svc: DOM/Pulmonary Key Words: corticosteriod gallium seitigraphy interstitial lung disease bronchoalveolar lavage open lung biopsy	(10)	Assoc Investigators: Michael E. Perry, LTC, MC Jimmy Gilbert, MAJ, MC William Strampel, MAJ, MC Michael Schlachter, CPT, MC
(12)	Accumulative MEDCASE:*  *Refer to Unit Summary Sheet of	. •	Est Accum OMA Cost:* report.
(14)	a. Date, Latest HUC Review June	83	b. Review Results:
c.	Number of Subjects Enrolled Duris	ag Re	porting Period: 0
d.	Total Number of Subjects Enrolled	i to i	Date: 4
е,		ed IN	ted to the FDA or sponsor for stud- . (May be continued on a separate e.

Publications and Presentations: none

<sup>(15)</sup> Study Objective: Through the correlation of gallium scitigraphy, bronchoalveolar lavage, open lung biopsy and pulmonary function testing, the investigators are striving to determine the role of immune complexes and neutrophils in the pathogenesis and treatment (with corticosteroids) of interstitial lung disease.

<sup>(16)</sup> Technical Approach: Consenting patients with interstitial lung disease (ILD) are evaluated initially by gallium scintigraphy, bronchoalveolar lavage, pulmonary function studies and open lung biopsy. Those patients having ILD of undetermined etiology on biopsy are re-evaluated by gallium scanning, bronchoalveolar lavage, and pulmonary function studies 6 weeks after biopsy (before steroids) and after 6 weeks of steroids. The purpose is to correlate disease activity with diagnostic procedures.

<sup>(17)</sup> Progress: Terminated

30 Sep 84 (2) Protocol WU#: 82/109 Status: Ongoing (1) Date: (4) Title: Correlation of Birth Weight with Maternal Hemoglobin S. Concentration: A Retrospective Study Start Date: 1982 Est Compl Date: Indefinite (5) Principal Investigator: (8) Facility: FAMC John R. Hess, MD, MAJ, MC (9) Dept/Svc:Hema/Oncol/MED (10) Assoc Investigators: (11) Key Words: J. Benjamin Hall, MAJ, MC Lynn G. Stansbury, MD, DAC hemoglobin S Nicholas J. DiBella, COL, MC sickle cell trait Jay M. Hill, COL, MC (12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\* \*Refer to Unit Summary Sheet of this report. (14) a. Date, Latest HUC Review: NA b. Review Results: c. Number of Subjects Enrolled During Reporting Period: NA Total Number of Subjects Enrolled to Date: NA Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. (May be continued on a separate

- (15) Study Objective: a) To reaccess the association of maternal sickle cell trait and low infant birth weight. b) To correlate infant birth weight with maternal hemoglobin S concentration.
- (16) Technical Approach: The relation of infants birth weight to their mothers' levles of Hb S and duration of gestation will be accessed with the techniques of linear and multiple linear regression or analysis of variance and covariance. Difference will be judged significant at the .05 level.
- (17) Progress: The numbers are too small and the study will need to continue for 3 to 4 years for additional comparative statistics.

Publications and Presentations: none

sheet, and designated as "(14)e". NA

	00/110
(1) Date: 30 Sep 84 (2) Protocol	WU#: 82/110 (3) Status: completed
(4) Title: An investigation of imm	nunologic reaction to human serum albumin
(5) Start Date: 1982	(6) Est Compl Date: completed 1984
(7) Principal Investigator: HS Nelson, MD, COL, MC	(8) Facility: FAMC
(9) Dept/Svc: Medicine/Allergy (11) Key Words:	(10) Assoc Investigators:
human serum albumin	JS Brown, LTC, MC
Immunologic reaction	
(12) Accumulative MEDCASE:* *Refer to Unit Summary Sheet of	(13) Est Accum OMA Cost:* this report.
(14) a. Date, Latest HUC Review:	b. Review Results:
e. Number of Subjects Enrolled Durin	ng Reporting Period: 100
d. Total Number of Subjects Enrolled	
e. Note any adverse drug reactions i	reported to the FDA or sponsor for studed IND. (May be continued on a separate

- (16) Technical Approach: Patients at three Army medical centers who have been receiving injections of allergy extracts containing 0.03% human serum albumin were skin tested with a diluent containing the same concentration of albumin, and blood was drawn from every tenth patient for in vitro studies. These consisted of assays for IgG antibodies in a microtiter system.
- (17) Progress: A total of somewhat over 200 patients were skin tested. None had any evidence of IgE mediated reactivity. Approximately 45 serum samples were collected and evaluated for the presence of IgG antibody and none was detected.

Publications: Brown JS, Ledoux R, Tipton WR, Nelson HS: An investigation of the immunologic reaction to human serum albumin (abst). Ann allergy 52:221;1984.

<sup>(15)</sup> Study Objective: To determine whether allergy patients receiving injections of allergy extracts containing human serum albumin develop evidence of IgE or IgG antibodies directed toward human serum albumin.

PRESENTATIONS	FOD	EV 84	Annual	Drogress	Penart
PKESENTATIONS	ruk	ri 04	Annual	rrogress	KeDort

Proto No. 82	/	1	1	0	
--------------	---	---	---	---	--

SERVICE	Allergy	DEPARTMENT Medicine	
			_

Brown JS: Evaluation of possible immunologic response to human serum albumin in allergy extracts. Presented: Carl W. Tempel Allergy-Immunology and Pulmonary Symposium, Fitzsimons AMC, 26 Jan 84.

Brown JS: An investigation of the immunologic reaction to human serum albumin. Presented: 40th annual congress of the American College of Allergists, San Francisco, CA, 7 Apr 84.

Brown JS: An investigation of the immunologic reaction to human serum albumin. Presented: 2nd Annual Aspen Allergy Conference, Aspen, CO, 28 July 1984.

- (1) Date: 30 Sep 84 (2) Protocol WU#: 82/111D (3) Status: ongoing (4) Title: Investigation of the efficacy and side effects of oral and inhaled beta adrenergic bronchodilators in patients on optimal theophylline therapy.
- (5) Start Date: 1983
  (7) Principal Investigator:
  HS Nelson, MD, COL, MC
  (9) Dept/Svc: Medicine/Allergy
  (11) Key Words:
  adrenergic bronchodilator
  (6) Est Compl Date: 1984
  (8) Facility: FAMC
  Allergy-Immunology Clinic
  (10) Assoc Investigators:
- subsensitivity Mark Vandewalker, MAJ, MC
- (12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*

  \*Refer to Unit Summary Sheet of this report.
- (14) a. Date, Latest HUC Review: b. Review Results: c. Number of Subjects Enrolled During Reporting Period: 15 d. Total Number of Subjects Enrolled to Date: 25
- e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. (May be continued on a separate sheet, and designated as "(14)e".

none

- (15) Study Objective: To determine whether the addition of oral or inhaled beta adrenergic medication to treatment with optimal doses of theophylline significantly improves the treatment of patients with bronchial asthma.
- (16) Technical Approach: Patients will be placed on oral theophylline and either oral or inhaled terbutaline. They will then undergo a double-blind crossover of terbutaline and placebo. During this time pulmonary function and asthma symptoms and requirement for asthma medication will be monitored.
- (17) Progress: Twenty-three patients completed the oral phase of the study. Most have now also completed the inhaled phase, which should be completed in several more months.

Publications: None

Presentations: Kray KT: Double-blind study of long-term oral terbutaline: Efficacy and side effects. Presented: 2nd Aspen Allergy Conference, Aspen, CO, 27 July 84.

(1) Date: 30 Sep 84 (2) Protoco	1 WU#:82/112 (3) Status: completed
(4) Title: The use of modified RA	ST in determining initial immunotherapy
doses.	
(5) Start Date: 1982	(6) Est Compl Date: 1984
(7) Principal Investigator:	(8) Facility: FAMC
HS Nelson, MD, COL, MC	Allergy-Immunology Service
(9) Dept/Svc: Medicine/Allergy	(10) Assoc Investigators:
(11) Key Words:	
immunotherapy	
modified RAST	David Moyer, CDR, MC, USN
(12) Accumulative MEDCASE:*	(13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet o	f this report.
(14) a. Date, Latest HUC Review:	b. Review Results:
c. Number of Subjects Enrolled Dur	
d. Total Number of Subjects Enroll	
e. Note any adverse drug reactions	reported to the FDA or sponsor for stud-
ics conducted under an FDA_awar	ded IND (May be continued on a separate

none

sheet, and designated as "(14)e".

Publications: Moyer DB, Bowen R, Nelson HS: The use of the modified RAST in determining initial immunotherapy doses (abst) Ann Allergy 52:220; 1984.

<sup>(15)</sup> Study Objective: To determine whether use of the modified RAST will allow inititation of allergy immunotherapy with more concentrated extracts than normally would be employed.

<sup>(16)</sup> Technical Approach: Patients in whom the decision had been made to institute immunotherapy, and who had a clearcut seasonal allergic history, had modified RAST performed to that allergen. An assessment was made based on the predicted starting dose whether the patient could have initiated immunotherapy by the modified RAST dosing schedule at a higher concentration than that customary schedule employed.

<sup>(17)</sup> Progress: Fifty-two patients were evaluated. It was found that there was no advantage to the modified RAST.

PRESENTATIONS	FOR	FY	84	Annual	Progress	Report
---------------	-----	----	----	--------	----------	--------

Proto No.	82/112	
-----------	--------	--

SERVICE Allergy-Immunology

**DEPARTMENT** Medicine

Moyer DB: Prediction of allergy immunotherapy starting dose---use of the modified RAST. Presented: Carl W. Tempel Allergy-Immunology Pulmonary Symposium, Fitzsimons AMC, 25 Jan 84.

Moyer DB: The use of the modified RAST in determining initial immunotherapy doses. Presented: 40th Annual Congress of the American College of Allergists, San Francisco, CA, 7 Apr 84.

Moyer DB: The use of the modified RAST in determining initial immunotherapy doses. Presented: 2nd Aspen Allergy Conference, Aspen, CO 28 Jul 84.

FAMC A.P.R.	(RCS ME	D 300)	Detail	Summary	Sheet	(Ref.	<b>HSCR</b>	40-23,	as	amended)
-------------	---------	--------	--------	---------	-------	-------	-------------	--------	----	----------

(1) Date: 30 Sep 84 (2) Prot	ocol WU#: 82/113 (3) Status: on going
	ed corticosteroids on the development of beta
adrenergic subsensitivity	·
(5) Start Date: not started	(6) Est Compl Date: indefinite
(7) Principal Investigator:	(8) Facility: FAMC
HS Nelson, MD, COL, MC	Allergy-Immunology Clinic
(9) Dept/Svc: Medicine/Allergy	(10) Assoc Investigators:
(11) Key Words:	
Corticosteroids	
beta adrenergic subsensitivity	RW Weber, COL, MC
(12) Accumulative MEDCASE:*	(13) Est Accum OMA Cost:*
*Refer to Unit Summary Shee	t of this report.
(14) a. Date, Latest HUC Review:	b. Review Results:
c. Number of Subjects Enrolled	······································
d. Total Number of Subjects Enr	
•	ons reported to the FDA or sponsor for stud-
•	warded IND. (May be continued on a separate
sheet, and designated as "(1	·
	none

- (15) Study Objective: To determine whether the administration of inhaled corticosteroids in conjunction with inhaled beta adrenergic bronchodilators prevents the development of subsensitivity to the bronchodilator action of the beta agonists.
- (16) Technical Approach: Patients will be tested for their response to inhaled terbutaline before and following a 3-week course of inhaled terbutaline or placebo administered in a double-blind, random crossover design.
- (17) Progress: This study has been postponed until completion of the ketotifen beta adrenergic subsensitivity study.

	Date: 30 Sep 84 (2) Protocol	
(4) of th	Title: Growth of Basal Cell Card neir Growth and Immunological Cha	cinoma Cells in Defined Medium and Study tracteristics.
(5)	Start Date: Nov 82	(6) Est Compl Date: Oct 85
(7)	Principal Investigator:	(8) Facility: FAMC DCI
	Ronald E. Grimwood, M.D. LTC, MC	
	Dept/Svc: Dept of Med/Derm Svc	(10) Assoc Investigators:
(11)	Key Words:	J. Clark Hutf, M.D.
	Basal Cell Carcinoma	Charles Ferris, CPT, MSC
	Defined Culture media for Keratinocytes	Richard A.F. Clark, M.D.
(12)	Accumulative MEDCASE:* *Refer to Unit Summary Sheet of	(13) Est Accum OMA Cost:* this report.
(14)	a. Date, Latest HUC Review: N/A	b. Review Results: N/A
e. I	Number of Subjects Enrolled Durin	ng Reporting Period: N/A
d. '	Total Number of Subjects Enrolled	i to Date: N/A
	<del>-</del>	reported to the FDA or sponsor for studed IND. (May be continued on a separate N/A

(15) Study Objective:

Growth and study of basal cell carcinoma cells in culture.

- of the media formulated by Dr Ham's Lab at the University of Colora. Boulder termed MCDB 153. We have been successful to date in culturing norman keratinocytes in this medium but not successful in culturing basal cell car nomas. This has included an attempt utilizing fibronectin coated plates. We next will be attempting growth utilizing basal cell tumors that we have successfully grown in nude mice. There is experimental evidence with other tumors grown in nude mice to suggest that there is a greater success rate of in vitro culture once the tumors have been grown in the animal model.
- (17) Progress: As stated above, progress has been made in the area of BCC tumor transplantation to nude mice which we hope will facilitate growing the tumor cells in culture (Protocol # 84/115). We also have available two CO<sub>2</sub> controlled incubators that are an absolute requirement for the propogation of keratinocytes as well as BCC cells.
- (18) Presentations/Publications: None to date.

(1) Date: 30 Sep 84 (2) Protocol WU#: 83/115D (3) Status: on-going (4) Title: The effect of oral ketotifen on the development of subsensitivity to beta agonists.

(5) Start Date: 1984	(6) Est Compl Date: 1985
(/) Principal Investigator:	(8) Facility: FAMC
HS Nelson, MD, COL, MC	Allergy-Immunology Clinic
•	0,
(4) Dept/Svc: Medicine/Allergy	(10) Assoc Investigators:
(11) Key Words:	Ĭ
ketotifén	
subsensitivity	W Dolen, MAJ, MC
beta agonists	RW Weber, COL, MC
3	BT Miller, CPT, MC
	<b>4</b>
(1≥) Accumulative MEDCASE:#	(13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of	this report.
(14) a. Date, Latest HUC Review:	h. Review Results:
c. Number of Subjects Enrolled Duri	- · · · · · · · · · · · · · · · · · · ·
d. Total Number of Subjects Enrolled	
e. Note any adverse drug reactions	reported to the FDA or sponsor for stud-

none

ies conducted under an FDA-awarded IND. (May be continued on a separate

Publications and Presentations: None

sheet, and designated as "(14)e".

<sup>(15)</sup> Study Objective: To determine whether the drug, ketotifen, can prevent the development of subsensitivity to inhaled beta agonists in humans.

<sup>(16)</sup> Technical Approach: The bronchodilator response to inhaled terbutaline will be measured before and following chronic terbutaline administration during two periods of time, one when the patients are receiving in addition oral ketotifen, the second when they are receiving a placebo.

<sup>(17)</sup> Progress: This study is ready to commence, but no patients have been enrolled to date.

	8 July 1982
(1) (4) A Mul of bu	Date: FY 84 (2) Protocol WU Nr.: 83/114 (3) Status: terminate Title:  lti-centered, double-blind, randomized study of the steroid sparing effected sonide versus placebo in adult patients with chronic asthma.
(5) (7) Harol	Start Date: (6) Est Compl Date: Principal Investigator (8) Facility: FAMC ld S. Nelson, MD, COL, MC
(9) (11)	Dept/Svc: Medicine/Allergy (10) Assoc Investigators:  Key Words: Robert Bowen, CPT, MC William Long, MAJ, MC
(12)	Accumulate MEDCASE:* (13) Est Accum OMA Cost:*  *Refer to Unit Summary Sheet of this report.
d. : e. l	Number of subjects enrolled during reporting period: Total number of subjects enrolled to date: Note any adverse drug reactions reported to the FDA or sponsor for
(Cont	tinue on a separate sheet, designating this continuation as (14)e.)  Study Objective:

# (16) Technical Approach:

(Ref: HSCR 40-23 &

HSPA-I Ltr,

# (17) Progress:

This protocol was terminated before any patients had completed the study because of animal data which raised questions regarding its safety. Termination was at direction of the Food and Drug Administration. The safety question was raised due to an increase in brain tumors in a particular strain of mice from a normal 1% to 10% when they received injection of doses of this drug well in excess of anything which had been contemplated in human use.

Publications and Presentations: None

(FAMC FL 7807-C1 Page 2)

FAMC	A.P.R. (RCS MED 300) Detail Summar	ry Sheet (Ref. HSCR 40-23, as amended)
	Date: 30 Sep 84 (2) Protocol WU	
(4)	Title: Growth of human Kerati	inocytes
(5)	Start Date: Jul 83 (6	
(7)	Principal Investigator: (8	B) Facility: FAMC
	RONALD E. GRIMWOOD, M.D., LTC,	
(9)	Dept/Svc: Dept of Med/Derm Svc (1	0) Assoc Investigators:
$(\overline{11})^{\overline{1}}$	Key Words:	J. Clark Huff, M.D.
	Cell culture	Charles Ferris, PhD, MSC
	Keratinocytes	Phil O'Barr, PhD, DAC
(12)	Accumulative MEDCASE:* (1 *Refer to Unit Summary Sheet of the	3) Est Accum OMA Cost:* nis report.
(14)	a. Date, Latest HUC Review:	b. Review Results:
	Number of Subjects Enrolled During	Reporting Period: N/A
	Total Number of Subjects Enrolled t	
	• •	oorted to the FDA or sponsor for stud- IND. (May be continued on a separate
(15)	Study Objective:	

Growth and study of human keratinocytes in culture.

- (16) TECHNICAL APPROACH: The technical approach as stated last year has been to grow human keratinocytes obtained from newborn foreskins in MCDB 153 serum free medium. This has been accomplished and cells have been successfully frozen down in liquid nitrogen and subsequently cultured. We have not accomplished the final phase which will be to attempt to identify specific antigens (i.e. bullous pemphigoid) expressed by these cells. This will be accomplished with SDS page gel electrophoresis and nitrocellulose transfer. (Dr. O'Barr's lab).
- (17). PROGRESS: As stated above, we can successfully grow human keratinocytes and have been able to freeze the cells and subsequently culture these same cells from the frozen state. We have also utilized these cells for prostaglandin studies after they have been irradiated with ultraviolet light.

PUBLICATIONS AND PRESENTATIONS: None.

FAMC	A.P.R. (RCS MED 300) Detail Summ	nary :	Sheet (Ref. HSCR 40-23, as amended)
	Date: 30 Sep 84 (2) Protocol Title: Steroid Therapy in Chron of Response by Lung Mecha	ic Ob	structive Lung Disease - Prediction
	Start Date: August 1983 Principal Investigator: G. Keith Wolfe, M.D., CPT, MC	(6)	Est Compl Date: April 1984 Facility: FAMC
	Dept/Svc:Pulmonary/MED Key Words:	(10)	Assoc Investigators: Reuban M. Cherniack, MD, National Jewish Hospital E. Fernandez, MD, National Jewish Hospita
(12)	Accumulative MEDCASE:* *Refer to Unit Summary Sheet of	. •	
	a. Date, Latest HUC Review:	- Do	b. Review Results:
С. Г	Number of Subjects Enrolled Durin	ig kej	porting Period: 10

(!5) Study Objective: Classification of degree of responsiveness to steroids based on detailed study of lung mechanics.

e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. (May be continued on a separate

- (16) Technical Approach: A double-blinded trial with methyl prednisolone versus placebo in consecutive 3 week periods with testing of lung mechanics, exercise performance and bronchial reactivity to histamine before, between consecutive trials and after the study.
- (17) Progress: Study has been terminated short of desired number ofpatients. Non-blinded patients from National Jewish Hospital will also be studied (7 Pt's) before and after steroid (completed). Results are only now being tabulated and reviewed. Final results should be available by the end of 1984.

Publications and Presentations: None

d. Total Number of Subjects Enrolled to Date:

sheet, and designated as "(14)e". none

FAMC A.P.R. (RCS MED 300) Detail Su	mmary Sheet (Ref. HSCR 40-23, as amended)
(1) Date: 30 Sep 84 (2) Protoco	1 WU#: 83/109 (3) Status: Ongoing
(4) Title:	TTIES IN NON-TRANSMURAL MYOCARDIAL INFARCTION
(5) Start Date: Mar 1983	(6) Est Compl Date:
(7) Principal Investigator:	(8) Facility: FAMC
Matthew J. McMahon DO MAJ MC	
(9) Dept/Svc: Dept Medicine/Cardio	s(t0) Assoc Investigators:
(11) Key Words:	RICHARD C. DAVIS, JR, MD, PhD, LTC, M
ECHOCARDIOGRAPHY MYOCARDIAL INFARCTION	GUY N. PIEGARI, JR, MD, MAJ. MC
(12) Accumulative MEDCASE:*  *Refer to Unit Summary Sheet o	(13) Est Accum OMA Cost:*  f this report.
(14) a. Date, Latest HUC Review:	
c. Number of Subjects Enrolled Dur	
d. Total Number of Subjects Enroll	ed to Date: 17 reported to the FDA or sponsor for stud-
	ded IND. (May be continued on a separate
NA.	
(15) Study Objective:	

To assess the utility of two-dimensional echocardiography in facilitating the early diagnosis of non-transmural myocardial infarction.

(16) Technical Approach:

Patients entering the FAMC CCU are given: 2-D echocardiography examination within 12 hours of admission. These studies are then evaluated for cardiac wall motion abnormalities. The study is applied only to those patients admitted for chest pain without obvious transmural MI.

(17) Progress: Data on 17 patients has been accumulated. This represents approximately half the minimum number of subjects desired. The study is presently ongoing in the data collection stage in the fiscal year 1984.

PUBLICATIONS AND PRESENTATIONS: None.

(Ref: HSCR 40-23 & HSPA-I Ltr, 8 July 1982

(1)		Protocol WU Nr.: 83/108 (3) Status: Terminated
(4)	Title: Multicenter, Do	ouble-Blind, Randomized, Parallel Comparison of
		Oosage Regimens of Naproxen Sodium in Patients
		Due to Metastatic Cancer
(5)	Start Date: Jan 83	(6) Est Compl Date: Terminated
$\frac{(3)}{(7)}$	Principal Investigator	
( / /	Arlene J. Zaloznik, M.	•
	milene of Balobnik, m	21, 1110, 110
(9)	Dept/Svc: Hematology/Or	cology (10) Assoc Investigators:
$\overline{(11)}$	Key Words:	Nicholas J. DiBella, M.D., COL, MC
	Naprosyn	Micholas J. Dibella, M.D., COL, MC
	Bone pain	
	Metastatic cancer	
$\overline{(12)}$	Accumulate MEDCASE:*	(13) Est Accum OMA Cost:*
	*Refer to Unit Summary	
(14)	a. Date, Latest HUC R	eview: b. Review Results:
c.	Number of subjects enro	lled during reporting period: 0
d.	Total number of subject	s enrolled to date: 0
e.	Note any adverse drug r	eactions reported to the FDA or sponsor for
	studies conducted under	an FDA-awarded IND.: Not applicable
		et, designating this continuation as (14)e.)
(15)	Study Objective:	e efficacy and safety of a higher total dose of
		ower total daily dose in patients with moderate
	•	one pain due to metastatic cancer.
(16)	•	one parn due to metastatic cancer.
(16)	Technical Approach:	d to receive either high dose or low dose Naproxen
		to control severe persistent home pain

(17) Progress:
Because of some inherent problems in the design of the protocol, no patients have been registered. A meeting was held with the people from Syntex Laboratories to resolve some of these problems. They were unresolvable and the protocol was terminated without any patients having been registered.

(1)		WU#: 83/107 (3) Status: ONGOING
(4)	Title: USE OF ISOTRETINOIN IN	PREVENTION OF BASAL CELL CARCINOMA.
(5)	Start Date: APP 1 Oct 84	(6) Est Compl Date: 5 years from start.
(I)	Principal Investigator:	(8) Facility: FAMC
	J. RAMSEY MELLETTE, M.D., COL, M	MC DERMATOLOGY SERVICE
(9)	Dept/Svc: Medicine/Dermatology	(10) Assoc Investigators:
	Key Words: Isotretinoin	LINDA M. SERWATKA, MAJ, MC Co-Principa
	Retinoids	Investigato
	Basal cell carcinoma	
(12)	Accumulative MEDCASE:*	(13) Est Accum OMA Cost:*
	*Refer to Unit Summary Sheet of	this report.
		/A b. Review Results: N/A
	lumber of Subjects Enrolled Durin	
	otal Number of Subjects Enrolled	
j		reported to the FDA or sponsor for stud- led IND. (May be continued on a separate

- a. To evaluate the effectiveness of low dosage levels of Isotretinoin in reducing the incidence of basal cell carcinomas in high risk population.
- b. To examine possible side-effects associated with long term asministration of low doses of Isotretinoin.
- (16). TECHNICAL APPROACH: This will be a double-blind study with participants randomly assigned to active drug (Isotretinoin) or placebo. Patients will take their assigned drug or placebo for three years and will be followed for an additional two years after discontinuing medication. Compliance, side-effects and appearance of new basal cell carcinomas will be noted.
- (17). Study has not yet started pending hiring of Nurse Specialist. This has now been accomplished and it is expected that the study will commence in October 1984.

, ; ;	D. 4. 20 C- 0/ (2) D41	1.111.4	83/106D (3) Status: Ongoing	
	Date: 30 Sep 84 (2) Protocol		(3)	
(4)	Title: Efficacy of Weekly Pulse			
	Rheumatoid Arthritis: A	A doub	ole blind crossover study	
$(\bar{5})^{-}$	Start Date: 1983	(6)	Est Compl Date: 1987	
(7)	Principal Investigator:	(8)	Facility: FAMC	
	Peter A. Andersen, MD, MAJ, MC	l		
	Sterling G. West, MD, MAJ, MC	1		
	, , ,	1		
		ì		
		1		
(9)	Dept/Svc:	(10)	Assoc Investigators:	
	Key Words:	1	-	
	RA	ł	Robert G. Claypool, MD, COL, MC	
	Methotrexate		Richard C. Welton, MD, MAJ, MC	
		!	Charles S. Via, MD, MAJ, MC	
		1		
$\overline{(12)}$	Accumulative MEDCASE:*	(13)	Est Accum OMA Cost:*	
	*Refer to Unit Summary Sheet of	this	report.	
(14)	a. Date, Latest HUC Review: N	Δ	b. Review Results: NA	
	Number of Subjects Enrolled Durin			
	<u> </u>	_	·	
	Total Number of Subjects Enrolled to Date: 13  Note any adverse drug reactions reported to the FDA or sponsor for stud-			
	· -	-	- · · · · · · · · · · · · · · · · · · ·	
			D. (May be continued on a separate	
5	sheet, and designated as $"(14)e"$ .	n	one	

- (15) Study Objective: part I Evaluate effectiveness of weekly pulse MTX to control activity of RA in patients who have failed therapy with gold shots and D-Penicillamine. Part II Evaluate the potential of weekly pulse MTX to halt or decrease the progress of destructive changes of articular cartilage and bone. Part III Evaluate the potential for toxicity of weekly pulse MTX.
- (16) Technical Approach: Part I 27 week double blind crossover study of MTX vs placebo comparing joint counts, functional tests, laboratory parameters and subjective scores. Part II Blinded comparison of pretreatment and q6month sequential roentenographs of involved joints. Part III Evaluation of biochemical liver function studies and comparison with sequential changes on liver biopsy.
- (17) Progress: During the past year there have been 15 patients enrolled in the study, nine at Fitzsimons and six at Brooke Army Medical Center; 13 have completed the study 1 April 1984. Currently these data are being evaluated and compiled on the patients who have completed this study for presentation at the ARA National Meeting in June 1984.

HSPA-I Ltr, 8 July 1982
(1) Date: FY 84 (2) Protocol WU Nr.: 83/103(3) Status: Ongoing (4) Title:
Role of Vitamin K Deficiency in Bone Metabolism
(5) Start Date: 1983 (6) Est Compl Date: Maybe 1985
(7) Principal Investigator (8) Facility: FAMC
Vasundhara G. Iyengar
(9) Dept/Svc: Medicine/Hematology/ (10) Assoc Investigators:
(11) Key Words: Oncology
Vitamin K
Coumadin
Osteoporosis Osteopenia
(12) Accumulate MEDCASE:* (13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this report.
(14) a. Date, Latest HUC Review: Feb 83 b. Review Results: On-going
c. Number of subjects enrolled during reporting period: 8
d. Total number of subjects enrolled to date:
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND.:
,
(Continue on a separate sheet, designating this continuation as (14)c.) (15) Study Objective:
To find out in a cross sectional study design, if Coumadin in long term therapeutic doses can induce significant osteopenia or osteoporosis
(16) Technical Approach: Obtain one time bone density measurements of patients on Coumadin and control population and comparing results to see if there is significant difference between the two populations.

No progress has been made since last report due to my involvement with another research project at the University of Colorado.

(17) Progress:

(1)	Date:	30 Sep 84	(2) Protocol WU#: 83/102 (3) Statu	s:ongoing
(4)	Title:	A survey of	extrachromosomal elements of Legionel	la pneumophilia
		serotype 1,	from environmental and clinical isola	ites.

(5)	Start Date: February 1983	(6)	Est Compl Date: December 1984
(7)	Principal Investigator: Steven M. Opal, MD, MAJ, MC Carol Ciesielski, MD, Infect. Disease Svc, CU Med Center	(8)	Facility: FAMC
(9) (11)	Dept/Svc: DOM, Infectious Dis. Key Words: Legionella pneumophilia Serotype I, virulence plasmids	(10)	Assoc Investigators:  Ms. Pari Morse, GS-9, Microbiologist Paul G. Engelkirk, LTC, MSC, PhD
(12)	Accumulative MEDCASE:# #Refer to Unit Summary Sheet of		Est Accum OMA Cost:* report.

(14) a. Date, Latest HUC Review: NA b. Review Results: NA c. Number of Subjects Enrolled During Reporting Period:

d. Total Number of Subjects Enrolled to Date: none

e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. (May be continued on a separate sheet, and designated as "(14)e". None.

(15) Study Objective:
The objective of this protocol is to isolate the plasmid DNA of several environmental and clinical isolates of <u>L</u>. pneumophilia, and to compare their plasmid profiles.

(16) Technical Approach:

Legionella pneumophilia plasmid DNA will be prepared by rapid alkaline precipitation method and analyzed by agarose gel electrophoresis.

(17) Progress:

The plasmid DNA samples are being isolated from Legionella pneumophilia at the present time. Delays in performing agarose gell electrophoresis preps owing to lack of DNA transilluminator (now available).

(1) Date: 30 Sep 84 (2) Protocol WU#: 83/101 (3) Status: Ongoing

(4) Title: Genetics of Exfoliatin B production from clinical isolates of Staphylococcus aureus which produced staphylococcal scalded skin syndrome.

(5) Start Date: February 1983 (6) Est Compl Date: June 1985
(7) Principal Investigator: (8) Facility: FAMC
Steven M. Opal, MD, MAJ, MC.
Allan S. Cross, MD, LTC, MC,
WRAIR, Washington, D.C.

(9) Dept/Svc: Medicine/Infectious Dis(10) Assoc Investigators:

(11) Key Words:
Exfoliatin B,
Staphylococcal scalded skin
syndrome,
Staphylococcal plasmids.

Ms. Pari L. Morse, GS-9,
Microbiologist, FAMC.
Paul G. Engelkirk, LTC, MSC, PhD,
FAMC.

(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this report.

(14) a. Date, Latest HUC Review: b. Review Results:

c. Number of Subjects Enrolled During Reporting Period: Not applicable.

. Total Number of Subjects Enrolled to Date: Not applicable.

e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. (May be continued on a separate sheet, and designated as "(14)e".

Not applicable.

(15) Study Objective:

The objective of this study is to isolate plasmid DNA responsible for the production of exfoliatin B production in <u>Staphylococcus</u> aureus strains. The restriction endonuclease digestion pattern of this isolate will be compared with that of other exfoliatin B producers as well as reference strain from the CDC.

(16) Technical Approach:

Staphylococcal plasmid DNA was isolated by cleared lysis technique and by cesium chloride ultracentrifugation density gradients. The isolated plasmid DNA was then run on agarose gel eletrophoresis for molecular weight sizing. The endonuclease digestion pattern will then be obtained by digesting this plasmid with restriction endonuclease enzymes.

(17) Progress:

The initial plasmid isolation and characterization of the plasmid molecular weight on agarose gel has been accomplished. This information was submitted for publication without the restriction endonuclease digestion since the co-authors of this paper felt that it should be rapidly published. However, the reviewer in General Infectious Disease felt that restriction endonulcease digestion pattern was required prior to publication. Therefore, this work will be accomplished in this next fiscal year. The protocol is therefore ongoing, and the remaining studies that need to be performed are the restriction endonulcease digest patterns. The aforementioned progress was made during fiscal year 1984.

(Ref: HSCR 40-23 & HSPA-I Ltr, 8 July 1982

(1) Pate: FY 84 (2) Protocol WU Nr.:83/100 (3) Status: COMPLETED (4) Title: A survey of bacterial virulence factors in E. coli, and their significance in the pathogenesis of gram negative bacillary infections in man.

(5) Start Date: L Feb 83	(0) Est compi Date: Jan 84
(7) Principal Investigator Opal, Steven M. MD, MAJ, MC	(8) Facility: FAMC
Cross, Alan S. MD, LTC, MC	
Gemski, Peter PhD	
(9) Dept/Svc: Med/Inf Dis	(10) Assoc Investigators:
(11) Key Words: E. coli	Morse, Pari L.
virulence factors	Engelkirk, Paul G. LTC, MSC
gram-negitive bacillary infections	
(12) Accumulate MEDCASE: *	(13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of	this report.
(14) a. Date, Latest HUC Review:	b. Review Results:
c. Number of subjects enrolled during	ng reporting period:
d. Total number of subjects enrolled	to date:
	reported to the FDA or sponsor for

(Continue on a separate sheet, designating this continuation as (14)c.)

(15) Study Objective: The objectives are three-fold: 1) to determine the frequency with which certain virulence factors are found in bacteremic <u>E. coli</u> isolates; 2) to compare this frequency with that found in urinary and stool isolates from normal individuals; and 3) to determine the relationship between these virulence factors and host response to infection.

(16) Technical Approach:

Fifty random stool isolates were obtained from normal patients and compared with over 100 blood and urinary isolates for the presence of virulence factors.

(17) Progress: The K, and rough phenotype, hemolysin production, serum sensitivity, iron uptakes, colicin production, hemagglutinin phenotype, and plasmid profile for all 50 stool isolates as well as urinary and blood isolates has been completed. The final statistical analysis and preparation of the manuscript is in progress.

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (Ref. HSCR 40-23, as amended) (l) Date: 30 Sep 84 (2) Protocol WU#: 82/116 (3) Status: Ongoing (4) Title: ASSESSMENT OF REGIONAL WALL MOTION ABNORMALITIES BY RADIONUCLIDE ANGIOGRAPHY: EFFECT OF SUBLINGUAL NITROGLYCERIN (6) Est Compl Date: (5) Start Date: Principal Investigator: (8) Facility: FAMC STEVEN J. RAIBLE MD MAJ MC Medicine/Cardiology (10) Assoc Investigators: (9) Dept/Svc: (11) Key Words: RICHARD C. DAVIS JR MD PhD LTC MC JOHN JACKSON, MD MAJ MC nitroglycerin PETER W. BLUE MD LTC MC introglycerin angiography (12) Accumulative MEDCASE:# (13) Est Accum OMA Cost:\* \*Refer to Unit Summary Sheet of this report. (14) a. Date, Latest HUC Review: NA b. Review Results: e. Number of Subjects Enrolled During Reporting Period: d. Total Number of Subjects Enrolled to Date: e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. (May be continued on a separate

- (15) Study Objective: This study is designed to analyze the sensitivity and specificity of radionuclide angiography in assessing segmental wall motion abnormalities after nitroglycerin administration and after coronary artery bypass grafting.
- (16) Technical Approach: Forty patients with stable angina and atherosclerotic heart disease involving one or more vessels with a wall motion abnormality documented by cardiac catheterization within six months prior to gated radionuclide ventriculography (RVG) will be studied. Patients will be between the ages of 30 and 65. No study candidate will have had a prior transmural myocardial infarction or have aortic or mitral valvular heart disease. Those patients undergoing coronary artery bypass grafting will have repeat RVG approximately 10 days after surgery. All patients will be tested in a basal fasting state and will have all nitroglycerin preparations withheld for 24 hours prior to the study.
- (17) Progress: No accountable progress has been made on this study due to technical problems, finding suitable patients and arranging suitable time with physicians and technicians.

PUBLICATIONS AND PRESENTATIONS: None.

sheet, and designated as "(14)e".

(1) Date: 30 Sep 84 (2) Protocol WU#: 82/115 (3) Status: Ongoing			
(4) Title: SERIAL TWO-DIMENSIONAL ECHOCARDIOGRAPHIC EVALUATION OF ACUTE ANTERIOR MYOCARDIAL INFARCTIONS FOR DETECTION OF LEFT VENTRICULAR THROMBI			
(5) Start Date: November 1982 (6) Est Compl Date: (7) Principal Investigator: (8) Facility: FAMC			
GUY N. PIEGARI JR MD MAJ MC			
(9) Dept/Svc: MEDICINE/CARDIOLOGY (10) Assoc Investigators:			
(11) Key Words: RICHARD C. DAVIS JR MD PhD LTC MC			
2-D echocardiography left ventricular thrombus  HARRY M. THOMAS JR MD COL MC			
(12) Accumulative MEDCASE:# (13) Est Accum OMA Cost:# #Refer to Unit Summary Sheet of this report.			
(14) a. Date, Latest HUC Review: NA b. Review Results: NA			
c. Number of Subjects Enrolled During Reporting Period: NA  d. Total Number of Subjects Enrolled to Date: NA			
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. (May be continued on a separate sheet, and designated as "(14)e".			
NA NA			
(15) Study Objective: Assess incidence of mural thrombi in patients with acute anterior MI.			
(16) Technical Approach: Patients admitted to CCU with acute anterior MI receive serial 2-D echocardiogram over 10-day period.			
(17) Progress: Since transfer of principal investigator, this study has been placed on hold status until availability of another principal investigator to continue the study.			
PUBLICATIONS AND PRESENTATIONS: None.			

(Ref: HSCR 40-23 &

HSPA-I Ltr. 8 July 1982 (2) Protocol WU Nr.: 83/116 (3) Status: Terminated (1) Date: FY (4) Title: Intraarterial Cisplatin Therapy for Unresectable or Recurrent Adenocarcinoma of the Pancreas. A Phase II Study. Start Date: 1 April 1983 (6). Est Compl Date: 7 August 1984 (7) Principal Investigator (8) Facility: FAMC Nicholas J. DiBella, M.D. Hematology/Oncology Svc (9) Dept/Svc: Dept of Medicine (10) Assoc Investigators: (11) Key Words: (13) Est Accum OMA Cost:\* (12) Accumulate MEDCASE:\* \*Refer to Unit Summary Sheet of this report. (14) a. Date, Latest HUC Review: b. Review Results: c. Number of subjects enrolled during reporting period: 2 d. Total number of subjects enrolled to date: e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND.: None (Continue on a separate sheet, designating this continuation as (14)e.) (15) Study Objective: To determine whether intraarterial cisplatin can be used for local control of adenocarcinoma of the pancreas. (16) Technical Approach: Intraarterial cisplatin was infused via arterial catheter at 4 week intervals using CT scan and other objective measurements of tumor activity to determine whether the tumor was responding. (17) Progress: One patient received nine courses of intraarterial cisplatin with no change in the CT scan appearance of the pancreatic mass. There was a fall in the renal function to a creatinine clearance of approximately 55 cc/min so that chemotherapy was discontinued. CT directed biopsy of the mass revealed only fibrosis and the patient continues to do well. He is being followed at regular intervals with repeat CT scans and liver function tests. He regained

Incl la new form of systemic chemotherapy. Both patients experienced mild to

his weight and has remained basically asymptomatic during the course of treatment. The second patient had four doses of intraarterial cisplatin with some decrease in renal function but was taken off the study due to progression of disease within the liver. He has been switched to reach the course of the study due to progression of disease within the liver.

Continuation of (17)e

moderate nausea and vomiting which was controlled with metoclopramide, diphenhydramine and dexamethasone. These side effects and the decrease in renal function were both expected from use of intraarterial cisplatin.

(1)	Date: 30 Sep 84 (2) Protocol	WU#:	83/117 (3) Status: Ongoing	_
(4)	Title:			
	The Role of Altered Arachidonic	Acid	Metabolism in the Atherogenesis and	đ
	Bleeding Tendency of Hypothyroic	dism,	and the Response of This System to	_Thyroid
(5)	Start Date: 1 Aug 83	(6)	Est Compl Date: 1 Aug 85	Hormone
(7)	Principal Investigator:	(8)	Facility: FAMC	Replacement
	Gerald S. Kidd, MD, LTC, MC			
	Robert J. Sjoberg, MD, CPT, MC	İ		
	T. P. O'Barr, Ph.D., DAC	į		
	Ellen Swanson, DAC			
<del></del>		(10)		_
(9)	Dept/Svc: Medicine/Endocrine	1(10)	kasaa Investigators: (Cont)	
(11)	Key Words:	į.	Principal	
	arachidonic acid metabolism	ì	Donald Corby, MD, COL, MC	
	hypothyroidism	l	Fred D. Hofeldt, MD, COL, MC (Ret)	
	$PGI_3$ , $Tx A_2$ , $B_2$			
(12)	Accumulative MEDCASE:*	(13)	Est Accum OMA Cost:*	-
	*Refer to Unit Summary Sheet of	this	report.	
(14)	a. Date, Latest HUC Review:		b. Review Results:	-
			porting Period: Approx 200 Sprague-I	Dawley rats
	Total Number of Subjects Enrolled			_
			ted to the FDA or sponsor for stud-	
			D. (May be continued on a separate	
	sheet, and designated as $"(14)e"$ .	•		4
	N/A			
(15)	Study Objective:			-
<b>、エノノ</b>	Duddy objective.			

To evaluate the effects of hypothyroidism or rat platelet thromboxane A2

 $(TxA_2)$  and aortic ring prostacycline by measuring thromboxane  $B_2$   $(TxB_2)$  and 6-ketoprostaglandin Fla (6K-PGFla ), respectively in hypothyroid Sprague-Dawley rats. Second, to determine the effects of treatment on the same parameters with "low and high" dose levothyroxine.

#### (16) Technical Approach:

Rats made hypothyroid and controls were sacrificed at various intervals after collecting blood, counting platelets and aggregating platelets. TxB2 was measured after aggregation by specific RIA segments of aorta were removed, sliced and incubated. Incubate solutions (at various times) were removed for the measurement of 6K-PGFla by RIA. Similar procedures were performed on hypothyroid L-thyroxine treated rats.

### (17) Progress:

During FY84, the majority of the study has been completed however more control data needs to be collected. Preliminary results have been presented on two occasions and accepted for presentation at another meeting. Approximately 200 rats have been studied (all groups) and this data has been evaluated. Several minor aspects related to treatment and the effects of aging on the control animals needs further work.

# SERVICE Endocrinology/Biochemistry DEPARTMENT Medicine/Clinical Investigation

- (1) Sjoberg, R.J., Kidd, G.S., Swanson, E., O'Barr, T.P., Corby, D., and Hofeldt, F.D.: Platelet and Vessel Wall Arachidonic Acid Metabolism in Hypothyroidism. Presented: ACP Associated Meeting, Denver, CO, 1984.
- (2) Sjoberg, R.J., Kidd, G.S., Swanson, E., O'Barr, T.P., Hofeldt, F.D.. Platelet Thromboxane and Arterial Wall Prostacyclin Generation in Hypothyroid Rats and Their Response to Thyroid Hormone Replacement. Presented: Hugh Mahon Lectureship Award, Fitzsimons Army Medical Center, Aurora, CO, 1984.
- (3) Sjoberg, R.J., Kidd, G.S., Swanson, E., O'Barr, T.P., Wetherill, S., Corby, D., and Hofeldt, F.D.: Thromboxane and Prostacyclin Generation in Hypothyroidism. Accepted for Presentation, Eastern Section, AFCR, Philadelphia, PA, 18 Oct 84.

PUBLICATIONS: NONE

(1) Date: 30 Sep 84 (2) Protocol	WU#: 83/119 (3) Status: Ongoing
(4) Title:Sardoidosis: Varying Lymph Bronchoalveolar Lavage	ocyte Concentration in Sequential
(5) Start Date: Mar 1983 (7) Principal Investigator: Clarence Hendrix, MAJ, MC	(6) Est Compl Date: Indefinite (8) Facility: FAMC
(9) Dept/Svc: Pulmonary/Medicine (11) Key Words:  BronchoAlveolar Lavage Sarcoidosis Alveolitis	(10) Assoc Investigators:  David Thomas MAJ, MC Talmadge King MD
(12) Accumulative MEDCASE:# #Refer to Unit Summary Sheet of	(13) Est Accum OMA Cost:* this report.
	ng Reporting Period: 10 i to Date: 10 reported to the FDA or sponsor for studed IND. (May be continued on a separate

Publications: None

Presentations: Hendrix, C., Bronchoalveolar Lavage Analysis in Sarcoidosis. Presented: American College of Physicians Associates Meeting, Denver, CO March, 1984.

<sup>(15)</sup> Study Objective: To establish the effect, if any, of sequential bronchoalveolar lavage on the proportion of lymphcytes recovered.

<sup>(16)</sup> Technical Approach: The bronchoscope is wedged in a peripheral location and aliquots of saline, 30 ml, injected into a segmental bronchus. Each aliquot is recovered and analyzed. A total of 300 ml are injected. From analysis of each aliquot, correlation between cell population and disease activity will be determined.

<sup>(17)</sup> Progress: A definite relationship between the amount of saline insdilled and the proportion of lymphocytes recovered has been established. Washings with only 30 ml of saline are misleading because of the high proportion of neutrophiles isolated. If the first 30 ml aliquot is discarded and the next threee aliquots collected more consistent data is collected. Collection of lavage fluid in excess of 90 ml has been found to yield little additional information.

FAMC	A.P.R. (RCS MED 300) Detail Sum	mmary Sheet (Ref. HSCR 40-23, as amended)
(1)	Date: 30 Sep 84 (2) Protocol	WU#: 83/120 (3) Status: Ongoing
(4)	Title: Correlation of Renal Cor	ncentrating Ability With Hemoglobin S Military Personnel With Sickle Cell
(5)	Start Date: 1984	(6) Est Compl Date:
(7)	Principal Investigator: John R. Hess, MAJ, MC	(8) Facility: FAMC
(9)	Dept/Svc:Hematology/MED	(10) Assoc Investigators:
	Key Words: sickle cell hemoglobin S	Gary Rombert, LTC, MC, USAF Richard Artim, MAJ, MC, USAF
(12)	Accumulative MEDCASE:* *Refer to Unit Summary Sheet of	(13) Est Accum OMA Cost:# 'this report.
e. ! d. :		ng Reporting Period: 11

sheet, and designated as "(14)e". none

<sup>(15)</sup> Study Objective: To crrelate renal concentrating ability with hemoglobin S concentration in individuals with sickle cell trait in the military age range.

<sup>(16)</sup> Technical Approach: Patient selection at the United States Air Force Academy with sickle cell trait and normal renal function as documented by a normal urine analysis and a serum creatinine concentration of 1.2 or less at prior screening would be accepted as volunteers for this study after giving informed consent. There are 23 such cadets at this time. Cadets would be instructed to abstain from drinking water after 1900 hr the day before the study and to report at 0700 hr to the study area. Hourly urine samples would be collected for six samples and measured for osmolality and urine volume and two blood samples would be drawn one at the beginning and one at the end of the urine collection period and measured for osmolality and electrolytes, glucose, BUN and creatinine. The six osmolalities and volumes for each individual would be plotted to see that they approach a maximum concentration ability.

<sup>(17)</sup> Progress: Eleven patients have been entered in the study thus far with no problems encountered. Correlation has been demonstrated, we will continue to collect data.

	mary Sheet (Net. Hock 40-2), as amended)
(h) Title:	WU#: 83/121 (3) Status: ongoing
of Pulmonary Impairment	ung Compartment Ratios for Assessment
(5) Start Date: Aug 83	(6) Est Compl Date: April 1986
(7) Principal Investigator: John D. Olsen, M.D. CPT, MC	(8) Facility: FAMC
(9) Dept/Svc:Pulmonary/DOM	(10) Assoc Investigators:
(11) Key Words:	7
Spirometry Ratios	Michael E. Perry, M.D. COL, MC
(12) Accumulative MEDCASE:*  *Refer to Unit Summary Sheet of	(13) Est Accum OMA Cost:*
(14) a. Date, Latest HUC Review:	b. Review Results:
c. Number of Subjects Enrolled Duri	<del></del>
d. Total Number of Subjects Enrolle	
ies conducted under an FDA-award sheet, and designated as "(14)e"	reported to the FDA or sponsor for stud- ed IND. (May be continued on a separate . none
(15) Study Objective:	(Mr.) DDU /DU DDU /ED/)
(1) Define normal ratios for FEV (1	, (-)
(2) Determine if these simple rational lung impairment than the FEV (1	os are a better mediator of obstructive /FVC )
spirometry, body plethysmogra treadmill at 0 grade and 2 mp	be enrolled and will undergo routing phy and a minimal exertion on a h for 4 min measuring minute vetilation this data and statistically analyzed.
	ls have been accumulated from Aug 83 to r is too few to make an analysis of the

(Ref: HSCR 40-23 & HSPA-I Ltr, 8 July 1982 (1) Date: FY 30 SEP 84(2) Protocol WU Nr.: 83/122 (3) Status: ONGOING (4) Title: The Role of Food Allergy in the Pathogenesis of Migraine Headaches JUN 85 Start Date: SEP 83 (6) Est Compl Date: (8) Principal Investigator Facility: FAMC Harold S. Nelson, M.D., Col., MC MC Allergy Imm. (10) Assoc Investigators: (9) Dept/Svc: (11) Key Words: Brian T. Miller, DO, Cpt., MC Wesley Stafford, MD, MAJ., MC Migraine headache, Thurman T. Vaughan, MD, CPT., MC Food Allergy, Prostaglandins (13) Est Accum OMA Cost:\* (12) Accumulate MEDCASE:\* \*Refer to Unit Summary Sheet of this report. (14) a. Date, Latest HUC Review: b. Review Results: c. Number of subjects enrolled during reporting period: d. Total number of subjects enrolled to date: e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND.: (Continue on a separate sheet, designating this continuation as (14)e.) In this study the value of skin testing to a battery (15) Study Objective: of food allergens will be determined in directing therapy and defining a diet which will cause a decreased frequency of migraine headaches in affected patients. (16) Technical Approach:

(17) Progress:
(See continuation sheet.)

(See continuation sheet.)

- 16. In this study, approximately 100 patients will be randomly referred from the Neurology Clinic who have at least three migraine headaches a month. Those patients will on a regular diet, keep dietary records and be taken off any chronic medications over a 30-day period. They will then undergo skin testing to 83 common foods and be placed on an allergy elimination diet for 30 days. If there is a reduction in the frequency of headaches, they will undergo an open challenge and if that is positive they will undergo double-blind challenges.
- 17. Progress: At the present time 24 people have been enrolled in the study. One patient has completed the full study including double-blind challenges and is headache-free when avoiding nitrates, benzoates, and wheat. This was confirmed six out of six times by double blind challenges. Six patients have completed both the elimination diet and the regular diet trial and are ready for entry into the open challenges. The remaining patients are currently undergoing Phase I in which they keep dietary records while stopping their chronic medications. In addition, we are in the act of obtaining a number of charcoal capsules filled with either dextros as a placebo or the appropriate foods for challenges in an effort to speed up the double-blind challenges.

(1)	Date: 30 Sep 84 (2) Protocol	WU#: 83/123 (3) Status: Ongoing
(4)	Title: In Vitro Testing of Cryop	reserved Parathyroid Tissue: Functional Capacity After Using a "Simplified"
(5)		(6) Est Compl Date:
(7)		(8) Facility: FAMC
	Dept/Svc: Endo/Medicine Key Words: crypreserved parathyroid	(10) Assoc Investigators: Don Mercill, DAC Les Kramer, SP5
(12)	Accumulative MEDCASE:* *Refer to Unit Summary Sheet of	(13) Est Accum OMA Cost:* this report.
c. d.		g Reporting Period: NA

sheet, and designated as "(14)e".

<sup>(15)</sup> Study Objective: Dog parathyroid tissue will be cryopreserved for various intervals using a "simplified" freezing technique which does not require a programmed freezer. The tissue is placed in tissue culture medium, 4°C, for two hours. The tissue is then transferred to chilled vials containing tissue culture medium, autologous serum, and DMSO and immediately placed in a freezer at -80°C. After 16 hours, the vials are directly transferred to a liquid nitrogen container for storage. Successful demonstration of adequate parathyroid function after cryopreservation will be the basis for attempting parathyroid autotransplantation of cryopreserved tissue in humans at our institution as well as a more general application at those institutions where only a "simplified" freezing technique could be accomplished.

<sup>(16)</sup> Technical Approach: Thawed tissue will be compared to fresh tissue using in vitro studies that measure functional viability and replicative capacity. Functional viability will be assessed by measuring the suppresibility of PTH from dispersed parathyroid cells in suspension when the calcium concentration in the solution is changed. Replicative capacity is the ability of a cell to incorporate nutrient materials for cell survival and replication will be assessed by measuring DNA, RNA and protein synthesis in the cryopreserved specimens.

CONTINUATION SHEET, FY 84 ANNUAL PROGRESS REPORT Proto No.: 83/123

(17) Progress: We have been able to isolate and remove parathyroid glands from a large dog without difficulty and have been able to run assays of PTH from both fresh and frozen specimens from one dog. The only problem encountered is cell suspension technique needs reginement. We have been temporarily suspended from dog research until further notice.

FAMC A.P.R. (RCS MED 300) Detail Summ	mary Sheet (Ref. HSCR 40-23, as amended)
	WU#: 83/124 (3) Status: Ongoing
(4) Title: A Prospective Evaluation Undergoing Esophageal Radiation	of Esophageal Changes in Patients
(5) Start Date: 27 April 84	(6) Est Compl Date: 31 December 85
(7) Principal Investigator:	(8) Facility: FAMC
F. Moses, MAJ, MC	
(9) Dept/Svc: Gastro/Med	(10) Assoc Investigators:
(11) Key Words:	M. Hurwitz, MAJ, MC
Radiation Esophagitis	P. Blue, LTC, MC
	R. Claypool, Col, MC
(12) Accumulative MEDCASE:	(13) Est Accum OMA Cost:#
*Refer to Unit Summary Sheet of	
(14) a. Date, Latest HUC Review:	b. Review Results:
c. Number of Subjects Enrolled Duris	<del></del>
d. Total Number of Subjects Enrolled	to Date: 2
	reported to the FDA or sponsor for studed IND. (May be continued on a separate
Sheet, and designated as (14)e	None.
(15) Study Objective:	
	rely in structure and function of the
esophagus while undergoing radiati of a standardized questionaire, up	on as an innocent bystander by means oper panendoscopy with viral and fungal can, 24 hour pH monitor and esophageal
(16) Technical Approach: Patients entered into the proto	col undergo the above listed tests (see
	al fashion at inception of radiation,
(17) Progress: Since the start of the protocol have been entered into the protoco	at the date as listed above, two patients
Dublications and Presentations: Non	e

(1)	Date: 30 Sep 84 (2) Protocol	WU#: 83/125 (3) Status: ongoing
(4)	Title: Carbon Dioxide Retention wit Ventilation	h PEEP during High Frequency Jet
(5)	Start Date: May 1984	(6) Est Compl Date: May 1985
(7)	Principal Investigator: Keith Wolfe Capt MC Michael Perry COL MC	(8) Facility: FAMC
(9) (11)	Dept/Svc: Medicine/Pulmonary Key Words:  Dead Space High Frequency Ventilation Carbon Dioxide	(10) Assoc Investigators:
	Accumulative MEDCASE:# #Refer to Unit Summary Sheet of	(13) Est Accum OMA Cost:* this report.
c. N d. T e. N i	a. Date, Latest HUC Review: umber of Subjects Enrolled Durir otal Number of Subjects Enrolled ote any adverse drug reactions r es conducted under an FDA-awarde heet, and designated as "(14)e".	ng Reporting Period: 6 animals to Date: 6 Animals reported to the FDA or sponsor for studed IND. (May be continued on a separate

(15) Study Objective: To ascertain if changes in CO<sub>2</sub> retention during high frequency jet ventilation are due solely to changes in tidal volume or whether some other factor such as dead space may be a factor.

Technical Approach
(16) Animals will be studied at a constant frequeny and I:E ratio, while varying the driving pressure to maintain a constant Tidal volume. Increases in CPAP (or PEEP) will be made and the corresponding changes in CO<sub>2</sub> retention' observed.

(17) Progress: A definite relationship between CPAP and CO<sub>2</sub> retention, independant of tidal volume was established at frequencies of 200/min. This may or may not also be the case for lower frequencies if we had sighed the dogs and ensured that the animals did not develope atelectasis at lower frequencies as we did for the higher frequencies. The time course of CO<sub>2</sub> retention was surprising, and it usually required at least an hour for this to fully develop. A modification to the protocol was requested and approved to study the possible effect of cardiac output which drops with the added CPAP. This possiblilty is being currently stadied.

Presentations: Wolfe, G.K., Perry, M.E.: CPAP-Induced Carbon Dioxide Retention During High Frequency Jet Ventilation. To be presented: Carl W. Tempel Pulmonary Disease Symposium, San Francisco, CA, October 1984.

FAMC	A.P.R. (RCS MED 300) Detail Summ	nary Sheet (Ref. HSCR 40-23, as amended)
(1)	Date: 30 Sep 84 (2) Protocol	WU#: 83/126 (3) Status: Ongoing
(4)	1,10 11010 01 111101 00 1110	taglandin Synthesis in the Impaired Water Renin-Aldosterone Axis of Hypothyroidism
(5)	Start Date: August 1983	(6) Est Compl Date: August 1985
(7)	Principal Investigator: Robert J. Sjoberg, MD, CPT, MC Gerald S. Kidd, MD, LTC, MC Thomas P. O'Barr, Ph.D. Fred D. Hofeldt, MD, COL, MC	(8) Facility: FAMC
(9)	Dept/Svc: Medicine/Endocrine	(10) Assoc Investigators:
(11)	Key Words: prostaglandin synthesis water metabolism hypothyroidism	None.
(12)	Accumulative MEDCASE:* *Refer to Unit Summary Sheet of	(13) Est Accum OMA Cost:* this report.
(14)	a. Date, Latest HUC Review:	b. Review Results:
	Number of Subjects Enrolled Durin	
	Total Number of Subjects Enrolled	
:		eported to the FDA or sponsor for studed IND. (May be continued on a separate

(15) Study Objective:

The objective of this study is to determine in an indirect manner, i.e. with prostaglandin synthesis inhibition, if the abnormal suppressibility of vasopressin and/or altered renal sensitivity to vasopressin seen in hypothyroid patients is caused by altered prostaglandin levels. This will be done by measuring serum vasopressin levels are urinary water excretion in response to a water load, as well as the renal response to exogenous vasopressin, in hypothyroid patients with and without prostaglandin synthesis inhibition, both before and after treatment with thyroid hormone to the point of euthyroidism. In the same way, the influence of altered prostaglandin levels on the renin-aldosterone axis of hypothyroidism will be studied by measuring plasma renin activity and aldosterone levels in these patients while in a relatively volume deplete state, that is before the water loading is performed.

Altered renal prostaglandin synthesis in hypothyroidism will also be assessed directly by measuring urinary PGE-2 excretion in the hypothyroid and euthyroid states. (Urinary PGE-2 excretion is thought to reflect primarily renal PGE-2 production.)

(16) Technical Approach:

By measuring urinary prostaglandin E and water loading responses in hypothyroid patients before and after indomethacin administration as well as measuring plasma, aldosterone, and plasma renin activity we will evaluate the effects of prostaglandin synthesis inhibition on water metabolism.

CONTINUATION SHEET, FY 84 ANNUAL PROGRESS REPORT Proto No.: 84/110

(17) Progress:

This study is ongoing with initial screening of over 30 isolates of Campylobacter species. This data will be collated and serum resistance of these strains will be compared. Serum resistant plasma containing species will then be cured of their plasmids and retested to determine if any contribution serum resistance is carried on the extrachromosomal elements of Campylobacter species. This is reported for Fiscal Year 1984.

- (1) Date: 30 Sep 84 (2) Protocol WU#: 84/110 (3) Status: On going (4) Title: Survey of the extrachromosomal elements of Campylobacter species obtained from environmental and clinical isolates.
- (5) Start Date: May 1984
  (6) Est Compl Date: May 1985
  (7) Principal Investigator:
  Steven M. Opal, MD, MAJ, MC
  Martin Blaser, MD, C, Inf Dis
  Service, VA Hospital.
- (9) Dept/Svc: Medicine/Infec. Diseas (10) Assoc Investigators:
  (11) Key Words:
  Campylobacter; virulence factors; plasmids.

  Pari Morse, GS-9, Clinical Microbiologist, DCI.
- (12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*

  \*Refer to Unit Summary Sheet of this report.
- (14) a. Date, Latest HUC Review: None b. Review Results: Not applicable c. Number of Subjects Enrolled During Reporting Period: Not applicable
- d. Total Number of Subjects Enrolled to Date: Not applicable.
- e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. (May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective:

The objective of this investigation is to study the extrachromosomal elements of Campylobacter species to determine their contribution to the virulence of these organisms. It has previously been demonstrated that virulence plasmids are present in virtually all the Enterobacteriaceae. These plasmids contribute to the resistance to the bacteriocidal effect of human serum. Campylobacter species C. fetus are uniformly serum resistant owing to a smooth LPS. Campylobacter jejuni are generally serum sensitive owing to rough LPS.

(16) Technical Approach:

Some relatively resistant <u>Campylobacter</u> species have been identified. These will be of great interest in studying the plasmid profile of these organisms to determine if any unique plasmid bands exist which might be contributing to the virulence of these isolates. It is anticipated that the finding of such plasmids will be confirmed by several methods of plasmid isolation and that plasmid curing experiments will be performed to remove the plasmids from the cytoplasma of these organisms. These cured organisms will then be retested to determine if a loss of serum resistance has occurred.

#### STUDY OBJECTIVE:

The objective of this project is designed to evaluate the value of two dimensional (2-D) echocardiographic analysis of exercise induced left ventricle wall motion abnormalities in the evaluation of patients with suspected ischemic heart disease. Pre and post exercise 2-D echocardiograms will be analyzed to identify exercise induced left ventricular wall motion abnormalities. These studies will be correlated with ST segment changes noted during exercise stress testing and to the findings at coronary cineangiography.

#### TECHNICAL APPROACH:

Twenty-five patients referred to FAMC for cardiac catheterization without evidence of a prior myocardial infarction will be enrolled in the study. The usual work up of these patients will be modified to include a 2-D echocardiogram at rest and after completing a treadmill stress test. The echocardiogram will be analyzed for changes in left ventricular wall motion that occur during exercise suggesting regional ischemic changes. These changes will be correlated with the data found at coronary cineangiography.

#### PROGRESS:

Since the start of this study in April 1984, 6 patients have been enrolled. In one patient the baseline echocardiogram was of technically poor quality and this patient was withdrawn from the study. Preliminary results of the remaining patients suggest a sensitivity and specificity of approximately 50%. These disappointingly poor results have been limited by the use of an echocardiography machine that yielded poor quality views, as well as a former echocardiogram technician that was less skillful at obtaining the appropriate views. By using the ATL echocardiography machine and our new technician, we are hopeful that these results will improve.

There have been no complications to date with the use of echocardiography added to treadmill stress testing.

(1) Date: 30 Sep 84 (2) Protocol	WU#: 84/109 (3) Status: Ongoing
Exercise-Induced	Echocardiographic Evaluation of Wall Motion Abnormalities: onary Artery Disease
(5) Start Date: April 1984	(6) Est Compl Date: June 1985
(7) Principal Investigator: William D. Bowden, CPT, M	(8) Facility: FAMC
(9) Dept/Svc: Cardiology/ DOM	(10) Assoc Investigators:
(11) Key Words:	COL H. Thomas, JR.
Exercise echo	
Ischemic Heart Disease	
(12) Accumulative MEDCASE:* *Refer to Unit Summary Sheet of	(13) Est Accum OMA Cost:* this report.
<ul> <li>d. Total Number of Subjects Enrolled</li> <li>e. Note any adverse drug reactions r</li> </ul>	ng Reporting Period:  I to Date: reported to the FDA or sponsor for studed IND. (May be continued on a separate
(15) Study Objective:	

Please see next page

(1)	Date: 30 Sep 84 (2) Protocol	WU# :	34/108 (3) Status: Ongoing
(4)		t lig	tht (UVB) on the production of
(5) (7)	Start Date: 15 Dec 1983 Principal Investigator:	(6) (8)	Est Compl Date: March 1985 Facility: FAMC
	James E. Fitzpatrick MD Maj, MC		•
(9)	Dept/Svc: Derm/DOM	(10)	Assoc Investigators:
	Key Words: UVB, endothelial cells, prostacyclin	1	Thomas P O' Barr PhD, DAC
		1	Ellen Swanson DAC
	prostacycrin		Don Mercell DAC
			Chuck Ferris PhD, Capt, MSC
(12)	Accumulative MEDCASE:	(13)	Est Accum OMA Cost:*
	*Refer to Unit Summary Sheet of	this	report.
(14)	a. Date, Latest HUC Review: N/A		
c.	Number of Subjects Enrolled Durin		
d.	Total Number of Subjects Enrolled		
e.			ted to the FDA or sponsor for stud-
	sheet, and designated as "(14)e".		D. (May be continued on a separate
	bilett, and designated as (14)e	•	N/A

Publications: Bennion SD, Fitzpatrick JE, Harbell J, Swanson E, O'Barr T: The effect of UVB on 6-keto-PGF, production by cultured human endothelial cells. J. Invest Dermatol 82:428a, 1984.

Presentations: Bennion SD, Fitzpatrick JE, Harbell J, Swanson E, O'Barr T: The effect of UVB on 6-keto-PFG<sub>la</sub> production by cultured human endothelial cells. Presented to Society of Investigative Dermatology meeting in Washington DC, May 1984.

<sup>(15)</sup> Study Objective:

To determine if UVB in physiological doses will stimulate the release of prostacyclin from human endothelial cells.

<sup>(16)</sup> Technical approach: Endothelial cells will be cultured from adipose tissue and irradiated with various doses of UVB and Prostacyclin will be assayed by a RIA.

<sup>(17)</sup> Progress; Preiminary results have shown an increase of prostacyclin as anticipated but further studies will be needed to confirm this.

CONTINUATION SHEET, FY 84 ANNUAL PROGRESS REPORT

Proto No.: 84/107

(17) Progress:

This protocol is on going and will be completed as soon as the construction is finished on the third floor. It is anticipated that this will be complete by December 1984. Additional sampling of the construction area prior to reoccupying these areas for patient care will have to be conducted as well. A brief sampling and survey system will be employed after reoccupation of the newly construction areas to insure no additional cases of Aspergillus infections develop. This report is made for Fiscal Year 1984.

	WU#: 84/107 (3) Status: On going						
	ntamination of the Environment During						
Hospital Renovation; and, the Efficac	y of Infection Control Measures in						
Preventing Nosocomial Aspergillosis.							
(5) Start Date: 30 Dec 83	(6) Est Compl Date: March 1985						
(7) Principal Investigator:	(8) Facility: FAMC						
Steven M. Opal, MD, MAJ, MC.							
Arnold Asp, MD, CPT, MC, Linda J.							
Burton, MAJ, ANC.							
(9) Dept/Svc: Medicine/Inf Disease	(10) Assoc Investigators:						
(11) Key Words:	Pari Morse, GS-9, Clinical Micro-						
Aspergillus infection.	biologist, DCI. Philip Hammer, SP5,						
Nosocomial infection.	Infection Control Service. Preston B.						
	Cannady, Jr., MD, COL, MC.						
(12) Accumulative MEDCASE:*	(13) Est Accum OMA Cost:*						
*Refer to Unit Summary Sheet of							
-							
(14) a. Date, Latest HUC Review:							
	g Reporting Period: Not applicable						
d. Total Number of Subjects Enrolled							
•	eported to the FDA or sponsor for stud-						
	d IND. (May be continued on a separate						
sheet, and designated as "(14)e".							

(15) Study Objective:

The objective of this study is to determine the efficacy of Infection Control measures in preventing the spread of <u>Aspergillus</u> infections during hospital construction at FAMC. This institution has experienced a significant outbreak of nosocomial aspergillosis associated with hospital construction on the 4th floor. Construction is on going on the third floor and attempts have been made by the Infection Control Service to prevent similar episodes of invasive aspergillosis associated with this contruction project.

(16) Technical Approach:

By the use of physical barriers, external venting, high efficiency filters, and Copper-8-quinolinolate treatments, the incidence of nosocomial aspergillosis has decreased to no cases during the Infection Control project. A sampling of the hospital air has demonstrated a significant decrease in the amount of Aspergillus spores generated in patient care areas following the institution of Infection Control measures.

FAMC A.P.R. (RCS MED 300) Detail Summ	mary Sheet (Ref. HSCR 40-23, as amended)
(1) Date: 30 Sep 84 (2) Protocol	WU#: 84/106 (3) Status: Ongoing
(4) Title:	
Respiratory Patterns in Hypogona	adal Patients
(5) Start Date: Feb 84	(6) Est Compl Date: Feb 85
(7) Principal Investigator:	(8) Facility: FAMC
Michael T. McDermott, MD, MAJ, MC Brenda Schneider, MD, Pulmonary Fellow, UCHSC	
(9) Dept/Svc: Medicine/Endocrine	(10) Assoc Investigators:
(11) Key Words:	
hypogonadism	Gerald S. Kidd, MD, LTC, MC
testosterone	
sleep apnea	
(12) Accumulative MEDCASE:*	(13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of	this report.
(14) a. Date, Latest HUC Review: Sep	p 84 b. Review Results:
c. Number of Subjects Enrolled Durin	
d. Total Number of Subjects Enrolled	
	reported to the FDA or sponsor for stud- ed IND. (May be continued on a separate
None.	
(15) Study Objective:	
to study the effect of sex horm	ones, testosterone and estrogen, on
respiratory patterns and sleep apnea	•
measuring tidal volume and respirato of oxygen and carbon dioxide and the for the presence and frequency of sl- gonadal males 4 days and 4 weeks aft	percapneic ventilatory drive studies by ry rate while breathing varying concentrations n undergo sleep studies under observation eep apnea. These studies are done in hypoer shots of depotestosterone, and in postor 4 weeks off Premarin and also once in the established normal controls.
and disordered respiratory patterns	d both phases of the study. Sleep apnea were much more prominent immediately after the process of statistical analysis.

 $\preceq \Delta$ 

123

FAMC	A.P.R. (RCS MED 300) Detail Summ	ary S	Sheet (Ref. HSCR 40-23, as amended)
(1)	Date: 30 Sep 84 (2) Protocol	WU#:	84/103 (3) Status: Ongoing
(4)	Title:		
	Gastric Inhibitory Polypeptide ( Metabolism	GIP)	in Various Disorders of Carbohydrat
(5)		(6)	Est Compl Date: Feb 88
(7)	Principal Investigator:	(8)	Facility: FAMC
М	ichael T. McDermott, MD, MAJ, MC		
		(10)	Assoc Investigators:
(11)	Key Words:		
	gastric inhibitory polypeptide (GIP)		Gerald S. Kidd, MD, LTC, MC
	hypoglycemia		
(12)	diabetes mellitus  Accumulative MEDCASE:#	(12)	Est Accum OMA Cost:*
(12)	*Refer to Unit Summary Sheet of		
(14)	a. Date, Latest HUC Review:		b. Review Results:
c. !	Number of Subjects Enrolled During	g Rep	porting Period:
d. :	Total Number of Subjects Enrolled	to D	)ate:
:	Note any adverse drug reactions re ies conducted under an FDA-awarded sheet, and designated as "(14)e".	eport d IND	ted to the FDA or sponsor for stud- O. (May be continued on a separate
	N/A		
(15)	Study Objective:		
(-//	To measure GIP in states of alte	red o	carbohydrate metabolism such as
diab	etes mellitus and reactive hypogl		
(16)	Technical Approach: Multiple serum samples on patien	te wi	ith diabetes mellitus and reactive
hvpo			ed according to previously approved
	ocols. In this study, we will us		
(17)	Progress:		
	No progress as of yet because the	e GII	P KIA is still in the process of
pein	g established.		
Pub1	ications and Presentations: None	€	

(1)	Date: 30 Sep 84 (2) Protocol	WU#: 84/102 (3) Status: Ongoing
(4)	Title:	
	Development of a Radioimmunoassa	ay for Gastric Inhibitory Polypeptides (GI
(5)	Start Date: Feb 84	(6) Est Compl Date: Feb 86
(7)	Principal Investigator:	(8) Facility: FAMC
Mi	ichael T. McDermott, MD, MAJ, MC	
(9) (11)	Dept/Svc: Medicine/Endocrine Key Words:	(10) Assoc Investigators:
	radioimmunoassay gastric inhibitory polypeptide (GIP)	Gerald S. Kidd, MD, LTC, MC
	*Refer to Unit Summary Sheet of	•
14)	a. Date, Latest HUC Review:	b. Review Results:
. N	umber of Subjects Enrolled Durin	g Reporting Period:
. T	otal Number of Subjects Enrolled	to Date:
i	ote any adverse drug reactions responding the conducted under an FDA-awarde heet, and designated as "(14)e".	eported to the FDA or sponsor for stud- d IND. (May be continued on a separate
N	I/A	

(16) Technical Approach:

A RIA for GIP will be developed using established RIA techniques after purchase of GIP antibodies and purified GIP.

# (17) Progress:

GIP antibodies and purified GIP have been obtained but thus far there has been difficulty iodinating the GIP. This will require further work.

(1)	Date: 30 Sep 84 (2) Protocol	WU#:	84/101	(3)	Status:	Ongoing
(4)	Title: Antibiotic Therapy of Ac A controlled study using			ions	of Chroni	c Bronchitis:
(5)	Start Date: Sept, 1984	(6)	Est Comp	l Dat	e: June,	1985
(7)	Principal Investigator: Michael Witte Maj, MC Jimmy Gilbert Maj, MC Steven Opal Maj, MC	(8)				
(9)	Dept/Svc: Medicine/Pulmonary	(10)	Assoc In	vesti	gators:	
	Key Words: Trimethaprim/Sulfamethoxazole Chronic Bronchitis					
(12)	Accumulative MEDCASE:* *Refer to Unit Summary Sheet of	-		m OMA	Cost:*	
(14)	a. Date, Latest HUC Review:		b. Revie	w Res	ults:	
	Number of Subjects Enrolled Duris	_		eriod	:	
	Total Number of Subjects Enrolled			1		
	Note any adverse drug reactions in ies conducted under an FDA-awarde sheet, and designated as "(14)e".	ed IN				

### (15) Study Objective:

This double-blind study was undertaken in an attempt to clarify whether a specific therapeutically useful antibiotic plays a significant role in in acute exacerbations of chronic bronchitis. The drug to be used is TMP/SMX. The patient population will include patients with documented moderate to severe bronchitis by clinical symptoms and pulmonary function tests who have acute exacerbations of their symptoms.

- (16) Technical approach: Patients admitted with worsening pulmonary symptoms, who have no documented allergy to TMP/SMX undergo a bettery of tests as a baseline and a patient questionaire and physical exam and CXR. These are repeated on day 4 & 7 to see if there has been any improvement. On day 1 the patient is placed blindly on either a placebo or the study drug, and kept on it for seven days.
- (17) Progress: One patient has been entered to date in fiscal year 1984 and, since the drug is unknown to the authors, it is not known whether the benefit seen is due to an antibiotic or placebo.

(1)	Date: 30 Sep 84 (2) Protocol	WU#:	84/100	(3)	Status:	Ongoing		
(4)	Title: The Effect of Abnormal Thyroid and Methylprednisolone	States	on the	Metab	olism of	Theophylline		
(5)	Start Date: Feb 84	(6)	Est Comp	ol Dat	e:Jul 87			
(7)	Principal Investigator:	(8)	Facility	: FA	MC			
	James S. Brown, MD, Maj, mc Michael T. McDermott, MD, MAJ, M							
(9)	Dept/Svc: Medicine/Endocrine	(10)	Assoc Ir	vesti	gators:			
$(\overline{11})$	Key Words:	]	Fred D.	Hofe]	dt. MD			
	theophylline				•	, MAJ, MC		
	methylprednisolone					COL, MC		
	hyperthyroidism	Ī						
(12)	hypothyroidism Accumulative MEDCASE:* *Refer to Unit Summary Sheet of			im OMA	Cost:*			
(14)	a. Date, Latest HUC Review: 30 S	ep 84	b. Revie	w Res	ults:	<del></del>		
c.	Number of Subjects Enrolled Durin					0		
d.	Total Number of Subjects Enrolled	to D	ate:			0		
e.	Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. (May be continued on a separat sheet, and designated as "(14)e".							
	None.							
7353	Ol de Obdes Adams		···					

(15) Study Objective:

To study the effects of hyperthyroidism and hypothyroidism on the metabolism of theophylline and methylprednisolone.

(16) Technical Approach:

Consenting hyperthyroid and hypothyroid patients will have a 12-hour intravenous infusion of theophylline or methylprednisolone or both (on separate days) and hourly blood levels of theophylline and/or methylprednisolone will be measured.

(17) Progress:

No patients yet enrolled.

(1) Date: 30 Sep 84 (2) Protocol	
	trial of individually polymerized grass
pollens in the treatment of seasonal	allergic rhinitis.
(5) Start Date: 1984	(6) Est Compl Date: 1985
(7) Principal Investigator:	(8) Facility: FAMC
HS Nelson, MD, COL, MC	Allergy-Immunology Clinic, FAMC, and
	Fort Carson Medical Activity
(9) Dept/Svc: Medicine/Allergy	(10) Assoc Investigators:
(11) Key Words:	
polymerized extract	
allergy immunotherapy	RW Weber, COL, MC
	BT Miller, CPT, MC
	ML Vandewalker, MAJ, MC
(12) Accumulative MEDCASE:#	(13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of	this report.
(14) a. Date, Latest HUC Review:	
c. Number of Subjects Enrolled Duris	ng Reporting Period: 43
d. Total Number of Subjects Enrolled	to Date: 43
e. Note any adverse drug reactions i	reported to the FDA or sponsor for stud-
ies conducted under an FDA-awarde	ed IND. (May be continued on a separate
sheet and designated as 11/11/01	•

none

- (16) Technical Approach: Patients received over a period of 8 weeks eleven injections of polymerized grass extract or of a placebo containing histamine and caramelized sugar. The immunologic response is measured by titrated skin test, specific IgE and specific IgG performed before and after immunotherapy. Symptom scores are collected through the grass pollen season.
- (17) Progress: Forty-three patients were randomized to placebo or active immunotherapy in the grass pollen season of 1984. It is now intended that those who receive the placebo will receive the active drug and for the grass pollen season of 1985, the effect of booster injections will be studied.

<sup>(15)</sup> Study Objective: To assess the immunologic and symptomatic response to allergy immunotherapy with polymerized grass in a double-blind, placebo-controlled study.

CONTINUATION SHEET, FY 84 ANNUAL PROGRESS REPORT Proto No.: 83/126

(17) Progress:

No patients have been entered in this study during the past year because of conflicting priorities in our unit. However, we anticipate studying five patients during the coming fiscal year.

(1) Date: 30 Sep 84 (2) Protocol WU#: 84/111 (3) Status: Ongoing

(4) Title: Incidence of Bacteremia Following Transbronchial Needle
Aspiration and Fiberoptic Bronchoscopy.

(5) Start Date: May, 1984 (6) Est Compl Date: June, 1984

(7) Principal Investigator: (8) Facility: FAMC

Dr. Michael Witte D.O. MAJ, MC Dr. Jimmy Gilbert M.D. MAJ, MC

Dr. Steven Opal M.D. MAJ, MC

(9) Dept/Svc: Medicine/Pulmonary

(10) Assoc Investigators:

(11) Key Words:

TBNA BACTEREMIA Dr. Jerry Pluss D.O. CPT, MC Dr. David Thomas M.D. MAJ, MC Dr. John Olsen M.D. MAJ, MC

(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this report.

(14) a. Date, Latest HUC Review: b. Review Results:

c. Number of Subjects Enrolled During Reporting Period: 22

d. Total Number of Subjects Enrolled to Date: 22

e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. (May be continued on a separate sheet, and designated as "() e".

None

### (15) Study Objective:

The objective of the study is to determine the incidence of bacteremia following transbronchial needle aspiration. This is a procedure which is gaining widespread use in diagnostic pulmonology as applied to lung neoplasms. The study is prospective. The current AHA recommendations are to not prophylax high risk patients for infective endocarditis when undergoing fiberoptic flexible bronchoscopy. This recommendation will need to be reassessed based on the findings of this study.

- (16) The patients undergoing TBNA have blood cultures drawn 5 minutes, 30 minutes, and any time in the 24 hours after the procedure if the oral temperature is 100.4° F. These cultures are handled in the microbiology division as per their routine protocol.
- (17) Progress: To date, 22 TBNA's have been completed on 20 patients. There has been no incidences of bacteremia at any time in the 24 hours following the procedure. There have been four incidences of fever, two of which were accounted for by the diagnosis of pneumonia. A larger number of patients will be seen in fiscal year 1985. This is data from fiscal year 1984.

(1)	Date: 30 Sep 84 (2) Protocol	WU#:	84/112	(3)	Status:	Ongoing
(4)	Title: Proteinuria and Congestive Hear	rt Fa	ilure			
(5)	Start Date: June 84	(6)	Est Comp	l Dat	e: July	85
(7)	Principal Investigator: JAMES A. HASBARGEN, MD MAJ, M.C. RICHARD F. KUCERA, M.D.	(8)	Facility	: FA	MC	
(9)	Dept/Svc:	(10)	Assoc In	vesti	gators:	<del></del>
	Key Words: proteinuria congestive heart failure				-	
$(\overline{12})$	Accumulative MEDCASE:*	(13)	Est Accu	m OMA	Cost:*	
•	*Refer to Unit Summary Sheet of			·		
	a. Date, Latest HUC Review:					
	Number of Subjects Enrolled Durin			eriod	: 5	
	Total Number of Subjects Enrolled			5		
e.	Note any adverse drug reactions r ies conducted under an FDA-awarde sheet, and designated as "(14)e".	d IN				

<sup>(15)</sup> Study Objective: Proteinuria generally connotates significant renal disease. normally investigated thoroughly up to and including renal biopsy. Congestive heart failure has been stated to be a cause of proteinuria in the past. This is not well substantiated in the literature and whether it improves with treatment, is unanswered. Consequent ly, it is important to know whether there is a true cause and effect relationship with congestive heart failure and proteinuria, and whether the proteinuria resolves with resolution of congestive heart failure. This study, therefore, will seek to determine the incidence of proteinuria in patients presenting with congestive heart failure, and whether the proteinuria resolves with resolution of congestive heart failure. (16) TECHNICAL APPROACH: The patient selected for the patient study will be over 18 years of age, and have no past history of renal disease. The patients will have the clinical diagnosis of congestive heart failure. The physician and the patient must be willing to submit to a wrine collection and follow up if the patient is found to have proteinuria. The following historical, physical exam and laboratory criteria must be met prior to the patient's entry into the study. Patient must have a negative history of renal disease with the exception of uncomplicated urinary tract infections. A comprehensive drug history will also be obtained from the patients. The patients will have a clinical diagnosis of congestive heart failure as ascertained using the following cirteria: history of shortness of breath, PND, edema, prior documentation of congestive heart failure physical exam findings to include neck vein distention, hepatojugular reflux, S2, and cardio megaly and edema. Radiologic findings to include cardiomegaly, cephalization of flow, and curly B-lines. Additional diagnostic studies to document congestive heart failure may be utilized at the discretion of the attending physician to include: echocardiography, radionuclide cardiography and cardiac catheterization. The patients will have complete urinalysis performed. They will have a spot urinalysis done to examine both creatinine and protein concentration utilizing that plus the serum creatinine to be able to

CONTINUATION SHEET, FY 84 ANNUAL PROGRESS REPORT Proto No.: 84/112

calculate a 24 hour urinary collection. Patients manifesting proteinuria and/or congestive heart failure. Patients whom are discharged prior to the resolution of the proteinuria will be followed as outpatients at the discretion of their attending physician.

(17) Progress: The study is in the preliminary stages. Five patients are enrolled at the current time. No data analysis has been done as yet.

1)	Date:	30 Sep 84	(2) Prot	tocol	WU#: 84/113	3 (3)	Statu	ıs:	on-going
(4)	Title:	Function	al assay	to	determine	shelf	life	of	methacholine
and	atrop	ine methy	lnitrate	so.	lutions				

and atropine methylnitrate sol	utions						
(5) Start Date: 1984	(6) Est Compl Date: 1984						
(7) Principal Investigator: W. Ronald Tipton, MD, COL, MC	(8) Facility: FAMC						
(9) Dept/Svc: Medicine/Allergy (11) Key Words: methacholine atropine methylnitrate	(10) Assoc Investigators:  Robert A. Ledoux, BS Ray Vaughan, MD, CPT, MC						
(12) Accumulative MEDCASE:* *Refer to Unit Summary Sheet of	(13) Est Accum OMA Cost:* this report.						
(14) a. Date, Latest HUC Review: c. Number of Subjects Enrolled Durin	<del></del>						
<ul><li>d. Total Number of Subjects Enrolled</li><li>e. Note any adverse drug reactions r</li></ul>	to Date: NA eported to the FDA or sponsor for stud-						

e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. (May be continued on a separate sheet, and designated as "(14)e".

NA

<sup>(15)</sup> Study Objective: To determine the duration of potency in solution of two medications used in the diagnosis and treatment of obstructive pulmonary disease.

<sup>(16)</sup> Technical Approach: Using the guinea pig trachea model, the shelflife of methacholine up to one year after mixture will be compared to freshly made solution. Likewise, inhibition of a methacholine contraction by atropine methylnitrate also insolution having been mixed for periods up to one year will be used. When compared to fresh solutions, these determinations should give an indication of the functional shelflife of these two drugs.

<sup>(17)</sup> Progress: Thus far the medications are being accumulated, and animals will be ordered shortly to do these assays.

FAMC A.P.R	. (RCS MED	300)	Detail	Summary	Sheet	(Ref.	<b>HSCR</b>	40-23,	as	amended)
------------	------------	------	--------	---------	-------	-------	-------------	--------	----	----------

(1) Date: 30 Sep 84 (2) Protocol	WU#: 84/114 (3) Status: on-going					
(4) Title: The relative developmen	t of subsensitivity to the bronchodilator					
<del>-</del>	specific beta-2 adrenergic agonists.					
and musculoskeletal side effects of	specific beca-2 adrenergic agonists.					
(5) Start Date: 1984	(6) Est Compl Date: 1985					
(7) Principal Investigator:	(8) Facility: FAMC					
HS Nelson, MD, COL, MC	Allergy-Immunology Clinic					
• •						
(9) Dept/Svc: Medicine/Allergy	(10) Appen Investigators					
	(10) Assoc Investigators: Westley Stafford, MAJ, MC					
(11) Key Words:	westley Stafford, MAJ, MC					
beta adrenergic agonists						
subsensitivity						
(12) Accumulative MEDCASE:#	(13) Est Accum OMA Cost:*					
*Refer to Unit Summary Sheet of	this report.					
(14) a. Date, Latest HUC Review:	h Review Results:					
c. Number of Subjects Enrolled Duri						
d. Total Number of Subjects Enrolle	d to bate:					
	reported to the FDA or sponsor for stud-					
	ed IND. (May be continued on a separate					
sheet, and designated as "(14)e"	•					

none

<sup>(15)</sup> Study Objective: To compare the development of subsensitivity with chronic administration to terbutaline and albuterol using measurements of bronchodilator effect and tremor.

<sup>(16)</sup> Technical Approach: Patients will receive oral albuterol, oral terbutaline, or placebo on three separate days and the bronchodilator response and tremor response will be measured. They will then receive in a crossover fashion 3 weeks of oral albuterol and 3 weeks of oral terbutaline. At the end of each 3 week treatment period the bronchodilator and tremor response to the drug that they had been receiving and to placebo will be measured.

<sup>(17)</sup> Progress: Approval of this protocol was not received until 24Aug84; therefore, study has not yet been initiated.

(1)	Date: 30 Sep 84 (2) Protocol	WU#: 84/115 (3) Status: Ongoing					
(4)	Title:	Basal Cell Carcinomas to Nude Mice.					
(5)	Start Date: Aug 84	(6) Est Compl Date: Jul 86					
(7)	Principal Investigator: Ronald E. Grimwood, M.D. LTC,MC	(8) Facility: FAMC					
		(10)					
$\frac{(9)}{(11)}$	Dept/Svc: Medicine/Dermatology Key Words:	(10) Assoc Investigators: Charles Ferris, PhD, CPT, MSC					
(11)	Carcinoma	J. Clark Huff, M.D.					
	Basal cell	J. Clark hall, h.b.					
	Nude mice						
(12)	Accumulative MEDCASE:* *Refer to Unit Summary Sheet of	(13) Est Accum OMA Cost:* this report.					
(14)	a. Date, Latest HUC Review:	b. Review Results:					
	Number of Subjects Enrolled Durin						
	Total Number of Subjects Enrolled						
:	•	reported to the FDA or sponsor for studed IND. (May be continued on a separate					

- (15) Study Objective:
  - To develop an in-vivo model of human basal cell carcinoma in the athymic mouse.
- (16).TECHNICAL APPROACH: Basal cell carcinoma tissue obtained from excess tissue obtained from Moh's surgery is transplanted to a subcutaneous pocket created by a linear incision on the abdomen of the nude mouse. The mouse will have been splenectomized and transplantation is followed by weekly intraperitoneal injections of antilymphocyte serum. Tumor weight is taken before implantation and measurements of tumor size taken at weekly intervals. Autoradiography and immunofluorescent studies are performed at the time of tumor harvest as well as routine histology and tumor weight.
- (17). PROGRESS: To date we have successfully transplanted 15 tumors which maintain the histology and protein products of the originally transplanted tumor. We are now actively defining the growth perameters of these tumors but do not have completed data yet.

### PUBLICATIONS/PRESENTATIONS:

- a. Grimwood RE, Johnson CA, Ferris CF, Mercill DB, Mellette JR, Huff JC: Transplantation of Human Basal Cell Carcinomas in Athymic Mice. Accepted for publication in Cancer, 1984.
- b. Grimwood RE, Harbel J, Clark RAF: Fibronectin in Basal Cell Epitheliomas: Sources and Significance. Journal of Investigative Derm 82: 145-149, 1984.

CONTINUATION SHEET, FY 84 ANNUAL PROGRESS REPORT Proto No.: 84/115

### PRESENTATION:

a. Grimwood RE, Johnson CA, Kramer LC, Mercill DB and Huff JC: Heterotransplantation of Human Basal Cell Epitheliomas in Nude Mice. Presented at the SID Meeting in Washington, DC, May 84.

(1)	Date: 30 Sep 84 (2) Protocol	WU#: 84/116 EU(3) Status: Terminated
(4)	Title: EU: Carnitine	
(5)	Start Date: 1984	(6) Est Compl Date: N/A
(7)	Principal Investigator: Daniel L. Hurst, MAJ, MC	(8) Facility: FAMC
(9)	Dept/Svc: Neurology, MED	(10) Assoc Investigators:
(11)	Key Words: Carnitine	
(12)	Accumulative MEDCASE:* *Refer to Unit Summary Sheet of	(13) Est Accum OMA Cost:* this report.
c. 1	a. Date, Latest HUC Review: New Sumber of Subjects Enrolled During Total Number of Subjects Enrolled	ng Reporting Period: 1
į		reported to the FDA or sponsor for studed IND. (May be continued on a separate . None
	Study Objective: Emergency Use: L-Carnitine	
	Progress: The use of carniting ond to therapy. No side effects	e was discontinued when patient failed to were encountered. The drug was returned

SURGERY

(1) Date: 30 Sep 84 (2) Protocol WU#: 73/219 (3) Status: Ongoing (4) Title: Treatment of Urinary Tract Trauma in the Laboratory Animal (5) Start Date: May 1973 (6) Est Compl Date: Indefinite (7) Principal Investigator: (8) Facility: FAMC
Treatment of Urinary Tract Trauma in the Laboratory Animal  (5) Start Date: May 1973 (6) Est Compl Date: Indefinite
(7) Principal Investigator: (8) Facility: FAMC
LCDR William E. Shipton, MC
(9) Dept/Svc: Surgery/Urology (10) Assoc Investigators:
(11) Vey Words: Cpt John Wolthuis, MC; Cpt winston vaught, MC;
Trauma  LTC Torrence Wilson, MC; LTC Michael J. Raife, M
Renal transplantation Inosine  LTC Jonathan Vordermark, MC; Col H. E. Favuer, M
(12) Accumulative MEDCASE:* (13) Est Accum OMA Cost:*  *Refer to Unit Summary Sheet of this report.
(14) a. Date, Latest HUC Review: b. Review Results:
c. Number of Subjects Enrolled During Reporting Period: N/A
d. Total Number of Subjects Enrolled to Date: N/A
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. (May be continued on a separate sheet, and designated as "(14)e".  N/A
(15) Study Objective: Investigation of, and comparison of various modes of treatment of urological trauma with emphasis on newer surgical techniques to include renal vascular repair, bench surgery, autotransplantation and pre- and intraoperative chemical intervention, e.g., use of inosine.
(16) Technical Approach:
Various techniques of vascular reanastomosis and autotransplantation will be
performed. Function preservation in the face of these surgeries, and in face of temporary suspension of renal blood flow will be evaluated using inosine as a
preservative. IVP and/or renal scans may be used at intervals to ascertain
success or failure.
(1i)
Progress:
This protocol continues to be an invaluable and irreplaceable tool for teaching of residents and staff.

DEPARTMENT Surgery

- (1) Levisay, G.L.: Renal Autotransplantation in the Dog. Presented: Kimbrough Urological Seminar, Washington, D. C., January 1974.
- (2) Levisay, G.L.: Renal Autotransplantation in the Dog. Presented: South Central Section Meeting of the AUA, Denver, CO, September 1974.
- (3) Jackson, J.E.: Renal Autotransplantation with Partial Nephrectomy in the Dog. Presented: South Central Section of the AUA, Denver, CO, 15-19 September 1974.
- (4) Jackson, J.E.: Renal Autotransplantation with Partial Nephrectomy in the Dog. Presented: Kimbrough Urological Seminar, San Antonio, TX, 14-19 November 1974.
- (5) Page, M.E.: Renal Autotransplantation with Vena Caval Occlusion. Seattle, Washington, October 1975.
- (6) Page, M.E. and Weigel, J.W.: Exhibit-renal transplantation with Proximal Vena Caval. Presented: South Central Section Meeting in Urology, September 1975.

#### **PUBLICATIONS:**

- (1) Levisay, G.L.: Renal Autotransplantation in the Dog. Proc of the Kimbrough Urolo Sem, January 1974.
- (2) Jackson, J.E.: Renal Autotransplantation with Partial Nephrectomy in the Dog. Proc of the South Central Sect, AUA, Denver, CO 15-19 September 1974.
- (3) Page, M.E.: Renal Autotransplantation with Venal Caval Occlusion. Proc of the Kimbrough Urolo Sem, Seattle, WA, 5 October 1975.

FAMC A.P.R. (RCS MED 300) Detail Summ	mary Sheet (Ref. HSCR 40-23, as amended)						
(1) Date: 30 Sep 84 (2) Protocol	WU#: 78/200 (3) Status: Ongoing						
(4) Title:	#U#: /8/200 (3) Status: Ongoing						
Anastomosis of the Dog Vas Deferens L	sing Microsurgical Technique						
(5) Start Date: April 1978 (7) Principal Investigator:	(6) Est Compl Date: Indefinite (8) Facility: FAMC						
(/) Frincipal investigator.	(O) racifity. Paric						
Col Howard E. Fauver, M.D., MC							
(9) Dept/Svc: Surgery/Urology	(10) Assoc Investigators:						
(11) Key Words:	Lt Col Torrence M. Wilson, MD						
•	LF Col Michael J. Raife, MD						
Microsurgery-vasovasostomy	LCDR William E. Shipton, MD						
	Cpt John S. Wolthuis, MC Cpt Winston W. Yaught, MC Mai Isabelo Castillo						
(12) Accumulative MEDCASE:#	(13) Est Accum OMA Cost:*						
*Refer to Unit Summary Sheet of	this report.						
(14) a. Date, Latest HUC Review:	b. Review Results:  ng Reporting Period: N/A						
d. Total Number of Subjects Enrolled							
	reported to the FDA or sponsor for stud-						
	d IND. (May be continued on a separate						
(15) Study Objective:	, <u> </u>						
To master the microsurgical anastomos							
(16) Technical Approach: Standard bilateral vasectomy performed on mongrel male dogs. Three weeks later a two layer microsurgical anastomosis using 10-0 nylon is completed. Three weeks later the dog is sacrificed and bilateral vasograms completed.							
(17) Progress: This protocol continues to be an invaluable and irreplacable tool for teaching of residents and staff in the technique of microsurgery.							

Continuing experimentation with various sutures and microsurgical technique is being performed. Since it is felt that a minimum of thirty hours of microscope time is essential before this procedure can be performed in human subjects, this current protocol represents the only practical way in which experience can be gained.

Publications: Vaccaro, J.A.: Microscopic Vasovasostomy: The Fitzsimons Experience. Kimbrough Urological Proceedings, Vol. 14, 1980.

Presentations: None

(1) Date: 30 Sep 84 (2) Protocol	WU#: 78/201 (3) Status: Ongoing					
(4) Title:						
Clinical Study for In	traocular Lens					
(5) Start Date: September 1976	(6) Est Compl Date: Unknown					
(7) Principal Investigator:	(8) Facility: FAMC					
Floyd M. Cornell, M.D.						
,						
(9) Dept/Svc:	(10) Assoc Investigators:					
(11) Key Words:	Douglas A. Freeley, M.D., LTC/P, MC					
	John A. McCubbin, M.D., CPT/P, MC					
	William R. Wilson, M.D., MAJ, MC					
	Anthony R. Truxal, M.D., CPT, MC					
	Ricardo J. Ramirez, M.D., CPT, MC					
(12) Accumulative MEDCASE:*	(13) Est Accum OMA Cost:*					
*Refer to Unit Summary Sheet of						
(14) a. Date, Latest HUC Review: Apr	83 b. Review Results: Ongoing					
c. Number of Subjects Enrolled Durin						
	to Date: 1100 intraocular lenses					
	reported to the FDA or sponsor for stud-					
	ed IND. (May be continued on a separate					
sheet, and designated as "(14)e".						

(15) Study Objective:

(cont'd)

<sup>1).</sup> To determine postoperative visual acuity of patients receiving an intraocular lens, and to compare those results with those of a control group of patients who undergo cataract surgery but do not receive an intraocular lens.

<sup>2).</sup> To describe the occurrence and time course of postoperative ocular complications and adverse reactions both for intraocular lens implant subjects and for control subjects.

<sup>3).</sup> To compare the occurrence of adverse reactions and ocular complications in the implant group and in the control group, in order to delineate any significant difference.

<sup>4).</sup> To describe the occurrence of postoperative lens complications for the implant group, and their relationship to ocular complications.

<sup>5).</sup> To identify subgroups within the implant study population that are at "high risk" of particular complications as compared to the control group.

(16) Technical Approach:

After didactic courses, observations, laboratory practice and assistance with an experienced implant surgeon, a surgeon who can perform an accomplished cataract extraction, is then allowed to perform intraocular lens surgery under proper tutorage. Postoperative examinations include: pachyometry, keratometry, and specular microscopy. Contraindications to surgery include: patients with good visual potential in only one eye, proliferative diabetic retinopathy,

CONTINUATION SHEET, FY 84 ANNUAL PROGRESS REPORT

Proto No.: 78/201

(10)
Michael J. Trynosky, M.D., CPT, MC
Luis E. Colon, M.D. CPT/P, MC

(16) rubeosis irides, high axial myopia, and inadequately controlled glaucoma, Fuch's endothelial dystrophy, and a history of previous retinal detachments or uveitis.

#### (17) Progress:

Due to the initial 25 implants between September 1976 and February 1978, the implantation of intraocular lenses at FAMC was expanded. We now have implanted over 1100 intraocular lenses.

As a result of the past seven years experience, we have evolved better guidelines for patient selection, better surgical techniques and improved guidance for postoperative care. Our study includes tabulation of operative complications, postoperative complications, visual results, endothelial cell loss, corneal thickness changes, changes in corneal astigmatism, and residual refractive error.

The results of every ophthalmologist implanting intraocular lenses in the United States is additionally compiled by computer in Washington, D.C. by the FDA. Our results are a small part of this overall study. Final data from this massive study is to be completed in the future. As a result of this study many intraocular lenses have been taken off the protocal due to their proven safety. These devices that have been taken off the protocol study need only be registered when implanted at this time. Others have been discontinued from manufacture as a result of the development of superior lens devices.

Publications: None

CONTINUATION SHEET for Annual Progress Report 84 Protocol No 83/203

DEPARTMENT: Surgery

SERVICE: Ophthalmology

(17) Progress: continued

Low-dose laser trabeculoplasty seems to be effective in the treatment of open angle glaucoma. Risks remain minimal as no complications have occurred. Benefits are a lowering of the intraocular pressure. The rate of "failure" of the trabeculoplasty seems to reflect the rate of worsening of the glaucoma.

(1) Date: 30 Sep 84 (2) Protocol	
(4) Title: Laser Trabeculoplasty: C Applications to Short- an	orrelation of the Number of Laser d Long-Term Effects
(5) Start Date: April 1983 (7) Principal Investigator: CPT John A. McCubbin, MC MAJ William G. Carey, MC	(6) Est Compl Date: 1984 (8) Facility: FAMC
(9) Dept/Svc: Surgery/Ophthalmology (11) Key Words: laser trabeculoplasty intraocular pressure trabecular meshwork	(10) Assoc Investigators: Ronald R. Holweger, MAJ, MC Thomas H. Mader, MAJ, MC William R. Wilson, CPT, MC
(12) Accumulative MEDCASE:# *Refer to Unit Summary Sheet of	(13) Est Accum OMA Cost:* this report.
	ng Reporting Period: 20  if to Date: 20 reported to the FDA or sponsor for studed IND. (May be continued on a separate

- (15) Study Objective: This study is designed to correlate the number of laser burns applied during laser trabeculoplasty in patients with simple chronic open angle increase in intraocular pressure.
- (16) Technical Approach: Selected patients will randomly be assigned the number of laser burns to be applied to each eye. Patients will be assigned either 10, 20, 30, or 40 burns in the inferior  $180^{\circ}$  of each eye. The patients will be followed during the immediate post-procedure period and closely monitored for complications and then followed for a period of one year at least to determine the long-term efficacy.
- (17) Progress: A total of 40 eyes in 20 patients have been entered into the study, and Argon laser trabeculoplasties have been performed on these eyes. Three patients have returned to their original intraocular pressures or above, requiring additional medical control of their glaucoma. All patients have had a lowering of intraocular pressure during the initial months following the trabeculoplasty. Three subjects at or around 6 months after a steady pressure rise surpassed safe levels and required additional medication. These patients had the more advanced glaucoma going into the study. This is felt to reflect a worsening of the glaucoma and not secondary to the procedure.

		7 77 7 11		(0)	<del></del>	<del></del>
(1)	Date: 30 Sep 84 (2) Protocol	WU#:	83/202	(3) St	atus:Ongoing	
(4)	Title: Microbiology of Eyebank E	ges	Taken from	Septic	Donors	
(5)	Start Date: October 1983	(6)	Est Compl	Date:	Unknown	
(7)	Principal Investigator:	(8)	Facility:	FAMC		
	Andrew J. Cottingham, Jr., M.D.					
(9) (11)	Dept/Svc:Ophthalmology/Surgery Key Words:	(10)	Assoc Inve		ors: ey, LTC, MC	
(11)	Eye Bank, Septic, Donor Eyes, Corneal Transplant		Calvin E. Floyd M. Ronald R.	Mein, Cornell Holweg		(con'd)
(12)	Accumulative MEDCASE:* *Refer to Unit Summary Sheet of		Est Accum report.	OMA Co	st:*	
c. : d. : e. :	a. Date, Latest HUC Review:  Number of Subjects Enrolled Durin Total Number of Subjects Enrolled Note any adverse drug reactions r ies conducted under an FDA-awarde sheet, and designated as "(14)e".	ng Re l to repor ed IN	porting Per Date: 0 ted to the	riod: 0  FDA or	sponsor for	

<sup>(15)</sup> Study Objective: The questions this project shall attempt to answer are:

<sup>1)</sup> What is the incidence of positive cultures from various compartments of eyes taken from potentially bacteremic or septic donors?

<sup>2)</sup> What donor factors affect the incidence of positive cultures or species of organism(s) cultured?

<sup>3)</sup> Does the manner in which the tissues is handled or stored affect the incidence of positive cultures?

<sup>4)</sup> What is the origin of the bacteria cultured from the cornea and within the eye? Does it correlate with organisms known or suspected to be present systemically?

<sup>(16)</sup> Technical Approach: Eyes from septic death cases and control non-septic death cases are cultured (one eye immediately and one after storage at <sup>4</sup>C for 48 hours). The culturing techniques are accomplished in multiple ways.

<sup>(17)</sup> Progress: Suitable donor material for this project has not been as readily available as anticipated. From the onset of the project only two pair of donor eyes have been available.

<sup>(10)</sup> continued: William R. Wilson, CPT, MC; Anthony R. Truxal, CPT, MC; and Ricardo J. Ramirez, CPT, MC

(1) Date: 30 Sep 84 (2) Protocol	WU#: 83/201 (3) Status: Ongoing
(4) Title:	Ungiring
CT Diagnoses of Medial Meniscal Tear	s
(5) Start Date: 1 May 83	(6) Est Compl Date: 1 May 85
(7) Principal Investigator:	(8) Facility: FAMC
CPT Ricky Wilkerson, MC	
LTC Walton W. Curl, MC	
CPT Marlene J. Severson, MC	
(9) Dept/Svc:Orthopedic/Surgery	(10) Assoc Investigators:
(11) Key Words:	
Medial meniscus Tears and CT Scan	none
	į
(12) Accumulative MEDCASE:*	(13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of	this report.
(14) a. Date, Latest HUC Review:	N/A b. Review Results: N/A
c. Number of Subjects Enrolled Durin	ng Reporting Period: 5
d. Total Number of Subjects Enrolled	
	reported to the FDA or sponsor for stud-
ies conducted under an FDA-awarde	ed IND. (May be continued on a separate

(15) Study Objective: To evaluate the possible usefulness in diagnosis of medial meniscal tears of the knee using the CT scan and to compare it to the accuracy of the knee arthrogram. Subject population will consist of approximately 15 adult patients who on physical examination have suspected medial meniscal tears.


#### (16) Technical Approach:

sheet, and designated as "(14)e".

Clinical Examination by Drs. Curl & Wilkerson

as soon as able to be scheduled

none



(17) Progress: To date, 5 knees have been examined and arthroscoped. These 5 patients were all identified during fiscal year 83. Currently the results are equivocal, however, since only 5 patients have been done, then no conclusive results have been obtained. We are continuing with this protocol, anticipating at least 10 more patients over the next severaly months to include in the protocol.

Di.

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (Ref. HSCR 40-23, as amended) Date: 30 Sep 84 (2) Protocol WU#: 83/200(3) Status: ongoing Title: Evaluation of a Nonabsorbable Anterior Cruciate Ligament Prosthesis Start Date: (6) Est Compl Date: May 1983 (7) Principal Investigator: (8) Facility: FAMC Walton W. Curl, LTC, MC (9) Dept/Svc: Orthopedic/Surgery (10) Assoc Investigators: (11) Key Words: Anterior Cruciate Ligament and Prosthesis Ricky Wilkerson, CPT, MC (12) Accumulative MEDCASE:# (13) Est Accum OMA Cost:\* \*Refer to Unit Summary Sheet of this report. (14) a. Date, Latest HUC Review: NA b. Review Results: NA c. Number of Subjects Enrolled During Reporting Period:

(15) Study Objective: To determine efficacy of repairing a ruptured anterior cruciate ligament and stinting this repair with an artificial ligament. To determine the biomechanical and histologic parameters of the ligament/prosthetic complex at 6 months and 1 year. To determine the effect of an intra-articular prosthetic device on the articulating cartilage and surrounding synovial tissues within the knee.

Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. (May be continued on a separate

- (16) Technical Approach: 12 mongrel dogs initially had their left stifle joint used as a control, arthrotomy and rupture of the anterior cruciate ligament, the right knee underwent rupture of the anterior cruciate ligament and augumentation using the patella tendon with supplementation using an artifical ligament prosthesis. Originally the intent was to sacrifice 6 of the dogs at 6 months and 6 of the dogs at 12 months and then study the synovium and cruciate ligament complex both histologically and histochemically.
- (17) Progress: The first 6 dogs are completed, the second 6 to be sacrificed in 1984. The limbs are sent to Howmedica for evaluation, no conclusions can be made yet.

Publications and Presentations: none

d. Total Number of Subjects Enrolled to Date:

sheet, and designated as "(14)e".

CONTINUATION SHEET, FY 84 ANNUAL PROGRESS REPORT Proto No.: 82/205

Publications: None

Presentations: Houseworth, Stephen W., Curl, Walton W., Smith, Cheryl K. and

Eilert, Robert E. Use of the Arthroscope to Evaluate Immediate and Delayed Anterior Cruciate Ligament Reconstruction: An

Experimental Study in the Dog: Presented: Yearly Barnard Seminar with the University of Colorado Orthopedic Surgery

Program, 5 December 1984.

- 30 Sep 84 (2) Protocol WU#: Date: 82/205 (3) Status: Completed Title: The Effects of Immediate and Staged Repair of the Torn Anterior Cruciate (cranial cruciate) Ligament in Dogs as Evaluated by Serial Arthroscopic Examinations Start Date: (6)Est Compl Date: April 1983 May 1984 (7) Principal Investigator: (8) Facility: FAMC Stephen W. Houseworth, CPT, MC Dept/Svc: Orthopedic/Surgery (10) Assoc Investigators: (11) Key Words: Robert E. Eilert, M.D. Anterior Cruciate Ligament and Cheryl K. Smith, DVM, CPT Arthroscopy (12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\* \*Refer to Unit Summary Sheet of this report. (14) a. Date, Latest HUC Review: NA b. Review Results: c. Number of Subjects Enrolled During Reporting Period: 12 Total Number of Subjects Enrolled to Date: 12 Note any adverse drug reactions reported to the FDA or sponsor for stud-
- (15) Study Objective: The objective of this study is to evaluate arthroscopically the effects of staged anterior cruciate ligament repairs with augumentation in the dog knee(stifle). Specific attention will be directed at the onset and progression of degenerative changes within the joint.

ies conducted under an FDA-awarded IND. (May be continued on a separate

sheet, and designated as "(14)e".

- (16) Technical Approach: 12 dogs have been divided into 3 groups of 4 dogs one knee joint of each dog will be used as a control and the other for an operative procedure. 3 of the dogs will have a repair of the anterior cruciate ligament with augumentation, 3 dogs will have repair of the anterior cruciate ligament with augumentation one month following the initial section of the anterior cruciate ligament and group 3 will have augumented repairs of the anterior cruciate ligament 3 months following initial section of the ligament. All dogs will have arthroscopic examination at 6, 8, 12, 16, 32 and 40 weeks, and will be sacrificed.
- (17) Progress: The protocol has been completed. A total of 186 arthroscopic procedures were performed. IN May 1984, the dogs were euthanized and a post mortem examination was performed on each knee (stifle). The paper from this project has been completed. It has currently been submitted for a National Sports Medicine Research Award.

- (1) Date: 30 Sep 84 (2) Protocol WU#: 82/204 (3) Status: Completed
  (4) Title: Evaluation of Treatment Methods for Extravasation of Chemotherapeutic Agents
- Start Date: August 1982 Est Compl Date: July 1983 Principal Investigator: Facility: Timothy Loth, MD CPT, MC (9) Dept/Svc: (10) Assoc Investigators: Surgery/Orthopedic (11) Key Words: William W. Eversmann, Jr., MD chemotherapeutic COL, MC extravasation necrosis
- (12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*

  \*Refer to Unit Summary Sheet of this report.
- (14) a. Date, Latest HUC Review: <u>July 83</u> b. Review Results: <u>Completed</u> c. Number of Subjects Enrolled During Reporting Period: NA
- d. Total Number of Subjects Enrolled to Date: NA
- e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. (May be continued on a separate sheet, and designated as "(14)e". None
- (15) Study Objective: To evaluate and compare various methods of treating experimental chemotherapeutic agent extravasations.
- (16) Technical Approach: A rat model was used in which a number of vesicants were injected into thin skin and treated using surgical debridement or conventional antidotes. One study on each animal served as a control.
- (17) Progress: This study was re-opened to increase numbers of animals for statistical evaluation. The paper has been re-submitted to JHS, and is awaiting their evaluation.

Publications: None.

## Presentations:

- 1. Loth, T.S. and Eversmann, W.W.: Evaluation of Treatment Methods for the Extravasation of Chemotherapeutic Agents: A Comparative Study. Presented: Third Annual Military Current Concepts in Hem/Onc Meeting, San Antonio, TX, 1983.
- 2. Loth, T.S. and Eversmann, W.W.: Evaluation of Treatment Methods for the Extravasation of Chemotherapeutic Agents: A Comparative Study. Presented: Joseph E. Baugh Resident Competition, Washington, D.C., 1983.
- 3. Loth, T.S. and Eversmann, W.W.: Evaluation of Treatment Methods for the Extravasation of Chemotherapeutic Agents: A Comparative Study. Presented: American Society for Surgery of the Hand Annual Meeting, Atlanta, GA, February, 1984.

(1)	Date: 30 Sep 84 (2) Protocol	WU#: 82/203-N (3) Status: Ongoing
(4)	Title:	wow. 02/2032h (3/ Schools. Onpoths
	Effectiveness of EMG Biofeedback	in Maintaining Fluency Obtained in an
	Intensive Stuttering Treatment P	rogram
(5)	Start Date: 1982	(6) Est Compl Date: 30 months after start
(7)	Principal Investigator:	(8) Facility: FAMC
	Jon M. Hasbrouck, Ph.D.	
(9)	Dept/Svc: Surgery/Speech Path	(10) Assoc Investigators:
(11)	Key Words:	
	Stuttering	Fran Lowry-Romero, M.S.
	Biofeedback	
(12)	Accumulative MEDCASE:# *Refer to Unit Summary Sheet of	(13) Est Accum OMA Cost:* this report.
$\overline{(14)}$	a. Date, Latest HUC Review:	b. Review Results:
	Number of Subjects Enrolled Durin	ng Reporting Period: 18
	Total Number of Subjects Enrolled	
	Note any adverse drug reactions r	reported to the FDA or sponsor for studed IND. (May be continued on a separate

(15) Study Objective: Compare effects of extensive EMG biofeedback training and practice to EMG monitoring with no biofeedback and to no EMG monitoring and no biofeedback, to determine how EMG biofeedback related to the acquisition and maintenance of fluency in an intensive adult stuttering treatment program.

(16) Technical Approach: SS in 3 groups will be pretested, receive 3 concurrent treatment procedures (airflow, relaxation, biofeedback) followed by a lith treatment (discriminative stimulus control) and be post-tested. Grp. 1 will receive extensive EMG biofeedback monitoring, training, and practice. Grp. 2 will receive the same treatment as Grp. 1, but will receive no auditory and visual feedback of performance. Grp. 3 will receive no EMG biofeedback training or monitoring, but will receive the same amount of time in activities similar to Grps. 1 and 2.

(17) Progress: During this fiscal year, 18 subjects in Grp: 3 have completed the specified treatment program and have been followed on a regular basis since release from treatment. Group 2 SS will be the next subjects to be run in addition to additional Group 1 SS.

FAMC	A.P.R.	(RCS	MED	300)	Detail	Summary	Sheet	(Ref.	HSCR	40-23,	as	amended)
------	--------	------	-----	------	--------	---------	-------	-------	------	--------	----	----------

(1)	Date: 30 Sep 84 (2) Protocol	WU#:	82/202 (3)	Status: Terminated
(4)	Title: Lateral electrical stir	nulat		
(5)	Start Date: March 1982	(6)	Est Compl Date	: March 1986
	Principal Investigator:	(8)	Facility: FAM	
	Joe K. Ozaki, COL, MC			
(9)	Dept/Svc: Orthopedic/Surgery	(10)	Assoc Investiga	ators:
	) Key Words:	, ,	- 0	
	Scoliosis			
(12)	Accumulative MEDCASE:# *Refer to Unit Summary Sheet of		Est Accum OMA ( report.	Cost:*
$\overline{(14)}$	) a. Date, Latest HUC Review: NA		b. Review Resu	lts: NA
	· · · · · · · · · · · · · · · · · · ·	_		22
d.	Total Number of Subjects Enrolled			5
e.	Note any adverse drug reactions r	-		

None.

Publications and Presentations: none

sheet, and designated as "(14)e".

<sup>(15)</sup> Study Objective: To demonstrate the nocturnal transcutaneous electrical stimulation of paraspinal muscles is as effective as the use of a full-time spinal orthosis (brace) in the treatment of idiopathic scoliosis occurring in skeletally immature adolescents.

<sup>(16)</sup> Technical Approach: The scoliosis patients who qualify for the study will be fit with electrical stimulation unit and instructed in its use. They will then have a two week trial period at home to insure that they can conform to the protocol. They are then followed closely at regular intervals to ascertain the outcome.

<sup>(17)</sup> Progress: Since the scolitron one unit has been cleared by the FDA for general use as of 6 Jan 83, the protocol will be discontinued.

(1)	Date: 30 Sep 84 (2) Protocol	WU#:	82/201 (3) Status: Ongoing	
(4)	Title: Prospective Double Blind	Rand	omized Study of the Effects of	
Supp	lemental Dietary Calcium and Vita	amin :	D on the Healing of Distal Radius	
Frac	tures in Adults			
(5)	Start Date: January 1982	(6)	Est Compl Date: 1986	
(7)	Principal Investigator:	(8)	Facility: FAMC	
	Timothy S. Loth, M.D. Captain, MC			
(9)	Dept/Svc: Surgery/Orthopedic	(10)	Assoc Investigators:	
	Key Words:	1		
•	Dietary Calcium	1	Steve Flood, M.D., CPT, MC	
	Dietary Vitamin D	1	Peter Blue, M.D., LTC, MC	
	Fractures		Nasser Ghaed, M.D., COL, MC	
(12)	Accumulative MEDCASE:#	(13)	Est Accum OMA Cost:*	
	*Refer to Unit Summary Sheet of	this	report.	
$\overline{(14)}$	a. Date, Latest HUC Review: 4/8	3	b. Review Results: Ongoing	
c.	Number of Subjects Enrolled Duri	ng Re	porting Period: 9	
d. Total Number of Subjects Enrolled to Date: 14				
	ote any adverse drug reactions reported to the FDA or sponsor for stud-			
	ies conducted under an FDA-awarded IND. (May be continued on a separa sheet, and designated as "(14)e".			

<sup>(15)</sup> Study Objective: To determine whether dietary calcium can increase the rate and quality of fracture healing.

<sup>(16)</sup> Technical Approach: Volunteers will be assigned randomly to Group A (which will receive calcium and vitamin D) or Group B (which will receive placebo). Bone densities will be performed on both wrists 3,6,12, and 24 who after fracture. An additional bone density will be performed within 1 week of fracture on the uninjured extremity to act as a control. After 50 cases have been collected the code will be broken for this study.

<sup>(17)</sup> Progress: We have enrolled 14 patients in the study thus far. Additional cases will be required prior to final analysis.

(1) Date: 30 Sep 84 (2) Protocol	
(4) Title: Treatment of Recurrent Of Tympanostomy Tubes	citis Media: Chemoprophylaxis va
(5) Start Date: January 1982	(6) Est Compl Date: Indefinite
(7) Principal Investigator: Carlos Gonzales, MD COT, MC	(8) Facility: FAMC
(9) Dept/Svc: Surgery/ENT (11) Key Words:     recurrent otitis media     tympanostomy tubes     chemoprophylaxis	(10) Assoc Investigators: James Arnold, MD, CPT, MC John W. Kolmer, MD, COL, MC Thomas Kueser, MD, CPT, MC Edward A. Woody, MD, CPT, MC
(12) Accumulative MEDCASE:*  *Refer to Unit Summary Sheet of	(13) Est Accum OMA Cost:# this report.
•	ng Reporting Period: 0

- (15) Study Objective: To determine which modality of treatment for recurrent otitis media, chemoprophylaxis or P.E. tubes or both and if one or both offers better control of future otitis media episodes considering morbidity and complications.
- (16) Technical Approach: Patients who meet criteria of study will be randomly placed in three different groups. Patients will be followed on a monthly basis for six months. Episodes of recurrent otitis media will be reported and seen by us.
- (17) Progress: This protocol will be continued until 65 patients are enrolled and followed for 6 months. Dr. Arnold, Associate Investigator, has been transferred to MAMC where he is to start this protocol and results will be combined.

Publications and Presentations: none

sheet, and designated as "(14)e". none

(1) Date: 30 Sep 84 (2) Protocol	WU#: 80/201 (3) Status: Terminated
(4) Title: Comparison of Cardiac Ou	tput and Left Ventricular Stroke Work
Before and After Standard Anesthesia Correction of Combined Mitral Valve	Induction of Patients Undergoing Surgica Disease and Coronary Artery Disease
(5) Start Date: Oct 1980	(6) Est Compl Date:
(7) Principal Investigator: William J. Reynolds, MD	(8) Facility: FAMC
LTC, MC	
(9) Dept/Svc: Surgery/Anes&Opr Svc	(10) Assoc Investigators:
(11) Key Words:	Ì
fantanyl, cardiovascular anes-	ł
thesia, coronary artery disease,	
mitral valvular disease, open	
heart surgery	<u> </u>
(12) Accumulative MEDCASE:*	(13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of	this report.
(14) a. Date, Latest HUC Review: Oct	83 b. Review Results: ongoing
c. Number of Subjects Enrolled Duris	
d. Total Number of Subjects Enrolled	i to Date: 11
	reported to the FDA or sponsor for stud-
•	ed IND. (May be continued on a separate
shoot and designated as !!(1 1)e!!	

Publications and Presentations: none

<sup>(15)</sup> Study Objective: To determine the presence or absence of significant statistical difference of left ventricular work as affected by conventional cardiac anesthesia techniques.

<sup>(16)</sup> Technical Approach: Real-time data is obtained from pulmonary artery and radial artery catheters using transistor-generated analog data. Portable digital microprocessor provides all second generation data analysis. Cardiac anesthesia uses routine technique.

<sup>(17)</sup> Progress: Study was terminated due to the transfer of principal investigator.

#### DETAIL SUMMARY SHEET

(Ref: HSCR 40-23 & HSPA-I Ltr, 8 July 1982

(12) Accumulate MEDCASE:\*

(1) Date: FY 84 (2) Protocol WU Nr.: 80/200(3) Status: Terminated (4) Title: Hearing Loss in Hypothyroidism

(5) Start Date: 1980 (6) Est Compl Date:
(7) Principal Investigator (8) Facility: FAMC
Marc Sachs, CPT, MC

(9) Dept/Svc: Surgery/Otolaryngologio Assoc Investigators:
(11) Key Words:
hypothyroidism
hearing loss

John Kolmer, COL, MC
fred Hofeldt, COL, MC

\*Refer to Unit Summary Sheet of this report.

(14) a. Date, Latest HUC Review: b. Review Results:

c. Number of subjects enrolled during reporting period:

d. Total number of subjects enrolled to date:

e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND.:

(13) Est Accum OMA Cost:\*

(Continue on a separate sheet, designating this continuation as (14)e.)
(15) Study Objective: The objectives are to determine if there is a relation-

ship of hearing loss to hypothyroidism, the locus of this defect, and the potential reversability of this effect.

(16) Technical Approach: Newly diagnosed hypothyroid patients are given a routine hearing evaluation, tympanograms and a BSER. They are then restudied four weeks after beginning therapy, and again at least twelve weeks later.

(17) Progress: Terminated - Principal Investigator failed to reply.

Publications and Presentations: None

FAMC A.P.R.	(RCS M	ED 300)	Detail	Summary	Sheet	(Ref.	<b>HSCR</b>	40-23,	as	amended)
-------------	--------	---------	--------	---------	-------	-------	-------------	--------	----	----------

(1)	Date: 30 Sep 84 (2) Protocol	WU#: 83/204 (3) Status: Ongoing
(4)	Title: The Role of Minimal Surg Extravasations	ical Debridement in the Treatment of Vesicant
(5)	Start Date: Sept. 83	(6) Est Compl Date: Dec. 84
(7)	Principal Investigator:	(8) Facility: FAMC
	Timothy S. Loth, M.D. Captain, MC	
	Dept/Svc: Surgery/Orthopedics Key Words:	(10) Assoc Investigators:
	Extravasations	
	Vesicants	
	Debridement	
(12)	Accumulative MEDCASE:# #Refer to Unit Summary Sheet of	
	a. Date, Latest HUC Review:	
		ng Reporting Period:
	Total Number of Subjects Enrolled	
	<u> </u>	reported to the FDA or sponsor for stud- ed IND. (May be continued on a separate

<sup>(15)</sup> Study Objective: The objective of this study was to define the role of minimal surgical debridement in the treatment of vesicant extravasations.

<sup>(16)</sup> Technical Approach: An animal model was employed to determine the efficacy of minimal surgical debridement on vesicant extravasations. Rats were injected bilaterally in the flanks with one side being operated on at various intervals while the opposite side was unoperated on and served as a control. Serial measurements of ulcer diameter up to 35 days after the vesicant injection were compared among the treatment groups and controls to determine the effectiveness of surgery in limiting ulcer size and in decreasing the number of persistent ulcers. Agents tested were doxorubicin, renograph, and fluroscene.

<sup>(17)</sup> Progress: The first phase of this study has been completed which demonstrated that minimal surgical debridement is an effective means of preverting vesicant induced ulcers and of limiting their size in doxorubicin extravasations. This paper was presented to the Hugh Mahon Lectureship in 1984 and to the Mid-Central States Orthopedic Society. Ongoing work is in progress to define the role of early surgical debridement in renograph and extravasations.

PRESENTATIONS FOR FY 84 A	Annual Pro	ogress Re	port
---------------------------	------------	-----------	------

Proto	No.	83/204
	110.	0.37 604

SERVICE Orthopedics

DEPARTMENT Surgery

Denver Children's Hospital Orthopaedic Day, April 26, 1984 Mid-Central States Orthopedic Society Resident's Award, June 1, 1984 Hugh Mahon Lectureship Award, Denver, Colorado, June 1984

FAMC A.P.R. (RCS MED 300) Detail Su	ummary Sheet (Ref. HSCR 40-23, as amended)
(1) Date: 30 Sep 84 (2) Protoco	ol WU#: 84/200 (3) Status: Terminated
(4) Title: Prevention of Macular	Injury From High Illumination Levels of the ope by the Use of a Corneal Light Blocking
(5) Start Date: Feb 84	(6) Est Compl Date:
(7) Principal Investigator:	(8) Facility: FAMC
Ronald R. Holweger, MAJ, MC	
(9) Dept/Svc: Opth/Surgery	(10) Assoc Investigators:
(11) Key Words:	
opaque filter	
(12) Accumulative MEDCASE:* *Refer to Unit Summary Sheet of	(13) Est Accum OMA Cost:* of this report.
(14) a. Date, Latest HUC Review:	b. Review Results:
e. Number of Subjects Enrolled Dur	ring Reporting Period:
d. Total Number of Subjects Enroll	
	s reported to the FDA or sponsor for stud- rded IND. (May be continued on a separate
randomized study using an opaque f	objective in this investigation is to do a ilter to block the high illumination from demonstrate with certain objective criterianess of ligh blocking procedures.
(16) Progress:	
The study was terminated due Investigator.	to the transfer of the Principal

(1)	Date: 30 Sep 84 (2) Protocol	WU#:	84/201	(3)	Status:	Ongoing
(4) (Dev	Title: Q-Switched Nd: YAG Laser ice: Microruptor MR-2 Nd: YAG I sor: VTI. Inc., Torrance, CA)	in aser	Discissi ; MFR:	ion of LASAG	Secondary AG, Thun,	Membranes Switzerland;
(5)	Start Date: Feb 84	(6)	Est Con	pl Da	te:	
(7)	Principal Investigator: Douglas A. Freeley, LTC, MC	(8)	Facilit	cy: F	AMC	
(9) (11)	Dept/Svc:Opth/Surgery Key Words: YAG Laser	(10)	Assoc ]	Invest	igators:	
(12)	Accumulative MEDCASE:# #Refer to Unit Summary Sheet of				A Cost:*	
c. I	a. Date, Latest HUC Review: Number of Subjects Enrolled Durin Total Number of Subjects Enrolled Note any adverse drug reactions r	g Re	porting Date:	Period 55	d: 55	sor for stud-

(15) Study Objective: The overall purpose of this study is to determine the degree of safety and efficacy of the MR-2 Nd: YAG laser manufactured by LASAG AG of Thun, Switzerland, in performing non-invasive intraocular surgery for discission of secondary membranes.

ies conducted under an FDA-awarded IND. (May be continued on a separate

- (16) Technical Approach: Subjects will be chosen out of a candidate propulation of patients who are visually symptomatic from opacified secondary membranes but with healthy eyes. These candidates will be reviewed for contraindications to laser therapy. They will be in a state of health which will allow them to be able to sit at the laser surgical unit without discomfort. Patients entering the study will be given a preoperative evaluation including slit lamp microscopy and ophthalmoscopy.
- (17) Progress: To date 55 patients have been entered in the study. There have been no problems encountered thus far will continue to enter patients in the study.

Publications and Presentations: None

sheet, and designated as "(14)e".

CLINICAL INVESTIGATION

( <u>1</u> ) ( <u>4</u> )		WU#: 72/302 (3) Status: Ongoing and Functional Changes in Defects of
(5)	Start Date: 1972	(6) Est Compl Date: 1984
(7)	Principal Investigator: Donald G. Corby, M.D., COL, MC,	(8) Facility: FAMC
(9)	Dept/Svc: DCI/Biochemistry Svc	(10) Assoc Investigators:
(11)	Key Words: platelet function newborn	T.P. O'Barr, Ph.D., DAC
(12)	Accumulative MEDCASE:# #Refer to Unit Summary Sheet of	(13) Est Accum OMA Cost:* this report.
<ul><li>c. 1</li><li>d. 5</li><li>e. 1</li></ul>	<del>-</del>	g Reporting Period: NA

## (16) Technical Approach:

sheet, and designated as "(14)e". NA

Subjects: In most part, this study will deal with the further investigation of the platelet "defect" found in the normal newborn infant. However, since the techniques of studying the biochemical aspects of platelet function developed in previous studies permit the thorough evaluation of qualitative platelet disorders in older children and adults, the protocol is also intended to cover the diagnostic evaluation of patients with functional platelet syndromes associated with the "hemorrhagic state".

Platelet Function Studies: When indicated clinically, platelet counts, bleeding times, platelet adhesion, and whole blood and PRP aggregation in response to ADP, collagen, epinephrine, or ristocetin will be performed in the Coagulation Section, Department of Pathology or the Biochemistry Service, Department of Clinical Investigation.

<sup>(15)</sup> Study Objective: To correlate biochemical and functional parameters to gain a better understanding of the pathophysiology of the disorders of platelet function.

Prot No.: 72/302

(16) Technical Approach (cont'd):

Biochemical Studies: Assessment of the content and release of the content of the platelet's subcellular storage organelies (alpha and dense granules) and evaluation of the Platelet membrane will include, but not be limited to the following:

- a. Electron microscopy and mepacrine staining of dense granules.
- b. Content of platelet factor 4 and B-thromboglobulin activity in the alpha granules.
- c. Production of platelet-derived growth factor by H-thyamide incorporation in 3T3 mouse fibroblasts by platelet lysates.
- d. Measurement of secretable acid hydrolases (B-glucuronidase, B-galactosidase, and membrane P-nitrophenyl phosphatase) activities.
  - e. Membrane glycoprotein and phospholipid content.
- f. Release of arachidonate from membrane phospholipids by phospholipase C and diglyceride lipase.
  - g. Mobilization of Ca++.
  - h. Other studies as they become available.
- (17) Progress: Due to the need to assign personnel for other approved protocols and shortage of personnel due to transfers and resignations, work on this protocol has been temporarily discontinued. We intend to evaluate leucotrienes plus lipooxygenase pathway products derived prostaglandins, and begin work on phosphorylative schema in newborn platelets in the next FY.

# DEPARTMENT of Clinical Investigation

- (1) Corby, D.G., Shigeta, F.H., Greene, H.L., and Stifel, F.B.: Platelet Dysfunction in Glycogen Storage Disease Type I (GSDI): Reversal with Total Parenteral Alimentation (TPA). (Abst.) Clin. Res. 21:304, 1973.
- (2) Corby, D.G., Preston, K.A., Shigeta, F.H., O'Barr, T.P., and Zuck, T.F.: Adverse Effect of Gel Filtration on the Adenine Nucleotides of Human Platelets. (Abst., P. 107), III Congress, International Society on Thrombosis Hemostasis (Vienna, Austria), June 1973.
- (3) Corby, D.G., (Intr. by Wm. E. Hathaway): Mechanism of Platelet Dysfunction in Newborn Infants. J. Ped. Res., Vol. 8, No. 4, April 1974.
- (4) Corby, D.G., Preston, K.A., O'Barr, T.P.: Adverse Effect of Gel Filtration on the Function of Human Platelets. Proceedings of the Society for Experimental Biology and Medicine, 146:96-98, 1974.
- (5) Corby, D.G., Putnam, C.W., Greene, H.L.: Impaired Platelet Function in Glucose-6-Phosphatase Deficiency. The J. Ped., 85:71-76, July 1974.
- (6) Corby, D.G., and Zuck, T.F.: Newborn Platelet Dysfunction: A Storage Pool and Release Defect. Thrombosis and Haemostasis, 36:200-207, 1976.
- (7) Corby, D.G., Goad, W.C., Barber, J., and O'Barr, T.P.: Evaluation of Cyclo-Oxygenase Pathway in Platelets of the Newborn, Thrombosis and Haemostasis (Stuttgart), 38:35, 1977 (Abstract).
- (8) Corby, D.G., O'Barr, T.P.: Decrease in -Adrenergic Binding Sites in Newborn Platelets: Cause of Abnormal Response to Epinephrine? Blood, 52:161, 1978.
- (9) Corby, D.G.: Aspirin in Pregnancy: Maternal and Fetal Effects. Pediatrics, 62:930, 1978.
- (10) Corby, D.G., O'Barr, T.P.: Decreased Alpha-Adrenergic Receptors in Newborn Platelets: Cause of Abnormal Response to Epinephrine. Dev Pharmacol & Ther, 2:215-225, 1981.
- (11) Corby, D.G., O'Barr, T.P.: Neonatal Platelet Function: A Membrane-Related Phenomenon. Haemostasis, 10(4):177-232, 1981.

Publications for FY 84 Annual Progress Report (72/302) - continued

- (12) Corby, D.G., O'Barr, T.P.: Newborn Platelet Function. Chapter in Book "Acquired Bleeding Disorders in Childhood". Masson Publ, pages 31-37, 1981.
- (13) Corby, D.G., O'Barr, T.P., and Swanson, E.E.: Evidence for a Deficiency of Alpha-Granule Proteins in the Platelets of Newborn Infants. Soc Ped Res, May 1983.

## Presentations:

- (1) Corby, D.G., Shigeta, F.H., Greene, H.L., and Stifel, F.B.:
  Platelet Dysfunction in Glycogen Storage Disease Type I (GSDI):
  Reversal with Total Parenteral Alimentation (TPA). Presented:
  Western Society for Pediatric Research, Carmel, California,
  February 1973.
- (2) Corby, D.G., Preston, K.A., Shigeta, F.H., O'Barr, T.P., and Zuck, T.F.: Adverse Effect of Gel Filtration on the Adenine Nucleotides of Human Platelets. Presented: III Congress, International Society on Thrombosis and Hemostasis, Vienna, Austria, June 1973.
- (3) Corby, D.G.: Mechanism of Platelet Dysfunction in Newborn Infants, Society for Pediatric Research, APS-SPR, Washington, D.C., May 1974.
- (4) Corby, D.G., Goad, W.C., Barber, J., and O'Barr, T.P.: Evaluation of Cyclo-Oxygenase Pathway in Platelets of the Newborn. Presented: VIth International Congress on Thrombosis and Haemostasis, Philadelphia, Pennsylvania, June 1977.
- (5) Corby, D.G. and O'Barr, T.P.: Decreased Adrenergic Receptors in Newborn Platelets: Cause of Abnormal Response to Epinephrine? Presented: VIIth Congress International Society of Thrombosis and Haemostasis, London, England, 1979.

(1) (4) (5) (7)	Title: Immunologic Disorders in Immune Functions in the Immunode Immune Functions of Leukemia and Start Date: 1 Oct 77	WU#: 77/300 (3) Status: Ongoing Children and Adults: 1. Correlation of ficiency State. II. Correlation of other Childhood Malignancies. (6) Est Compl Date: Open ended (8) Facility: FAMC
(9) (11)	Dept/Svc: DCI/Immunology Svc Key Words: immunologic disorders	(10) Assoc Investigators:  Donald G. Corby, M.D.  COL, MC
(12)	Accumulative MEDCASE:* *Refer to Unit Summary Sheet of	(13) Est Accum OMA Cost:* this report.
c.   d. ' e.		to Date: 718 eported to the FDA or sponsor for stud- d IND. (May be continued on a separate

- (15) Study Objective: Existing specialized immuno-chemical procedures will be consolidated into a registered protocol for use, on a consultative basis, by the hospital staff.
- (16) Technical Approach: A clinical laboratory immunology consultation service has been established. Main emphasis is performance and evaluation of specialized immuno-chemical tests, for training house-staff personnel and consultative support of hospital. The major areas of studies include humoral and cellular immunity and leukocyte function evaluation. Patients are selected on the basis of severity of recurrent infections, clinical immunodeficiency state, lack of response to medical management and availability of Department of Clinical Investigation for laboratory evaluations for patient care.
- (17) Progress: A total of 141 patients were evaluated on a consultative basis for immunologic disorders. During this period seven physician house-staff personnel were also trained in laboratory clinical immunology procedures. Patients Studied: 37 in the area of serum protein gammapathies, 43 in the area of cell-mediated function, and 61 in the area of combined humoral-cellular function. Subjects with indicated major findings were as follows:

  1) Humoral immunologic disorders -serum protein profile evaluations: 5 cryo-globulinemias, 18 serum protein gammopathies, 7 immunoglobulin disorders (heavy or light chain or benign spike), 5 hypogammaglobulinemias, (cont'd)

CONTINUATION SHEET for FY 84 ANNUAL PROGRESS REPORT Proto. No.: 77/300

(17) Progress: cont'd

12 hypergammaglobulinemias, 3 complement abnormalities; II) Cellular immunologic disorders - 104 lymphocyte transformations, of these 9,5, and 2 patients were recorded suppressed to PHA, PWM, and candida stimulations respectively, 57 T-lymphocyte enumerations with 4 patients recorded as low T-lymphocyte percentages, 57 B-lymphocyte enumerations with 0 patients recorded as abnormal, 32 NBT evaluations with 4 patients recorded as abnormal.

Publications: none

#### Presentations:

1. Brown, G.L. and Heggers, J.: Medical Mycology: Assessment of Bacteriologic and Seroligic Parameters of Clinically-important Mycoses Normal and Immunologic Comprised Host. Presented: American Medical Technologist Educational Seminars, Denver, CO, July 1979.

(1)	Date: 30 Sep 84 (2) Protocol	WU#:	79/300 (3) Status: Terminated
(4)	Title: A Study of the Hormone-de Tumors <u>In Vitro</u>	epend	ent Growth of Human mammary
(5)	Start Date: 1979	(6)	Est Compl Date:
(7)	Principal Investigator:	(8)	Facility: FAMC
	Charles F. Ferris, Ph.D., CPT, MSC		
(9) (11)	Dept/Svc:DCI/Cell Physiology Key Words:	(10)	Assoc Investigators: John W. Harbell, Ph.D., CPT, MSC
	breast tumors		Donald B. Mercill, B.S., DAC
	organ culture		SP5 Norman R. Jones, B.S.
		l	SP5 Leslie C. Kramer, B.S.
(12)	Accumulative MEDCASE:* *Refer to Unit Summary Sheet of		Est Accum OMA Cost:* report.
c. i	a. Date, Latest HUC Review: Mar Number of Subjects Enrolled Durin Total Number of Subjects Enrolled	g Re	porting Period:NA
e. I	Hore any adverse drug reactions i	ebor.	red to the the of shouson for sta

(15) Study Objective: To examine the hormone requirements for the growth of human mammary tumors using explant organ culture.

sheet, and designated as "(14)e". NA

ies conducted under an FDA-awarded IND. (May be continued on a separate

- (16) Technical Approach: Tissue samples are obtained from biopsy or mastectomy specimens. Each sample is cut into many small pieces and distributed, for culture, in a battery of hormone combinations. Replicate samples from each hormone combination are subjected to the appropriate radiolabelled precursor to determine DNA, RNA, and protein synthesis. Histology and macromolecular synthesis measure response.
- (17) Progress: Reasons for termination 1) meaningful data already compiled and reported, 2) transfer of former principal investigator, and 3) work of Service concentrated on physician protocols more recently approved.

#### Publications:

1. Harbell, J.W.: Insulin Action on Normal and Transformed GR/A Strain Mouse Mammary Tissues. In Vitro 16(3):247, 1980.

## Presentations:

1. Harbell, J.W.: Insulin Action on Normal and transformed GR/A Mouse Mammary Tissues. Presented: 31st Annual Meeting, Tissue Culture Association, St. Louis, MO, June 4, 1980.

(1) (4)	Date: 30 Sep 84 (2) Protocol Title:	WU#:	79/301 (3) Status: Completed
<b>、</b> . ,		ecove	ry from or Help Prevent Bone Injury
(5)	Start Date: 1979	(6)	Est Compl Date: October 1984
(7)	Principal Investigator: David T. Zolock, MAJ, MSC	(8)	Facility: FAMC
(9)	Dept/Svc:DCI/Biochemistry Svc	(10)	Assoc Investigators:
	Key Words: vitamin D, calcium, bone,	,,	David D. Bikle, MD, PhD, Veterans Administration Med. Ctr. San Francisco, CA
	intestine, calcium binding protein		Elwyn Chadwick, SP6
(12)	Accumulative MEDCASE:# #Refer to Unit Summary Sheet of	_	Est Accum OMA Cost:* report.
(14)	a. Date, Latest HUC Review:		b. Review Results:
c.	Number of Subjects Enrolled Durin	g Re	porting Period: NA
	Total Number of Subjects Enrolled		
е.	Note any adverse drug reactions r	epor	ted to the FDA or sponsor for stud-

(May be continued on a separate

ies conducted under an FDA-awarded IND.

sheet, and designated as "(14)e".

<sup>(15)</sup> Study Objective: To reduce the incidence of fracture wounds and to reduce the time involved to heal fracture wounds by increasing the absorption and retention of calcium and phosphorus through nutritional and medical therapeutic improvements.

<sup>(16)</sup> Technical Approach: Since bone mineralization is indirectly regulated by intestinal absorption, the bone as well as the intestinal responses to various therapeutic measure, will be studied. In general, the animal of choice will be chicks which will be fed a vitamin D deficinet diet containing 0.43% phosphorus for approximately three weeks.

<sup>(17)</sup> Progress: All experiments have been completed and all the data collected. The protocol has been completed and the principal investigator has been transferred to the 10th Medical Laboratory in Germany. A final abstract will be forthcoming.

CONTINUATION SHEET, FY . ANNUAL PROGRESS REPORT Proto No.: 79/301


#### (17) Progress: cont'd


intestinal mucosa in response to 1,24,25-THCC and 1,25,26-THCC was less than 25% of the response with 1,25-DHCC. When these chicks were given cycloheximide, a protein synthesis inhibitor along with the different metabolites, the intestinal calcium transport was unaffected, but the bone calcium uptake was blocked. Since the stimulated intestinal calcium transport by the vitamin D metabolites does not require protein synthesis, the mechanism of action of the metabolites on the epithelial cell probably is a direct one. A possible mechanism would be the alteration of the membrane structure in the brush border directly by the vitamin D metabolite. Bone calcium uptake does depend on protein synthesis for all three of the vitamin D metabolites. When all the results are compared, 1,25-DHCC is the most active metabolite of the three tested in both the intestine and the bone. Although the results are not significant in all cases, 1,24,25-THCC appeared to be more active in the intestine than 1,25,26-THCC and 1,25,26-THCC appeared to be more active in the bone than 1,24,25-THCC. These results indicate a mechanism of action similar for all three vitamin D metabolites, a mechanism of action which is different for the intestine and the bone, and two different receptor mechanisms with different metabolite specificities for intestinal calcium transport and for CaBP synthesis.

In order to determine if 1,25-DHCC has an effect on the distribution and excretion of calcium in the body, a dose of  $^{45}$ Ca was administered i.v. to rachitic chicks and rachitic chicks receiving a dose of 1,25-DHCC 24 hours before. Serum calcium for the rachitic and 1,25-DHCC treated chicks were 6 and 8 mg/dL, respectively. No significant difference was found between the two groups of chicken in serum  $^{45}$ Ca or bone  $^{45}$ Ca uptake. However, the 1,25-DHCC treated chicks had lower intestinal mucosal accumulation of  $^{45}$ Ca and higher  $^{45}$ Ca content in luminal fluid as compared to the rachitic chicks. These results suggest that 1,25-DHCC not only has an effect on the brush border membrane, but also on the basolateral membrane of the epithelial cell. These results also support our theory that CaBP is necessary for maintaining a low cellular concentration of calcium in the intestinal cell.

#### PUBLICATIONS:

- Zolock, David T., Morrissey, Robert L., and Bikle, Daniel D.: Meaning of Non-parallel 1,25 (OH) 2D3 Mediated Response Relationships in Intestine and Bone to Dose and Time in Vitamin D; Biochemical, Chemical and Clinical Aspects Related to Calcium Metabolism.
   Walter DeGruter, Inc., New York, 1979.
- Bikle, Daniel D., Morrissey, Robert L., Zolock, David T. and Herman, R.H.: Stimulation of Chick Gut Alkaline Phosphatase Activity by Actinomycin D and 1,25-dihyroxyvitamin D<sub>3</sub>: Evidence for Independent Mechanisms. J Lab Clin Med 94:88-94, 1979.





MICROCOPY RESOLUTION TEST CHART
NATIONAL BUREAU OF STANDARDS 1963-A

- 3. Bikle, Daniel D., Morrissey, Robert L., and Zolock, David T.: The Mechanism of Action of Vitamin D in the Intestine. Am J Clin Nutr 23:2322-2338, 1979.
- 4. Morrissey, Robert L., Zolock, David T., Mellick, P.W. and Bikle, Daniel D.: Influence of Cycloheximide and 1,24-dihydroxyvitamin D<sub>3</sub> on Mitochondrial and Vesicle Mineralization in the Intestine. Cell Calcium 1:69-79, 1980.
- 5. Bikle, Daniel D., Askew, E.W., Zolock, David T., Morrissey, Robert L. and Herman R.H.: Calcium Accumulation by Chick Intestinal Mitochondria: Regulation by Vitamin D<sub>3</sub> and 1,25-dihydroxyvitamin D<sub>3</sub>. Biochem Pharmacol 89\*63-142, 1981.
- 6. Bikle, Daniel D., Empson, R.N., Morrissey, Robert L., Zolock, David T., Bucci, T.J., Herman, R.H. and Pechet, M.M.: Effect of 1 alphahydroxyvitamin  $D_3$  on the Rachitic Chick Intestines: A Comparison to the Effects of 1,12-dihyroxyvitamin  $D_3$ . Cal Tiss Int 32:9-17, 1980.
- 7. Bikle, Daniel D., Morrissey, Robert L., Zolock, David T. and Rasmussen, H.: The Intestinal Response to Vitamin D. Rev Physiol Biochem Pharmacol 89:63-142, 1981.
- 8. Bikle, Daniel D., Zolock, David T. and Morrissey, Robert L.: Action of Vitamin D on Intestinal Calcium Transport. Annals NY Academy of Sciences 372:481-501, 1981.
- Charles, M.A., Tirunagura, P., Zolock, David T. and Morrissey, Robert L.: Duodenal Calcium Transport and Calcium Binding Protein Levels in Experimental Diabetes Mellitus. Mineral Electrolyte Metab 5:15-22,1981.
- 10. Bikle, Daniel D., Peck, C.C., Holford, N.H.S., Zolock, David T. and Morrissey, Robert L.: Pharmacokinetics and Pharmacodynamics of 1,25dihyroxyvitamin D<sub>3</sub> in the Chick. Endocrin 111:939-946, 1982.

## PRESENTATIONS:

 Zolock, David T., Morrissey, Robert L. and Bikle, Daniel D.: Meaning of Non-parallel 1,25 (OH) 2 D3 Mediated Response Relationships in Intestine and Bone to Dose and Time. Presented: Proceedings of the Fourth Workshop on Vitamin D, Berlin (West) Germany, February 1979.

- Date: 30 Sep 84 (2) Protocol WU#: 80/302 (3) Status: Completed (4) Title: Rapid detection of bacterial antigens in patient specimens using counterimmunoelectrophoresis (CIE) Start Date: 1 Jan 1981 Est Compl Date: 1 Jun 1984 (8) Facility: FAMC (7) Principal Investigator: Pari L. Morse, DAC (10) Assoc Investigators: Dept/Svc: Micro Svc, DCI (11) Key Words: Donald D. Paine, DAC Paul G. Engelkirk, LTC, MSC Bacterial antigens Counterimmunoelectrophoresis CIE (12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost: \* \*Refer to Unit Summary Sheet of this report. b. Review Results: (14) a. Date, Latest HUC Review: c. Number of Subjects Enrolled During Reporting Period: Total Number of Subjects Enrolled to Date:
- (15) Study Objective: To develop and/or evaluate CIE procedures capable of detecting bacterial antigens in patient specimens within a few hours of receipt.

Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. (May be continued on a separate

sheet, and designated as "(14)e".

- (16) Technical Approach: Using commercial antisera and published methodologies, we introduced to FAMC the capability of detecting bacterial antigens in patient specimens using CIE. Once reliable procedures were established, Dept of Pathology personnel were trained to routinely perform these procedures.
- (17) Progress: a) Bacterial antigen detection: a total of 303 specimens from 257 patients were tested by CIE. Fifty-three (17.5%) of the specimens gave positive results. On 1 Nov 1982, the Microbiology Svc, Dept of Pathology, assumed responsibility for these procedures.
  - b) <u>Clostridium difficile</u> toxin detection: a total of 263 specimens from 210 patients were tested by CIE. Positive results were obtained on 118 (44.9%) of the specimens. On 1 Jun 1984, the Microbiology Svc, Dept of Pathology, assumed responsibility for this procedure.

	PUBLICATIONS	for	FY	84	Annual	Progress	Report
--	--------------	-----	----	----	--------	----------	--------

Proto No. 80/302

SERVICE Microbiology Service

DEPARTMENT DCI

Morse, P.L., and Opal, S.M.: (Letter) Adsorption of <u>Clostridium difficile</u> Antiserum for Rapid Detection of Toxin. Diagn. Microbiol. Infect. Dis. 2: 169, 1984.

- 30 Sep 84 (2) Protocol WU#: 80/303 (3) Status: Ongoing Title: Study of Sensitivity of Tumors to Chemotherapy Est Compl Date: Start Date: December 1980 (6) indefinite Principal Investigator: (8) Facility: FAMC Charles F. Ferris, Ph.D., CPT, MSC Arlene J. Zaloznik, M.D., MAJ, MC Elder Granger, MD, CPT, MC (10) Assoc Investigators: (9) Dept/Svc: pcI/cell Physiology (11) Key Words: John W. Harbell, Ph.D., CPT, MSC SP5 Norman R. JOnes chemotherapy SP5 Leslie Kramer in vitro, in vivo Donald B. Mercill, DAC tumor cell (13) Est Accum OMA Cost:# (12) Accumulative MEDCASE:\* \*Refer to Unit Summary Sheet of this report. (14) a. Date, Latest HUC Review: Jan 83 b. Review Results: c. Number of Subjects Enrolled During Reporting Period: NA Total Number of Subjects Enrolled to Date: NA Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. (May be continued on a separate sheet, and designated as "(14)e".
- (15) Study Objective: a) To perform in vitro chemotherapeutic sensitivity testing using tumor cell systems. b) To correlate in vitro chemotherapeutic sensitivity testing results with in vivo chemotherapeutic responses. c) To provide better patient care, i.e., better tumor cell kill, by using in vitro chemotherapeutic sensitivity testing. d) To study alternative therapeutic regimes for various types of solid tumors using the cell lines produced in part a.
- (16) Technical Approach: Human tumor cell lines are established in monolayer culture. After purification and cell type varification, replicate cultures are subjected to physiological concentrations of chemotherapeutic agents. Efficacy is determined through measurement of macromolecular synthesis labeling index and cell loss. Correlations between in vitro parameters and patient responses are then established.
- (17) Progress: To date, 900 primary cultures from over 196 samples have been processed. Retrospective comparison of in vivo and in vitro responses have been encouraging though firm statistical correlation will require more samples from tumors which respond to chemotherapy. Over 60 cell lines have been produced. Adjunct subprojects using the cell lines and assay system have been completed and presented at national meetings. This also includes basic knowledge used for dermatology service tissue culture protocols.

### SERVICE: Cell Physiology

DEPARTMENT of Clinical Investigation

- Moore, G.E., Harbell, J.W., Woods, L.K., Morgan, R.T., and Semple, T.U.: RPMI 8226, a Human Myeloma Cell Line: an Update. (Abst) Proceedings of the American Association for Cancer Research 23:33, 1982.
- Harbell, J.W. and DiBella, N.J.: Studies on the Interaction of Tetra-hydrocannabinol (THC) with Chemotherapeutic Agents Against Human Tumors
   In Vitro. (Abst) Proceedings of the American Association for Cancer Research 23:226, 1982.
- Harbell, J.W., Mercill, D.B., Jones, N.R. and Woods, L.K.: Establishment of a Human Leiomyosarcoma Cell Line. (Abst) In Vitro 18(3):295, 1982.
- 4. Harbell, J.W., Papkoff, J.S. and Daniel, C.W.: Hormone Requirements of the Pregnancy-Dependent Mammary Tumor of GR/A Mice: An In Vitro Study. J Natl Cancer Inst 69(6):1391-1402, December 1982.
- 5. Harbell, J.W., DiBella, N.J., Jones, L.E., Kramer, L.C., and Mercill, D.B.: Assessment of Synergism Between Hyperthermia (HT) and Chemotherapy (CT) Against Human Melanoma Cell Lines In Vitro. Pro Amer Assoc for Can Res 24:310, 1983 (Abst).
- Harbell, J.W., Mercill, D.B. and Woods, L.K.: Use of Athymic Nude Mice to Establish Human Tumor Cell Lines. In Vitro 19(3):275, March 1983.
- 7. Correll, L.L., Neilsen, L.N., Kelleher, P.J., Harbell, J.W. and Minden, P.: Enhanced Immunogenicity of Line-10 Guinea Pig Hepatocarcinoma Cells after Culture. Accepted for Publication in J Natl Cancer Inst, 1983.
- 8. Wang, V., Gutman, D., Harbell, J., and Moore, G.E.: A Unique Gastro-intestinal Cell Line. In Vitro 20(3):246, 1984. (abs)
- 9. Wang, V., Gutman, D., Harbell, J., and Moore, G.E.: A Cell Line Established from Malignant Distal Renal Tubule Cells. In Vitro (20(3):247, 1984. (Abs)
- Mercill, D.B., Jones, N.R., and Harbell, J.W.: Human Tumor Cell Destruction by Distilled Water: An <u>In Vitro</u> Evaluation. Cancer (in press).

SERVICE: Cell Physiology

DEPARTMENT: of Clinical Investigation

- Mercill, D.B., Jones, N.R., and Harbell, J.W.: Distilled Water Lavage to Kill Human Tumor Cells: an <u>In Vitro</u> Evaluation of a Traditional Surgical Technique. Presented: Society of Armed Forces Medical Laboratory Scientists Tri-services Annual Meeting, Reno, Nevada, March 1982.
- Harbell, J.W. and DiBella, N.J.: Studies of the Interaction of Tetrahydrocannabinol (THC) with Chemotherapeutic Agents Against Human Tumors <u>In Vitro</u>. Presented: American Association for Cancer Research, St. Louis, MO, May 1982.
- 3. Moore, G.E., Harbell, J.W., Woods, L.K., Morgan, R.T., and Semple, T.U.: RPMI 8226, a Human Myeloma Cell Line: an Update. Presented: American Association for Cancer Research, St. Louis, MO, April 1982.
- 4. Harbell, J.W., Mercill, D.B., Jones, N.R., and Woods, L.K.: Establishment of a Human Leiomyosarcoma Cell Line. Presented: Tissue Culture Association, San Diego, CA, June 1982.
- 5. Harbell, J.W., DiBella, N.J., Jones, L.E., Kramer, L.C., and Mercill, D.B.: Assessment of Synergism Between Hyperthermia (HT) and Chemotherapy (CT) Against Human Melanoma Cell Lines <u>In Vitro</u>. Presented: American Association for Cancer Research, San Diego, CA, May 1983.
- 6. DiBella, N.J. and Harbell, J.W.: Interaction of Chemotherapy (CT) and Hyperthermia (HT). Presented: Triservices Medical Oncology Meeting, San Antonio, TX, 1983.
  - 7. Harbell, J.W., Mercill, D.B., and Woods, L.K.: Use of Athymic Nude Mice to Establish Human Tumor Cell Lines. Presented: Tissue Culture Association Annual Meeting, Orlando, FL, June 1983.

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (Ref. HSCR 40-23, as amended)

(1)	Date: 30 Sep 84 (2) Protocol	WU#:	81/302 (3) Status: Completed
(4)	Title: Induction of Cerebellar F Innoculation of Canine Pa	iypop rvov	lasia in Pups by Intrauterine irus
(5)	Start Date: Sep 1982	(6)	Est Compl Date:
(7)	Principal Investigator: Albert H. McCullen, D.V.M. Captain, VC	(8)	Facility: FAMC
(9)	Dept/Svc: DCI/Animal Res Svc	(10)	Assoc Investigators:
(11)	Key Words: canine parvovirus cerebellar hypoplasia		Sp5 Leslie C. Kramer Charles F. Ferris, Ph.D., CPT, MSC
(12)	Accumulative MEDCASE:	(13)	Est Accum OMA Cost:*
(,	*Refer to Unit Summary Sheet of		
(14)	a. Date, Latest HUC Review:		b. Review Results:
c.	Number of Subjects Enrolled Duri	ng Re	porting Period: NA
d.	Total Number of Subjects Enrolle		
е.		ed IN	rted to the FDA or sponsor for stud- ID. (May be continued on a separate

<sup>(15)</sup> Study Objective: To determine if canine parvovirus will induce cerebellar hypoplasia in puppies as the feline parvovirus does in kittens.

<sup>(16)</sup> Technical Approach: Puppies will be taken from the bitches at birth to prevent ingestion of colostrum and fed a commercially available puppy formula. The pups will be divided into four groups. One group of pups will be injected with 0.5ml of virus preparation intraperitoneally and one group will be injected intracerebrally. Control pups will be innoculated with 0.5ml of saline either IP or IC. Pups will then be enthanized at three weeks of age with an overdose of halothane anesthesia. Tissue will be taken for histolopathologic examination to a veterinary pathologist.

<sup>(17)</sup> Progress: Experimental procedures have been completed on the project. We are currently in the process of writing the paperon the project .

(1) Date: 30 Sep 84 (2) Protocol WU#: 81/304 (3) Status: Ongoing (4) Title: Ultrastructural and immunological aspects of in vitro interactions between Giardia lamblia trophozoites and host leukocytes.

(5)	Start Date: Feb 82	(6)	Est Compl Date: Feb 85
(7)	Principal Investigator: Paul G. Engelkirk, LTC, MSC Steven K. Koester, DAC	(8)	Facility: FAMC
	Dept/Svc: Micro & Immunol SvcDCI Key Words:	(10)	Assoc Investigators: Donald D. Paine, DAC Dick J. Wuerz, DAC Stanley L. Erlandsen, Ph.D. Samuel Roger Wetherill, III, MAJ, MSC
(12)	Accumulative MEDCASE:# #Refer to Unit Summary Sheet of		
c.	a. Date, Latest HUC Review:  Number of Subjects Enrolled Durin  Total Number of Subjects Enrolled	g Re	porting Period:

- e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. (May be continued on a separate sheet, and designated as "(14)e".
- (15) Study Objective: a) To determine the effects of anti-Giardia antibodies, complement and sensitized host cells on the phagocytosis and destruction of Giardia lamblia trophozoites in vitro. b) To determine the time frame in which host phagocytic cells attach to and phagocytose live Giardia trophozoites in vitro. c) To determine the host cell types that play a role in the phagocytosis of Giardia trophozoites in vitro.
- (16) Technical Approach: Giardia lamblia trophozoites will be incubated with various combinations of host cells, anti-Giardia antibodies, and complement. Light microscopic, TEM, and SEM observations will be made to determine the type and extent of host cell/parasite interactions under the various experimental conditions. In addition, Indium-labeled trophozoites will be used in cytotoxicity studies involving human peripheral blood leukocytes.
- (17) Progress: Fourteen experiments were conducted during FY 1984: nine Indium experiments, four phagocytosis experiments using human peripheral blood leukocytes, and one complement experiment. a) Cytotoxicity experiments: demonstrated that G. lamblia and Trichomonas vaginalis trophozoites could be labeled using 111Indium oxine. Human peripheral blood leukocytes are considerably more cytotoxic to G. lamblia trophozoites in the presence of heat-labile human serum components (complement?). b) Phagocytosis experiments: demonstrated that human peripheral blood eosinophils are capable of phagocytizing G. lamblia trophozoites in vitro. Special staining procedures were used to demonstrate the deposition of eosinophil peroxidase onto the surface of partially and fully ingested parasites. A transmission electron micrograph from these studies has been accepted for publication on the cover of the ASM News (American Society for Microbiology). c) Complement experiment: The results of this complement experiment indicate that G. lamblia trophozoites are capable of activating rat complement, but further experimentation will be necessary to determine whether such activation is by the classical or alternate pathway.

Proto	No.	81/304
-------	-----	--------

SERVICE Microbiology Service

DEPA	RIMEN	T	DCI

Koester, S.K., Engelkirk, P.G., Paine, D.D., Wuerz, D.J., and Rothlaur, M.V.: Influence of Anti-Giardia Antibody, Heat-Labile Serum Components, and Sensitized Host Cells on Short-Term in Vitro Interactions Between G. lamblia Trophozoites and Rat Peritoneal Leukocytes. Presented: Annual Meeting of the American Society for Microbiology, St. Louis, Missouri, March 1984.

Koester, S.K., and Engelkirk, P.G.: Glass Cover Slip Technique for Studying in Vitro Interactions Between <u>Giardia</u> Trophozoites and Host Leukocytes by TFI, SEM, and Light Microscopy. Presented: Rocky Mountain Franch of the American Society for Microbiology, Summer Symposium on Host-Microbe Interactions, Pingree Park, Colorado, August 1984.

Engelkirk, P.G.: Of Eosinophils, Mast Cells, and Parasites. Presented: Booky Mountain Branch of the American Society for Microbiology, Summer Symposius of Host-Microbe Interactions, Pingree Fark, Colorado, August 1984.

## **PUBLICATIONS:**

Koester, S.K., and Engelkirk, P.G.: A Glass Cover Slip Technique for Studying in Vitro Interactions Between Giardia Trophozoites and Host Leukocytes by TEM, SEM and Ligh Microscopy. J. Parasitol. 70: (in press).

Koester, S.K., Engelkirk, P.G., Paine, D.D., Wuerz, D.J., Rothlauf, M.V. and Erlandsen, S.L.: Immunological and Ultrastructural Aspects of Short Term in Vitro Interactions Between Giardia lamblia Trophozoites and Rat Peritoneal Leukocytes. J. Parasitol. (submitted).

# DETAIL SUMMARY SHEET

(Ref: HSCR 40-23 & HSPA-I Ltr, 8 July .52

Pari L. Morse, DAC Clifford Butler, DAC	(8) Facility: FAMC
) Dept/Svc: Pathology & DCI	(10) Assoc Investigators:
1) Key Words: MIC alpha-hemolytic streptococci	Paul G. Engelkirk, LTC, WSC Robert E. Holcomb, LTC, WSC
2) Accumulate MEDCASE:*	(13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet	b. Review Results:
Number of subjects enrolled du	ring reporting period:
Total number of subjects enrol	led to date:
Note any adverse drug reaction studies conducted under an FDA	s reported to the FDA or sponsor for -awarded IND.:
ontinue on a separate sheet, des 5) Study Objective:	ignating this continuation as (14)c.)
	sceptable method for determining the M

Phases 1 through 3 were completed. Unfortunately, the Microbiology Service of the Dept of Pathology has switched to a new type of MIC broth. This protocol has been terminated because the information thus obtained is no longer applicable to MIC testing at FAMC.

#### DETAIL SUMMARY SHEET

(Ref: HSCR 40-23 & HSPA-I Ltr, 8 July 1982

(1)	Pate: FY 1984	(2) Proto	col WU Nr. :81.	<b>-306</b> (3) St.	tus: Terminated
(4)	Title:				
	Wistonathologic	and alectro	microscopie	obsomustions	of the in wive

Histopathologic and electron microscopic observations of the <u>in vivo</u> interactions between <u>Giardia lamblia</u> trophozoites and the small intestinal mucosa of a variety of small laboratory animals

(5) Start Date: 2 Feb 1982	(6) Est Compl Date: N/A
(7) Principal Investigator	(8) Facility: FAMC
Paul G. Engelkirk, LTC, MSC	DCI
Michael Daly, CPT, MC	
(9) Dept/Svc: DCI/Pathology	(10) Assoc Investigators:
(11) Key Words: Giardia lamblia	Dick Wuerz, GS-9
In vivo interactions	
Electron microscopy	
(12) Accumulate MEDCASE:*	(13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of	this report.
(14) a. Date, Latest HUC Review:	b. Review Results:
c. Number of subjects enrolled during	ng reporting period:
d. Total number of subjects enrolled	d to date:
Note any adverse drug reactions i	reported to the FDA or sponsor for
studies conducted under an FDA-au	

(Continue on a separate sheet, designating this continuation as (14)c.)

a. To determine whether our laboratory strain of <u>G. lamblia</u> is capable of colonizing intestinal mucosa. b. To establish an animal model for giardiasis. c. To determine the time required for <u>G. lamblia</u> trophozoites to adhere to intestinal mucosa. d. To examine infected mucosa by light microscopy and EM.

(16) e<sub>TecTolivork Approach bodology</sub> for studying immunized or naturally infected animals.

G. lamblia trophozoites were inoculated into ligated small intestinal loops.

After varying periods of time, sections of small intestinal mucosa were processed for light and electron microscopy to determine the degree of colonization, and the type and extent of host cell/parasite interaction.

Relatively few ligated loop experiments were conducted due to the PCS of the original principal investigator. Of the experiments performed, results were not encouraging. There was a lack of interaction between the inoculated trophozoites and the intestinal mucosa, which could have been due to a variety of reasons. Rather than pursuing this line of investigation, it was felt that a greater amount of information could be gained about human giardiasis by amending and devoting additional manhours to IRC-approved protocol no. 81-304.

APP. A - DETAIL SHEET

(1) Date: 30 Sep 84 (2) Protocol	WU#: 82/300 (3) Status: Completed
(4) Title: Studies of Immunological	ly Mediated Thrombocytopenia
(5) Start Date: May 1982	(6) Est Compl Date: April 1984
(7) Principal Investigator:	(8) Facility: FAMC
R. Stephen Whiteaker, Ph.D. CPT, MSC	
(9) Dept/Svc: DCI/Immunology Svc	(10) Assoc Investigators:
(11) Key Words:	(10) ASSOC INVESTIGATORS.
thrombocytopenia	Donald C. Corby, COL, MC
antiplatelet antibody	Jean E. Howard, MAJ, MC
immune complexes	
(12) Accumulative MEDCASE:*  *Refer to Unit Summary Sheet of	(13) Est Accum OMA Cost:* this report.
(14) a. Date, Latest HUC Review: May	
c. Number of Subjects Enrolled Durir	
d. Total Number of Subjects Enrolled	
<del>_</del>	reported to the FDA or sponsor for stud-
·	ed IND. (May be continued on a separate

<sup>(15)</sup> Study Objective: To develop an assay to differentiate anti-platelet thrombocytopenia from "innocent bystander" thrombocytopenia.

<sup>(16)</sup> Technical Approach: Patient serum is mixed with pooled type 0 platelets and platelet adsorable IgG is detected and quantitated using an anti-IgG ELISA procedur .

<sup>(17)</sup> Progress: tudy is completed with no complications or problems encountered. A may ipt has been submitted for publication.

- (16) Twenty five reproductive age women are to be studied in a double-blind, crossover study to determine the effectiveness of Danazol in premenstrual syndrome. The study is 4 months in duration, 2 months placebo, 2 months Danazol. Patients will take medication from the onset of symptoms to onset of manages. Symptoms will be evaluated with a menstrual symptom diary and results between treatment and placebo cycles will be analyzed statistically. In addition, levels of FSH, LH, progesterone, and estradiol will be obtained and evaluated.
- (17) During the fiscal year 1984, significant progress was made in the study. At present, ten patients have completed the study, and an additional ten patients are still on study.

To date, there have been no reported side effects noted. Two patients have voluntarily dropped out of the study due to personal reasons.

It is anticipated that the study will be completed by February 1985 and submitted for publication by May 1985.

			Sheet (Ref. HSCR 40-23, as amended)
(1)	Date: 30 Sep 84 (2) Protocol	WU#:	33/351 (3) Status:Ongoing
(4)	Title: Danazol in the treatm	nent	of Premenstrual Syndrome.
(5)	Start Date: 1 Aug. 83	(6)	Est Compl Date: Feb. 85
(7)	Principal Investigator: Albert P. Sarno Jr., M.D. Cpt., MC	(8)	Facility: FAMC
(9)	Dept/Svc: OB/GYN	(10)	Assoc Investigators:
	Key Words: premenstrual syndrome Danazol	(10)	Edward G. Lundblad, M.D. LTC, MC
(12)	Accumulative MEDCASE:# *Refer to Unit Summary Sheet of		Est Accum OMA Cost:* report.
(14)	a. Date, Latest HUC Review:		b. Review Results:
	Number of Subjects Enrolled Durin	g Re	
d. 1	otal Number of Subjects Enrolled	l to I	Date: 20
į		ed INI	ted to the FDA or sponsor for stud- O. (May be continued on a separate

None

(15) Study Objective: The objective of this study is to perform a prospective double-blind, crossover study to determine if Danazol is more effective than placebo in treating reproductive age women with premenstrual syndrome.

- 16. PROTOCOL 60: A Phase III Randomized Study of PAC +/- BCG. Four patients entered, all with mild to moderate myelosuppression without sequelae. Ongoing.
- 17. PROTOCOL 61: A Phase III Randomized Study of Cis-Platinum and Cytoxan Vs Hexamethylmelamine. Ongoing.
- 18. PROTOCOL 63: A Clinical-Pathologic Study of Stage II-B. Ongoing.
- 19. PROTOCOL 64: A Randomized Comparison of Rapid Vs Prolonged Infusion of Cis-Platinum. Ongoing.
- 20. PROTOCOL 66: Ultrastructure of Small Cell Carcinoma. Ongoing.
- 21. PROTOCOL 70: Randomized Study of Methotrexate and Methotrexate with Citrovorum Rescue. Ongoing.
- 22. PROTOCOL 72: A, B and C. Ovarian Tumors of Low Malignant Potential. One patient entered. Ongoing.
- 23. PROTOCOL 73: A Clinical-Pathologic Study of Malignant Melanoma of the Vulva. Ongoing.
- 24. PROTOCOL 74: Early Stage I Vulvar Carcinoma. Ongoing.
- 25. PROTOCOL 75: Postoperative Radiation Therapy in Mixed Mesodermal Tumors.
  Ongoing.
- 26. PROTOCOL 7601: Ovarian Cancer Study Group Protocol. Closed.
- 27. PROTOCOL 7602: Ovarian Cancer Study Group Protocol for All Stage I-C and II. Section A. Ongoing.

  Section B. Closed secondary to lack of accrual.
- 28. PROTOCOL 77: A Randomized Comparison of Carboplatin Vs CHIP. Two patients entered without significant response noted; no toxicity noted. Closed.

GEORGE L RAILLIES, OK, MD

LTC(P), MC

Chief, GYN & GYN-Oncology Service Asst Chief, Dept of OB-GYN

(All studies are shown in brief titles, only)

- 1. PROTOCOL 26:
  - Section A. Master Protocol for Phase II Drug Studies. As on document.
  - Section C. A Phase II Trial of "Cis-Platinum". Closed to all, but first line therapy for uterine sarcomas.
  - Section D. A Phase II Trial of VP16. Ongoing.
  - Section L. A Phase II Trial of Tamoxifen. Ongoing.
  - Section N. A Phase II Trial of DHAD. Ongoing.
  - Section O. A Phase II Trial of AZQ. Ongoing.
  - Section Q. A Phase II Trial of Aminothiadiazole. One patient entered with sustained partial response without significant toxicity. The protocol is now closed.
  - Section R. A Phase II Trial of Progestin. Ongoing.
  - Section S. A Phase II Trial of VM26. Ongoing.
  - Section T. A Phase II Trial of 4'-Deoxydoxorubicin. Ongoing.
- 2. PROTOCOL 34: A Randomized Study of Adriamycin as an Adjuvant. Ongoing.
- 3. PROTOCOL 40: A Clinical-Pathologic Study of Stage I and II Uterine Sarcomas.

  Two patients entered for clinical-pathologic study. Ongoing.
- 4. PROTOCOL 41: Surgical Staging of Ovarian Cancer. Ongoing.
- 5. PROTOCOL 44: Evaluation of Adjuvant Vincristine. Ongoing.
- 6. PROTOCOL 45: Evaluation of Vinblastine, Bleomycin. Ongoing.
- 7. PROTOCOL 48: A Study of Progestin Therapy and a Randomized Comparison. Ongoing.
- 8. PROTOCOL 49: A Surgical-Pathologic Study of Women with Invasive Cancer.
  - Section A. Closed.
  - Section B. Ongoing.
- 9. PROTOCOL 52: A Phase III Study of Cyclophosphamide. Ongoing.
- 10. PROTOCOL 54: The Treatment of Malignant Tumors of the Ovary with Combination Vincristine, Dactinomycin and Cyclophosphamide. Ongoing.
- 11. PROTOCOL 55: Hormonal Contraception and Trophoblastic Sequelae. Ongoing.
- 12. PROTOCOL 56: Randomized Comparison of Hydroxyurea. Ongoing.
- 13. PROTOCOL 57: Randomized Comparison of Multi-agent Chemotherapy. Ongoing.
- 14. PROTOCOL 58: A Study of Cytoplasmic Progestin. One patient entered. Closed.
- 15. PROTOCOL 59: Extended Field Radiation Therapy. Closed.

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (Ref. HSCR 40-23, as amended) 30 Sep 84 (2) Protocol WU#:80/350 (3) Status: ongoing (see (4)Title: attached list) Gynecologic-Oncology Group Protocols Est Compl Date: Indefinite August 1980 (6) Start Date: Principal Investigator: (8) Facility: FAMC (7)Frank Major, MD Denver General Hospital Dept/Svc: OB-GYN/GYN-Oncology (10) Assoc Investigators: (11) Key Words: GEORGE L PHILLIPS, JR, MD Gynecologic-Oncology Group Studies LTC(P), MC Chief, GYN & GYN-Oncology Service Asst C, Dept of OB-GYN (13) Est Accum OMA Cost: (12) Accumulative MEDCASE: \*Refer to Unit Summary Sheet of this report. (14) a. Date, Latest HUC Review: 3 Apr 84 b. Review Results: SEE ATTACHED LIST c. Number of Subjects Enrolled During Reporting Period: d. Total Number of Subjects Enrolled to Date: Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. (May be continued on a separate sheet, and designated as "(14)e". previously delineated as closed as per progress report of 3 Apr 84, have been deleted from the list in their entirety. (15) Study Objective: Please see previous report dated 30 Sep 83.

- (16) See previous report dated 30 Sep 83.
- (17) PROGRESS: See attached list.

一下のからないと 一日からん

GEORGE PHILLIPS, JR, MD

LTC(P), MC

Chief, GYN & GYN-Oncology Service

Asst C, Dept of OB-GYN

OB-GYN

(1)	Date: 30 Sep 84 (2) Protocol	WU#:	84/300 (3) Status: Ongoing
(4)	Title: Protein A as an Extracory Canine Mammary Adenocarc		l Immunotherapeutic Treatment for
(5)	Start Date: 1984	(6)	Est Compl Date: Indefinite
(7)	Principal Investigator:	(8)	Facility: FAMC
	Victor Feuerstein, DAC CPT Ian B. Stewart Nicholas Bethlenfalvay, MD, DAC		
(9)	Dept/Svc: DCI	(10)	Assoc Investigators:
	Key Words:		T.P. O'Barr, Ph.D., DAC Albert McCullen, CPT(P), VC Donald G. Corby, COL, MC Larry Jones, DAC L. Kramer, SP5
(12)	Accumulative MEDCASE:*	(13)	Est Accum OMA Cost:*
	*Refer to Unit Summary Sheet of	this	report.
(14)	a. Date, Latest HUC Review:		b. Review Results:
c.	Number of Subjects Enrolled Durin	g Re	porting Period: 0
	Total Number of Subjects Enrolled		
			ted to the FDA or sponsor for stud- D. (May be continued on a separate

Publications and Presentations: None

<sup>(15)</sup> Study Objective: To determine the effects of ex vivo plasma perfusion over a protein A bearing gel on naturally occurring canine mammary adenocarcinomas.

<sup>(16)</sup> Technical Approach: This protocol will evaluate the effects of autologous plasma after circulation through protein A sepharose CL-4B on spontaneous canine mammary adenocarcinomas. Previous literature has reported the ex vivo treatment of plasma with protein A to effectively enhance the host's tumoricidal capabilities. Utilizing this especially pure, standardized and irreversibly bound protein A will eliminate leaching and facilitate the removal of the bound proteins from the gel following perfusion. This will allow the subsequent laboratory analysis of these proteins to establish both identity and quantity.

<sup>(17)</sup> Progress: To date the study has not been started. The temporary ban on the use of dogs makes uncertain the future supply of dogs.

CONTINUATION SHEET, FY 84 ANNUAL PROGRESS REPORT Proto No.: 83/301

Publications and Presentations for FY 84 Annual Progress Report

#### Publications:

 Decker, W.J., St. Claire, R.L., III, and Corby, D.G.: Psyllium Mucilloid: A Potential Trapping Agent for Ingested Solvents. International Congress of Clinical Toxicology, August 1982 (Abst).

## Presentations:

 Decker, W.J., St. Claire, R.L., III and Corby, D.G.: Psyllium Muciloid: A Potential Trapping Agent for Ingested Solvents. Presented: 1982 International Congress of Clinical Toxicology, Snowmass, Colorado, August 1982.

(1) Date: 30 Sep 84 (2) Protoco	l WU#: 83/301 (3) Status: Ongoing		
(4) Title: Evaluation of Psyllium for Ingested Solvents	m Mucilloid: A Potential Trapping Agent		
(5) Start Date: 1982	(6) Est Compl Date: Indefinite		
(7) Principal Investigator: Donald G. Corby, M.D., COL, MC Walter J. Decker, Ph.D.	(8) Facility: FAMC		
(9) Dept/Svc: DCI	(10) Assoc Investigators:		
(11) Key Words: psyllium mucilloid ingested solvents	A.H. McCullen, DVC, CPT(P), VC		
(12) Accumulative MEDCASE:* *Refer to Unit Summary Sheet o	(13) Est Accum OMA Cost:* f this report.		
(14) a. Date, Latest HUC Review:			
d. Total Number of Subjects Enrolled to Date: NA e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. (May be continued on a separate sheet, and designated as "(14)e".			

- (15) Study Objective: To evaluate 1) the stability of P/gel complexes in the GI tract of the laboratory animal, and 2) the ability of P to entrap solvents in vivo thus preventing their absorption and resultant systemic toxic manifestations and/or death.
- (16) Technical Approach: The study will be conducted in 4 phases. Phases 1-3 will be experimental subjects (lab animals). The species will be determined from data derived from the literature concerning the known LD50 for ethylene glycol, methanol and kerosene (all commonly found in the home and can be easily swallowed), if available. If data is not available, sutdies of LD50 will be performed. Phase 4 will only be conducted if phases 1-3 show conclusively that P entraps solvents thus reducing systemic absorption, toxicity and death in lab animals. In Phase 4, the subjects will be patients (adult or child) who present for treatment of acute iron intoxication at hospital emergency rooms or who contact poison treatment centers in five states. At that time an addendum covering the exact clinical protocol and human use requirements will be submitted to FAMC and IRC for approval to continue study.
- (17) Progress: Studies during the past FY have concentrated on reaffirming LD50 of various solvents in the various animal models. As soon as this preliminary work is completed definite testing with psyllium mucilloid will begin.

CONTINUATION	SHEET,	FY	84	ANNUAL	PROGRESS	REPORT	Proto	No.:	<u>83/30</u> 0
DEPARTMENT	DCI								

Progress - continued

administered FeSO4 tablets (650 mg/lb). 30 or 60 min later, the dogs were given Mg)H2 at either 5 or 10X the dose of elemental iron. Serum iron levels in all animals given Mg0H2 were significantly lower that those of controls. No significant differences were observed regardless of dose or time of administration of MgHOH2. Although serum Mg++ levels were significantly elevated in all treated animals 4 and 6 hr post iron, no clinical manifestations of hypermagnesemia were observed. These studies demonstrate the effectiveness of MgOH2 in the management of experimental iron intoxication and warrant a clinical trial of its effectiveness in humans.

Publications: Corby, D., Chadwick, E., McCullen, A., and Decker, W.: Effect of Oral Magnesium Hydroxide in Experimental Iron Intoxication. (Abstract, Annual Scientific Meeting, AAPC/AACT/ABMT/CAPCC, San Diego, CA, Oct 7-12, 1984)

Presentations: Corby, DG, et al: Effect of Oral Magnesium Hydroxide in Experimental Iron Intoxication. Presented: AAPC/AACT/ABMT/CAPCC, Annual Scientific Meeting, October 7-12, 1984 San Diego, California

(1) Date: 30 Sep 84 (2) Protoco	1 WU#: 83/300 (3) Status: Completed				
for Acute <sup>2</sup> Iron Salt Ov	<pre>gnesia) a Potentially Effective Antidote erdose?</pre>				
(5) Start Date: 1982	(6) Est Compl Date: 30 Sept 84				
(7) Principal Investigator: Donald G. Corby, M.D., COL, MC Walter J. Decker, Ph.D.	(8) Facility: FAMC				
(9) Dept/Svc: pci	(10) Assoc Investigators:				
(11) Key Words:					
iron salt overdose	Elwyn Chadwick, SP6				
magnesium hydroxide	Albert McCullen, DVC, CPT(P), VC				
(12) Accumulative MEDCASE:* *Refer to Unit Summary Sheet o	(13) Est Accum OMA Cost:*  f this report.				
(14) a. Date, Latest HUC Review: N	A b. Review Results:				
c. Number of Subjects Enrolled Dur	ing Reporting Period: NA				
d. Total Number of Subjects Enroll	<del></del>				
	reported to the FDA or sponsor for stud- ded IND. (May be continued on a separate ". NA				

- (15) Study Objective: To determine the feasibility of administering Milk of Magnesia (Mg(OH)) suspensions to reduce the absorption of iron salts from the gastrointestinal tract in experimental iron salt intoxication. To determine the optimal time of administration; optimal dose of administration; the temporal limits of effectiveness and potential hazards of this form of therapy.
- (16) Technical Approach: The study will be conducted in 3 phases using experimental subjects consisting of laboratory animals. If phases 1-3 show conclusively that Mg(OH) is an effective antidote in the treatment of acute iron overdose in the lab<sup>2</sup>animal, phase 4 will be conducted. This phase will consist of subjects (patients adult or child) who present for treatment of acute iron intoxication at hospital emergency rooms or who contact poison treatment centers in five states and have obtained informed consent will be divided randomly into two groups for treatment using conventional therapy and identical treatment.
- (17) Progress: We have previously shown that Fe++ and Fe++ ions readily form complexes with magnesium hydroxide (Mg0H2) thus reducing absorption of iron salts from the gastrointestinal tract. However, several questions were previously left unanswered: What is the optimal dose, time of administration, optimal limits of effectiveness, and potential hazards of this form of therapy? Dogs were

(1)	Date: 30 Sep 84 (2) Protocol	<b>#</b> : 82/303 ( <b>3</b> )	Status: Terminated
(4)	Title: A Study of Canine and Fel Steroid Hormone Receptors of the Metastases	e Mammary Tumors: f Primary Tumor S	Correlation of Sites with those
(5)	Start Date: Sep 82	) Est Compl Date	eSep 84
(7)	Principal Investigator: Albert H. McCullen, DVM, CPT(P)	) Facility: FAI Cell Physiolog	
( <u>9)</u> (11)	Mammary Tumors Steroid Hormone Receptors		mer, B.S., SP5
(12)	Accumulative MEDCASE:# #Refer to Unit Summary Sheet of	3) Est Accum OMA is report.	Cost:#
(14) a. Date, Latest HUC Review: <u>Sep 83</u> b. Review Results: <u>ongoing</u> c. Number of Subjects Enrolled During Reporting Period: NA			

- d. Total Number of Subjects Enrolled to Date: NA

  e. Note any adverse drug reactions reported to the FDA or sponsor for stud-
- e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. (May be continued on a separate sheet, and designated as "(14)e". NA

- (16) Technical Approach: Samples of tumors and their metastases are minced, placed in culture medium with labeling compound, incubated, then rinsed. Tissue is flash frozen in liquid nitrogen and sectioned in the darkroom into 5 micrometer sections and mounted to previously prepared emulsion-coated slides. Following exposure at -20, for up to 3 weeks, slides are stained and silver grains over the nuclei of receptor positive cells are counted.
- (17) Progress: Work on this project has been terminated as examination of material collected to date is not of diagnostic quality. Further, the temporary ban on the use of dogs makes uncertain the future supply of dogs with tumors.

Publications and Presentations: None

<sup>(15)</sup> Study Objective: To compare steroid hormone receptors in the primary mammary tumors of dogs and cats with receptors found in metastatic lesions, using the autoradiographic technique.

- Date: 30 Sep 84 (2) Protocol WU#: 82/302 (3) Status: Ongoing (1) Title: The evaluation of recently introduced, commercially available clinical microbiology products for possible use in the FAMC diagnostic microbiology laboratory. Est Compl Date: 1 July 1985 Start Date: 1 July 1982 (8) Facility Principal Investigator: Pari L. Morse, DAC Clifford Butler, DAC (10) Assoc Investigators: Dept/Svc: Dept of Pathology/DCI (11) Key Words: Paul G. Engelkirk, LTC, MSC Diagnostic microbiology J.T. Stocker, LTC, MC Microbiological products (12) Accumulative MEDCASE:# (13) Est Accum OMA Cost:# \*Refer to Unit Summary Sheet of this report. (14) a. Date, Latest HUC Review: Jul 84 b. Review Results: ongoing c. Number of Subjects Enrolled During Reporting Period: N/A Total Number of Subjects Enrolled to Date: N/A Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. (May be continued on a separate sheet, and designated as "(14)e".
- (15) Study Objective: To evaluate recently introduced products which are of interest to the Microbiology Section, Dept of Pathology, FAMC, but which cannot adequately be evaluated within that laboratory due to time, personnel, and monetary constraints. This evaluation will include cost effectiveness, ease of use, reproducibility and speed.
- (16) Technical Approach: A separate protocol will be designed for each product evaluated.
- (17) Progress: There was no progress on this protocol during LY 1984, due primarily to a shortage of personnel in the Microbiology Section, Dept of Pathology. Several ideas are being discussed, and some new products will be evaluated during FY 1985.

#### DETAIL SUMMARY SHEET

(Ref: HSCR 40-23 & HSPA-I Ltr, 8 July 1982

individual moieties.

(1)		tocol WU Nr.: 82/301 (3) Status: Completed
(4)	Title: The Antigenic Evaluati Giardía lamblia.	ion of Axenically-Cultivated
(5) (7)	Start Date: 1 July 1982 Principal Investigator	(6) Est Compl Date: 1 July 1984 (8) Facility: FAMC
	Victor Feuerstein DAC,DCI	Biochemistry Service Immunology Service Microbiology Service
(9)	Dept/Svc: DCI, FAMC Key Words: Giardia Antigenic	(10) Assoc Investigators: P.G. Englekirk, Ph.D., LTC,MSC. T.B. Brewer,M.D.,MAJ,MC. R.S. Whiteaker, Ph.D.,CPT,MSC.
(14) c. d. d.	Accumulate MEDCASE:*  *Refer to Unit Summary Sheet a. Date, Latest HUC Review: Number of subjects enrolled di Total number of subjects enro Note any adverse drug reaction studies conducted under an FDA	L July 83 <sup>b</sup> . Review Results: continued during reporting period: NA colled to date: NA consorred to the FDA or sponsor for
(15)	Study Objective: To ellucidate and immunologic of the trophozoites of axenic Giardia lamblia. Technical Approach: Following	cally characterize the antigenic make-up cally-cultivated Portland and NIH strain ag mechanical, chemical or immunological
	separation into components do	louble diffusion, electrophoretic, iso-electric

(17) Progress: As many as thirty individual antigen moieties have been separated. The specific techniques have been refined. An inate time-related lability for many of the antigens has been characterized, as well as the extremely weak pature of the antigens isolated be these procedures. The characteristics of the antigens isolated make any future work with stimulation of specific cell populations in culture prohibitive, Additionally, the inability to separate strains of the parasite by these highly sophisticated and sensitive assays suggests the need to look at the encysted stage of the parasite.

and chromatographic analysis will be utilized to isolate and characterize

(1) Date: 30 Sep 84 (2) Protocol	WU#: 84/350 (3) Status: ongoing			
(4) Title: "A Prospective Study of	the Effects of CO2 Laser Vaporization of			
	lial Neoplasia on Cervical Factors and			
Subsequent Fertility."				
(5) Start Date: 1 Aug 84	(6) Est Compl Date: 31 Jul 86			
(7) Principal Investigator:	(8) Facility: FAMC			
GEORGE L PHILLIPS, JR, MD				
LTC(P), MC				
Chief, GYN & GYN-Oncology Service				
Asst C, Dept of OB-GYN				
GYN-One	plogy Service			
(9) Dept/Svc: Dept of OB-GYN/	(10) Assoc Investigators:			
(11) Key Words:	EDWARD G LUNDBLAD, MD			
CO2 Laser Vaporization	LTC,MC			
Cervical Intraepithelial Neoplasia	Chief, Family Planning Service			
Vertility Effects				
•				
(12) Accumulative MEDCASE:*	(13) Est Accum OMA Cost:#			
*Refer to Unit Summary Sheet of	this report.			
(14) a. Date, Latest HUC Review:	b. Review Results:			
c. Number of Subjects Enrolled During Reporting Period: one (1)				
d. Total Number of Subjects Enrolle	d to Date: one (1)			
e. Note any adverse drug reactions	reported to the FDA or sponsor for stud-			
ies conducted under an FDA-award	ed IND. (May be continued on a separate			
	No adverse effects have been noted			

GEORGE L PHILLIPS, JR, MD

LTC(P), MC

Chief, GYN & GYN-Oncology Service

<sup>(15)</sup> Study Objective: To assess the impact, if any, of CO2 laser vaporization of the cervix for cervical intraepithelial neoplasia upon cervical factors related to potential fertility and subsequent fertility impact, if any.

<sup>(16)</sup> TECHNICAL APPROACH: Patients with the diagnosis of CIN who are candidates for laser vaporization of the cervix will undergo pre- and postvaporization post-coital tests and long-term follow-up of fertility.

<sup>(17)</sup> PROGRESS: Only one patient has been entered on this study since its inception. This, in a large part, is due to the lack of a suitable smoke evacuation device in the area where the CO2 laser is operated. This device has been approved and should be received shortly. It is anticipated that accrual will increase following receipt of this device.

**PEDIATRICS** 

# DETAIL SUMMARY SHEET

(Ref: HSCR 40-23 & HSPA-I Ltr, 8 July 1982

717	Date: FY8	4 (2)	Protocol	WU Nr.: 81/4	02	3) Sta	tus: Termir	
(4)	Title:						TOTALL	iace
	Diagnosis Enzyme-Lin	of Respirato ked Immunoso	ry Syncyti rbent Assa	al Virus (RS y (ELISA)	V) Infe	ection i	n Infants	bу
(5)	Start Date	7 January	1981 (6	) Est Compl	Date:	N /A		
(7)	Principal Donald R. I	Investigator Moffitt, MAJ Paine, GS-11	(8)	Facility:	FAMC	N/A		
(9) (11)	Key Words:	Pediatrics/Do	(10	William H	. Parry	, COL, I		
	ELISA RSV infecti	on		Paul G. E	ngelkir	k, LTC,	MSC	
(12)	Accumulate			Est Accum (	MA Cos	t:*		
		nit Summary		his report.				
		atest HUC Re		b. Revi		ılts:		
c. i	Number of su	bjects enrol	led during	reporting p	eriod:	***************************************		-
d. '	Total number	of subjects	enrolled	to date:	Ž.	3		
e. 1	Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND.:							

(Continue on a separate sheet, designating this continuation as (14)e.)

(15) Study Objective: Development of an ELISA procedure for the detection of RSV antigen using commercially available reagents, and determination of the efficacy of the procedure for the diagnosis of RSV infections in infants.

(16) Technical Approach: An ELISA procedure will be developed using commercially availab reagents and virus controls. Nasal secretions and urine specimens will be obtained from infants with suspected RSV infection, and urine specimens will be obtained from control children. These specimens will be tested by the ELISA procedure.

(17) Progress:

To date, a total of 18 inpatients have been entered into this study. Urine and nasal ELISA procedures for the detection of RSV antigen have been performed on urine and nasal specimens from these patients. In addition, ELISA procedures have been performed on urine specimens from 35 control children. This protocol is being terminated due to the low number of RSV patients available for entry into this studyand unresolved irregularities in the assay procedure for urine specimens. The number of RSV patients was far lower than anticipated at the outset of the study, and is too small for valid statistical analyses.

(FAMC FL 7807-Cl Page 2)

(1)	Date: 30 Sep 84 (2) Protocol	WU#: 82/400 (3) Status: Ongoing		
(4)	Title: The Effect of Glycerin S On Bilirubin Levels in I	uppository Administration nfants Receiving Phototherapy		
(5)	Start Date: October 1982	(6) Est Compl Date: October 1984		
(7)	Principal Investigator:	(8) Facility: FAMC		
	Gail Murphy, M.D. CPT, MC			
( <u>9)</u>	Dept/Svc: Pediatric/Newborn	(10) Assoc Investigators:		
(11)	Key Words: Hyperbilirubinemia	John R. Pierce, M.D., LTC, MC		
	re: glycerin suppositories	Gerald B. Merenstein, M.D., COL, MC		
(12)	Accumulative MEDCASE:* *Refer to Unit Summary Sheet of	(13) Est Accum OMA Cost:* this report.		
(14)	a. Date, Latest HUC Review: Ma	r 83 b. Review Results: Ongoing		
	Number of Subjects Enrolled Duris			
	Total Number of Subjects Enrolle			
	Note any adverse drug reactions reported to the FDA or sponsor for stud-			

Publications and Presentations: None

sheet, and designated as "(14)e". N/A

<sup>(15)</sup> Study Objective: To determine whether the utilization of glycerin suppositories to enhance stooling effects peak serum bilirubin or influences changes in bilirubin levels in infants 36 weeks gestational age being treated with phototherapy for hyperbilirubinemia.

<sup>(16)</sup> Technical Approach: Sixty infants 36 weeks gestation and I week of age who require phototherapy for treatment of hyperbilirubinemia will be studied. Infants will be randomly assigned to a treatment group of glycerin suppositories every 4 hours or a control group Bilirubin levels will be determined every 6-8 hours while under phototherapy for treatment and control patients. Results will be tabulated and statistically evaluated for any benefit.

<sup>(17)</sup> Progress: Due to heavy clinical and research work load, no patients are yet enrolled. However, enrollment is anticipated in the near future.

(1)	Date: Fy 84 (2) Protocol	WU#: 82/401 (3) Status: Completed
(4)	Title: Modified Immune Serum Gl	
(5)	Start Date: 7 Apr 82	(6) Est Compl Date: 30 Sep 83
(7)	Principal Investigator: John R. Pierce, M.D. LTC, MC	(8) Facility: FAMC
(9)	Dept/Svc: Pediatric/Newporn	(10) Assoc Investigators:
(11)	Key Words: Modified immune	
	serum globulin, kinetics, neonates	Gerald W. Fischer, M.D. LTC, MC
(12)	Accumulative MEDCASE:*  *Refer to Unit Summary Sheet of	(13) Est Accum OMA Cost:* this report.
c. 1 d. 2 e. 1	a. Date, Latest HUC Review: Number of Subjects Enrolled Durin Total Number of Subjects Enrolled Note any adverse drug reactions r ies conducted under an FDA-awarde sheet, and designated as "(14)e".	to Date: 15 eported to the FDA or sponsor for stud- d IND. (May be continued on a separate

- (15) Study Objective: To analyze the ability of Modified Immune Serum Globulin (MISG) to elevate neonatal IGG levels. We will specifically look at pre and post MISG serum for evidence of increased activity against Group B streptococcususing invetro assays for opsonic antibody.
- (16) Technical Approach: Infants will be assigned to the control or treatment group. The treatment group will receive an infusion of MISG given over 4-8 hours. Blood samples will be drawn prior to and following the infusion at specific intervals. Sera will be forwarded to the Uniformed Services University of the Health Sciences in Bethesda, Maryland for all determinations. Infants will be monitored closely during the infusion for any side-effects or adverse reactions.
- (17) Progress: This protocol was a cooperative protocol between several of the Army Medical Centers. The study has been completed by the addition of patients from the other medical centers. It was not necessary during this past calendar year to enroll any new patients here at Fitzsimons in this protocol.

Publications and Presentations: None

#### DETAIL SUMMARY SHEET

8 July 1982 (1) Date: FY Sep 30, 842) Protocol WU Nr.: 82/403 (3) Status: Ongoing (4) Title: POG Studies Est Compl Date: Start Date: Oct 1981 1986 (7) Principal Investigator (8) Facility: FAMC Askold D. Mosijczuk, LTC, MC (9) Dept/Svc: Pediatrics (10) Assoc Investigators: (11) Key Words: Thomas Carter, COL, MC Neursurgery Service Jeffrey Clark, COL, MC, C, Surgery Service POG Studies William Daniel, M.D., Radiation Oncology Vishnu Reddy, LTC, MC, C, Hematopathology Thomas Stocker, LTC, MC, C, Ped Pathology (12) Accumulate MEDCASE:\* (13) Est Accum OMA Cost:\* \*Refer to Unit Summary Sheet of this report. (14) a. Date, Latest HUC Review: Oct 83 b. Review Results: Continue study c. Number of subjects enrolled during reporting period: 7 Total number of subjects enrolled to date: \_\_\_\_\_16\_ Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND.: None (Continue on a separate sheet, designating this continuation as (14)e.) (15) Study Objective: See attached sheet

(17) Progress: See attached sheet

(16) Technical Approach: See attached sheet

(Ref: HSCR 40-23 &

HSPA-I Ltr,

#### SUMMARY OF PROTOCOL PROGRESS

## PROBLEMS ENCOUNTERED:

A. Fitzsimons' participation in POG protocols was audited by Dr. Trueworthy, Ped Oncologist from Kansas University and Chris Blevin, Data Manager, from Los Angeles as part of an NCI directive to all POG intitutions to insure compliance with NCI guidelines involving research studies in cancer patients. Our compliance with data management requirements on POG protocols was excellent. Two problems, however, were found in the audit. (1) lack of documentation of having obtained consent forms for 3 patients enrolled on POG studies between 1980 and 1982, and (2) lack of documentation by our IRB officials that a Cooperative Group Assurance Policy was in effect regarding POG studies. Both problems have been addressed and corrected.

#### **ENCLOSURERS:**

- (1) copy of POG Audit Findings
- (2) copy of memorandum Aug 6, 1984.

## 3. MODIFICATION OF PROTOCOL DESIRED:

- See attached list of Revisions, Addendums, modifications which have occurred in the last fiscal year.
  - 4. (a) Adverse reactions no unusual reactions to chemotherapy, surgery or radiation therapy have been encountered. Myelosuppression secondary to chemotherapy has been severe on occasion, but not unexpected. Myelosuppression has been reversible in all cases.
    - (b) Kinds and number of subjects enrolled:
      There have been 16 children enrolled

PT Initials	DIAGNOSIS	POG STUDY
	Mills Space sugar state state space space states	~
L. P.	melanoma	Rare Tumor Reg 7799
J.H.	ALL	ALINC #13 8035/36
J.F.	ALL	8035/36
A.D.	sarcoma	Rare Tumor Reg 7799
D.I.	ALL	8035/36
C.B.	ALL	ALINC #13 8035/36
S.K.	ALL	8035, 7837
D.D.	histiocytosis X	Natural study 7376
F.B.	rhabdomyosarcoma	IRS II
D.W.	medulloblastoma	MOPP/VsRT 7909
D.B.	neuroblastoma	8104/05
M.F.	ependymoma	7621
R.O.	rhabdomyosarcoma	81 <i>57</i>
R.H.	histiocytosis X	7376
K.C.	rhabdomyosarcoma	7898
N.D.	aggressive fibromatosis	7799
D.W.	osteosarcoma	8107

(c) On ALINC #13 (POG 8035/36) all FAMC patients have achieved complete remission status and none have relapsed to date; however time on study is extremely short as of this date. Pt initials F.B. with rabdomyosarcoma on POG 7898 completed therapy in Jul 83 and continues in CR. Pt. D.W. with medulloblastoma on POG 7909 completed in Aug 83 and continues in Patient D.B. with neuroblastoma on 8104/05 achieved PR, relapsed and died. Pt M.P. with ependymoma on 7621 developed progressive disease while on protocol; was later taken off study and subsequently died. Pt. R.O. with Stage IV rabdomyosarcoma on 8157 achieved CR; subsequently relapsed, was taken off study, treated with alternate chemotherapy but progress and died. Pts R.H. and D.D. with histiocytosis X on 7376 both achieved CR and are currently disease free. Pt K.C. with rhabdomyosarcoma on 7898 is alive in PR. Pt. M.D. with aggressive juvenile fibromatosis on 7799 is alive in CR. Pt L.P. with melanoma of the eye on 7799 is alive in CR. Pt A.D. with congenital undiffereniated sarcoma on 7799 achieved PR with VAC chemotherapy but soon progress and died. Pt D.W. with metastatic osteosarcoma on 8107 showed no response to T-12 a regimen chemotherapy and has progressive metastatic disease.

# 4. (d) Significant results are as follows:

MOPP vs rad therapy alone for medulloblastoma. Pts randomized to MOPP arm are showing much better survival than those treated with the radiation therapy alone arm. Difference is approaching statistical significance.

Pts with metastatic rhabdomyosarcoma on 8157 - although most patients showed an excellent initial response to total body irradiation (TBI) and aut bone marrow transplant, all have subsequent relapsed and died. Study will soon be closed.

fts with rhabdomyosarcoma on IRS II 7898 continue to show good overall survival, especially those with head and neck and GU primaries. The addition of adriamycin for advanced stage disease has not increased response rates or survival as compared to VAC chemotherapy. IRS III will soon be opened which will look at the possible benefit of VP 16 and cis-platinum chemotherapy in advanced stage rhabdomyosarcoma.

POG 8035 - classification of ALL -it appears that there is a certain subtype of null cell CALLA positive ALL which is also positive for cytoplasmic IGM. This subtype is called pre-B cell ALL. Thus far, patients with this subtype have not fared as well on ALINC #13 treatment protocol (POG 8036) as other children with CALLA positive null cell ALL on this protocol.

- (e) Current risk of therapy appear to be acceptable in light of the response rate and quality of life achieved by pts on POG studies, both at FAMC and group wide.
  - (f) Refer to (4d).
- (g) Consent forms are still sufficient to the best of my judgment. Judgment regarding the legal sufficiency of the consent forms is deferred to JAG.

## DETAIL SUMMARY SHEET

- 14. (e) None.
- 15. FOG studies can be divided into two basis types:
- (1) Therapeutic studies- Objective is to develop improved treatment modalities for a variety of pediatric malignant tumors.
- (2) Non-therapeutic studies- Objective is to further study the biology of a variety of pediatric tumors. This is accomplished by obtaining various specimens of the tumor and other lab data which is then forwarded to central reference laboratories.
- 16. Technical Approach: Various laboratory data pertaining to the patient malignant tumor is obtained which is forwarded to central reference labs and to a central POG Statistical Office. This data is used to increase basic knowledge regarding these tumors and is also utilized to stratify patients to various prognostic subgroups. After stratification, patients are randomly assigned to one of 2 or 3 treatment modalities. The response rate to treatment and individual data is compared among different treatment regimens. In addition, long term survivors are monitored for several years after completing therapy for possible long term effects of therapy.
- 17. PROGRESS: Since the last review by DCI in Oct 83, the following specific procols under the heading "82-403 POG Studies" have been closed to new patient e = y. B(c)89#1 POG 7376, B(c)89#2 POG 8047, B(c)89#3 POG 7896, B(c)89#4 POG 7895, B(c)89#5 POG 8095, B(c)89#12 POG 7712, B(c)89#15 POG 7612.

The following protocol has not been activated at FAMC at Principal Investigator's request. B(c)89#7 which is POG 8103 entitled Hepatoma III.

The following protocols have been recently approved and should be added to "82-403 POG Studies" and this is POG 8303 SIMAL #3, pOG 8304 SIMAL #4, POG 8305 SIMAL Lab Subclassification.

NOTE: First 20 studies have been reported on in August 1984
This additional report to concerns itself with B(c) 89 #21, 22, 23,24

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (Ref. HSCR 40-23, as amended)

(1) Date: 30 Sep 84 (2) Protocol	WU#: 82/403 (3) Status: OnGoing
(4) Title: 24 Orig POG/SWOG Studies	
(5) Start Date: Nov 1982	(6) Est Compl Date: Indefinite
(7) Principal Investigator:	(8) Facility: FAMC
Askold D. Mosijczuk, M.D.,LTC, MC	
(9) Dept/Svc: Pediatrics_	(10) Assoc Investigators:
(11) Key Words:	Thomas Carter, COL, MC Neurosurgery Svc
(11) hey words.	Jeffrey Clark, COL, MC, C, Surg, Svc
	William Daniel, MD, Radiaton Oncology
	Vishnu Reddy, LTC, MC, C, Hematopathology
	Thomas Stocker, LTC, MC, C, Ped. Pathology
(12) Accumulative MEDCASE:#	(13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of	
-Refer to offic Summary Steet of	this report.
(14) a. Date, Latest HUC Review:	b. Review Results: Continue Study
c. Number of Subjects Enrolled Durin	
d. Total Number of Subjects Enrolled	
	eported to the FDA or sponsor for stud-
	d IND. (May be continued on a separate

(15) Study Objective: and (16) Technical Approach are continued in the protocol for the 24 POG/SWOG studies involved under WU #82/403.

(17) Progress

Protocol B9c)89 #24 - POG 8156 Live Varicella protocol has been recommended for termination at FAMC on 25 April 1983. No patients have been enrolled at FAMC on this study.

In April 1983 the following 3 POG protocols were approved by IRB and should be added to "82/403 Orig POG/SWOG Studies"

- 1. POG 8303-SIMAL #3 (B104)
- 2. POG 8304-SIMAL #4 (B105)
- 3. POG 8305-SIMAL LAB Subclassification (B106)

To date (19 Sep 84) no patients have as yet been enrolled into these 3 studies at FAMC.  $\cdot$ 

## DETAIL SUMMARY SHEET

(Ref: HSCR 40-23 & HSPA-I Ltr, 8 July 1982

71\ =	
(1) Date: FY 84 (2) Proto	ocol WU Nr.:83/400 (3) Status: Terminated
(4) Title: A Comparative Study of	Body Temperature Measured at Different
Sites in Very Low Birth	Weight Infants.
	~
(5) Start Date:	(6) Est Compl Date:
(7) Principal Investigator	(8) Facility: FAMC
	(b) I dell'icy.
M. Gail Murphy, CPT, MC	
(9) Dept/Svc: Pediatrics	(10) Assoc Investigators:
(11) Key Words:	7
Temperatures, VLBW infants	LTC John R. Pierce, M.D., MC
remperatures, viba illiants	Lie dollin R. Fierce, M.D., Mc
··	(13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet o	f this report.
(14) a. Date, Latest HUC Review:	b. Review Results:
c. Number of subjects enrolled dur	ing reporting period:
d. Total number of subjects enroll	
	reported to the FDA or sponsor for
studies conducted under an FDA-	awarded IND.:
(Cartiana an a caranta about dosi	anatina this continuation as (1/)
(15) Study Objective:	gnating this continuation as (14)c.)
(1)) study objective:	
•	
(16) Technical Approach:	

# (17) Progress:

 $\label{protocol} \begin{picture}(20,20) \put(0,0){\line(1,0){100}} \put(0$ 

(1)	Date: 30 Sep 83 (2) Protocol W	U#: 83/401 (3) Status: Ongoing
(4)	Title: Prevalence of Endometrios: of Severe Dysmenorrhea	is Externa in Adolescent Women Complaining
(5)	Start Date: 4 April 1983	(6) Est Compl Date: June 1986
(7)	Principal Investigator Mark E. Blaedel, LTC, MC Edward Lundblad, LTC, MC	(8) Facility: FAMC
(9)	Dept/Svc: Pediatrics/OB-GYN	(10) Assoc Investigators
(11)	Key Words: Endometriosis Dysmenorrhea	Jerald F. Dirks, Psy D.
(12)	Accumulative MEDCASE: * *Refer to Unit Summary Sheet of the	(13) Est Accum OMA Cost:*
	a. Date, Latest HUC Review: NA Number of Subjects Enrolled During	Review Results: NA Reporting Period:
	Stage I 700 Stage II 66 Stage III 3	

- d. Total Number of Subjects Enrolled to Date: Same
- e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. (May be continued on a separate sheet, and designated as "(14)e". None

- 1. An epidemiologic survey of young women will document the prevalence of symptomatic endometriosis externa in a middle class primary care population of adolescent women complaining of dysmenorrhea. This prevalence figure will tell the health care provider how alert he has to be to this condition.
- 2. Background biosocial data will be collected in hopes that certain distinctive historical markers will distinguish the young woman with secondary dysmenorrhea due to endometriosis from the patient with severe primary dysmenorrhea.
- 3. A registry of young women with endometriosis will be developed. In the future, trials of medication can be given to these young women to determine the therapy of greatest benefit. These women can also be followed for a prolonged period of time to determine the incidence of complications of endometriosis.

<sup>(15)</sup> Study Objective:

- Proto No.: 83/401
- (16) Technical Approach: This retrospective stage of epidemiologic survey is designed to isolate by questionaire those young women who might have endometriosis and subject them to laparoscopy.
- (17) Progress: As of 30 September 1984, approximately 700 patients have completed the Stage I questionnaire. Out of these approximately 60 have completed the Stage II requirements and, to date, three patients have had a laparoscopy.

Publications and Presentations: None.

(1) Date: 30 Sep 84 (2) Protocol	WU#: 83/402 (3) Status: Ongoing
(4) Title: B2-Microglobulin as a Mea	sure of Renal Tubular Function
in the Neonate	
(5) Start Date: 11/1/83	(6) Est Compl Date: 8/85
(7) Principal Investigator:	(8) Facility: FAMC
Ronald J. Portman, M.D. MAJ MC USA	
	Children's Hospital at Washington University
	St. Louis, MO.
(9) Dept/Svc: Rediatrics/Newborn	(10) Assoc Investigators:
(11) Key Words:	John R. Pierce, M.D. LTC MC USA
B2-Microglobulins	Alan M. Robson, M.D. Director Pediatric Renal
Intrauterine Distress	Division in St. Louis
Renal Tubular Function	Michael Southgate, M.D. CPT MC USA
	Rosie Gibbons CPT ANC
(12) Accumulative MEDCASE:#	(13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of	this report.
(14) a. Date, Latest HUC Review:	b. Review Results:
c. Number of Subjects Enrolled Durin	ng Reporting Period: 49
d. Total Number of Subjects Enrolled	to Date: 49
e. Note any adverse drug reactions r	reported to the FDA or sponsor for stud-

sheet, and designated as "(14)e".

The purpose of this study is to examine the renal handling of this low molecular weight protein at various gestational and postpartum ages in neonates who manifest evidence of normal or abnormal intrauterine environments (e.g., infants of diabetic mothers, small for gestational age infants, prolonged rupture of membranes, meconium stained amniotic fluid, and history of maternal drug abuse).

ies conducted under an FDA-awarded IND. (May be continued on a separate

<sup>(15)</sup> Study Objective:

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (Ref. HSCR 40-23, as amended) 30 Sep 84 (2) Protocol WU#: 74/651 Status: Ongoing (3)(1)Date: (4) Title: Establishment of and Training in Methods for Special Studies of Abnormal Hemoglobins Start Date: January 1974 (6) Est Compl Date: Indefinite (7) Principal Investigator: (8) Facility: FAMC Nicholas C. Bethlenfalvay, M.D., DAC Dept/Svc: Primary Care (10) Assoc Investigators: (9)(11) Key Words: Abnormal Hemoglobins Techniques on Joseph Lima, DAC Identification T. Waldrup, DAC (12) Accumulative MEDCASE:# (13) Est Accum OMA Cost:\* \*Refer to Unit Summary Sheet of this report. (14) a. Date, Latest HUC Review: 12/82 b. Review Results: ongoing c. Number of Subjects Enrolled During Reporting Period: d. Total Number of Subjects Enrolled to Date: e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. (May be continued on a separate sheet, and designated as "(14)e". NA (15) Study Objective:

To establish and conduct training in methods for special studies of abnormal hemoglobins.

(16) Technical Approach: To acquaint and to train existing personnel in the performance of various procedures as they pertain to biochemical study of hemoglobins and red cell enzymes involved in hemoglobin function.

In FY84, the following was accomplished: quantitation of erythrocyte glycolytation ontermediates, electrofocusing and electrophoresis of adenosine deraminase and of purine nucleoside phosphorylase.

<sup>(17)</sup> Progress: Since 1974 the following can now be performed. Column chromatography; electrophoresis and iso-electrofocusing of hemoglobin; column chromatography and electrophoresis and iso-electrofocusing of globin and electrophoretic demonstration of iso-enzymes of both NADH and NADPH dependent methemoglobin reductases. Quantitation of NDAH-cytochrome  $b_{\varsigma}$  and HADPH MR, glutathione, glutathione reductase now can be done. G-6 PD iso-enzyme patterns now can be determined. Recently equipment for the determination of hemoglobin oxygen dissociation curve has been obtained, and is operational. Carbohydrate and nucleoside utilization of red cells can now be assessed using cold or radioactive substrates.

PRIMARY CARE AND COMMUNITY MEDICINE

(1) Date: 30 Sep 84 (2) Protoco	ol WU#: 84/600 (3) Status: Ongoing
(4) Title:	
Prospective Study of the Effects of	<sup>r</sup> D <b>iagnostic</b> Ultrasound on the Human Auditory
Mechanism Following in Utero Exposu	ire
(5) Start Date: February 1984	(6) Est Compl Date: June 1986
(7) Principal Investigator:	(8) Facility: FAMC
Marlene J. Severson, M.D., CPT, MC	
Gioria Hubred Komppa, M.D.	
Jeffrey Davies, PHD, CPT, MSC	
Fred Garner, M.D., CPT, MC	
James Potter M.D., CPT, MC	
(9) Dept/Svc:Radiology/Ultrasound	(10) Assoc Investigators:
(11) Key Words:	Nasser Ghaed, M.D., COL, MC
Diagnostic Ultrasound, Biological	John Kolmer, M.D., COL, MC
Effects, Human Auditory Mechanism	
(12) Accumulative MEDCASE:#	(13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet	of this report.
(14) a. Date, Latest HUC Review:	b. Review Results:
c. Number of Subjects Enrolled Dur	ring Reporting Period: Approximately 150
d. Total Number of Subjects Enrol	led to Date: Approximately 150
e. Note any adverse drug reactions	s reported to the FDA or sponsor for stud-
ies conducted under an FDA-awai	rded IND. (May be continued on a separate
sheet, and designated as "(14)	e <sup>#</sup> .

(15) Study Objective:

N/A

To determine whether children exposed (to diagnostic ultrasound) in utero have detectable hearing loss as compared to a non exposed population.

- (16) Technical Approach: Pregnant women are being randomized into two groups. The control group is not receiving obstetric ultrasound. Family, birth and post natal histories are being collected on all study participants. Ultrasound data is collected on all women receiving it. Three to four months following delivery, the infants will be examined and audiological tests performed. The data will be compared.
- (17) Progress: In the fiscal year 1984, obstatric ultrasound data has been collected on approximatley 150 patients. None have had post natal hearing testing to date. Approximately five low risk pregnant women are currently enrolled in our control group. One has delivered approximatley one month ago. ENT examination and audiological testing should begin in approximately two to three months. Selection of the control group and collection of ultrasound data will continue.

PRESENTATIONS/PUBLICATIONS: Mone.

(1)	Date: 30 Sep 84 (2) Proto	col WU#: 83/601 (3) Status: Ongoing
(4)	Title: Evaluation of Indium Components	Oxine In-111 Labeled Cellular Blood
(5)	Start Date: 1 Oct 83	(6) Est Compl Date: 1985
(7)	Principal Investigator: Peter W. Blue LTC, MC	(8) Facility: FAMC
(9)	Dept/Svc:	(10) Assoc Investigators:
(11)	Key Words:	
	Indium Oxine	Nasser Ghaed COL, MC
(12)	Accumulative MEDCASE:* *Refer to Unit Summary Sheet	(13) Est Accum OMA Cost:* of this report.
(14)	a. Date, Latest HUC Review:	11/83 b. Review Results: Ongoing
	Number of Subjects Enrolled $\overline{\mathfrak{D}}$	
	Total Number of Subjects Enro	
:		ns reported to the FDA or sponsor for stud- arded IND. (May be continued on a separate )e". None.
(15)	Study Objective:	
	To evaluate Indium Oxine Lab fate, currently labeled WBC	eled Blood Components and their metabolic in infection.
(16)	Technical Approach:	
		WBC) are removed from patient, labeled, renned (labeled WBC will localize the infec-
(17)	Progress: Two abnormals. Six normals.	

Presentations/Publications: None

Test is useful.

(1) Date: 30 Sep 84 (2) Protocol	WU#: 82/602 (3) Status: Ongoing
(4) Title: Gallium Index: Qualita	tive vs. Quantitative Analysis
(5) Start Date: July 1983	(6) Est Compl Date: 1985
(7) Principal Investigator: Peter W. Blue LTC, MC	(8) Facility: FAMC
(9) Dept/Svc:	(10) Assoc Investigators:
(11) Key Words: Gallium Index	Nasser Ghaed COL, MC
(12) Accumulative MEDCASE:*  *Refer to Unit Summary Sheet of	(13) Est Accum OMA Cost:# f this report.
(14) a. Date, Latest HUC Review: 1	1/83 b. Review Results: Ongoing
c. Number of Subjects Enrolled Duri	
d. Total Number of Subjects Enrolle	ed to Date: 30
	reported to the FDA or sponsor for stud- ded IND. (May be continued on a separate '. None.

- (15) Study Objective:
  - To evaluate a computer quantitative assessment of gallium uptake in normal and abnormal lungs and compare it to a previously used qualitative method.
- (16) Technical Approach:
  All gallium studies are acquired on computer and pulmonary functions acquired. The gallium index is calculated both ways (vide supra) and when enough patients seen, data analyzed.
- (17) Progress:

  Data collection in progress. Results pending.

Presentations/Publications: None

(1) Date: 30 Sep 84 (2) Protocol	WU#: 32/(01 (3) Status: Completed Jan 3/4
(4) Title:	
	ism Following In Utero Exposure to Plagnostic
Ultrasound	
(5) Start Date: 11/82	(6) Est Compl Date:
(7) Principal Investigator:	(8) Facility: FAMC
Gloria H. Komppa, M.D., C, Diagnosti Ultrasound Section; Marlene Severson H.D., CPT, MC, US Army, Jeffrey Davies PHD., CPT, MC, US Army	
(9) Dept/Svc: Radiology, ENT	(10) Assoc Investigators:
(11) Key Words:	Nasser Ghaed, M.D., COL, MC, C, Dept of
Ultrasound, in Utero, Hearing	Radiology; John Kolmer, M.D., LTC, MC C, Dept of ENT
(12) Accumulative MEDCASE:* *Refer to Unit Summary Sheet of	(13) Est Aceum OMA Cost:* this report.
(14) a. Date, Latest HUC Review:	b. Review Results:
	ng Reporting Period: Approx 100, 22 tested
•	reported to the FDA or sponsor for stud- ed IND. (May be continued on a separate
None	

#### (15) Study Objective:

To determine whether children exposed in utero have detectable hearing loss as compared to a normal polulation.

- (16) Technical Approach: The auditory test results of approximately 100 children, exposed to ultrasound in utero, were to have been compared to approximately 30 nonexposed children.
- (17) Progress: A normal control group of children not exposed to ultrasound was not successfully obtained. The results of the hearing tests performed on the exposed children were reviewed. All results were within normal limits but skewed to one end of the expected bell shaped curve. A prospective study was initiated (see work unit NR 84/600).

PRESENTATIONS/PUBLICATIONS: None.

(1)	Date: 30 Sep 84 (2) Protocol	WU#: 80/602 (3) Status: Ongoing
(4)	Title:	
		B iodomethylnorcholesterol (NP-59)
	for adrenal evaluation and imag	
(5)	Start Date: 1980	(6) Est Compl Date: Indefinite
(7)	•	(8) Facility: FAMC
rete.	r W. Blue LTC, MC	
		_
(9)	Dept/Svc: Nuc Med Svc	(10) Assoc Investigators:
(11)	Key Words:	N- 01 1 00- W0
	iodocholesterol adrenal	Nasser Ghaed COL, MC
	acrenar	
$\overline{(12)}$	Accumulative MEDCASE:*	(13) Est Accum OMA Cost:*
	*Refer to Unit Summary Sheet of	
(14)	a. Date, Latest HUC Review: 11	/83 b. Review Results: Ongoing
	Number of Subjects Enrolled Durin	
	Total Number of Subjects Enrolled	
		reported to the FDA or sponsor for stud-
:	ies conducted under an FDA-awarde	d IND. (May be continued on a separate
	sheet, and designated as "(14)e".	
(15)	Study Objective:	
	Clinical evaluation of NP-59 as	a diagnostic agent for the detection of
		s a potential scanning agent for detect-
	ing structural abnormalities of	the adrenal medulla.
(16)	Technical Approach:	
	Fach patient will be studied whi	le taking Lugol's or SSKI to protect
		have adrenal function suppressed with
		llicure dose of NP-59, each patient
	will be scanned at day 3 and pos	
	<b>5</b>	
(17)	Progress:	
	One patient evaluated with norma	l results. Test helpful.
	•	•
Pub1	lcations/Presentations: None.	

RADIOLOGY

(1)	Date:	30 Sep 84 (2) Protocol WU#:84/403 (3) Status: Ongoing	3
(4)	Title:	Hypercalciuria in Children with Isolated Hematuria.	

	Start Date: 1984 Principal Investigator: Ronald J. Portman, MD, MAJ, MC	(8)	Est Compl Date: January 1986 Facility: FAMC University of Colorado Health Science Center Southwest Pediatric Nephrology Group
(9) (11)	Dept/Svc: Pediatrics/Nephrology Key Words: hypercalciuria hematuria	(10)	Assoc Investigators:  Gary M. Lum, Renal Division, University of Colorado Medical Center
(12)	Accumulative MEDCASE:* *Refer to Unit Summary Sheet of		Est Accum OMA Cost:# report.

(14) a. Date, Latest HUC Review: b. Review Results:

c. Number of Subjects Enrolled During Reporting Period:
 d. Total Number of Subjects Enrolled to Date: NA

e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. (May be continued on a separate sheet, and designated as "(14)e". NA

Publications and Presentations: None

<sup>(15)</sup> Study Objective: To determine the incidence of hypercalciuria in children presenting with isolated gross or microscopic hematuria. To determine if hypercalciuria is due to a) idiopathic renal calcium wasting, b) intestinal hyperabsorption of calcium or c) hyperparathyroidism.

<sup>(16)</sup> Technical Approach: Patients who are found to have hematuria, but without protein in the urine, will have a twenty-four hour urine collection for calcium excretion and a blood test for calcium. If these studies are normal, no further studies will be performed. If the calcium secretion is abnormal, the patient will be placed on a specific low calcium diet for one week and then another twenty-four hour urine collection for calcium repeated. After this is completed, the child will have a calcium challenge test consisting of an oral calcium supplement and a specific breakfast high in calcium. Four hour urine collections will follow this calcium load and a blood test for parathyroid hormone levels. Also, an intravenous pyelogram will be obtained to be sure the patient does not have kidney stones or other urinary tract abnormalities.

<sup>(17)</sup> Progress: Study is new, so no progress as of this date.

(1) Date: 30 Sep 84 (2) Protocol WU#: 84/402 (3) Status: Ongoing (4) Title:

# Hypertension in adolescents

(5) Start Date: 1 sept 1984	(6) Est Compl Date: 30 May 1985
(7) Principal Investigator:	(8) Facility: FAMC
Victor I. Lugo-Miro, M.D. Captain, MC.	

Robert Slover, M.D., MAJ MC.
------------------------------

(12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\*

\*Refer to Unit Summary Sheet of this report.

(14) a. Date, Latest HUC Review: \_\_\_\_\_ b. Review Results:

c. Number of Subjects Enrolled During Reporting Period: 426

d. Total Number of Subjects Enrolled to Date: 426

e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. (May be continued on a separate sheet, and designated as "(14)e".

N/A

## (15) Study Objective:

Establish the best measure of normal and abnormal blood pressure in children based on age, height, weight and body mass indices.

## (16) Technical approach:

In our study we will measure height, weight and blood pressure on all the adolescents that will visit our clinic. We will calculate ponderosity index and then establish if the patient is hypertensive or not by values from previous studies. At the end we will be able to establish our own normal values and will identify what is the best determinant for blood pressure ( Ht, Wt, Ponderosity, etc.)

#### (17) Progress:

We have been able to take all meassurements in 426 patients with an initial yield of 11% of the patients showing hypertensive readings based on The Bogalusa Heart Study 95th percentile value for systolic and diastolic blood pressure. Those patients have been followed up by us for a second and third blood pressure determination and those who keep showing hypertension will be fully evaluated to establish their pertinent diagnosis. These number of patients (50 in total) made possible for us to establish a hypertension clinic for the evaluation mentioned above.

Our preliminary data is also sugesting the relationhsip of height and ponderosity index as the best determinants for blood pressure development but it is however too early for drawing any conclusions.

- Protocol WU#: 84/401 30 Sep 84 (2) Status: Ongoing (1)Date: (4) Title: Neonatal Xanthine and Aminoglycoside Kinetics. Start Date: May 1984 (6) Est Compl Date: June 1985 Principal Investigator: (8) Facility: M. Gail Murphy, M.D., CPT, MC Dept/Svc: Pediatrics (10) Assoc Investigators: (11) Key Words: Gerald B. Merenstein, M.D., COL, MC Computer program John R. Pierce, M.D., LTC, MC Drug kinetics (12) Accumulative MEDCASE:# (13) Est Accum OMA Cost:# \*Refer to Unit Summary Sheet of this report. (14) a. Date, Latest HUC Review: First b. Review Results: c. Number of Subjects Enrolled During Reporting Period: 21 patients d. Total Number of Subjects Enrolled to Date: 22 e. Note any adverse drug reactions reported to the FDA or sponsor for stud-
- (15) Study Objective: To employ a Bayesian computer program to individualize xanthine and aminoglycoside drug dosing decisions.

ies conducted under an FDA-awarded IND. (May be continued on a separate

None.

sheet, and designated as "(14)e".

- (16) Technical Approach: Sixty infants in nursery who require xanthine or aminoglycoside therapy will be studied. Dosing decisions based on program predictions of pharmacokinetics will be analyzed for prediction accuracy.
- (17) Progress: 21 preliminary patients receiving gentamicin have been studied. The computer predictions have made therapeutic decisions quicker and more accurate.

Presentations: Murphy, M.G. & Peck, C: Revisions of gentamicin therapy with a Bayesian Program. Presented: Aspen Conference on Perinatal Research, Aspen, CO, July, 1984.

(1) Date: 30 Sep 84 (2) Protocol WU#				
(4) Title: Myelography in Medullobla	stoma			
(5) Start Date: November 1983 (6)	Est Compl Date:			
(7) Principal Investigator: (8)				
Askold D. Mosijczuk, M.D., LTC, MC	·			
}				
(9) Dept/Svc: Pediatrics (10	) Assoc Investigators:			
(11) Key Words:				
Myelography in Medulloblastoma	Daniel McNeil, LTC, MC			
(12) Accumulative MEDCASE:* (13	) Est Accum OMA Cost:*			
*Refer to Unit Summary Sheet of this				
(14) a. Date, Latest HUC Review:	b. Review Results:			
c. Number of Subjects Enrolled During Reporting Period: 0				
d. Total Number of Subjects Enrolled to Date: 0				
e. Note any adverse drug reactions reported to the FDA or sponsor for stud-				
ies conducted under an FDA-awarded IND. (May be continued on a separate				
sheet, and designated as "(14)e".				
(15) Study Objective:				
Assess the potential benefit of metrizam	ide CT scan of the spine following metrizamide			
myelography in detecting spinal metastas	es due to medulloblastoma.			
16. Technical Approach:				
As described in protocol				
17. Progress:				
No patients have been entered on this study at FAMC since patients with newly				

Publications and Presentations: None

diagnosed or recurrent medulloblastoma have been admitted to our institution in the past 10 months. Other Army medical centers (WRAMC, BAMC, TAMC, LAMC) have either not had any eligible patients for this protocol or for other reasons have not entered patients into this study. For these reasons, I request that this protocol be terminated.

# PUBLICATIONS for FY 84 Annual Progress Report

Proto No. 83/402

SERVICE Newborn/Ped. Nephrology Sec. DEPARTMENT Pediatrics

- (1) Portman, R.J., Cole, J.W., Perlman, J.M., Yin, L., and Robson, A.M.: Tubular Dysfunction in Infants with Meconium Stained Amniotic Fluid-Diagnosis Using B2-Microglobulin. Ped. Res. 18:341A 1984
- (2) Cole, J.W., Portman, R.J., Lim, Y., Perlman, J.M., and Robson, A.M. Urinary Beta-2-Microglobulin in Full Term Mewborns: Evidence for Proximal Tubular Dysfunction in Infants with Meconium Stained Amniotic Fluid Submitted for publication to Pediatrics

#### PRESENTATIONS:

- (1) Portman, R.J., Cole, J.W., Perlman, J.M. Lim, Y., and Robson, A.M. Tubular Dysfunction in Infants with Meconium Stained Amniotic Fluid-Diagnosis Using B2 Microglobulins. Presented at the Society for Pediatric Research, San Francisco, CA May, 1984.
- (2) Portman, R.J.: Tubular Dysfunction in Neonates Diagnosed by the Urinary Concentration of B2 Microglobulins. Presented to the Aspen Conference on Military Perinatal Research, Aspen, CO, August 1984.

CONTINUATION SHEET, FY 84 ANNU	AL PROGRESS REI	PORT Proto No.:_	83/402
--------------------------------	-----------------	------------------	--------

- 16. Patients are selected on admission to the newborn nursery for either the normal group or for a specific pathologic condition. After consent is obtained, a urine bag is placed and urine collected for creatinine and B2M determinations. Blood is obtained at the routine four hour hematocrit heel stick for the same determinations. This is repeated with the urine collection on days 3 and 14 of life at the time of PKU determinations. Creatinine is performed by the routine chemistry lab and B2M by the RIA lab. Data will be analyzed on the NOAA computer/MISS system.
- 17. Fourty-nine newborns have been enrolled in the study in fiscal year 1984.

  No complications have been noted from the urine bags nor the heelstick procedures. There were no problems in obtaining consent for the study. The patients included 27 normal infants, nine with meconium stained amniotic fluid, three with acute tubular necrosis, amd nine with various other processes. The major difficulty with the study was obtaining all four pieces of data on three different occasions which occurred only in three patients. The normal urinary B2M for our 27 patients was 0.6 mg/l on day one and 1.6 mg/l on day three of life. Not enough numbers were obtained in the ather groups as yet to show any significant trends except for the ATN which had a mean value on the first day studied 12.7 mg/l indicative of marked tubular dysfunction. Request approval of this protocol and its modification.

(1) Date: 30 Sep 84 (2) Protocol	WU#: 78/650 (3) Status: Ongoing	
(4) Title: Evaluation of Thalassem	ia as Cause of Hypochromic Microcytic	
Anemia and in Interacti	on with Hemoglobin Variants	
(5) Start Date: March 1978	(6) Est Compl Date: Indefinite	
(7) Principal Investigator:	(8) Facility: FAMC	
Nicholas C. Bethlenfalvay, MD, DAC		
(9) Dept/Svc: Primary Care	(10) Assoc Investigators:	
(11) Key Words:		
Thalassemia-hemoglobin variants	Joseph Lima, DAC	
<b>3</b>		
(12) Accumulative MEDCASE:*	(13) Est Accum OMA Cost:*	
*Refer to Unit Summary Sheet of	this report.	
	83 b. Review Results: ongoing	
c. Number of Subjects Enrolled During Reporting Period: 3		
d. Total Number of Subjects Enrolled		
	reported to the FDA or sponsor for studed IND. (May be continued on a separate	
Sheet, and designated as "(14)e";	None	
(15) Study Objective:		
To establish phenotype and genotype i anemia due to imbalance in globin cha	n patients with microcytic hypochromic in synthesis.	
(16) Technical Approach:		
· · · · · · · · · · · · · · · · · · ·	tic anemai (b) patients whose hemoglobin	
electrophoretogram reveals a variant hemoglobin in amounts greater than 50 or		

(17) Progress: Since the inception of the study, 63 patients were evaluated resulting in the identification of the following conditions: HbC/alpha thalassemia HbS/beta plus thalassemia HbS/beta 0 thalassemia, HbH disease, \*2 cases of acquired HbH disease alpha-thalassemia - 1 and type II normal HbA2 - beta plus thalassemia. Active consultation is provided, in selected case to the Staff Division of Hematology, University of Colorado Medical Center, Denver, under this protocol. In FY 1983 and in collaboration with investigators at the University of Oxford, U.K., and the University of California, San Francisco, work is continuing on the definition of the molecular lesion in the zeta-alpha globin gene complex of isolated chromosomes #16 of three patients who represent a new syndrome of hemoglobin H disease with mental retardation. In FY 84 work has been completed on a case

less than 40% will be evaluated. Periperal blood will be incubated with  $14_{\rm C}$ 

leucine. Alpha/beta globin synthetic ratios will be calculated.

Proto No.: 78/650

having a hitherto not described type of congenital dyserythropoietic anemia. The report of the case has been accepted by the British Journal of Haematology.

### **PUBLICATIONS:**

- 1. Boehme WM, Piira TA, Kurnick JE and Bethlenfalvay NC: Acquired hemoglobin H in refractory sideroblastic anemia: A preleukemic marker. Arch Int Med, 138:603-606, 1978.
- 2. Weatherall DJ, Higgs DR, Bunch MB, Old JM, Hunt DM, Pressley L, Clegg JB, Bethlenfalvay NC, Sjolin S, Kiler RD, Magenis E. Francis JL and Bebbington, D: Hemoglobin H disease and mental retardation. A new syndrome or a remarkable coincidence? New Eng J Med 305:607, 1981.

### PRESENTATIONS:

Bethlenfalvay, N.D., Hadnagy, C. and Heimpel, H.: Unclassified type of Congenital Dyserythropoietic Anemia: Evidence for a Disturbance of Red Cell Denucleation. Presented: 20th Annual Meeting of the Hungarian Society of Hematology, Szeged, Hungary, August 1984.

(1) Date: 30 Sep 84 (2) Protocol	WU#:80/650 (3) Status:
(4) Title: The Ontogenesis of Hemog (Didelphis Virginia).	lobin in the American Opossum
(5) Start Date: 18 March 1980	(6) Est Compl Date: Indefinite
(7) Principal Investigator:	(8) Facility: FAMC
Nicholas C. Bethlenfalvay, MD, DAC	
(9) Dept/Svc: Primary Care	(10) Assoc Investigators:
(11) Key Words:	
Opossum Hemoglobin Red Cell Energy Metabolism Methemoglobin formation & reduction	J. E. Lima, DAC T. Waldrup, DAC
(12) Accumulative MEDCASE:* *Refer to Unit Summary Sheet of	(13) Est Accum OMA Cost:* this report.
(14) a. Date, Latest HUC Review: 4/8	33 b. Review Results: ongoing
c. Number of Subjects Enrolled Duris	
<ul> <li>d. Total Number of Subjects Enrolled</li> </ul>	
•	reported to the FDA or sponsor for studed IND. (May be continued on a separate

NA

(15) Study Objective:

sheet, and designated as "(14)e".

This is a continuation of a previous Clinical Investigation study that was completed in June 1975. The overall objective is to follow and define the kinetics of methemoglobin reduction of opossum hemoglobin, in specific, as part of the overall energy metabolism of the red cell of this species.

(16) Technical Approach:

In-vivo and in-vitro reduction of nitrite induced methemoglobinemia will be followed hourly by quantitative, electrophoretic and spectroscopic means. Methemoglobin reductases will be quantitated and electrophoretically demonstrated, and compared to human reductases.

<sup>(17)</sup> Progress: Opossum Hb was found to oxidize faster than human Hb in solution, the converse was observed on inteact, glucose depleted erythrocytes even at acidic pH. Although opossum red cells were shown to be permeable to glucose, they did not require this substrate for methemoglobin reduction in-vitro methylene blue was found to accelerate methemoglobin reduction on intact opossum erythrocytes at a rate exceeding that seen in human erythrocytes. This reaction, in contrast, was shown to be dependent on glucose in the red cell environment. In FY 1983, work has been completed on the utilization of 6, 5 and 3 C carbohydrates and purine nucleosides as substrates for lactate and ATP in intact erythrocytes. The data were published in FY 1984. Quantitation of red

CONTINUATION SHEET, FY 84 ANNUAL PROGRESS REPORT Proto No.:\_\_\_\_

cell glycolytic intermediates, electrophoretic demonstration of adenosine deaminase and of purine nucleoside phosphorylase was accomplished. In preparation for HPLC analysis of catabolism of purine nucleotides as the putative energy source for methemoglobin reduction on glucose depleted erythrocytes, orienting experiments were performed utilizing various ensyme inhibitors to assess their ability to block this process.

SERVICE Clinic

DEPARTMENT Primary Care & Community
Medicine

- Petty C, Bethlenfalvay NC and Bageant T.: Spectrophotometric measurement of hemoglobin oxygen saturation in the Opossum, Didelphis Virginiana. Comp. Biochem. Physiol, 50:273, 1975.
- Bethlenfalvay NC, Block, M and Brown GB: Hemoglobins of the Opossum (Didelphis Virginiana Kerr) I. Developmental changes from yolk sac to definitive erythropoiesis. Lab. Animal Sci, 26:106-165, 1976.
- Bethlenfalvay NC, Brown GL and Waterman M: I. Hemoglobins of the Opossum (Didelphis Marsupialis) II. Electrophoretic and Chromatographic observations. Lab Animal Sci, 26:908-912, 1976.
- John ME, Bethlenfalvay NC and Waterman MR: Oxidation reduction properties of the hemoglobin of the opossum <u>Didelphis Virginiana</u>. <u>Comp. Biochem. Physio</u>. 73B:585-591, 1982.
- Bethlenfalvay NC, Waterman MR, Lima JE and Waldrup T: Cystolic and membrane-bound methemoglobin reductases in erythrocytes of the opossum Didelphis Virginiana. Comp. Biochem. Physiol. 738:594, 1982.
- Bethlenfalvay NC, Waterman MR, Lima JE, Waldrup T: Comparative aspects of methemoglobin foration and reduction in opossum <u>Didelphis Virginiana</u> and human erythrocytes. Comp. Biochem. Physiol. 75A:635-639, 1983.
- Bethlenfalvay NC, Lima JE and Waldrup T: Studies on the energy metabolism of opossum (Didelphis Virginiana) erythrocytes. I. Utilization of carbohydrates and purine nucleosides.

  Journal of Cellular Physiology. 120:69-74, 1984.

NURSING

- 30 Sep 84 (2) Protocol WU#: 83/700 (3) Status: Ongoing Title: A Comparison of Fluid Assessment Methods Utilizing Central (4) Venous Pressure Versus Serum Osmolarity In Conjunction with Conventional Methods In Adults Undergoing Abdominal Surgery. Est Compl Date: 15 October 1984 Start Date: December 1983 Principal Investigator: Facility: FAMC Cynthia Bernard, CPT, ANC Michael Buxton, CPT, ANC James Eiring, CPT, ANC Donald Johnson, CPT, ANC Richard Palley, CPT, ANC Gregory Whitfield, CPT, ANC Dept/Svc: Nursing (10) Assoc Investigators: (11) Key Words: None Comparison of Fluid Assessment Methods (12) Accumulative MEDCASE:\* (13) Est Accum OMA Cost:\* \*Refer to Unit Summary Sheet of this report. b. Review Results: (14) a. Date, Latest HUC Review: c. Number of Subjects Enrolled During Reporting Period: 40 Total Number of Subjects Enrolled to Date: Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. (May be continued on a separate
- (15) Study Objective: There is no difference in calculated intraoperative fluid requirements as determined by CVP and conventional methods versus serum osmolarity and conventional methods.

sheet, and designated as "(14)e".

- (16) The need for fluid replacement intraoperatively was made using the central venous pressure reading and other conventional fluid assessment parameters. Serum osmolarities were drawn during the surgical procedure and retrospectively evaluated to determine if serum osmolarities would provide a better means of calculating fluid replacement in the surgical patient.
- (17) All data has been collected, statistical analysis of the data is in progress and the project will be completed by December 1984.

FAMC TENANT

たない、自己となるないというというというないからいとうとうとうというというというと

(1) Date: 30 Sep 84 (2) Protocol	WU#:83/800 (3) Status: ongoing
(4) Title: The Health Evaluation Health Promotion Program)	on Project (of the OCHAMPUS Employee
(5) Start Date: March 1985 (7) Principal Investigator: William H. Hendrix, Ph.D. Associate Professor of Mgt. Clemson University Clemson, S.C.	(6) Est Compl Date: September 1985 (8) Facility: FAMC
(9) Dept/Svc: OCHAMPUS (11) Key Words: Job Satisfac- Health Promotion tion Wellness Somatic symp- Transport toms Emotional Exhaustion Stress	CDR, MC, USN Medical Director
(12) Accumulative MEDCASE:*  *Refer to Unit Summary Sheet of	(13) Est Accum OMA Cost:* this report.
<ul> <li>(14) a. Date, Latest HUC Review:</li> <li>c. Number of Subjects Enrolled During</li> <li>d. Total Number of Subjects Enrolled</li> <li>e. Note any adverse drug reactions respective ies conducted under an FDA-awarde sheet, and designated as "(14)e".</li> <li>N/A (no drugs given)</li> </ul>	ng Reporting Period: 175 I to Date: 235 reported to the FDA or sponsor for studed IND. (May be continued on a separate

(15) Study Objective:

The major objective is to establish what individual, organizational, and extra-organizational factors are predictive of stress, coronary artery disease potential, and desired organizational outcomes-i.e., increased productivity and decreased turnover and absenteeism. In turn, modification of these factors and their resulting effects will be assessed over time from the identified dependent variables (measured stress, indexed potential for developing CAD, and desired organizational outcomes). (16) Technical approach: Evaluation of data will be in the form of path analyses to establish relationships between factors leading to stress and in turn to health-related and organizational factors. A pretest, post-test design is being used to establish effectiveness of interventions employed such as stress management and exercise.

CONTINUATION SHEET, FY 84 ANNUAL PROGRESS REPORT Proto No.: 83/800

Reporting Period: September 1983 to September 1984.

- (1) There was a 25% withdrawal rate since the original evaluation March 1983.
- (2) Preliminary findings indicate correlation between health promotion involvement and life stress, job stress, job satisfaction, commitment to work, absenteeism, and job performance. These correlations as well as indices of stress effects on health are provided (Encl 1).
- (3) Although FAMC Management originally agreed to provide support service to draw blood during the period of this study, the service is not available for the two final make up sessions September 1984. This crisis situation was eventually resolved by agreement with Lowry Health Clinic.

· To and the second of the se

PRESENTATIONS	FOR FY	84	Annual	Progress	Report	Proto	ì
---------------	--------	----	--------	----------	--------	-------	---

••				
SERVICE	N/A	DEPARTMENT	N/A	

1. Hendrix, W.H., and Rodriquez, A.R.: Effects of Stress on Individual Productivity, Absenteeism, and Wellness. Presented: Ninth Biennial Psychology in the DOD Symposium, USAFA, Colorado, April 1984.

83/800

- 2. Hendrix, W.H., Rodriquez, A.R., and Presley, A.: Effects of Stress and Exercise on Employee Health. Presented: Fifth Annual Meeting of the Society of Behavioral Medicine, Philadelphia, Pa., May 1984.
- 3. Hendrix, W.H., Rodriquez, A.R., and Presley, A.: Job and Personal Factors Related to Job Stress and Risk of Developing Coronary Artery Disease.

  Presented: American Industrial Hygiene Conference, Detroit, Michigan, May 1984.
- 4. Hendrix, W.H., Rodriquez, A.R., and Presley, A.: Stress Effect on Organizational Outcomes and Prediction of CAD Risk. Presented: 92nd Annual American Psychological Association Convention, Toronto, Canada, August 1984.
- 5. Rodriquez, A.R., Iverson, D.C., Hendrix, W.H., Presley, A.: An Employee-Directed Wellness Project: Early Findings from the OCHAMPUS Health Promotion Program. Presented: American Public Health Association Meeting, Dallas, Texas, November 1983.

MEDDAC

(1)	Date: 30 Sep 84 (2) Protocol		107
(4)	Title: Training Study, Emergency	Medi	cal Procedures
(5)	Start Date: Nov 1982	(6)	Est Compl Date: Indefinite
(7)	Principal Investigator: MATTHEW J. WALSH, LTC, MC	(8)	Facility: FAMC Ft Carson Veterinary Activity and Ft Carson MEDDAC Emergency Medical Service
(9)	Dept/Svc: Emer Med & Vet	(10)	Assoc Investigators:
(11)			LTC David Roberts, MC
(12)	Accumulative MEDCASE:*	(13)	Est Accum OMA Cost:*
•	*Refer to Unit Summary Sheet of	-	
(14)	a. Date, Latest HUC Review:		b. Review Results:
c. N	lumber of Subjects Enrolled Durin	g Rep	porting Period: N/A
d. 1	otal Number of Subjects Enrolled	l to I	Date: N/A
j		d INI	ed to the FDA or sponsor for stud- . (May be continued on a separate

Publications and presentations: None

رجه بده

<sup>(15)</sup> Study Objective: This project is a refresher/teaching course in Emergency Medicine operative procedures. It is conducted on a quarterly basis for EMS physicians and PA's.

<sup>(16)</sup> Technical approach: Under general anesthesia animals are subjected to common Emergency Medicine operative procedures, including venous cutdown, peritoneal lavage, chest tube insertion, and thorocotomy with aortic cross clamp with cardiac laceration repair. At the end of the exercise, the animals are killed by lethal injection.

<sup>(17)</sup> Progress: This has been a beneficial exercise in maintaining physical skills in technical procedures done infrequently. These skills are essential for good patient care in true emergencies.

(1)	Date: 30 Sep 84 (2) Protocol	WU#: 83/903 (3) Status: Completed		
(4)	Title: Stabilization of Hemoglo Traveling from Lower to	bins and Hematocrits in Females Higher Elevations		
(5)	Start Date: May 1983	(6) Est Compl Date: May 1984		
(7)	Principal Investigator:	(8) Facility: FAMC		
	Linda S. Wallace, CPT, ANC	Fort Carson Army Hospital		
		Fort Carson, CO		
(9) (11)	Dept/Svc: OB-GYN & Pathology Key Words: higher altitudes	(10) Assoc Investigators:		
	adaptation time			
	hemoglobin level			
(12)		(13) Est Accum OMA Cost:* this report.		
(14) a. Date, Latest HUC Review: NA b. Review Results: NA c. Number of Subjects Enrolled During Reporting Period: 58 d. Total Number of Subjects Enrolled to Date: 58				
e. I	e. Note any adverse drug reactions reported to the FDA or sponsor for stud-			

(15) Study Objective: To establish baseline hemoglobin and hematocrit levels of transcient (incoming) females both pregnant and nonpregnant at an altitude over one mile allowing for body compensation time and reinforce the time of stabilization. This would standardize care in as much as doctors could treat females with bleeding disorders and anemias in pregnancy with more consistency within a transcient population such as in the military as well as to note whether or not pregnant females require more time to adjust to the higher altitude since their bodies are under stress at this time.

ies conducted under an FDA-awarded IND. (May be continued on a separate

sheet, and designated as "(14)e".

- (16) Technical Approach: Participants will be screened for eligibility before entering the study. Three hematological studies will be done: at time of entrance to study, at four to six weeks, and lastly at then to thirteen weeks. Results will be compared to findings from a Denver study documenting adjustment levels and rates for a predominantly male population.
- (17) Progress: The study findings confirmed that adaptation progresses rapidly within the first three months and even leans toward a time frame within six weeks. The hemoglobin desplayed a 75% to 80% increase within the first six weeks after arrival at 6,000 feet. Between six weeks and three months the percent of increase was twenty to thirty-two. The hematocrit averges were a bit more puzzling. There was a definite increase of an averaged 1.88% point between the initial and second samplings. However,

## KEY WORD INDEX

Key Words	<u>Page</u>
abnormal hemoglobins	226
acute leukemia	049 -061
myocardial infarction	071
adaption time	240
adolescents	217
adrenal	
adrenergic bronchodilator—	
airway resistance	037
allergy immunotherapy—————	118
allergy immunotherapy—————allopurinol————alpha-hemolytic streptococci—————	044
alpha-hemolytic streptococci	182
alveolar gaspressure	039
pressure	037
alveolitis	107
aminocaproic acid	059
amiodarone	046
angiography	090
anterior cruciate ligament	152,154
anti-GBM antibody	075
antiplatelet antibody	184
arachidonic acid	105
aspergillus infection	124
assessment methods	233
arthroscopy	152
atropine methylnitrate	056,134
-	
B2-microglobulins	212
bacteremia	131
bacterial antigens	174
basal cell CA	088,096,136
Berger's Disease	066
beta	034,102,135
adrenergic subsensitivity	087
hi of and hack	150
biological effects	224
body plethysmography	037
poue	171
density	062
pain	
breast tumors	
breathing patterns	039
broncho-alveolar lavage	080,107
bronchodilators	056
calcitonin deficiency	062
	171
binding protein	171
campylobacter	
	179
carbohydrate intolerance	050
carbon dioxide	115
carcinoma	135
cardiac arrhythmias	046
cardiovascular anesthesia, screening/	• • • • • •
CHD	140.243

KEY WORD INDEX

NAME	PAGE
Shackelford, A	030
Shipton, W	140,142
Sjoberg, R.J	050,105,116
Slover, R	217
Smith, C.K	152
Southgate, M	212
Stafford, W	110,135
Stansbury, L.G	081
Stewart, I.B	192
Stocker, J.T	186,204,208
Strampel, W	080
Swanson, E	036,105,126
Szefler, S.J	119
Thomas, D	107,131
Thomas, H.M	089,127
Tipton, W.R	034,047,055,058,134
Trnka, K.E	071
Trukal, A.R	143
Vandewalker, M	084,118
Vaughan, R	056,134
Vaughan, T.T	110
Vaught, W	142
Via, C.S	095
Vogel, J	243
Vordermark, J	140
Daldana m t	20/ 202
Waldrup, T.L	226,229
Wallace, L.S	240
Walsh, M.J	239
Weber, R.W	087,118
Welton, R.C	095
West, S.G	060,095
Wetherill, S.R	180
Whiteaker, R.S	058,168,184,185
Wilkerson, R	154,155
Wilson, T.M.	140,142
Wilson, W.R.	143,157
Witte, M	120,131
Wolfe, G.K	099,115
Wolthuis, J	140,142
Woody, E.A	147
Wuerz, D.J	180,183
Yaney, S	243
Zaloznik, A.J	043,044,045,049,057,061,097,
	163,176
Zimmerer, R.W	U37
Zolock, D.T	171

NAME	PAGE
Miller, T	102,110,118 201 068 091,092,093,124,129,174,182,186 114 204,208,215 085 202,209,216
Nelson, H.S Nelson, J.K Nelson, M	055,056,082,084,085,087,101,110, 118,135 047 060
O'Barr, T.P	036,050,100,105,116,126,164,192 131 109 091,092,093,120,124,129,131 077 149
Paine, D.D.——————————————————————————————————	174,180,201 233 201 037,039,041,079,080,109,115 194,199 089,098 202,203,209,212,216 131 212,217,218 224
Raife, M.J	142 143 204,208 140 080 239 212 235
Sachs, M	145 197 246 080 123 068 096 155,221,224

NAME	PAGE
Holweger, R.R	156,157,161
Houseworth, S.W	152
Howard, J.E	184
Huff, J.C	088,100,136
Hurst, D.L	138
Hurwitz, M	114
·	
Inscore, S	242
Iyengar, V	047,094
Jackson, J	090
Johnson, D	233
Jones, L	192
Jones, N.R	170,176
Kidd, G.S	030,050,051,062,064,065,078,105
kidd, d.b	112,116,121,122,123
Kindig, N.B	039,041
King, T	107
Koester, S.K	180
Kolmer, J.W	145,147,221,224
Komppa, G.H	221,224
Kramer, L.C	112,170,176,179,187,192
Kucera, R.F	132
Kueser, T	147
Rucoci , 1	47)
Ledner, W	243
LeDoux, R.A	134
Lima, J.E	055,226,227,229
Long, W	101
Loth, T.S	148,159
Lowry-Romero, F	150
Lugo-Miro, V.I	127
Lum, G.M	218
Lundblad, E	197,199,210
Mader, T.H	157
Major, F.J	157
McCubbin, J.A	194 143,156,157
McCullen, A.H	•
McDermott, M.T	112,179,187,188,190,192 062,064,065,078,119,121,122,123
McNeil, D	215
McMahon, M.J	098
Mein, C.E	156
Mellette, J.R	096
Mendoza, C.A	071
Mercill, D.B	036,112,126,170,176
Merenstein, G.B	202,216
· · · · · · · · · · · · · · · · · · ·	

NAME	PAGE
Davis, Jr., R.C Decker, W.J DiBella, N.J Dirks, J.F Dolen, W	046,071,089,090,098 188,190 043,045,061,077,081,097,103 210
Eadline, S	242 152 233 091,092,093,174,180,182,183,185, 186,201,177,192 180 244 151
Fauver, H	140,142 099 088,100,126,136,170,179 185,192 203 036,126 148 143,156,162
Gardner, L	243 224 091 051 062,148,220,221,222,223,224 212 080,120,131 147 176
Grimwood, R.E.———————————————————————————————————	088,100,136 081 246 124 170,176,187 066,068,069,075,076,132 150 107,235 081,108 081 030,050,062,064,065,078,105,116, 119,145
Holcomb, R.E	182

# INVESTIGATORS INDEX

<u>N AME</u>	PAGE
Andersen, P.A	60,95
Arnold, J	140
Artim, R.A	108
Ashton, A	243
Asp, A	124
Austin, H.A	76
•	•
Balow, J.E	76
Bedynek, J	243
Beougher, K	44
Berg, J.W	246
Bernard, C	233
Bethlenfalvay, N.C	192,226,227,229
Bikle, D.D	171
Blaedel, M.E	210,217
Blaser, M	129
Blue, P	062,090,114,148,220,222,223
Bornemann, M	030,051
Bowden, W.D	127
Bowen, R	056,101
Brewer, T.G	053,073,185
Brown, J.S	058,082,119
Browning, R.J	037,039
Burton,	124
Butler, C	182,186
Buxton, M	233
Cannada, P.B	124
Carey, W.G	157
Carter, T	204,208
Castillo, I	140,142
Chadwick, E.W	171,188
Cherniack, R.M	099
Ciesielski, C	093
Clark, J	204,208
Clark, R.A.F	088
Claypool, R.G	095,115
Colazzo, W. A	112
Corby, D.G	105,164,168,184,188,190,192
Cornell, F.M	143,156
Cottingham, Jr., A.J	156
Cross, A.S	091,092
Curl, W.W	154,155
Dagenhandt F	2/12
Daly, M	243
Daniels, W	183
Davies, J	204,208,243 221,224
Davico, 0	CC1, CC7

INVESTIGATORS INDEX

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (Ref. HSCR 40-23, as amended)

(1) Date: 30 Sep 84 (2) Protocol WU#: 82/950 (3) Status: Terminated

(4) Title:

Case-Control Study of Invasive Cervical Cancer

(5) Start Date: June 1, 1982	(6) Est Compl Date: July 31, 1984
(7) Principal Investigator:	(8) Facility: FAMC
David A. Savitz, Ph.D. Department of Preventive Medicine & Biometrics University of Colorado School of Medicine	
(9) Dept/Svc: UCHSC	(10) Assoc Investigators:
(11) Key Words:  Cervical Cancer, Epidemiology	R. Hamman, M.D., Dept. Preventive Medicine & Biom. J. Berg, M.D., Department of Pathology University of Colorado School of Medicine

(12) Accumulative MEDCASE: (13) Est Accum OMA Cost: \*

\*Refer to Unit Summary Sheet of this report.

(14) a. Date, Latest HUC Review: b. Review Results:

c. Number of Subjects Enrolled During Reporting Period: 4

d. Total Number of Subjects Enrolled to Date: 10 from FAMC; 400 total

e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. (May be continued on a separate sheet, and designated as "(14)e".

### NONE

- (15) Study Objective: Ascertain risk factors for cervical cancer including diet, smoking, sexual behaviors, sexually transmitted diseases, and oral contraceptives.
- (16) Technical Approach: Case-control design comparing exposure histories of women with invasive cervical cancer, carcinoma in situ of the cervix, and healthy controls.
- (17) Progress: The data collection ended July 31, 1984. The National Cancer Institute will provide us with a data type for analysis. We will send a summary of the study to all collaborating physicians and institutions when analyses are completed.

Publications and Presentations: None

CIVILIAN HOSPITALS

FAMC	A.P.R. (RCS MED 300) Detail Summ	mary Sheet (Ref. HSCR 40-23, as amended)
(1)	Date: 30 Sep 84 (2) Protocol	WU#84/900 (3) Status: Terminated
(4)	Title: Clinical Evaluation of AM	
(5)	Start Date: 1984	(6) Est Compl Date:
(7)	Principal Investigator: Thomas A. Eskestrand, LTC, MC	(8) Facility: FAMC
(9) (11)	Dept/Svc:Ortho/Ft. Carson, CO Key Words: electro-magnetic	(10) Assoc Investigators:
(12)	Accumulative MEDCASE:* *Refer to Unit Summary Sheet of	(13) Est Accum OMA Cost:* this report.
	a. Date, Latest HUC Review:	
d. ' e. I		to Date:  reported to the FDA or sponsor for stud- ed IND. (May be continued on a separate
ınion		an electro-magnetic field to the non- order to heal the fracture, or to heal

(16) Progress: Principal Investigator has left the Army. The study was never started.

Publications and Presentations: none

			~			
(1)	Date:	30 Sep 84 (2)	Protocol Wilds	83/005	(2)	Status: Terminated
		3 1,0 P G (12)	TICOCCCI WOW.	03/303	(3)	Status: Terminated
(4)	Title	Cannananu And	Diagna			
( - /	TIULE.	Cornonary Art	ery Disease			

(5) Start Date: 1982	(6) Est Compl Date: May 1985
(7) Principal Investigator: Lytt Gardner, Ph.D. Matt Wayne Ledner, Ph.D., MC James Vogel, Ph.D. CPT Sandra Yaney, ANC (continued)	(8) Facility: FAMC Munson Army Community Hospital Ft. Leavenworth, KS Command & General Staff College Ft. Leavenworth, KS (continued)
(9) Dept/Svc: Cardiology/Medicine (11) Key Words:     cardiovascular screening/CHD CAD	(10) Assoc Investigators: MAJ Arden Ashton, MD, MC COL Julius Bedynek, MD, PhD., MC CPT Ernest Dagenhardt, ANC MAJ William Daniels, Ph.D., MSC (continued)
(12) Acqueulative MEDCACE.	

(12) Accumulative MEDCASE: (13) Est Accum OMA Cost: Refer to Unit Summary Sheet of this report.

d. Total Number of Subjects Enrolled to Date: 1.776

(15) Study Objective:

The purpose of this study is to detect previously unindentified cardiovascular disease in a young asymptomatic population, using a multistaged screening method.

Progress: The study was termined this year due to failure to report.

<sup>(14)</sup> a. Date, Latest HUC Review: <u>Aug 83</u> b. Review Results: <u>ongoing</u> c. Number of Subjects Enrolled During Reporting Period: <u>927</u>

e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. (May be continued on a separate sheet, and designated as "(14)e". NA

FAMC A.P.R.	(RCS MED	300)	Detail	Summary	Sheet	(Ref.	<b>HSCR</b>	40-23.	as	amended
-------------	----------	------	--------	---------	-------	-------	-------------	--------	----	---------

(1)	Date: 30 Sep 84 (2) Protocol	WU#:	83/904 (3) Status: Ongoing	
(4)	Title:			
	Activated Charcoal and Ph	ototh	erapy in the Treatment of Neonatal	
	Jaundice	17.53		
<u>(5)</u>	Start Date: August 1983	(6)	Est Compl Date: December 1984	
(7)	Principal Investigator:	(8)	Facility: FAMC	
	Stephen Inscore, MD, CPT, MC		Munson Army Hospital, Ft. Leavenworth, Irwin Army Hospital, Ft. Riley, Ks	Ks
(9)	Dept/Svc: Pediatric	(10)	Assoc Investigators:	
(11)	charcoal		Steven Eadline, MD, CPT, MC	
	phototherapy			
	hyperbilirubinemia	ł		
	jaundice	l		
(12)	Accumulative MEDCASE:*	(13)	Est Accum OMA Cost:*	
	*Refer to Unit Summary Sheet of	this	report.	
	a. Date, Latest HUC Review: May			
c.	Number of Subjects Enrolled Durin	ng Re	porting Period: 2	
d.	Total Number of Subjects Enrolled	i to !	Date:	
e.	Note any adverse dru <mark>g reactions</mark> r	repor	ted to the FDA or sponsor for stud-	
	ies conducted under an FDA-awarde sheet, and designated as "(14)e".		O. (May be continued on a separate	

Publications and Presentations: none

<sup>(15)</sup> Study Objective: To examine the effectiveness that oral activated charcoal has in limiting the severity of nonphysiologic hyperbilirubinemia in otherwise normal newborns treated with phototherapy.

<sup>(16)</sup> Technical Approach: Term newborns who are otherwise normal except for non-physiologic jaundice will be alternately placed into a group receiving photo-therapy alone and in combination with charcoal. Parameters will be measured to determine in the combination of charcoal and phototherapy will enchance elimination of bilirubin.

<sup>(17)</sup> Progress: Too few numbers to derive any conclusions from, but no adverse reaction or complications noted thus far.

CONTINUATION SHEET, FY 84 ANNUAL PROGRESS REPORT Proto No. 83/903

there was a loss of 0.25% between the last two samplings.

The study relates time to physical adaptation, giving health care professionals better tools with which to evaluate the status of an individual who needs care and may have recently come into the area, or who may be in the area for a limited length of time.

Publications: Stabilization of Hemoglobins and Hematocrits in Females Travelling

from a Lower to Higher Altitude. Submitted for publication

Presentations: Stabilization of Hemoglobins and Hematocrits in Females Travelling

from a Lower to Higher Altitude. Presented: Nursing Research

Symposium, 10-14 September 1984, Washington, D.C.

Key Words	Page
carnitine	138
œll culture	100
cerebellar hypoplasia	179
cervical cancer	246
cervical intraepithelial neoplasia	199
charcoal	242
charcoal————————————————————————————————————	147
chemotherapeutic agents	151
chemotherapy	043,045,057,176
chemotherapychlorambucil	060
chronic bronchitis	120
CIE	174
ClQ laboratory assays	047
CO2 laser vaporization	199
collagen	036
comparison of fluid	233
computer program	216
congestive heart failure	132
corneal transplant	156
coronary artery disease	140
corticosteroids	058,080,087
coumadin	094
counterimmunoelectrophoresis	174
counter-regulatory hormones	030
cryopreserved	112
CT scan	155
cyclophosphamide	075
danazol	197
debridement	159
deadspace	015
defined culture media	088
diabetes mellitus	122
diagnostic microbiology	186
diagnostic ultrasound	224
diarrhea	053
dietary calcium	148
dietary vitamin D	148
donor eyes	156
dosage of steroids	058
drug kinetics	216
dysmenorrhea	210
echocardiography	098
E-coli	091
electromagnetic	244
electron microscopy	183
ELISA	201
emergency medicine	239
emotional exhauston	235
endametriosis	218
endothelial cells	126
epidemiology	246
esophageal varices	073

<u>د</u>اند د. ب

Key Words	Page
exercise echo	127
exfoliatin B	092
extravasation	
eye bank	156
eye baik	130
fantanyl	140
fiberoptic vein sclerosis	073
fibroblasts	036
five (5)-azacytidine	049
food allergy	110
fractures	148
furosemide	068
gallium index	222
gallium scintigraphy	080
giardia	185
Giardia lamblia	053,183
immunodiagnosis	053,103
giardiasis	053
GIP	121,122
glomerulonephritis idiopathic	161 / 146
crescentic	076
rapidly progressive	076
glucose tolerance	030
glycerin suppositories	202
gonadal function	064
gonadotropin releasing hormone	065
gram negative bacillary infection	091
guinea pig trachea	034
gynecomastia	078
hearing	221
loss	
hematocrit level	240
hematuria	218
hemoglobins	081,108
high frequency jet ventillation	079,115
higher altitudes	240
histopathology	183
HPG axis	
human auditory mechanism	224
human serum albumin	082
hyperbilirubinemia—	202,242
hypercalciuria	218
hypertension	
hypertranfusion	
hyperuricemia	
hypogonadism	123
hypoglycemia	122
hypothyroidism	064,105,116,119,145
IgA nephropathy skin tests	066
immune complexes	047,184
immunodeficiency	
immunologic disorders—	
reaction	082

Key Words	Page
immunosuppressive drug	076
imminotherany	085
indium oxine	223
infection	055
ingested solvents	190
interstitial lung disease	080
intestine	171
intra-coronary streptokinase	071
intraocular pressure	157
intraocular pressure——————intrauterine distress——————————————————————————————————	212
introglycerin	090
in utero	221
in vitro	176
in vivo	176
interactions	183
iodocholesterol	220
iron salt overdose	188
ischemic heart disease	127
isosine	140
isotretinoin	096
2500200202	
jaundice	242
ketotifen	102
keratinocyte	088,100
kinetics	203
laboratory tests	055
laser trabeculoplasty	157
left ventricular thrombus	089
legionella pneumophilia	093
lymphocyte	077
blastogenesis	058
magnesium hydroxide	188
mammary tumors	187
medial meniscus tears	155
metastatic CA	097
methacholine	134
methemoglobin	229
methotrexate	095
methylprednisolone	119
MIC	182
microbiological products	182
microsurgery-vasovasostomy	142
migraine headache	110
minoxidil	036
mitral valvular disease	140
myelography in medulloblastoma	215
myocardial infarction	098
naprosyn	097
nausea and vomiting control	043
necrosis	151
neonate	203
manulania	^~~

Key Words	Page
newborn	164
nitroglycerin	090
nosoconial infection	124
nude mice	136
oat cell lung CAoliguric	045
oliquric	068
opaque filter	161
open-heart surgery	140
open-lung biopsy	080
opossum hemoglobin	229
organ cultures	170
osteopenia	094
osteoporosis	062,094
parathyroid	112
PGl	105
phototherapy pituitary plasmapheresis	242
pituitary	051
plasmapheresis	075
platelet function	164
polymerized extract	118
premenstrual syndrome	179
prednisone	075
primary renal hematuria	069
prospective evaluation	066,069
prostacyclin	126
prostaglandins	110
synthesis	116
prosthesis	154
proteinuria	132
psyllium mucilloid	190
RA	095
radiation esophagitis	114
radioimmunoassay	121
RAST	085
reactive hypoglycemia	030
recurrent otitis media	147
red cell energy metabolism	229
renal failure	068
transplantation	140
renal tubular function	212
retinoids—	096
	201
•	090
sarcoidosis	107
scleroderma	036
scoliosis	149
septic	156
serotype I	093
serum globulin (modified immune)	203
sickle cell train	081,108
gingle breath diffusion	020

Key Words	Page
sleep apnea	123
small cell	045
somatic symptoms	235
spirometry ratios	109
staphyloccal scalded skin syndrome	092
plasmids	092
steady-state diffusion DLCO	041
steroid hormone receptors	187
steroids	060,076
stuttering	150
subsensitivity	034,056,084,102,135
SV1 Fq methoxozale	120
tamoxifen	078
temperature	209
TBNA	181
testosterone	123
theophylline	119
thalassemia-hemoglobin variants	219
	059,184
thrombocytopeniathyroid axis	051
functional reserve	051
thyrotropin releasing hormone————	065
thyrotoxicosis	050
trabecular meshwork	157
trauma	140
trimethaprim	120
TRH infusion	051
tumor cell	176
two (2)-D echocardiography	089
TX A2 B5	105
tympanostomy tube	147
cympanoscomy case	141
ultrasound	221
upper gastrointestinal hemorrage	073
urinary VLBW Infants	209
UVB	126
vertility effects	199
vesicants	159
virulence factors in E. coli 091,	,129
plasmids	093,129
vitamin D	171
K	094
water metabolism	116
yag laser	162

DISTRIBUTION

# DISTRIBUTION LIST

DISTRIBUTION F121	
2 Copies	Commander US Army Medical Research Command Fort Detrick, ATTN: SGRD-AJ Frederick, MD 21701
2 Copies	Commander US Army Medical Research Command Fort Detrick, ATTN: SGRD-HR Frederick, MD 21701
12 Copies	Defense Documentation Center ATTN: DDC-TCA, Cameron Station Alexandria, VA 22314
2 Copies	Commander HQ, US Army Health Services Command ATTN: HSHN-I Fort Sam Houston, TX 78234
1 Copy	Superintendent Academy of Health Sciences, US Army ATTN: AHS-COM Fort Sam Houston, TX 78234
1 Сору	Chief, Department of Clinical Investigation Brooke Army Medical Center Fort Sam Houston, TX 78234
l Copy	US Army Medical Center ATTN: Chief, Department of Clinical Investigation Fort Gordon, Georgia 30905
1 Сору	Madigan Army Medical Center ATTN: Chief, Department of Clinical Investigation Tacoma, Washington 98431
1 Сору	Letterman Army Medical Center ATTN: Chief, Department of Clinical Investigation Presidio of San Francisco, CA 94129
1 Сору	Tripler Army Medical Center ATTN: Chief, Department of Clinical Investigation Homolulu, Hawaii 96819
1 Сору	Walter Reed Army Medical Center ATTN: Chief, Department of Clinical Investigation Washington, D.C. 20310

# END

# FILMED

7-85

DTIC